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 Chapter 1  
General Introduction 
1.1 Drug metabolism 
Drug metabolism i.e. biotransformation of xenobiotics (exogenous compounds entering 
the body) describes the process of converting lipophilic, easily absorbable substances 
into more hydrophilic substances, which are readily excreted from the body in order to 
prevent accumulation of the xenobiotic.1 Drug metabolism is catalyzed by various 
enzyme systems and can be divided into four reaction categories: hydrolysis, reduction, 
oxidation and conjugation. Since the first three introduce a functional group, they are 
often called functionalization reactions and are summarized under the term phase I 
reactions, whereas conjugation reactions are referred to as phase II reactions. Some 
major phase I and phase II enzymes are summarized in Table 1.1. Although functionali-
zation often facilitates subsequent conjugation, phase I and phase II reactions do not 
necessarily occur sequentially but independently of each other. 
Table 1.1. Major enzymes involved in phase I and phase II metabolism.1 
Phase I enzymes Phase II enzymes 
Hydrolases (esterases, amidases) 
Cytochrome P450 
Flavin-monooxygenases 
Monoamine oxidase 
Oxidoreductases 
UDP-Glucuronosyltransferases (UGTs) 
Sulfotransferase 
Glutathione S-transferases (GSTs) 
Acetyltransferase 
Amino acid transferase 
Mainly, drug metabolism takes place in the liver, but also intestine, kidney, skeletal 
muscle, skin or plasma can contribute to biotransformation.2 Concerning intracellular 
distribution of drug metabolizing enzymes, the highest activities are located in the 
endoplasmic reticulum and in the cytosol.2 The most crucial role in drug metabolism is 
associated with the cytochrome P450 (CYP) enzyme system.1 All CYP enzymes are 
heme (protoporphyrin IX)-containing proteins that catalyze a monooxygenation of a 
broad variety of substrates. The reaction involves the transfer of one atom of oxygen into 
the substrate, while the other is reduced to water. Necessary reducing equivalents are 
furnished by the closely associated NADPH cytochrome P450 reductase.1 It is reported 
that in humans more than 50 % of the orally effective drugs in current use are 
metabolized by two CYP enzymes, namely CYP3A4 and CYP2D6.3 
Drug metabolism does not only influence the physicochemical properties of a drug but 
can also alter the pharmacodynamic features. Most commonly, the pharmacological 
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activity of an active drug is terminated. However, drug metabolism can also result in the 
formation of pharmacologically active metabolites.4 Therefore, it can be utilized to over-
come various problems associated with a drug´s pharmacokinetic or pharmacodynamic 
properties, by the sophisticated design of drugs, comprising distinct soft “spots” for 
intentional biotransformation reactions. The development of prodrugs follows this 
approach (cf. section 1.2.1). 
A further crucial aspect of drug metabolism is the metabolic conversion of certain 
xenobiotics, leading to the formation of reactive metabolites/intermediates (cf. section 
1.3.1). Although less common, this activation process plays an important role in chemical 
toxicity and chemical mutagenicity/carcinogenicity.1 
Figuratively speaking, drug metabolism can be considered as two sides of the same 
coin; one leading to desired, beneficial effects, whereas the other one results in adverse 
side effects due to toxification. 
1.2 Beneficial effects of drug metabolism: Using prodrug biotransfor-
mation as a key strategy towards antihypertensive transdermal 
therapeutic systems 
1.2.1 The prodrug approach 
The term “pro-drug” was first introduced by Albert in 1958 to describe any compound that 
needs biotransformation prior to exhibiting its pharmacological effect.5-6 This broad 
definition can be refined to signify “the transformation of a drug in an inactive transport 
form that releases the drug either at or near the site of action in vivo through chemical or 
enzymatic reaction.6 On one hand a further differentiation leads to the classification of 
carrier prodrugs, bearing a temporary, usually covalent and non-toxic transport moiety 
(promoiety), which is cleaved in 
vivo by a hydrolytic reaction to 
release the active principle 
(Figure 1.1). On the other hand 
bioprecursors can be designed 
by a molecular modification of 
the active principle, generating a 
new compound, which is meta-
bolized to regain the active 
principle in vivo.7 In general, the 
prodrug approach is taken into 
account, when an improvement 
of physicochemical, biopharmaceutical or pharmacokinetic properties of a potent phar-
macologically active compound is desired. Thus, by prodrugs, problems related to for 
example drug formulation and delivery such as poor aqueous solubility, chemical insta-
bility, insufficient oral absorption or skin permeability, high first-pass metabolism and 
 
Figure 1.1. A simplified illustration of the carrier prodrug concept. 
Adopted from Stella.5 
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toxicity can be solved.8-9 In addition, with respect to improved patient compliance, 
elimination of unacceptable taste or odor and avoidance of irritation or pain upon drug 
administration become possible.9-10 Another interesting objective of prodrug strategies is 
tissue-selective delivery including, e.g., enzyme-prodrug cancer therapy.10 The current 
percentage of the drugs approved worldwide is estimated to approx. 5-7 %, and from 
2000-2008 about 20 % of all worldwide approved new small molecules have been 
prodrugs, indicating that the prodrug concept has become an integral part of the drug 
design and delivery process.8, 11 
1.2.2 Transdermal drug delivery 
In order to overcome problems associated with traditional modes of drug administration, 
in the last decades great effort was made to explore the transdermal route for delivery of 
drugs into the systemic circulation.12 Consequentially, besides oral therapy the trans-
dermal administration was stated the most innovative research area for drug delivery.13 
Compared to the oral route transdermal drug delivery is associated with a variety of 
advantages including avoidance of gastrointestinal side effects and hepatic first-pass 
metabolism, sustained delivery to provide a steady plasma profile without plasma con-
centration peaks typical for oral administration. Thereby, systemic side effects are 
reduced and patient compliance by convenient, patient-friendly and flexible administra-
tion as well as a potentially reduced frequency of dosing is improved. Furthermore, the 
drug input can be promptly interrupted on intoxication, thus increasing safety.14-16 
However, disadvantages of transdermal application are possible skin irritations and sen-
sitizations and the fact that it is not suitable for drugs that require high blood levels.15 
Despite extensive research efforts, since the launch of the first transdermal patch against 
motion sickness by the end of 1979, the transdermal drug delivery market is currently 
based on only a few low molecular weight drugs for a limited number of therapeutic 
areas (cf. Table 1.2). The main problem associated with passive transdermal delivery 
arises from the highly efficient barrier properties of the skin, which can be overcome only 
by molecules with specific physicochemical properties.17 Due to their potential for 
providing constant and sustained drug plasma levels and reduced application frequency, 
transdermal therapeutic systems are particularly advantageous for the treatment of 
diseases requiring long-term pharmacotherapy as, e.g., cardiovascular diseases.15 
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Table 1.2. Examples of currently available transdermal therapeutic systems approved by the US Food and Drug 
Administration (Mar 2011).17-18 
Drug Trade name Indication Company Approval date 
Buprenorphine Butrans Analgesia Purdue Pharma LP 2010 
Clonidine Catapres-TTS Hypertension Boehringer Ingelheim 1984 
Estradiol Alora HRTa Watson Labs 1996 
 Climara HRTa Bayer HLTHcare 1994 
 Estraderm HRTa Novartis 1986 
 Estradiol HRTa Mylan Technologies 2000 
 Menostar HRTa Bayer HLTHcare 2004 
 Vivelle HRTa Novartis 1994 
 Vivelle-Dot HRTa Novartis 1996 
Ethinyl estradiol/ 
levonorgestrol 
Climara pro HRTa Bayer HLTHcare 2003 
Ethinyl estradiol/ 
norelgestromin 
Ortho Evra Contraception Ortho-McNeil 2001 
Ethinyl estradiol/ 
norethindrone 
Combipatch HRTa Novartis 1998 
Fentanyl Duragesic Analgesia Alza 1990 
 Fentanyl Analgesia Mylan Technologies 2005 
 Fentanyl Analgesia Lavipharm Labs 2006 
 Fentanyl Analgesia Watson Labs 2007 
Lidocaine Lidoderm Analgesia Teikoku Pharma 1999 
Lidocaine/ tetracaine Synera Analgesia Zars Pharm 2005 
Methylphenidate Daytrana ADHDb Noven Pharms Inc 2006 
Nicotine Habitrol Smoking cessation Novartis 1999 
 Nicoderm CQ Smoking cessation Sanofi Aventis US 1991 
 Nicotine Smoking cessation Aveva 1997 
Nitroglycerin Minitran Angina Graceway 1996 
 Nitroglycerin Angina Mylan 1996 
 Nitroglycerin Angina Hercon Labs 1998 
 Nitroglycerin Angina Kremers Urban Pharms 2004 
Oxybutynin Oxytrol Overactive bladder Watson 2003 
Rivastigmine Exelon Alzheimer’s disease Novartis 2007 
Rotigotine Neuproc Parkinson’s disease Schwarz Pharma 2007 
Selegiline EMSAM Depression Somerset 2006 
Scopolamine Transderm Scop Motion sickness Novartis 1979 
Testosterone Androdrem Hypogonadism Watson Labs 1995 
a HRT = hormone replacement therapy, b ADHD = attention deficit hyperactivity disorder, c discontinued 
1.2.3 Renin-angiotensin-aldosterone system 
The renin-angiotensin-aldosterone system (RAAS) plays a key role in the regulation of 
blood volume and blood pressure.19 In response to decreases in blood volume and renal 
perfusion, the aspartyl protease renin is secreted by juxtaglomerular cells of the kidney 
and cleaves angiotensinogen, produced in the liver, to form the inactive decapeptide 
angiotensin I (Ang I). Ang I is further converted into the biologically active octapeptide 
angiotensin II (Ang II) by angiotensin-converting enzyme (ACE) and non-ACE enzymes 
such as cathepsin G and chymase. Ang II is a potent vasoconstrictor and promotes 
secretion of the mineralocorticoid aldosterone from the adrenal gland, which causes 
enhanced sodium reabsorption, thereby increasing blood pressure. Furthermore, Ang II 
inhibits renin release via a negative feedback mechanism.20 
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1.2.3.1 Angiotensin-converting enzyme 
The angiotensin-converting enzyme (ACE), a type-I membrane-anchored dipeptidyl 
carboxypeptidase, serves as a key component in the RAAS by cleaving the carboxy 
terminal His-Leu dipeptide from Ang I to produce Ang II. Moreover, ACE inactivates the 
vasodilatory peptide bradykinin.21 ACE exists in two isoforms. The somatic form (sACE) 
is almost ubiquitously expressed, especially in endothelial cells of arterioles, lung, kid-
ney, small intestine and in a variety of neuronal cells in the brain.22 The second isoform, 
testicular ACE (tACE), is found in male germinal cells and has a single active site, 
whereas the somatic form is a two-domain protein, each containing a conserved His-
GluXXHis zinc metallopeptidase binding motif.22 The active site zinc ion is coordinated by 
the two histidines in the conserved binding motif, a glutamate 24 residues downstream 
and an activated water molecule.23 
1.2.3.2 Angiotensin II receptors 
Most of the physiological effects of angiotensin II (Ang II) are mediated by the angio-
tensin type 1 receptor (AT1R) and the angiotensin type 2 receptor (AT2R), both belonging 
to the seven-transmembrane superfamily of G protein-coupled receptors. The AT1R is 
widely distributed in all organs, including liver, adrenals, brain, lung, kidney, heart and 
vasculature.24 The AT2R is ubiquitously expressed at high density in developing fetal 
tissue, but is much less abundant in adult tissues.24-25 
The signaling pathway of Ang II turned out to be very complex, since a series of signaling 
cascades is activated by Ang II on binding to the AT1R. Evidentially, one of the major 
biological functions of Ang II, vasoconstriction, is mediated via activation of the classic G 
protein-mediated pathways by coupling to Gq/11, G12/13, and Gβγ complexes. In addition, 
Ang II cross-talks with several kinases, including MAP kinases, receptor tyrosine kinases 
(e.g. EGFR) and nonreceptor tyrosine kinases (e.g. Janus kinases (JAK)) via AT1Rs. 
Furthermore, the AT1R-mediated activation of NAD(P)H oxidase leads to the generation 
of reactive oxygen species. These signaling cascades lead to physiological and patho-
physiological effects such as vasoconstriction, smooth muscle cell growth, hypertrophy 
and cell migration.24 
Regarding the signaling pathways of AT2R, coupling to Giα2 and Giα3 proteins is dis-
cussed26 leading to the activation of pathways including tyrosine or serine/threonine 
phosphatases24, phospholipase A2, nitric oxide and cyclic guanosine monophosphate25. 
Studies have shown that AT1R and AT2R have counter regulatory effects on the cardio-
vascular and renal system.27 
1.2.4 Hypertension 
Hypertension is recognized as one of the leading risk factors for cardiovascular morbidity 
and mortality.28 In 2000 the worldwide number of adults suffering from hypertension was 
estimated to 972 million, two thirds living in developing countries. By 2025, the total 
number is expected to reach 1.56 billion.29 According to the European Society of 
Hypertension (ESH) and the European Society of Cardiology (ESC) hypertension is 
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diagnosed at a systolic blood pressure of ≥ 140 mmHg or a diastolic blood pressure of 
≥ 90 mmHg.30 Lifestyle factors, such as physical inactivity, a salt-rich, fatty diet or alcohol 
and tobacco use are assumed to promote the disease.29 Furthermore, hypertension is 
known to be a major risk factor for concomitant and secondary diseases such as myo-
cardial infarction, congestive heart failure, stroke and end-stage renal disease, all of 
which are associated with significant morbidity and mortality.31 
1.2.5 Antihypertensives 
For the pharmacological treatment of hypertension following classes of antihypertensive 
drugs are recommended in mono- or combination therapy: ACE inhibitors, angiotensin 
receptor antagonists (ARBs), diuretics, β-blockers and calcium channel blockers.30 
Furthermore, aldosterone receptor antagonists (e.g. spironolactone, eplerone) or α2 
adrenergic agonists like clonidine are used as add-on therapy.32 In the last decade new 
potential therapeutic targets for antihypertensive therapy beyond the classical RAAS 
pathway were discovered (cf. Figure 1.2). In 2007, the first direct renin inhibitor, aliskiren, 
was approved by the US FDA.33 
In the following, special emphasis is laid on a closer discussion of ACE inhibitors and 
angiotensin receptor antagonists, as these drug classes are of particular relevance for 
this thesis. 
  
Figure 1.2. Vasoactive balance of the re-
nin-angiotensin-aldosterone system. Es-
tablished and possible therapeutic targets 
for antihypertensive therapy include (1) 
Renin inhibition; (2) ACE inhibition; (3) 
AT1R blockade; (4) AT2R stimulation; (5) 
(P)RR blockade; (6) NEP inhibition; (7) 
aldosterone-receptor blockade or aldoste-
rone-synthase inhibition; (8) NO-cGMP 
stimulation. Abbreviations: BKR = brady-
kinin receptor; cGMP = cyclic guanosine 
monophosphate; NEP = neutral endopep-
tidase; NO = nitric oxide; (P)RR = (pro)re-
nin receptor; ROS = reactive oxygen spe-
cies. 
Reprinted by permission from Macmillan 
Publishers Ltd: Nat. Rev. Cardiol.28, 
copyright 2010. 
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1.2.5.1 ACE inhibitors 
In the nineteen-sixties the ACE-inhibiting properties of peptides present in Bothrops 
jararaca snake venom were discovered by serendipity.34 Consequentially, in 1977 the 
first orally available ACE inhibitor (ACEi), captopril, was designed based on the 
sequence of the nonapeptide SQ 20,881 (Glu-Trp-Pro-Arg-Pro-Gln-Ile-Pro-Pro) and the 
structure of bovine pancreatic carboxypeptidase A, a zinc-dependent carboxypeptidase 
assumed to have a catalytic mechanism and an active site comparable to ACE.35-36 
Furthermore, a similar approach, based on the inhibition of the zinc-dependent 
proteinase thermolysin, led to the development of enalapril and lisinopril. Until today a 
variety of ACE inhibitors was designed (cf. Figure 1.4), nearly all of them containing a 
Zn2+ binding group (sulfhydryl, carboxylate or phosphinate), a free carboxylate group 
interacting with a positively charged protein amino acid and a hydrophobic residue 
(mostly a phenylpropyl moiety) that undergoes van der Waals interactions with amino 
acid side chains in the S1 pocket. Details 
about substrate binding were provided by 
crystal structures in complex with captopril37, 
enalaprilat37 and lisinopril21 (Figure 1.3). 
Except for captopril and lisinopril, all ACE 
inhibitors depicted in Figure 1.4 are pro-
drugs. By esterification of one of the car-
boxylic acid groups the lipophilicity is in-
creased resulting in a considerable increase 
in absorption after administration.38 Following 
absorption from the GI-tract, the prodrug 
esters require enzymatic hydrolysis by 
esterases to liberate the corresponding ac-
tive principle, which is able to coordinate the 
active site zinc ion and to efficiently inhibit ACE. 
ACE inhibition directly reduces the amount of circulating Ang II, thus promoting 
vasodilation and decreasing systemic vascular resistance resulting in reduced blood 
pressure. In addition to their established use as antihypertensives and for treatment and 
prevention of heart failure, patients with left ventricular dysfunction, post-myocardial 
infarction, peripheral vascular disease, diabetes, stroke, transient ischaemic attack or 
chronic kidney disease have also been proven to benefit from ACEis. Moreover, ACEis 
show significant cardio- and vasculoprotective effects.39 The most common adverse 
effect experienced with ACEis is cough, which is assumed to be caused by accumulation 
of bradykinin, often requiring cessation of the therapy. Additionally, as a rare but 
potentially life-threatening side effect angioedema is described.40 
 
Figure 1.3. Schematic view of lisinopril binding in 
the active site of tACE with distances marked in 
A°. The different binding subsites are labelled. 
Adapted by permission from Macmillan Publishers 
Ltd: Nature21, copyright 2003. 
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Figure 1.4. Inhibitors of the angiotensin-converting enzyme approved by the US FDA.18 Cilazapril is not available 
in the United States, but in Europe. Imidapril is only approved in Japan. 
1.2.5.2 Angiotensin II AT1 receptor antagonists 
The development of potent nonpeptide Ang II receptor antagonists (ARBs) with high AT1 
selectivity was initiated by the discovery of 1-benzylimidazol-5-acetic acid derivatives like 
S-8307 and S-8308 (Figure 1.5) derived from a screening program by Takeda Chemical 
Industries in 1982. Two different design strategies followed by DuPont and SmithKline 
Beecham, respectively, based on molecular modeling and knowledge of the structure-
activity relationships of the peptide were used to align the selective but weak antagonists 
S-8307 and S-8308 to the C-terminal region of putative active conformations of Ang II. 
These approaches resulted in the identification of the highly potent ARBs losartan and 
eprosartan (Figure 1.5).41 By modifying or replacing the imidazole ring of losartan a 
variety of different ARBs was obtained including imidazole, dihydroimidazol-4-one, 
benzimidazole and other heterocycles containing antagonists as well as acyclic ana-
logues. Particular enhancement of binding activity was achieved by introduction of the 
privileged 2’-tetrazole-biphenylmethyl structure.42 In general, the presence of an acidic 
group (either a tetrazole or carboxylic acid) seems to be favorable for the interaction with 
a basic amino acid group, presumably, the highly conserved arginine-167 (Arg167) in 
transmembrane region IV of the AT1R.43 Similarly, an acidic moiety at the 5-position of 
the imidazole ring and the 7-position of the benzimidazole ring, respectively, is proposed 
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to interact with a positively charged lysine (Lys199) residue in transmembrane region V 
of the AT1R.44 
At present, eight ARBs are approved by the US FDA (Figure 1.5), four of them 
representing prodrugs. Candesartan cilexetil, olmesartan medoxomil and azilsartan 
medoxomil show improved oral bioavailability compared to the corresponding diacids 
and release their active principles on enzymatic hydrolysis of the carrier promoieties. 
Losartan can be regarded as a bioprecursor, as it is oxidized in vitro to the metabolite 
EXP3174 that is about 20 times31 more potent than losartan itself. In Germany, all ARBs 
shown in Figure 1.5 except for azilsartan medoxomil are currently on the market. 
By selectively blocking the AT1R, ARBs effectively antagonize AT1R-mediated effects of 
Ang II. Furthermore, the blockade leads to a shift of the vasoactive balance (cf. Figure 
1.2), due to an enhanced activation of the AT2R. Resulting effects are a decrease in 
blood pressure as well as a protection of tissues from oxidative stress and resultant 
chronic vascular disease.45 
ARBs were found to exhibit a very favorable safety profile with low incidence of adverse 
effects. Cough, a frequent side effect of ACEi, is much less common with ARBs and only 
rare cases of angioedema have been noted.45 Consequentially, a discontinuation of 
ARBs is rare. In fact, it was shown that ARBs had the highest 1-year compliance among 
five major classes of antihypertensive drugs.46 
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Figure 1.5. Lead structures S-8307 and S-8308 discovered by Takeda Chemical Industries and subsequently 
developed angiotensin II AT1 receptor antagonists approved by the US FDA18. 
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1.3 Adverse effects of drug metabolism: Formation of reactive metabo-
lites by bioactivation 
1.3.1 Reactive metabolites and adverse drug reactions 
In contrast to metabolic detoxification, in certain cases bioactivation of xenobiotics can 
result in the formation of chemically reactive metabolites/intermediates. Due to their high 
reactivity such metabolites exhibit short half-lives of generally less than one minute and 
are usually not detectable in plasma.47 Their existence can only be indirectly proven, e.g. 
by in vitro trapping reactions (cf. Chapter 6) or investigation of covalent binding using a 
radiolabeled parent compound.48 Since the formation of reactive metabolites is usually 
catalyzed by cytochrome P450 enzymes, involving oxidation, the nature of such species 
is mostly electrophilic.47 In general, the tendency of a compound to form reactive 
metabolites is a function of its chemical structure.47 Today a variety of organic functional 
groups is known to be associated with bioactivation, such as aromatic amines, p-amino-
phenols, benzene rings or heterocycles like furan or thiophene.49 
The most prominent and widely studied compound that generates reactive metabolites of 
P450-mediated bioactivation is acetaminophen. Besides phase II glucuronidation or 
sulfonation, acetaminophen undergoes P450-mediated two-electron oxidation resulting in 
the formation of the reactive N-acetyl-p-benzoquinone imine (NAPQI) (Scheme 1.1). This 
species is readily trapped and detoxified by glutathione (GSH) addition. However, when 
hepatic GSH levels are depleted, NAPQI can form adducts with proteins, oxidize 
cysteine residues of proteins, covalently bind to liver and renal DNA and eventually 
disrupt cellular homeostasis.49 
 
Scheme 1.1. Metabolism and bioactivation of acetaminophen. 
 General Introduction 11 
Based on a multitude of examples, it is now widely accepted that there is a strong link 
between bioactivation and drug-induced toxicity as well as adverse drug reactions (ADR) 
such as hepatotoxicity or hypersensitivity (Scheme 1.2).49 
 
Scheme 1.2. Pathways of drug metabolism highlighting the link between formation of reactive metabolites and 
adverse toxic effect deriving from reaction of reactive metabolites with cellular macromolecules. Modified from 
Park et al.47 
However, it should be noted that not all the drugs that possess organic functional groups 
being prone to bioactivation are actually bioactivated, and that bioactivation does not 
inevitably result in toxicity.49 In fact, the balance between bioactivation, detoxification and 
defense mechanisms appears to be the key-determinant of chemical toxicity.1, 50 
Recently, it was suggested from published data that, besides lack of efficacy, preclinical 
toxicity was the primary cause for the high attrition rate in drug development.51 
Furthermore, ADRs were stated to be the major reason for patient morbidity and a 
significant cause of patient mortality.52-53 They often appear to be unpredictable from the 
knowledge of the basic pharmacology of the drug and show no simple dose-response 
relationship (idiosyncratic ADRs).54 Moreover, ADRs usually have a low incidence, which 
makes them very difficult to detect in phase three clinical trials, especially when the 
number of patients in those trials is small.55 Therefore, detection of reactive metabolites 
is considered a topic of serious concern in early stages of drug development to help 
avoid safety issues that could lead to compound failure at a later stage.56 
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1.3.2 NG-acylated hetarylpropylguanidines 
Based on the imidazolylpropylguanidine derivatives impromidine and arpromidine 
(Scheme 1.3), which were found to be highly potent histamine H2 receptor (H2R) agonists 
with an approximately 50 and 100-fold higher potency, respectively, than histamine on 
the spontaneously beating guinea pig right atrium,57-59 a novel class of NG-acylated 
analogues with improved pharmacokinetic properties was developed in our workgroup.60 
 
Scheme 1.3. Structures of the H2R agonists impromidine and arpromidine. 
Due to the strongly basic guanidine moiety (pKa ~ 13) guanidine-type H2R agonists are 
nearly quantitatively protonated at physiological pH. By introduction of a carbonyl func-
tion adjacent to the guanidine moiety basicity is decreased by 4-5 orders of magnitude 
(pKa ~ 8). Thus, the resulting NG-acylated guanidines (Scheme 1.4) are absorbed from 
the gastrointestinal tract and are capable of penetrating across the blood-brain barrier.60 
 
Scheme 1.4. General structures of NG-acylated imidazolylpropylguanidines and NG-acylated 2-
aminothiazolylpropylguanidines. 
Furthermore, bioisosteric replacement of the imidazole ring by a 2-aminothiazole or a 2-
amino-4-methylthiazole group led to equipotent or even more potent H2R (partial) 
agonists with remarkably improved selectivity over the H3R and H4R.61 
However, there is increasing evidence that cytochrome P450-catalyzed bioactivation of 
heterocycles like the imidazole and aminothiazole ring is associated with the formation of 
reactive intermediates or toxic metabolites.62 
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 Chapter 2  
Scope and Objectives 
The primary function of drug metabolism is the conversion of lipophilic, easily absorbable 
xenobiotics into more hydrophilic xenobiotics to facilitate excretion from the body to 
prevent accumulation. However, drug metabolism can also result in the activation of 
pharmacologically inactive drugs or in the formation of reactive metabolites/inter-
mediates, i.e. electrophilic compounds capable of reacting with cellular macromolecules. 
The former process can be exploited, mostly for the activation of prodrugs to overcome 
problems associated with a drug´s pharmacokinetic or pharmacodynamic properties, 
whereas the latter is often undesirable, as it can lead to adverse drug reactions and 
toxicity. Examples for both scenarios are highlighted in this work. 
 
The advantages associated with drug application via a transdermal therapeutic system 
(TTS) are well accepted. Particularly due to the potential for providing constant and 
sustained drug plasma levels and reduced application frequency, TTS are advantageous 
for the treatment of diseases requiring long-term pharmacotherapy as, e.g., cardio-
vascular diseases. Up to now, only the α2-adrenoreceptor agonist clonidine is approved 
in the USA as TTS for the treatment of hypertension. Thus, there is a strong discrepancy 
between the high incidence of hypertension and the practically non-existing supply of 
transdermally applicable antihypertensive drugs. Thus, the development of novel TTS for 
the treatment of hypertension is highly desirable. A prerequisite for transdermal appli-
cation is a sufficiently high systemic bioavailability of the drug, which requires appropriate 
physicochemical properties to overcome the barrier function of the skin. The subject of 
previous work was to find suitable prodrugs of the angiotensin II AT1 receptor antagonist 
candesartan and the angiotensin-converting enzyme (ACE) inhibitor trandolapril, which 
can be administered via a TTS.1 Therein, trandolapril was found to be inappropriate for 
this purpose, since its prodrugs have a strong tendency to decompose, giving diketo-
piperazines during synthesis and storage by intramolecular cyclization reactions. As 
those ACE inhibitors, which have a conformationally constrained structure like cilazapril, 
show no distinct tendency to diketopiperazine formation, cilazapril was considered a 
promising drug for TTS development. 
The aim of this work was the design, synthesis and bioanalytical as well as biopharma-
ceutical characterization of candesartan and cilazapril prodrugs with respect to suitability 
for application via a TTS. Carrier-prodrug structures were chosen by analogy with the 
orally administered prodrug candesartan cilexetil taking into consideration promoieties of 
various approved and successfully marketed prodrugs. The new potential prodrugs 
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should be investigated with respect to solid-state stability, susceptibility for enzymatic 
hydrolysis, i.e. half-lives in the presence of porcine liver esterase, porcine skin homo-
genate, human plasma and cultured human hepatocytes, and stability against spon-
taneous, non-enzymatic hydrolysis in buffer. In addition, investigation of the potential 
candesartan prodrugs for angiotensin II AT1 antagonism was envisaged by means of a 
spectrofluorimetric Ca2+-assay using AT1 receptor-expressing rat glomerular mesangial 
cells. 
To further elucidate the potential for transdermal application, selected candesartan and 
cilazapril prodrugs comprising the most promising properties in terms of physicoche-
mistry, stability and enzymatic hydrolyzability should be explored with respect to TTS 
manufacturing, quality, stability and transdermal permeation through animal and human 
skin using Franz diffusion cells. 
A further project focused on the adverse side of drug metabolism, namely on the 
detection and identification of reactive metabolites/intermediates. Based on the histamine 
H2 receptor (H2R) ligands impromidine and arpromidine, NG-acylated hetarylpropylguani-
dines were developed in our workgroup, which turned out to be highly potent H2R 
agonists2-3 and could serve as valuable pharmacological tools for in vitro and future in 
vivo studies. Two compound sub-classes were developed either comprising an imidazole 
ring or a 2-aminothiazole group. There is strong evidence that the 2-aminothiazole 
moiety is associated with adverse drug reactions by cytochrome P450-mediated 
formation of reactive metabolites.4 The aim of this project was the elucidation of the toxic 
potential of NG-acylated 2-aminothiazolylpropylguanidines derived from the bioactivation 
of the heterocycle. To investigate the formation of reactive metabolites/intermediates, 
representative NG-acylated 2-aminothiazolylpropylguanidines were selected to explore 
the applicability of trapping by glutathione (GSH) on incubation with liver microsomes 
and to identify potential GSH adducts and putative reactive molecular species, 
respectively, by means of liquid chromatography/tandem mass spectrometry (LC-
MS/MS). Furthermore, the impact of the substitution pattern at the 2-aminothiazole 
moiety concerning the formation of reactive metabolites should be investigated. 
Additionally, in view of further in vitro and in vivo investigations possible unspecific 
chemical toxicity of selected NG-acylated hetarylpropylguanidines should be taken into 
consideration by testing for hemolysis and cytotoxicity. 
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Prodrugs of Candesartan and Cilazapril 
3.1 Introduction 
The term prodrug describes an inactive transport form of a drug that releases the active 
drug in vivo after chemical or enzymatic conversion.1 Approximately 49 % of all prodrugs 
marketed in 20022 were classified as being activated by hydrolysis.3 Since esterases are 
widely distributed throughout the body rendering the ester bond quite labile in vivo, the 
development of ester-based carrier prodrugs became a popular strategy to improve 
certain drug properties as e.g. oral bioavailability.4 The choice of an appropriate pro-
moiety, which influences the physicochemical profile as well as the pharmacokinetic and 
metabolic behavior should be carefully considered.5 
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Scheme 3.1. Hydrolytic activation of prodrugs containing an (acyloxy)alkyl group (A), an [(alkoxycarbonyl)oxy]-
alkyl group (B) or a (2-oxo-1,3-dioxol-4-yl)methyl ester pro-moiety (C).5 D: Pathways for ester bond cleavage 
catalyzed by esterases or cytochrome P450 enzymes.4 
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Double esters, also referred to as cascade prodrugs, cyclic carbonates and simple esters 
are counted among well established ester-based pro-moieties that become hydrolyzed 
by different types of esterases or get activated by oxidation through cytochrome P450 
enzymes (Scheme 3.1). An important property of a prodrug is the rate of biotransforma-
tion, commonly indicated by the half-life. The rate of biotransformation is influenced, e.g., 
by the stereochemistry of the prodrug or molecular properties such as steric bulk as well 
as interindividual variations and species differences.4 Major enzymes involved in the 
bioconversion of ester-based prodrugs are carboxylesterases, cholinesterases as buty-
rylcholinesterase (BChE), paraoxonase and cytochrome P450 enzymes. In addition, 
acetylcholinesterase (AChE) was shown to take part in prodrug activation.4 Carboxyl-
esterase, AChE and BChE belong to the group of type B-esterases and are also referred 
to as serine esterases due to a conserved serine residue in their catalytic triad (Ser-Glu-
His). They are known to be involved in the activation of a variety of prodrugs.6-8 Carboxyl-
esterases show extremely wide and overlapping substrate specificities, presumably due 
to a large and flexible binding pocket, and are virtually present throughout the body. 
Besides high activity in the liver, kidney and small intestine, they are also present in the 
skin.4 In contrast to carboxylesterases, AChE has a much higher substrate-specificity 
with acetylcholine being its characteristic substrate, whereas BChE, besides preferential 
cleavage of butyrylcholine, also hydrolyzes a variety of other esters.4 AChE and BChE 
are mainly localized in brain and plasma, but human skin9 has also been shown to have 
cholinesterase activity.4 Paraoxonase is a calcium-dependent type A-esterase known to 
catalyze the hydrolysis of a broad spectrum of compounds including aromatic esters, 
organophosphates, lactones and cyclic carbonate esters.10 High paraoxonase activity is 
particularly found in plasma.4 Although carboxylic acid esters are typically cleaved by 
esterases, oxidative hydrolysis by cytochrome P450 enzymes represents an alternative 
route of ester-based prodrug activation.11 
 
Based on a model of ACE interacting with inhibitors such as 
captopril, optimization of binding energies by introduction of a 
7,6-bicyclic ring system with S,S-configuration resulted in the 
discovery of the highly potent angiotensin-converting enzyme 
inhibitor (ACEi) cilazaprilat.12 Cilazapril (Figure 3.1) is the 
monoethyl ester prodrug of the corresponding dicarboxylic 
acid cilazaprilat, designed for better oral bioavailability. After 
absorption it is hydrolyzed by esterases in vivo to yield the 
active principle cilazaprilat. In the following, compounds, which contain the partial 
structure of cilazapril and are additionally esterified at the heterocyclic carboxylic acid, 
are referred to as “cilazapril prodrugs” or “prodrugs of cilazapril”, although cilazaprilat of 
course is the active principle. 
  
Figure 3.1. Structure of the
ACEi cilazapril. 
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Flexible compounds like enalapril or moexipril have a more or less pronounced tendency 
to form a cyclic degradation product, a so-called diketopiperazine or piperazine-2,5-
dione.13 By increasing the rigidity of the ACEi the tendency to undergo an intramolecular 
ring-closure reaction becomes negligible. 
Cilazapril causes an increase in plasma renin activity and a decrease in plasma angio-
tensin II and aldosterone concentrations resulting in long-term reduction of arterial blood 
pressure by dilatation of peripheral vessels and decreased vascular resistance.14 
Candesartan (Figure 3.2) is a nonpeptide angiotensin II receptor antagonist (ARB) that 
selectively inhibits the binding of Ang II to the AT1 receptor. At clinically relevant concen-
trations, candesartan behaves like an insurmountable antagonist at the AT1R and produ-
ces a long-lasting blockade (in vitro and in vivo) of the vascular contractile effects of 
Ang II, resulting in an effective decrease of blood pressure.15 It is administered orally as 
the double ester prodrug candesartan cilexetil (Figure 3.2), which is rapidly and 
completely hydrolyzed by carboxylesterases during absorption from the gastrointestinal 
tract to release the active principle.16 
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Figure 3.2. Structures of the ARBs candesartan (I) and candesartan cilexetil (II). 
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3.2 Selection of appropriate prodrug candidates 
Due to inappropriate physicochemical properties candesartan and cilazapril are not 
suitable for transdermal application. However, it can be speculated that masking of acidic 
functional groups results in improved permeation. Based on this working hypothesis, the 
synthesis of different carrier prodrugs by esterification of the free carboxylic acid moiety 
in candesartan and cilazapril, respectively, was considered. 
Ideally, these prodrugs should be pharmacologically inactive and sufficiently stable 
during synthesis, purification, formulation and in the TTS-matrix, whereas after trans-
dermal absorption, i. e. under physiological conditions, a rapid and complete conversion 
to the active drug is desired. The liberated fragments of the carrier group must have at 
best no or tolerable toxicity and no unwanted pharmacology.17 Furthermore, certain 
requirements in terms of lipophilicity and water solubility should be fulfilled. 
By analogy of the structure of candesartan cilexetil the synthesis of appropriate prodrug 
candidates should focus on double ester prodrugs as 1-(alkoxycarbonyloxy)alkyl and 1-
(acyloxy)alkyl esters, which represent well established and approved carrier-prodrug 
structures and can be found in various successfully marketed drugs, e.g. β-lactam 
antibiotics, nucleotide analogue reverse transcriptase inhibitors or in the ACE inhibitor 
fosinopril. Thereby, the introduction of a 1-ethyl bridge is preferred to a methylene-
bridged double ester, as the latter generates toxic formaldehyde upon biotransformation 
and is chemically less stable. Likewise, pivalate-generating prodrugs appeared to be 
associated with some degree of toxicity, since pivalic acid influences carnitine homeos-
tasis. Thus, carnitine levels of patients receiving chronic treatment should be clinically 
controlled.18 
Inspired by the immunosuppressive drug mycophenolate mofetil, morpholinoethyl esters 
of candesartan and cilazapril were taken into consideration as water solubility can be 
increased by salt formation. Since double ester prodrugs such as 1-(acyloxy)ethyl and 1-
(alkoxycarbonyloxy)ethyl esters are assumed to be hydrolyzed faster than simple esters 
due to the better accessibility of the site of hydrolysis, a combination of a basic 
substituent with a double ester moiety (1-((alkylamino)oxycarbonyloxy)ethyl, 1-(mor-
pholinylalkyloxycarbonyloxy)ethyl or 1-(2-morpholinoacetoxy)ethyl), was considered. 
By analogy with marketed prodrugs such as olmesartan medoxomil, azilsartan 
medoxomil or lenampicillin, a cyclic carbonate prodrug structure ((oxodioxolyl)methyl 
moiety) should be synthesized and the effect of a bulky substituent in C-5 position should 
be explored. 
Recently, Majumdar and Sloan reported on N-alkyl-N-alkyloxycarbonylaminomethyl 
(NANAOCAM) and N-aryl-N-alkyloxycarbonylaminomethyl (NArNAOCAM) prodrugs of 
carboxylic acid containing drugs for topical delivery. These pro-moieties were found to be 
hydrolyzed chemically instead of enzymatically via an SN1 type pathway. In contrast to 
NANAOCAM esters NArNAOCAM derivatives are reported to be reasonably stable.19 
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Therefore, a small set of NArNAOCAM prodrugs was included in the list of appropriate 
prodrug candidates. 
The preparation of simple alkyl esters should be self-evident due to ease of synthesis. 
However, previous investigations of our working group on the hydrolysis of trandolapril 
ethyl ester revealed that the esterified heterocyclic carboxylic acid is too stable (un-
published results). Therefore, an ethyl ester of cilazapril was synthesized to corroborate 
this finding using another ACEi core structure. 
Table 3.1 summarizes the respective prodrug candidates of cilazapril and candesartan. 
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3.3 Chemistry 
3.3.1 Cilazapril derivatives 
Towards the synthesis of cilazapril ester prodrugs the free carboxylic acid moiety of 
cilazapril was coupled to various prodrug building blocks (cf. Table 3.1) by common 
esterification pathways. One should keep in mind that due to the conserved (S)-confi-
guration of the existing three stereocenters in cilazapril the introduction of another 
stereocenter in the pro-moiety leads to the generation of two diastereomers, which can 
be separated by chromatography. 
According to Scheme 3.2 the cilazapril 1-(alkyloxycarbonyloxy)ethyl esters 3.1-3.3 were 
synthesized by a substitution reaction of cilazapril with commercially available 1-(alkyl-
oxycarbonyloxy)ethyl chlorides in DMF under basic conditions. 
 
 
The 1-chloroethyl alkanoate building blocks 3.4 and 3.5 were prepared by a solvent-free 
reaction of acetaldehyde with the pertinent acid chloride under lewis acid catalysis20. 
Subsequent coupling to cilazapril using the same conditions as employed for the syn-
thesis of 3.1-3.3 yielded the cilazapril 1-(acyloxy)ethyl esters 3.6 and 3.7 (Scheme 3.3). 
 
 
Scheme 3.4 summarizes the synthesis of 4-tert-butyl-5-methyl-1,3-dioxol-2-one (3.9) 
using an umpolung strategy. The synthesis started from pivaldehyde which was 
converted to the corresponding thioacetal 3.8a by reaction with propane-1,3-dithiol under 
solvent-free conditions using LiBF4 as catalyst.21 Treatment with n-BuLi in THF/abs led to 
2-lithio-1,3-dithiane, which was immediately converted to 3.8b by addition of 
Scheme 3.3. Synthesis of cilazapril 1-(acyloxy)ethyl esters 3.6 and 3.7. Reagents and conditions: (i) 
acetaldehyde (1.04 eq), ZnCl2, -20 °C to rt, 1-3 h; (ii) 3.4, 3.5 (1.3 eq), K2CO3 (1.2 eq), DMF, 0 °C to rt, overnight.
Scheme 3.2. Synthesis of cilazapril 1-(alkyloxycarbonyloxy)ethyl esters 3.1-3.3. Reagents and conditions: (i)
ClCHCH3OCOOR (1.3 eq), K2CO3 (1.2 eq), DMF, 0 °C to rt, overnight. 
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acetaldehyde.22 The α-hydroxyketone 3.8 was obtained after hydrolysis of the thioacetal 
by treatment with mercury (II) salts in MeOH/H2O.22 Finally, 4-tert-butyl-5-methyl-1,3-
dioxol-2-one 3.9 was obtained by cyclocarbonylation of 3.8 with triphosgene and DMAP 
as a base.23 
 
 
Radical bromination of 4,5-dimethyl-1,3-dioxol-2-one and 3.9 in allylic position using N-
bromosuccinimide gave the building blocks 3.10 and 3.11, which were used for the 
esterification with cilazapril according to Scheme 3.5 to yield the cilazapril prodrugs 3.12 
and 3.13. 
 
 
The morpholinoethyl ester of cilazapril (3.14) was prepared by Steglich esterifiaction of 
cilazapril with 4-(2-hydroxyethyl)morpholine in the presence of DCC as a coupling 
reagent and DMAP as an acylation catalyst (Scheme 3.6). 
 
 
  
Scheme 3.6. Synthesis of 3.14. Reagents and conditions: (i) 4-(2-hydroxyethyl)morpholine (1 eq), DCC (1.1 eq), 
DMAP, DCM/abs, 0 °C – rt overnight. 
Scheme 3.5. Preparation of building blocks 3.10, 3.11 and of cilazapril prodrugs 3.12, 3.13. Reagents and 
conditions: (i) NBS (1.1 eq), AIBN (0.05 eq), CCl4, reflux, 1 h; (ii) 3.10 or 3.11 (1.4 eq), K2CO3 (1.5 eq), DMF, 0 °C 
to rt, overnight. 
Scheme 3.4. Synthesis of 4-tert-butyl-5-methyl-1,3-dioxol-2-one 3.9. Reagents and conditions: (i) 1,2-
propanedithiol (1 eq), LiBF4 (0.1 eq), rt, overnight; (ii) n-BuLi (1.05 eq), THF/abs, -25 °C, 5 h, acetaldehyde 
(1.5 eq), -78 °C to rt, overnight; (iii) HgCl2 (2.5 eq), HgO (1.5 eq), MeOH/H2O (9/1 v/v), reflux, 5 h; (iv) DMAP 
(1.5 eq), triphosgene (0.75 eq), DCM, rt, 2 h, 160 °C, 4 h. 
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Scheme 3.7 depicts the synthesis of a basic double ester prodrug of cilazapril (3.18). 
Starting from 1-chloroethyl chloroformate, 3.15 was prepared by a reaction with chloro-
sulfuric acid and was subsequently used to introduce a 1-chloroethyl-carboxylate moiety 
by reaction with cilazapril leading to the cilazapril derivate 3.16.24 The desired 1-(2-
morpholinoacetoxy)ethyl ester 3.18 was finally obtained by a nucleophilic substitution 
reaction of 3.16 with 2-morpholinoacetic acid 3.1725, which was synthesized according to 
Scheme 3.7 from tert-butyl bromoacetate and morpholine followed by acidic cleavage of 
the tert-butyl ester. 
 
 
The preparation of N-aryl-N-alkyloxycarbonylaminomethyl derivatives of cilazapril (3.25-
3.27) is shown in Scheme 3.8. In the first step N-arylcarbamic acid alkyl esters (3.19-
3.21) were made by acylation of an aromatic amine with an alkyl chloroformate.26 
Subsequently, 3.19-3.21 were chloromethylated with paraformaldehyde and trimethylsilyl 
chloride yielding the pertinent N-aryl-N-alkyloxycarbonylaminomethyl chloride building 
blocks 3.22-3.24.26-27 Esterification of cilazapril with 3.22-3.24 under the afore-mentioned 
conditions (cf. synthesis of 3.1-3.3) led to the desired derivatives 3.25-3.27. 
The synthesis of a simple ethyl ester of cilazapril (3.28, Scheme 3.9) was achieved by a 
common esterification pathway with trimethylsilyl chloride and EtOH/abs serving as both 
reagent and solvent. 
Scheme 3.7. Synthesis of 3.18. Reagents and conditions: (i) ClSO3H (1.08 eq), 0 °C, 4 h; (ii) 3.15 (2 eq), 
NaHCO3 (3.9 eq), (n-Bu)4N(HSO4) (0.1 eq), DCM/H2O (1/1 v/v), reflux, 4 h, rt overnight; (iii) morpholine (1 eq), 
NEt3 (1eq), THF, 0 °C - reflux, 2 h; (iv) TFA (1.6 eq), DCM, 0 °C – rt, overnight; (v) 3.17 (2 eq), CsCO3 (4 eq), 
DMF, 40 °C, 7 h, rt overnight.
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The active principle of cilazapril, cilazaprilat (3.29), was prepared to be used as a 
standard for LC analysis. For this purpose, the ethyl ester moiety in cilazapril was 
cleaved by treatment with LiOH in methanol (Scheme 3.9). 
 
  
Scheme 3.9. Synthesis of cilazapril derivatives 3.28 and 3.29. Reagents and conditions: (i) TMSCl (2.2 eq), 
EtOH/abs, reflux, 4 h; (ii) LiOH (3 eq), MeOH, rt, 6 d. 
Scheme 3.8. Preparation of 3.25-3.27. Reagents and conditions: (i) NH2PhR1 (1 eq), ClCOOR2 (1 eq), NEt3
(1 eq), DCM, 0 °C to rt overnight; (ii) 3.22: paraformaldehyde (1.7 eq), TMSCl (13 eq), DCM, reflux, 2.5 h; 3.23, 
3.24: paraformaldehyde (1.1-1.7 eq), TMSCl (5-10 eq), 10 g anhydr. MgSO4, toluol, rt, 2.5 d; (iii) 3.25-3.27 (1.5-
1.8 eq), K2CO3 (1.8 eq), DMF, 0 °C to rt, overnight.
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3.3.2 Candesartan derivatives 
The synthesis of the desired candesartan derivatives was achieved by common 
esterification pathways. In contrast to cilazapril, the introduction of a chiral pro-moiety 
gives two enantiomers, which cannot be resolved under achiral chromatographic 
conditions. 
Scheme 3.10 summarizes the synthesis of 1-(alkyloxycarbonyloxy)ethyl, 1-(acyloxy)ethyl 
and (5-alkyl-2-oxo-1,3-dioxol-4-yl)methyl esters of candesartan (3.31-3.34). In order to 
avoid side reactions, the acidic tetrazole moiety of candesartan was masked by a 
reaction with trityl chloride to give the trityl protected intermediate 3.30. Esterification of 
3.30 with the pro-moieties 1-(isopropyloxycarbonyloxy)ethyl chloride, 3.05, 3.13 and 3.14 
under basic conditions in DMF yielded the trityl protected compounds 3.31a-3.34a, which 
were subsequently deprotected by treatment with aqueous hydrochloric acid in 
MeOH/THF to yield the candesartan prodrugs 3.31-3.34. 
 
 
  
Scheme 3.10. Synthesis of candesartan prodrugs 3.31-3.34. Reagents and conditions: (i) ClCPh3 (1.2 eq), NEt3
(1.2 eq), DCM, rt, 1 h; (ii) ClCHCH3OCOOiPr, 3.5 (1.5 eq), K2CO3 (1.5 eq), DMF, 0 °C to rt, overnight; (iii) 3.10, 
3.11 (1.5 eq), K2CO3 (1.5 eq), DMF, 0 °C to rt, overnight; (iv) aq. HCl, MeOH/THF, rt, 2-5 h. 
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The synthesis of candesartan morpholinoethyl ester (3.35) was performed by a Steglich 
esterification with DCC and DMAP (Scheme 3.11). 
 
 
In the following, various attempts to synthesize basic double esters (1-((alkylamino)oxy-
carbonyloxy)ethyl and 1-(morpholinylalkyloxycarbonyloxy)ethyl ester) of candesartan are 
described. Firstly, a 1-chloroethyl 2-morpholinoethyl carbonate (3.36) and a 1-chloroethyl 
2-(diethylamino)ethyl carbonate (3.37) were synthesized according to Scheme 3.12. 
 
 
Compounds 3.36 and 3.37 were only stable as hydrochlorides and decomposed when 
the nitrogen was deprotonated. Therefore, the nucleophilic substitution of 3.36 and 3.37 
with tritylated candesartan (3.31) under basic conditions was not successful (Scheme 
3.13). 
 
 
Scheme 3.13. Unsuccessful synthesis of basic double esters of candesartan. Reagents and conditions: (i) 3.36
(1 eq), K2CO3 (1.2 eq), DMF, 0 °C to rt, overnight; (ii) 3.37 (1.5 eq), K2CO3 (2.5 eq), DMF, 0 - 60 °C, 1.5 h.
Scheme 3.12. Synthesis of basic double ester building blocks 3.36 and 3.37. Reagents and conditions: (i) 4-(2-
hydroxyethyl)morpholine (1 eq), DCM/abs, 0 °C to rt, 2.5 h; (ii) 2-(diethylamino)ethanol (1 eq), DCM/abs, 0 °C to
rt, 2.5 h. 
Scheme 3.11. Synthesis of candesartan morpholinoethyl ester 3.35. Reagents and conditions: (i) 4-(2-hydroxy-
ethyl)morpholine (1 eq), DCC (1.1 eq), DMAP, DMF, 0 °C to rt, overnight.
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Similarly, the reaction with the carboxylate of candesartan, prepared by deprotonation 
with NaH, and an excess of 1-chloroethyl 2-(diethylamino)ethyl carbonate (3.37) 
according to Scheme 3.14 did not give the desired product 3.39. However, by ESI-mass 
spectrometry of the crude product, instead of the basic double ester (3.39, m/z 869), a 
pseudomolecular ion [M+H+] at m/z 783 was detected. This corresponds to compound 
3.40 which might have been formed by a conversion of the starting material involving 
elimination of CO2 (Scheme 3.14). 
 
 
In contrast to synthesis of the 1-(2-morpholinoacetoxy)ethyl ester of cilazapril (3.18) 
basic double esters of candesartan, such as 1-((alkylamino)oxycarbonyloxy)ethyl or 1-
(morpholinylalkyloxycarbonyloxy)ethyl esters, were not synthetically accessible in an 
analogous manner. Due to the above mentioned stability problems this approach was not 
pursued. 
  
Scheme 3.14. Unsuccessful synthesis of 3.39 and suggested structure (3.40) of the product analyzed by mass
spectrometry. Reagents and conditions: (i) NaH (1.2 eq), DMF, rt; (iii) 3.37 (1.5 eq), 50 °C, 1 h. 
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3.4 Physicochemical properties of cilazapril and candesartan prodrugs 
To overcome the main barrier of the skin, the stratum corneum, transdermal drugs 
delivered by passive diffusion must have appropriate physicochemical properties. The 
stratum corneum can be compared to a “brick and mortar” structure, where the “bricks” 
are composed of keratin-rich corneocytes, whereas multiple lipid bilayers of ceramides, 
fatty acids, cholesterol and cholesterol ester comprise the “mortar”. According to this 
model proposed by Barry28 the inter-
cellular space is not considered as a 
simple lipid barrier. The idea is that 
the “mortar” is rather composed of 
stacks of intercellular lipid bilayers 
with an aqueous phase in between 
(cf. Figure 3.3). Thus, for effective 
penetration of a compound across the 
stratum corneum, an optimized ba-
lance of lipid and water solubility is a 
prerequisite.29 Besides lipophilicity 
and solubility molecular size, melting 
point as well as hydrogen bonding are 
known to affect permeation.30 Pre-
vious studies revealed a characteristic parabolic relationship between skin permeability 
and lipophilicity of various drugs with maximum permeability at a log P of approximately 
3-4.31-32 Recently, Choy and Prausnitz concluded from the investigation of 17 FDA-
approved drugs for transdermal delivery that a modified and more stringent version of 
Lipinski’s Rule of Five (0 ≤ log P ≥ 5, molecular weight ≤ 335 Da, no. of H-bond donors 
≤ 2, no. of H-bond acceptors ≤ 5) should be applied to transdermal drugs.33 
In the following, predicted and experimentally determined physicochemical properties of 
the synthesized cilazapril and candesartan prodrugs as well as of the active principles 
cilazaprilat and candesartan will be discussed. 
In Table 3.2 physicochemical properties of cilazapril, cilazapril produgs and cilazaprilat 
are summarized. The molecular weights of all synthesized cilazapril prodrugs lay 
between approximately 446 and 667 Da. Thus, the modified Rule of Five of Choy and 
Prausnitz is not fulfilled in terms of molecular weight cut off. However, the molecular 
weight of the active principle cilazaprilat (~ 389 Da) is considerably lower. 
  
 
Figure 3.3. Simplified diagram depicting the structure of the 
stratum corneum and two routes for drug penetration. 
Reprinted from Barry28 with permission from Elsevier. 
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Table 3.2. Physicochemical properties of cilazapril, cilazapril prodrugs and cilazaprilat. The colored pKa values 
refer to the correspondingly colored (de-)protonizable moieties of the cilazapril core structure or the pro-moiety. 
 
 
 
      
compound 
R 
molecular 
weight 
Da 
log P calc.a log Poct/H2O exp.b 
log D5.5 
calc.c pKa calc.
d pKa exp.e 
cilazapril H 417.50 2.21 ± 0.56 0.22 ± 0.03 -0.08 5.55 3.88 
2.28 
6.33 ± 0.01
 
3.45 ± 0.02
3.1 
 
533.61 3.10 ± 0.62 -0.38 ± 0.03 2.94 5.24 2.03 
3.28 ± 0.07
 
3.2  587.70 4.57 ± 0.62 2.70 ± 0.07 4.40 5.24 
2.03 
4.28 ± 0.06
 
3.3  547.64 3.46 ± 0.62 n.d. 3.29 5.24 
2.03 n.d. 
3.6  503.59 2.54 ± 0.63 n.d. 2.37 5.24 
2.06 n.d. 
3.7  545.67 3.81 ± 0.63 n.d. 3.65 5.24 
2.04 
n.d. 
3.12  529.58 2.03 ± 0.58 n.d. 1.86 5.26 
2.16 n.d. 
3.13 
 
571.66 3.31 ± 0.58 n.d. 3.13 5.26 
2.16 n.d. 
3.14  530.66 1.94 ± 0.61 1.07 ± 0.02 1.18 
5.94 
5.25 
2.10 
5.49 ± 0.07
4.51 ± 0.05
 
3.18  588.69 1.89 ± 0.66 n.d. 1.68 
5.24 
4.49 
2.02 
n.d. 
3.25 
 
594.70 3.47 ± 0.82 n.d. 3.30 
5.25 
2.12 
-0.37 
n.d. 
3.26 
 
666.76 4.17 ± 0.83 n.d. 4.00 
5.25 
2.12 
-2.92 
n.d. 
3.27 
 
652.73 3.66 ± 0.83 n.d. 3.49 
5.25 
2.12 
-2.94 
n.d. 
3.28 CH2CH3 445.56 2.98 ± 0.56 n.d. 2.81 
5.28 
2.30 n.d. 
cilazaprilat 
(3.29) 
 
389.45 2.68 ± 0.58 n.d. -0.72 
8.62 
3.96 
2.52 
2.13 
n.d. 
a log P values calculated by ACD/PhysChem Suite 12.00 (Advanced Chemistry Development Inc., Toronto, Canada), b 
octanol/water partition coefficient - experimentally determined by potentiometric titration34, performed by Across Barriers GmbH 
(Saarbrücken, Germany) and provided by HEXAL AG, c calculated log D values at pH 5.5 by ACD/PhysChem Suite 12.00, d pKa 
values calculated with ACD/PhysChem Suite 12.00, e pKa values, experimentally determined by potentiometric titration35, 
performed by Across Barriers GmbH and provided by HEXAL AG. 
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All calculated log P values are below 5, namely between 1.89 (3.18) and 4.57 (3.2), 
ranking the prodrugs as well as cilazapril and cilazaprilat moderately lipophilic. Given that 
the log P value fails to take into account variations of the lipophilicity with respect to the 
ionic state of a drug at a given pH, it is more reasonable to use the distribution coefficient 
log D, which refers to a pH-dependent mixture of all charged and uncharged species 
present at that pH.36-37 For permeation through the stratum corneum calculation of the 
log D at skin pH (log D5.5) is most interesting. At pH 5.5 the mono- and dicarboxylic acids 
cilazapril and cilazaprilat are fully deprotonated resulting in a difference between calcu-
lated log D5.5 and log P values in the range of two to three log units. Regarding the 
prodrugs, lowest log D5.5 values are calculated for compounds 3.14 and 3.18 due to their 
ionizable morpholine moiety. In the case of cilazapril, 3.2 and 3.14 the experimentally 
determined octanol/water partition coefficients and the calculated values are comparable 
by trend. Regarding the experimentally determined log Poct/H2O values, cilazapril is found 
to be the least lipophilic compound followed by 3.14, whereas 3.2 is the most lipophilic 
one due to the very unpolar cyclohexyl residue. The log Poct/H2O of 3.1 appears to be 
remarkably low. For accurate determination of log Poct/H2O using the potentiometric 
method the substance should have high purity, sufficient solubility as well as stability in 
the titration media (report discussion, Across Barriers GmbH). As the 1-(ethoxycarbonyl-
oxy)ethyl prodrug moiety of 3.1 is known to be prone to hydrolysis in aqueous media, the 
determined log Poct/H2O may have been affected by the presence of a defined amount of 
cilazapril, resulting in a lower log Poct/H2O value. In summary, the synthesized cilazapril 
prodrugs seem to be suitable in terms of lipophilicity for adequate transdermal 
permeation. In particular, prodrugs 3.14 and 3.18 appear to be promising candidates due 
to their ionizable morpholine moiety providing balanced lipophilicity and water solubility. 
Dissociation constants were determined by means of potentiometric titration using 
methanol as a co-solvent. For cilazapril two pKa values were obtained referring to the 
secondary amine and the carboxylic acid (6.33 and 3.45, respectively). For 3.1 and 3.2 
the pKa values of the secondary amine amounted to 3.28 and 4.28, respectively. Prodrug 
3.14 showed an additional pKa referring to the morpholine group (5.49). The experi-
mental data are roughly in agreement with the calculated values. 
 
Table 3.3 summarizes the calculated and experimentally determined physicochemical 
properties of candesartan and candesartan prodrugs. Comparable to the cilazapril pro-
drugs the molecular weights of all candesartan prodrugs range from approx. 553 Da to 
611 Da. Likewise the active principle candesartan (440.45 Da) does not fulfill the modi-
fied Rule of Five molecular weight criterion of Choy and Prausnitz. 
The calculated partition coefficients indicate a high lipophilicity of candesartan and all 
candesartan prodrugs. Due to the ionizable groups (tetrazole, benzimidazole, carboxylic 
acid, morpholine) the calculated log D5.5 values are markedly lower. Candesartan and the 
morpholinoethyl ester prodrug (3.35) show the lowest distribution coefficients with 
log D5.5 values of 1.41 and 2.17, respectively. Strikingly, the experimentally determined 
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log Poct/H2O values turned out to be two to four log-units lower than the calculated ones, 
ranging from approx. 2.4 – 3.6. Compared to log Poct/H2O exp. values of the cilazapril pro-
drugs the candesartan prodrugs show a higher lipophilicity, but may be well suited for 
adequate skin permeation. 
Two dissociation constants were obtained by means of potentiometric titration for the 
candesartan prodrugs 3.31, 3.32 and 3.33 referring to the benzimidazole and the tetra-
zole group. An additional pKa value was determined for 3.35 referring to the morpholine 
residue. All experimentally determined pKa values are in good correlation with the 
calculated ones. 
Table 3.3. Physicochemical properties of candesartan and candesartan prodrugs. The colored pKa values refer to 
the correspondingly colored (de-)protonizable moieties of the cilazapril core structure or the pro-moiety. 
 
 
 
      
compound 
R 
molecular 
weight 
Da 
log P calc.a log Poct/H2O exp.b 
log D5.5 
calc.c pKa calc.
d pKa exp.e 
candesartan H 440.45 4.65 ± 0.84 2.80 1.41 
5.60 
4.15 
2.06 
0.60 
n.d. 
3.31 
 
570.60 6.10 ± 0.90 3.34 ± 0.07 4.83 
4.16 
3.95 
0.60 
4.65 ± 0.01
4.21 ± 0.06
 
3.32 
 
568.62 6.75 ± 0.91 3.56 ± 0.06 5.47 
4.16 
3.95 
0.60 
4.60 
4.50 
 
3.33 
 
552.54 4.67 ± 0.85 2.41 ± 0.16 3.39 
4.16 
4.08 
0.60 
4.49 ± 0.02
3.51 ± 0.06
 
3.34 
 
594.62 5.94 ± 0.86 n.d. 4.67 
4.16 
4.08 
0.60 
n.d. 
3.35 
 
553.61 3.92 ± 0.90 3.45 ± 0.28 2.17 
5.89 
4.16 
4.02 
0.60 
6.52 
6.44 
4.86 
 
candesartan 
cilexetil 
 
610.66 7.21 ± 0.90 3.10 5.94 
4.16 
3.94 
0.60 
n.d. 
a log P values calculated by ACD/PhysChem Suite 12.00 (Advanced Chemistry Development Inc., Toronto, Canada),  
b octanol/water partition coefficient - experimentally determined by potentiometric titration34, performed by Across Barriers GmbH 
(Saarbrücken, Germany) and provided by HEXAL AG, c calculated log D values at pH 5.5 by ACD/PhysChem Suite 12.00, d pKa 
values calculated with ACD/PhysChem Suite 12.00, e pKa values, experimentally determined by potentiometric titration35, 
performed by Across Barriers GmbH and provided by HEXAL AG. 
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3.5 Bioanalytical studies of candesartan and cilazapril prodrugs 
The stability of a drug is a crucial aspect in drug development. It is indispensible to 
investigate the influence of various storage conditions as well as the stability of the drug 
in the respective formulation. With respect to prodrugs designed for transdermal appli-
cation stability as high as possible in the solid state as well as in the TTS-matrix is 
desired. Furthermore, after release and transdermal absorption the prodrug should be 
rapidly converted to the active principle. Ester pro-moieties are usually cleaved enzymati-
cally, but spontaneous non-enzymatic (“chemical”) hydrolysis should also be taken into 
consideration. Hence, the stability of the synthesized candesartan and cilazapril prodrug 
candidates in aqueous buffer solution as well as in the presence of various enzymes was 
analyzed by means of high performance liquid chromatography (HPLC) in a time-
dependent manner. Furthermore, the half-life of hydrolysis (t1/2) was determined and pro-
ducts of hydrolysis or degradation were identified by liquid chromatography coupled to 
tandem mass spectrometry (LC-MS). For the investigation of spontaneous “chemical” 
hydrolysis sodium phosphate buffer was used; enzymatic hydrolysis was studied by 
incubation of the compounds with porcine liver esterase, human CPD plasma and por-
cine skin homogenate, respectively. Moreover, the metabolic stability of the substances 
in the presence of cultured primary human hepatocytes (PHH) was investigated. 
Generally, the half-life (t1/2) of enzymatic hydrolysis is determined under substrate 
saturation conditions, assuming pseudo first-order kinetics. Under these conditions t1/2 is 
independent from the substrate concentration but still influenced by other factors such as 
the composition of the incubation medium and temperature. For spontaneous hydrolysis 
in buffer, the assumption of pseudo first-order kinetics is also valid, as the reactant water 
is present at high excess (approx. 55 M) and its concentration remains almost un-
changed. In these simplified cases t1/2 can be determined according to Equation 3.1. The 
slope k can be calculated by linear regression analysis of the half-logarithmic plot of the 
percental peak area of residual prodrug (determined by HPLC) versus incubation time. 
tଵ ଶൗ ൌ
lnሺ2ሻ
k  
Equation 3.1. Relationship between rate constant k and half-life t1/2 of hydrolysis. 
In cases where more than one step is involved in the formation of the active principle 
(AP), f50% values proved to be more useful and informative than the half-life t1/2. The f50% 
value represents the time at which 50 % of the drug (AP) have been formed.38 According 
to Equation 3.1, f50% values were determined from the slopes (k) of linear plots of the 
logarithm of the amount of active principle to be formed (APx, calculated according to 
Equation 3.2) against incubation time.39 
lnሺAP୶ሻ ൌ ln ሺ100 െ AP୲౟ሻ 
Equation 3.2. Calculation of ln(APx). APti = percentage of active principle after a distinct incubation period. 
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3.5.1 Solid state stability of candesartan and cilazapril prodrugs 
3.5.1.1 Solid state stability of candesartan prodrugs 
To investigate the stability of the candesartan prodrugs in solid state, the compounds 
were stored under defined conditions at different temperature and humidity (rel. h). After 
a certain period of time the compounds were analyzed by HPLC. The percentage of 
residual prodrug and degradation products like candesartan or unknown decomposition 
products were determined from the respective peak areas using the 100 % method. 
Table 3.4 summarizes the solid state stability data of candesartan cilexetil, 3.31, 3.32 
and 3.35. Over a storage period of ten months the double ester prodrugs 3.31 and 3.32 
turned out to be sufficiently stable at 5 °C/65 % rel. h. as well as at 25 °C/60 % rel. h. 
Only small amounts of unidentified degradation products were detected. Under accele-
rated storage conditions (40 °C/75 % rel. h.) 3.31 remained relatively stable, whereas 
3.32 was considerably decomposed, indicated by an increase in decomposition products 
of unknown structure to 17 %. By contrast, candesartan cilexetil and the morpholinoethyl 
ester 3.35 showed excellent stability under all storage conditions applied. 
Table 3.4. Stabilitya of candesartan prodrugs stored at different temperature and humidity. 
No. 
t0 
(%)b 
prodrug (%) candesartan (%) decomposition products (%) 
5 °C/ 
65 % rel. h. 
25 °C/ 
60 % rel. h. 
40 °C/ 
75 % rel. h.
5 °C/ 
65 % rel. h.
25 °C/ 
60 % rel. h.
40 °C/ 
75 % rel. h.
5 °C/ 
65 % rel. h. 
25 °C/ 
60 % rel. h. 
40 °C/ 
75 % rel. h.
CAN-
CILc, d 100 n.d. 100 100 n.d. 0 0 n.d. 0 0 
3.31 100 99 99 98 0 0 0 1 1 2 
3.32 100 99 98 83 0 0 0 1 2 17 
3.35 100 100 100 100 0 0 0 0 0 0 
a 6 months stability (CAN-CIL), 10 month stability (3.31, 3.32, 3.35), b percentage of compound at the beginning of storage. c 
CAN-CIL = candesartan cilexetil, D data provided by HEXAL AG. 
In Table 3.5 the results for the analysis of prodrug 3.33 after storage for six and 16 
months, respectively, are summarized. The (oxodioxolyl)methyl moiety seems to be high-
ly prone to degradation processes at high temperature or humidity. Storage under acele-
rated storage conditions resulted in a complete degradation of the compound after 16 
months and even at low temperature (5 °C/65 % rel. h.) the compound showed poor 
stability.  
Table 3.5. HPLC analysis of compound 3.33 after storage of 6 and 16 months, respectively at different 
temperature and humidity. 
No. t0 (%)a 
prodrug (%) 
6 months/16 months 
candesartan (%) 
6 months/16 months 
decomposition products (%) 
6 months/16 months 
5 °C/ 
65 % rel. h. 
25 °C/ 
60 % rel. h. 
40 °C/ 
75 % rel. h.
5 °C/ 
65 % rel. h.
25 °C/ 
60 % rel. h.
40 °C/ 
75 % rel. h.
5 °C/ 
65 % rel. h. 
25 °C/ 
60 % rel. h. 
40 °C/ 
75 % rel. h.
3.33 86 77 / 73 63 / 41 39 / 0 0 / 0 1 / 1 10 / 37 23 / 27 36 / 58 51 / 63 
a percentage of compound existing at the beginning of storage. 
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3.5.1.2 Solid state stability of cilazapril prodrugs 
The solid state stability of a selection of cilazapril prodrugs was determined according to 
the procedure described in chapter 3.5.1.1. Table 3.6 to Table 3.8 summarize the 
resulting stability data at 5 °C/65 % rel. h., 25 °C/60 % rel. h. and 40 °C/75 % rel. h., 
respectively. Beside cilazapril and cilazaprilat a corresponding degradation product of 
each prodrug was detected resulting from the loss of the ethyl ester of the homophenyl-
alanine substructure, while the introduced pro-moiety remains intact (cf. Scheme 3.15). 
 
Scheme 3.15. Possible pathways for the hydrolysis of cilazapril prodrugs. Pathway a refers to the loss of the ethyl 
ester of the homophenylalanine substructure resulting in the formation of the corresponding degredation prodrugs 
“3.x – EtOH”. Pathway b describes the loss of the pro-moiety, which leads to the formation of cilazapril. 
Cilazaprilat results from the cleavage of both ester groups (a + b). 
At 5 °C/65 % rel. h. hardly any degradation of all analyzed cilazapril derivatives was 
observed over a storage period of 16 months. Only the analysis of the double ester 
prodrugs 3.1 and 3.6 revealed small amounts of cilazapril. 
Table 3.6. Solid state stability of a selection of cilazapril prodrugs stored at 5 °C/65 % rel. h. for and 16 months. 
No. t0 (%)a 
prodrug (%) 
6 months/16 months 
cilazapril (%) 
6 months/16 months 
cilazaprilat (%) 
6 months/16 months 
“3.x – EtOH” (%)b 
6 months/16 months 
3.1 100 100 / 98 0 / 2 0 / 0 0 / 0 
3.2 100 100 / 100 0 / 0 0 / 0 0 / 0 
3.3 100 100 / 100 0 / 0 0 / 0 0 / 0 
3.6 100 100 / 97 0 / 3 0 / 0 0 / 0 
3.7 100 100 / 100 0 / 0 0 / 0 0 / 0 
3.14 100 100 / 100 0 / 0 0 / 0 0 / 0 
3.28 100 100 / 100 0 / 0 0 / 0 0 / 0 
a percentage of compound at the beginning of storage. b 3.x refers to the corresponding parent compound. Compounds “3.x –
 EtOH” result from the loss of the ethyl ester of the homophenylalanine substructure. (cf. Scheme 3.15). 
At 25 °C/60 % rel. h. a relationship between the structure of the pro-moiety and stability 
becomes obvious. The stability of the double ester prodrugs 3.1 – 3.3, 3.6 and 3.7 in-
creased with the steric demand of the alkyl side chain. Thus, 3.2 and 3.7 carrying a 
cyclohexyl and a tert-butyl side chain, respectively, turned out to be most stable, where-
as 3.6 with a methyl residue appeared to be most labile. The surprisingly clear difference 
between the very stable ethyl ester 3.28 and the rather labile morpholinoethyl ester 3.14 
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gives rise to the speculation about a catalytic effect of the morpholino group accelerating 
the degradation. 
Under accelerated storage conditions at 40 °C/75 % rel. h. complete degradation of com-
pounds 3.6 and 3.14 occurred within 16 months. Even of the most stable prodrug of this 
series, compound 3.2, only 28 % remained unchanged. In general, the stability of all 
analyzed cilazapril prodrugs, except for 3.28, under accelerated storage conditions 
turned out to be insufficient with respect to the development of a TTS. Strikingly, the 
ethyl ester of the homophenylalanine moiety in 3.28 appeared to be highly stable. How-
ever, the combination with a more labile prodrug moiety seems to affect the stability of 
the homophenylalanine ethyl ester group as well, giving rise to the assumption that as 
soon as the introduced prodrug ester is cleaved to cilazapril, the ethyl ester also 
becomes prone to hydrolysis yielding cilazaprilat. It is noteworthy that, regardless of the 
storage conditions and periods, no diketopiperazine degradation products were detected. 
Table 3.7. Six and 16 months solid state stability of a selection of cilazapril prodrugs stored at 25 °C/ 60 % rel. h. 
No. t0 (%)a 
prodrug (%) 
6 months/16 months 
cilazapril (%) 
6 months/16 months 
cilazaprilat (%) 
6 months/16 months 
“3.x – EtOH” (%)b 
6 months/16 months 
3.1 100 98 / 89 2 / 7 0 / 0 0 / 4 
3.2 100 100 / 98 0 / 2 0 / 0 0 / 0 
3.3 100 99 / 96 1 / 4 0 / 0 0 / 0 
3.6 100 93 / 34 7 / 41 0 / 18 0 / 7 
3.7 100 100 / 97 0 / 3 0 / 0 0 / 0 
3.14 100 96 / 70 3 / 25 0 / 3 0 / 2 
3.28 100 100 / 100 0 / 0 0 / 0 0 / 0 
a percentage of compound at the beginning of storage. b 3.x refers to the corresponding parent compound. Compounds “3.x –
 EtOH” result from the loss of the ethyl ester of the homophenylalanine substructure. (cf. Scheme 3.15). 
Table 3.8. Six and 16 months solid state stability of a selection of cilazapril prodrugs stored at 40 °C/ 75 % rel. h. 
a percentage of compound at the beginning of storage. b 3.x refers to the corresponding parent compound. Compounds “3.x –
 EtOH” result from the loss of the ethyl ester of the homophenylalanine substructure. (cf. Scheme 3.15). 
  
No. t0 (%)a 
prodrug (%) 
6 months/16 months 
cilazapril (%) 
6 months/16 months 
cilazaprilat (%) 
6 months/16 months 
“3.x – EtOH” (%)b 
6 months/16 months 
3.1 100 82 / 6 9 / 9 3 / 68 6 / 17 
3.2 100 96 / 28 4 / 15 0 / 38 0 / 19 
3.3 100 91 / 14 6 / 12 0 / 52 3 / 22 
3.6 100 9 / 0 40 / 0 45 / 92 6 / 8 
3.7 100 92 / 10 5 / 10 0 / 59 3 / 21 
3.14 100 38 / 0 42 / 0 16 / 100 4 / 0 
3.28 100 100 / 91 0 / 9 0 / 0 0 / 0 
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3.5.2 Stability of prodrugs of candesartan and cilazapril in buffer 
The rates of “chemical” (non-enzymatic) hydrolysis of prodrugs of candesartan and 
cilazapril were determined in sodium phosphate buffer (0.1 M, pH 7.4) at 37 °C. At 
appropriate intervals samples of the prodrug containing incubation mixture were taken 
and analyzed by HPLC. 
3.5.2.1 Spontaneous hydrolysis of candesartan prodrugs 
Candesartan cilexetil turned out to be very stable against hydrolysis in buffer. Only about 
4 % of the cleavage product candesartan were detected after an incubation period of 
72 h (Figure 3.4), corresponding to a half-life t1/2 of the prodrug of 57.7 d. 
Compared to the cilexetil pro-moiety the less bulky 1-(isopropyloxycarbonyloxy)ethyl resi-
due in 3.31 proved to be less stable; a half life t1/2 of 13.8 d was calculated (Figure 3.5). 
Figure 3.5. Kinetics of hydro-
lysis of 3.31 in 0.1 M phosphate 
buffer, pH 7.4, CAN = cande-
sartan. 
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Figure 3.4. Kinetics of hydro-
lysis of candesartan cilexetil in 
0.1 M phosphate buffer, pH 7.4. 
CAN-CIL = candesartan cilexe-
til, CAN = candesartan. 
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The kinetics of hydrolysis of candesartan 1-(2,2-dimethylpropanoyl)ethyl ester 3.32 is 
shown in Figure 3.6. The half-life was estimated to be 32.5 d, corresponding to a stability 
between those of candesartan cilexetil and 3.31. 
Figure 3.6. Kinetics of hydroly-
sis of 3.32 in phosphate buffer, 
CAN = candesartan. 
Compared to the 1-(alkyloxycarbonyloxy)ethyl and 1-(acyloxy)ethyl prodrugs of 
candesartan the (5-alkyl-2-oxo-1,3-dioxol-4-yl)methyl esters 3.33 and 3.34 were 
relatively unstable in buffer (t1/2 = 2.3 h and 14.2 h, respectively) (cf. Figure 3.7 and 
Figure 3.8). In general, the (oxodioxolyl)methyl moiety seems to be very prone to 
spontaneous hydrolysis. Interestingly, the exchange of the 5-methyl residue against a 
sterically more demanding tert-butyl group leads to a six-fold gain in stability. 
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Figure 3.7. Examples of 
HPLC chromatograms illus-
trating the kinetics of hydro-
lysis of 3.33 in phosphate 
buffer, CAN = candesartan. 
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Figure 3.8. Kinetics of hydro-
lysis of 3.34 in phosphate buffer 
0.1 M, pH 7.4, CAN = cande-
sartan. 
The morpholinoethyl ester 3.35 was reasonably stable in buffer (Figure 3.9). Its half-life 
of hydrolysis amounted to 6.1 d. In contrast to all other candesartan prodrugs, 3.35 is 
eluted before candesartan, as the morpholino group is protonated in the presence of the 
acidic HPLC eluent. 
Figure 3.9. Examples of HPLC 
chromatograms illustrating the 
kinetics of hydrolysis of 3.35 in 
phosphate buffer, CAN = cande-
sartan. 
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3.5.2.2 Spontaneous hydrolysis of cilazapril prodrugs 
As cilazapril containing a hydrolysable ethyl ester pro-moiety is a prodrug itself, its life-
time in aqueous solution at pH 7.4 is limited. About 16 % of cilazaprilat (3.29) were 
detected after an incubation period of 48.1 h (Figure 3.10). A half-life of 183 h was 
estimated. 
Figure 3.10. Examples of 
HPLC chromatograms illus-
trating the kinetics of hydrolysis 
of cilazapril (CIL) in 0.1 M 
phosphate buffer, pH 7.4. 
The t1/2 values of the cilazapril 1-(alkyloxycarbonyloxy)ethyl esters 3.1-3.3 were found to 
correlate with the steric demand of the 1-(alkyloxycarbonyloxy)ethyl pro-moiety. Both 
prodrug esters 3.1 and 3.3 were partially hydrolyzed to cilazapril during an incubation 
period of about 72 h (cf. appendix, Figure 9.1, Figure 9.2). Whereas t1/2 of the 1-(iso-
propyloxycarbonyloxy)ethyl ester 3.3 only slightly increased (t1/2 = 75.7 h) compared to 
the 1-(ethoxycarbonyloxy)ethyl ester 3.1 (t1/2 = 75.0 h), the bulky 1-(cyclohexyloxycarbo-
nyloxy)ethyl ester 3.2 was found to be totally stable over a period of 71.3 h (Figure 3.11). 
Figure 3.11. Kinetics of hy-
drolysis of 3.2 (two diastereo-
mers) in phosphate buffer. 
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An analogous behavior was observed for the cilazapril 1-(acyloxy)ethyl esters 3.6 and 
3.7. Again, the bulkier pro-moiety, the 1-(2,2-dimethylpropanoyl)ethyl residue in 3.7, 
conferred higher stability. No degradation of 3.7 was observed within 72 h (cf. appendix, 
Figure 9.3), whilst 3.6 was found to be considerably less stable (t1/2 = 40.3 h). Hence, the 
degradation products cilazapril as well as cilazaprilat (3.29) was detected (Figure 3.12). 
Figure 3.12. Kinetics of hydro-
lysis of 3.6 (two diastereomers) 
in phosphate buffer, CIL = cila-
zapril. 
The (5-alkyl-2-oxo-1,3-dioxol-4-yl)methyl esters of cilazapril (3.12 and 3.13) showed a si-
milar behavior as the analogous derivatives of candesartan (3.33 and 3.34). Both pro-
drugs were rapidly hydrolyzed to give cilazapril and cilazaprilat (3.29) (cf. Figure 3.13 
and Figure 3.14). The half-life amounted to 3.7 h (3.12) and 7.1 h (3.13), respectively, 
indicating that an exchange of the 5-methyl against the 5-tert-butyl residue improves 
stability. 
Figure 3.13. Examples of HPLC 
chromatograms showing the ki-
netics of hydrolysis of 3.12 in 
phosphate buffer, CIL = cilazapril. 
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Figure 3.14. Kinetics of hydro-
lysis of 3.13 in phosphate buffer, 
CIL = cilazapril. 
The morpholinoethyl ester 3.14 was found to be only moderately stable in buffer 
(t1/2 = 14.0 h) (cf. Figure 3.15). Cilazapril as well as cilazaprilat (3.29) were detected as 
products of hydrolysis. 
Figure 3.15. Examples of HPLC 
chromatograms showing the ki-
netics of hydrolysis of 3.14 in 
phosphate buffer, CIL = 
cilazapril. 
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The kinetics of hydrolysis of the cilazapril 1-(2-morpholinoacetoxy)ethyl ester 3.18 
(Figure 3.16) was very similar to that of 3.14, but, with a determined t1/2 of 18.6 h, 3.18 
was slightly more stable. 
Figure 3.16. Kinetics of 
hydrolysis of 3.18 (two diaste-
reomers) in phosphate buffer, 
CIL = cilazapril. 
From the small set of N-aryl-N-alkyloxycarbonylaminomethyl prodrugs (3.25-3.27) only 
3.25 was suitable for the determination of half-lives in buffer at pH 7.4, whereas 3.26 and 
3.27 turned out to be insufficiently soluble in the incubation buffer. Hence, in case of the 
latter two compounds, the resulting peak areas in the HPLC chromatograms were too 
small for reliablequantification. Prodrug 3.25 was degraded to an extent of 97 % in the 
course of the incubation (cf. Figure 3.17). Its half-life amounted to approximately 12 h. 
While the peak corresponding to 3.25 decreased with increasing ti, two peaks were in-
creasing simultaneously. Besides cilazapril at tR = 9.4 min the peak at tR = 13.9 min was 
identified by LC-MS as ethyl phenylcarbamate, a substructure of the degraded pro-
moiety. 
Figure 3.17. Kinetics of 
hydrolysis of 3.25 in phosphate 
buffer, CIL = cilazapril, EPC = 
ethyl phenylcarbamate. 
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The simple diethyl ester 3.28 turned out to be the most stable cilazapril prodrug (cf. 
Figure 3.18). With a half-life of 16.8 d it was even more stable against non-enzymatic 
hydrolysis than cilazapril itself, supporting the assumption that a free carboxylic acid 
group at the heterocyclic system renders the homophenylalanine ethyl ester more 
susceptible to hydrolysis. 
Figure 3.18. Kinetics of hydro-
lysis of 3.28 in phosphate 
buffer. 
 
3.5.3 Stability of prodrugs of candesartan and cilazapril against enzy-
matic hydrolysis 
The carrier pro-moiety of all designed cilazapril and candesartan prodrugs is ester-based 
and can therefore be cleaved by hydrolysis or oxidation, typically by esterases or 
cytochrome P450 enzymes. In order to investigate the stability of the prodrugs three 
different enzyme-containing test systems as well as cultured primary human hepatocytes 
(PHH) were used. 
As the synthesized prodrugs should be applicable as transdermal patches, the 
investigation of their potential hydrolysis in skin is self-evident. It is known that phase I 
and phase II metabolic reactions can take place in human skin.40 The metabolizing 
enzymes, in particular carboxylesterases and cytochrome P450 enzymes4, are mainly 
located within the viable epidermis.40 Since porcine skin is much easier accessible than 
human skin and shows similarities to the human tissue in terms of distribution and 
enzyme-activity41, a homogenate of fresh porcine skin in PBS was prepared and used for 
metabolic studies. 
Another well-established model for studies on enzymatic hydrolysis is human plasma. It 
contains cholinesterase, acetylcholinesterase and paraoxonase activity.4 For following 
studies human CPD plasma was used. As the third enzyme-containing test system a 
carboxylesterase was considered. Due to its comparably high activity and its low price 
porcine liver esterase was chosen and used as dilution in phosphate buffer at pH 7.4. 
0 5 10 15 20 25 30 35 40
-0.3
-0.2
-0.1
-0.0
0.1
0.2
0.3
0.4
0.5
t i[
h]
48.03
blank
0.92
3.00
72.00
23.18
5.98
retention time [min]
ab
so
rb
an
ce
 [m
AU
] 3.28
 Prodrugs of Candesartan and Cilazapril 49 
Furthermore, the capability of cultured primary human hepatocytes to metabolize the 
ester prodrugs should be investigated. 
The rates of hydrolysis for each prodrug in the respective enzyme-containing incubation 
mixture were determined at 37 °C according to the procedure described in section 3.5.2, 
but, additionally, the samples were deproteinated by addition of ice cold acetonitrile and 
centrifuged prior to HPLC analysis. 
For the investigation of hydrolysis by human liver cells, exemplary substances were 
incubated at 37 °C with cultured PHH, which were plated on multi-well plates. After an 
incubation period of one and six hours, respectively, samples were taken, deproteinated, 
centrifuged and analyzed by HPLC. 
3.5.3.1 Enzymatic hydrolysis of candesartan prodrugs 
Candesartan cilexetil was selectively hydrolyzed to candesartan on incubation with 
porcine skin homogenate, human plasma and porcine liver esterase (cf. Figure 3.19-
Figure 3.21). The half-lives in porcine skin homogenate and human plasma amounted to 
0.27 h and 35.0 h, respectively. Due to the high volume activity of porcine liver esterase 
used the hydrolysis of candesartan cilexetil was very fast. Thus, t1/2 could not be 
calculated, but was estimated to be < 3 min. 
Figure 3.19. Examples of 
chromatograms showing the 
kinetics of hydrolysis of 
candesartan cilexetil (CAN-
CIL) in the presence of porcine 
skin homogenate, CAN = can-
desartan. 
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Figure 3.20. Kinetics of hydro-
lysis of candesartan cilexetil 
(CAN-CIL) in the presence of 
human plasma, CAN = cande-
sartan. 
 
Figure 3.21. Examples of chro-
matograms showing the kinetics 
of hydrolysis of candesartan 
cilexetil (CAN-CIL) in the pre-
sence of porcine liver esterase, 
CAN = candesartan. 
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Candesartan 1-(isopropyloxycarbonyloxy)ethyl ester (3.31) was also selectively hydro-
lyzed to candesartan in all three incubation media. In the presence of porcine skin homo-
genate (Figure 3.22) and porcine liver esterase (Figure 3.23) the hydrolysis proceeded 
quantitatively with half-life times of 8 min and 6 min, respectively. When incubated with 
human plasma (Figure 3.24) a t1/2 of 47.5 h was calculated. 
Figure 3.22. Examples of 
HPLC chromatograms showing 
the kinetics of hydrolysis of 
3.31 in the presence of porcine 
skin homogenate, CAN = can-
desartan. 
 
Figure 3.23. Examples of HPLC 
chromatograms illustrating the 
kinetics of hydrolysis of 3.31 in 
the presence of porcine liver 
esterase, CAN = candesartan. 
Incubation of 3.31 with primary human hepatocytes revealed that human liver cells are 
also capable of hydrolyzing the ester pro-moiety. After an incubation period of one hour 
47 % of the prodrug was converted to candesartan, whereas after six hours the 
hydrolysis was quantitative (data not shown). 
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Figure 3.24. Kinetics of hydro-
lysis of 3.31 in the presence of 
human plasma, CAN = cande-
sartan. 
 
The results of the enzymatic hydrolysis of candesartan 1-(2,2-dimethylpropanoyl)ethyl 
ester (3.32) are similar to those for candesartan cilexetil and 3.31. 3.32 was also 
exclusively converted to candesartan in each of the used incubation media resulting in 
the following half-lives (t1/2): 0.45 h (porcine skin homogenate (Figure 3.25)), 32.2 h 
(human plasma (Figure 3.26)) and 2 min (porcine liver esterase (Figure 3.27)). 
Figure 3.25. Examples of HPLC 
chromatograms showing the ki-
netics of hydrolysis of 3.32 in 
the presence of porcine skin ho-
mogenate, CAN = candesartan. 
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Figure 3.26. Examples of HPLC 
chromatograms illustrating the 
kinetics of hydrolysis of 3.32 in 
the presence of human plasma, 
CAN = candesartan. 
 
Figure 3.27. Examples of 
chromatograms showing the 
kinetics of hydrolysis of 3.32 in 
the presence of porcine liver 
esterase, CAN = candesartan. 
 
Incubation of 3.32 with primary human hepatocytes for one hour resulted in the formation 
of 22 % candesartan. After an incubation period of six hours 72 % candesartan were 
detected (data not shown). 
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The kinetics of enzymatic hydrolysis of candesartan (5-methyl-2-oxo-1,3-dioxol-4-yl)-
methyl ester (3.33) by porcine skin homogenate, human plasma and porcine liver ester-
ase are shown in Figure 3.28 to Figure 3.30. In all cases candesartan was detected as 
the exclusive product of hydrolysis. For the hydrolysis by porcine liver esterase a t1/2 of 
2.2 h was estimated, which nearly equals the value found for the chemical hydrolysis of 
3.33 in buffer (2.3 h). Hence, the parent compound 3.33 seems to be no or only a poor 
substrate for the carboxylesterase from porcine liver. The generation of candesartan is 
therefore supposed to take place - at least in part - by spontaneous non-enzymatic 
hydrolysis. 
Figure 3.28. Kinetics of hy-
drolysis of 3.33 in the pre-
sence of porcine liver este-
rase, CAN = candesartan. 
However, the hydrolysis in porcine skin homogenate was found to be faster (t1/2 = 0.95 h) 
leading to the conclusion that the (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester pro-moiety 
was slightly better accepted as a substrate by esterases present in porcine skin 
homogenate. 
Figure 3.29. Examples of 
HPLC chromatograms show-
ing the kinetics of hydrolysis 
of 3.33 in porcine skin homo-
genate, CAN = candesartan. 
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The degradation of 3.33 in human plasma was strikingly fast. After an incubation period 
of one minute already 85 % of of the prodrug were converted to candesartan. Thus, t1/2 is 
shorter than one minute. The hydrolysis is supposed to be catalyzed by human serum 
paraoxonase, which is predominantly found in blood4 and is known to be capable of 
hydrolyzing the (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl moiety42. 
Figure 3.30. Examples of 
HPLC chromatograms show-
ing the kinetics of hydrolysis 
of 3.33 in the presence of 
human plasma, CAN = cande-
sartan. 
 
The results of the bioanalytical studies of candesartan (5-tert-butyl-2-oxo-1,3-dioxol-4-yl)-
methyl ester (3.34) are comparable to the results for the analogue 3.33. The conversion 
of the prodrug to candesartan was detected on incubation with porcine skin homogenate 
(Figure 3.31) as well as with porcine liver esterase (Figure 3.32). Since the half-lives 
(15.9 h and 15.7 h, respectively) were even higher than the value estimated for 
hydrolysis in buffer (14.2 h), the degradation of the pro-moiety under these conditions 
can presumably be attributed to non-enzymatic hydrolysis. By contrast, the hydrolysis of 
3.34 in the presence of human plasma (Figure 3.33) was fast (t1/2 = 0.82 h) suggesting 
that the (5-tert-butyl-2-oxo-1,3-dioxol-4-yl)methyl ester is a substrate of human serum 
paraoxonase. Compared to 3.33, the replacement of methyl by tert-butyl led to a 
considerable increase in stability. 
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Figure 3.31. Kinetics of hy-
drolysis of 3.34 in the pre-
sence of porcine skin homo-
genate, CAN = candesartan. 
 
Figure 3.32. Kinetics of hydro-
lysis of 3.34 in the presence of 
porcine liver esterase, CAN = 
candesartan. 
 
Figure 3.33. Examples of HPLC 
chromatograms showing the ki-
netics of hydrolysis of 3.34 in 
the presence of human plasma, 
CAN = candesartan. 
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Candesartan morpholinoethyl ester (3.35) was hydrolyzed to candesartan in the 
presence of porcine skin homogenate (Figure 3.34) and by porcine liver esterase (Figure 
3.35). The half-life of hydrolysis in porcine skin homogenate was estimated to be 6.1 d, 
which is comparable to the conversion in buffer. Thus, the cleavage of the morpho-
linoethyl ester has taken place by non-catalysed hydrolysis rather than enzymatically. In 
the presence of porcine liver esterase a half-life of 18.0 h was determined. 
Figure 3.34. Kinetics of hydro-
lysis of 3.35 in the presence of 
porcine skin homogenate. CAN 
= candesartan. 
 
Figure 3.35. Kinetics of hydro-
lysis of 3.35 in the presence of 
porcine liver esterase, CAN = 
candesartan. 
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Figure 3.36. Examples of 
HPLC chromatograms showing 
the kinetics of hydrolysis of 
3.35 in the presence of human 
plasma. 
No conversion of 3.35 was observed in the presence of human plasma within 72 h 
(Figure 3.36). Surprisingly, even the enzymes present in human hepatocytes were not 
capable of breaking the ester bond; 3.35 was found to be stable over an incubation 
period of six hours (cf. Figure 3.37). 
Figure 3.37. HPLC chromatogram 
of a sample of 3.35 incubated for a 
period of 6 h with primary human 
hepatocytes. The peak at tR ~ 2 min 
refers to DMSO. 
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3.5.3.2 Enzymatic hydrolysis of cilazapril prodrugs 
Theory: 
Considering the results of the stability testing in aqueous solution (chapter 3.5.2.2) it 
becomes obvious that spontaneous hydrolysis of all cilazapril prodrugs at first occurs at 
the less stable ester pro-moiety, leading to the formation of cilazapril, and subsequently 
takes place at the homophenylalanine ethyl ester group to give cilazaprilat. In the case of 
enzymatic hydrolysis these two reaction steps were found to take place simultaneously 
according to Scheme 3.16, in which A, B, C and D represent the respective cilazapril 
prodrug, cilazapril, the respective prodrug ester with cleaved homophenylalanine ethyl 
ester moiety and cilazaprilat, whilst kxy indicate the respective reaction rate constants. 
 
Scheme 3.16. Reaction scheme depicting the enzymatic hydrolysis of cilazapril prodrugs. 
Simplifying the simultaneous hydrolysis of A to B and C by presuming pseudo first-order 
kinetics the half-life t1/2 of A can be calculated according to Equation 3.3, in which the 
factor (kab+kac) equals the slopes of linear plots of the logarithm of the percental peak 
area of residual prodrug against incubation time. 
tଵ ଶൗ ൌ
lnሺ2ሻ
kୟୠ ൅ kୟୡ 
Equation 3.3. Rate of hydrolysis (t1/2) according to Scheme 3.16. 
According to Equation 3.3, f50% values for cilazaprilat (D, cf. Scheme 3.16) can be 
determined from the slopes (kbd+kcd) of linear plots of the logarithm of the amount of 
cilazaprilat (Dx) to be formed (cf. Equation 3.4) against incubation time. 
lnሺD୶ሻ ൌ ln ሺ100 െ D୲౟ሻ 
Equation 3.4. Calculation of ln(Dx). Dti = percentage of active principle after a distinct incubation period. 
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A more exact approach to the description of this reaction kinetics is to perform a global fit 
of the data sets obtained for each partial reaction using following model: 
dAሺtሻ
dt ൌ െሺkୟୠ ൅ kୟୡሻ · Aሺtሻ,
dBሺtሻ
dt ൌ kୟୠ · Aሺtሻ െ kୠୢ · Bሺtሻ,
dCሺtሻ
dt ൌ kୟୡ · Aሺtሻ െ kୡୢ · Cሺtሻ,
dDሺtሻ
dt ൌ kୠୢ · Bሺtሻ ൅ kୡୢ · Cሺtሻ 
Equation 3.5. Differential rate laws describing the reactions shown in Scheme 3.16. 
All four data sets were globally fitted using the least square method by Levenberg-
Marquardt43-44. From the resulting reaction rate constants the half-life can be calculated 
according to Equation 3.3. 
Results: 
As expected, cilazapril was selectively hydrolyzed to cilazaprilat (3.29) during incubation 
with porcine skin homogenate (Figure 3.38), human plasma (Figure 3.39) and porcine 
liver esterase (Figure 3.40), respectively. In the presence of porcine skin homogenate 
and porcine liver esterase the hydrolysis was quantitative after incubation periods of 
approximately 48 h and 24 h, respectively. The half-life amounted to 9.4 h and 3.3 h, 
respectively. The hydrolysis in human plasma was much slower (t1/2 = 88.8 h). 
Figure 3.38. Kinetics of hydro-
lysis of cilazapril (CIL) in porcine 
skin homogenate. 
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Figure 3.39. Examples of HPLC 
chromatograms showing the kine-
tics of hydrolysis of cilazapril 
(CIL) in the presence of human 
plasma. 
 
Figure 3.40. Kinetics of hydro-
lysis of cilazapril (CIL) in the 
presence of porcine liver ester-
ase. 
Also human hepatocytes were able to metabolize cilazapril to cilazaprilat. 26 % and 89 % 
of cilazaprilat were formed after incubation periods of 1 h and 6 h, respectively (data not 
shown). 
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Cilazapril 1-(ethoxycarbonyloxy)ethyl ester (3.1) was completely hydrolyzed to cilazapril 
(CIL) and cilazaprilat (3.29) in the presence of porcine skin homogenate, human plasma 
or porcine liver esterase within an incubation period of 72 h (Figure 3.41 - Figure 3.43). 
Figure 3.41. Examples of HPLC 
chromatograms showing the kine-
tics of hydrolysis of 3.1 in porcine 
skin homogenate. 
 
Figure 3.42. Kinetics of hydro-
lysis of 3.1 in human plasma. 
 
Figure 3.43. Kinetics of hydro-
lysis of 3.1 in the presence of 
porcine liver esterase. 
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Besides cilazapril and cilazaprilat two 
additional species (cf. Scheme 3.17) were 
detected by HPLC, which were further cha-
racterized by LC-MS (Figure 3.44). Com-
pound CILa (tR ~ 8.6 min, m/z 404 (MH+)) 
was only detected in the incubation mixtures 
containing human plasma or porcine liver es-
terase. The molecular mass of 403 Da cor-
responds to a methyl ester of cilazapril, which 
is very likely resulting from transesterification 
with methanol, which was the solvent of the 
stock solution of 3.1 used for the aforemen-
tioned experiments. By contrast, the stock solution for the incubation with porcine skin 
homogenate was prepared with DMSO. However, after an initial increase, CILa was 
hydrolyzed to cilazaprilat by porcine liver esterase, whereas in the presence of human 
plasma the amount of CILa increased continuously but very slowly. The two peaks 
appearing at tR ~ 19.3 min both possess a pseudomolecular ion (MH+) at m/z 506. Thus, 
they were identified as two diastereomers of structure 3.1a, resulting from the hydrolysis 
of the ethyl ester of compound 3.1, whereas the 1-(ethoxycarbonyloxy)ethyl ester 
remained intact. Comparing the results from all three incubation experiments it becomes 
obvious, that 3.1a was mainly formed by porcine skin homogenate, whereas in the other 
incubation mixtures the amounts of 3.1a were comparably low, suggesting that the 
esterases present in porcine skin homogenate preferably hydrolyze the ethyl ester, 
whereas the enzymes in human plasma and the carboxylesterase from porcine liver tend 
to initially cleave the double ester pro-moiety. Furthermore, the metabolizing enzymes 
were apparently able to distinguish between the two diastereomers of 3.1 as well as of 
3.1a. This effect was mainly distinctive in the presence of porcine skin homogenate und 
human plasma. 
The analysis of the incubation experiment in human plasma revealed a half-life of 0.58 h 
for 3.1 and a long f50% time for cilazaprilat (154 h). On incubation with porcine liver 
esterase t1/2 was estimated to be 0.67 h and the f50% value for cilazaprilat amounted to 
23.5 h. 
  
 
Scheme 3.17. Structures and exact masses of 
3.1 and suggested metabolites detected by LC-
MS in different incubation mixtures. 
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Figure 3.44. LC-MS analysis of a sample of 3.1 incubated for 3 h in the presence of porcine liver esterase. A:
TIC, B: UV, C: ESI-MS spectrum of 3.29, D: ESI-MS spectrum of CILa, E: ESI-MS spectrum of CIL, F+G: ESI-MS 
spectra of the two diastereomers of 3.1a. 
3.29 
CILa 
CIL
3.1a 3.1 
A 
B 
C 
D 
E 
F 
G 
 Prodrugs of Candesartan and Cilazapril 65 
The half-life in the presence of porcine skin homogenate was calculated after global 
fitting of the data using the least square method by Levenberg-Marquardt43-44, resulting in 
0.43 h (Figure 3.45). 50 % of cilazaprilat were formed within 13.0 h. 
Figure 3.45. Results from a global fit of the data 
obtained by incubation of 3.1 with porcine skin 
homogenate. A: 3.1, B: cilazapril, C: 3.1a, D: cila-
zaprilat 
Incubating primary human hepatocytes with 3.1 for one hour resulted in the formation of 
29 % cilazapril and 36 % cilazaprilat. After an incubation period of six hours 6 % 
cilazapril and 86 % cilazaprilat were detected (data not shown). 
Similar results as for the 1-(ethoxycarbonyl-
oxy)ethyl ester (3.1) were found for cilazapril 1-
(cyclohexyloxycarbonyloxy)ethyl ester (3.2). 
The hydrolysis by porcine skin homogenate 
(Figure 3.46) proceeded quantitatively to give 
cilazaprilat, but 3.2 was found to be more 
stable than 3.1 corresponding to a calculated 
half-life of 1.4 h. The f50% value for cilazaprilat 
was lower (8.6 h). In contrast to the results for 
3.1 only very small amounts of 3.2a (cf. 
Scheme 3.18) (cleaved ethyl ester but intact 
double ester pro-moiety) were detected by 
HPLC and confirmed by LC-MS (cf. appendix, Figure 9.4). 
The hydrolysis of 3.2 in human plasma (Figure 3.47) was markedly slower than in case 
of 3.1 (t1/2 = 3.2 h, f50% cilazapril = 4.9 h, f50% cilazaprilat = 228 h). Compound 3.2a was not 
detected, but small amounts of the methyl ester CILa (formed by transesterification with 
methanol) were found. Interestingly, comparing the respective chromatograms at 
ti ~ 2.8 h (Figure 3.46 and Figure 3.47), it becomes obvious that the hydrolyzing enzymes 
in porcine skin homogenate prefer one of the diastereomers of 3.2 (cf. peak at longer 
retention time) as a substrate, whereas in human plasma the second diastereomer (cf. 
peak at shorter retention time) is preferably hydrolyzed. 
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Scheme 3.18. Structures and exact masses of 
3.2 and suggested metabolites detected by LC-
MS in different incubation mixtures. 
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Figure 3.46. Kinetics of hydro-
lysis of 3.2 in porcine skin homo-
genate. 
 
Figure 3.47. Kinetics of hydro-
lysis of 3.2 in human plasma. 
Porcine liver esterase (Figure 3.48) completely hydrolyzed 3.2 to cilazapril and 
cilazaprilat within approximately 24 h. The half-life was estimated to be 4.2 h and the 
f50% cilazaprilat amounted to 62.2 h. Again, defined amounts of the methyl ester CILa were 
identified, whereas 3.2a was not detected. 
Primary human hepatocytes hydrolyzed 3.2 at similar rate as 3.1. After an incubation 
period of one hour 40 % cilazapril and 42 % cilazaprilat were detected. Incubation for six 
hours led to the formation of 19 % cilazapril and 81 % cilazaprilat (data not shown). 
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Figure 3.48. Kinetics of hydro-
lysis of 3.2 in the presence of 
porcine liver esterase. 
 
In terms of stability against enzymatic hydrolysis 
cilazapril 1-(isopropyloxycarbonyloxy)ethyl ester (3.3) 
is ranking between the 1-(ethoxycarbonyloxy)ethyl 
ester (3.1) and the 1-(cyclohexyloxycarbonyloxy)ethyl 
ester (3.2). Following half-lives were determined: 
t1/2 = 1.0 h (porcine skin homogenate), t1/2 = 1.9 h 
(human plasma), t1/2 = 1.5 h (porcine liver esterase). 
The hydrolysis of 3.3 by porcine skin homogenate 
gave cilazaprilat (3.29) as final product (f50% cilazaprilat = 
11.3 h). Furthermore, the appearance of the intermedi-
ate species 3.3a (two diastereomers, cf. Scheme 3.19) 
was observed (Figure 3.49). 
Figure 3.49. Examples of 
HPLC chromatograms illustra-
ting the kinetics of hydrolysis of 
3.3 in porcine skin homoge-
nate. 
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In human plasma the enzymatic hydrolysis of 3.3 resulted in the formation of cilazapril 
(f50% cilazapril = 5.4 h) and cilazaprilat (f50% cilazaprilat = 108 h). Moreover, small amounts of the 
methyl ester CILa and the intermediate 3.3a were detected (Figure 3.50). By analogy 
with the cleavage of 3.2, preferred hydrolysis of one or the other diastereomer of 3.3 by 
human plasma or by porcine skin homogenate is clearly evident from HPLC analysis.  
The results from the incubation of 3.3 with porcine liver esterase were very similar to the 
ones found for 3.1. The hydrolysis gave cilazaprilat (3.29) as major product. The f50% 
value for cilazaprilat amounted to 14.2 h. Again, minor amounts of 3.3a and CILa were 
detected. The discrimination between the two diastereomers of 3.3 is marginal (Figure 
3.51). 
Figure 3.50. Kinetics of hydro-
lysis of 3.3 in human plasma. 
 
Figure 3.51. Kinetics of hydro-
lysis of 3.3 in the presence of 
porcine liver esterase. 
Upon incubation with primary human hepatocytes, after an incubation period of six hours 
nearly the same amounts of cilazapril (6 %) and cilazaprilat (89 %) were found as for 3.1. 
After one hour 33 % cilazapril and 28 % cilazaprilat were formed (data not shown). 
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Cilazapril 1-(acetoxy)ethyl ester (3.6) turned out to 
possess rather short half-lives in all enzyme-containing 
incubation mixtures. The t1/2 values were more or less in 
the same range as those calculated for 3.1. In human 
plasma t1/2 of 3.6 amounted to 0.68 h and in the 
presence of porcine liver esterase t1/2 was estimated to 
be 0.63 h. The half-life in porcine skin homogenate was 
calculated after global fitting of the data using the least 
square method by Levenberg-Marquardt43-44. In this 
case two very similar results (0.50 h and 0.53 h) were 
obtained, although two different starting conditions were 
used for the fit (Figure 3.52 and Figure 3.53). 
Figure 3.52. Solution 1 of a global fit of the data ob-
tained by incubation of 3.6 with porcine skin homo-
genate. A: 3.6, B: cilazapril, C: 3.6a, D: cilazaprilat.
Figure 3.53. Solution 2 of a global fit of the data ob-
tained by incubation of 3.6 with porcine skin homo-
genate. A: 3.6, B: cilazapril, C: 3.6a, D: cilazaprilat. 
3.6 was completely hydrolyzed to cilazaprilat (3.29) by porcine skin homogenate within 
72 h (Figure 3.54). The f50% of cilazaprilat was estimated to be 14.0 h. 
Figure 3.54. Kinetics of 
hydrolysis of 3.6 in porcine skin 
homogenate. 
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Scheme 3.20. Structures of 3.6 and 
putative metabolites of 3.6 detected 
in different incubation mixtures.
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In human plasma the formation of 50 % of cilazapril was comparably fast (f50% cilazapril = 
2.2 h), whereas the subsequent hydrolysis to cilazaprilat was rather slow (f50% cilazaprilat = 
91.2 h) (Figure 3.55). The hydrolysis catalyzed by porcine liver esterase resulted in the 
formation of 100 % of cilazaprilat within approximately 50 h (f50% = 9.7 h) (Figure 3.56). 
Figure 3.55. Kinetics of hydro-
lysis of 3.6 in human plasma. 
 
Figure 3.56. Kinetics of hydro-
lysis of 3.6 in the presence of 
porcine liver esterase. 
As described above for the cilazapril prodrugs 3.1-3.3 an intermediate (3.6a, two 
diastereomers, cf. Scheme 3.20) was also detected in all three incubation mixtures, 
whereas the methyl ester CILa only appeared in the samples containing human plasma 
or porcine liver esterase. 
Similar values for the metabolism of 3.6 by primary human hepatocytes were found as 
for the aforementioned cilazapril prodrugs. After an incubation period of one hour 38 % 
cilazapril and 24 % cilazaprilat were detected. Incubation for six hours led to the 
formation of 7 % cilazapril and 82 % cilazaprilat (data not shown). 
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The exchange of the 1-(acetoxy)ethyl moiety in 3.6 
against a 1-(2,2-dimethylpropanoyl)ethyl group led to a 
considerably increase in stability of compound 3.7 
against enzymatic hydrolysis. Following half-life times 
were calculated: t1/2 = 1.0 h in porcine skin homo-
genate, t1/2 = 5.1 h in human plasma and t1/2 = 3.8 h in 
the presence of porcine liver esterase. 
Cilazapril 1-(2,2-dimethylpropanoyl)ethyl ester (3.7) was 
quantitatively hydrolyzed to cilazaprilat (3.29) in porcine 
skin homogenate (f50% (cilazaprilat) = 11.5 h). Evidently, 
either only one diastereomer of the intermediate 
product 3.7a was preferably formed or the other one 
was rapidly further hydrolyzed to cilazaprilat (Figure 3.57). 
Figure 3.57. Examples of 
HPLC chromatograms show-
ing the kinetics of hydrolysis 
of 3.7 in porcine skin homo-
genate. 
The hydrolysis of 3.7 in human plasma resulted in the formation of cilazapril and 
cilazaprilat. The time required to obtain 50 % of cilazaprilat was estimated to be 33.6 h. 
Furthermore, small amounts of the methyl ester CILa were detected. The discriminative 
conversion of the two diastereomers of 3.7 and 3.7a, respectively, was clearly evident 
from HPLC analysis (Figure 3.58). 
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Scheme 3.21. Structures of 3.7 and 
putative metabolites of 3.7 detected 
in different incubation mixtures. 
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Figure 3.58. Kinetics of hydro-
lysis of 3.7 in human plasma. 
Also porcine liver esterase was capable of hydrolyzing 3.7 to cilazaprilat (f50% = 16.3 h). 
In contrast to the results from the incubation with porcine skin homogenate and human 
plasma hardly any intermediate 3.7a was detected. However, considerable amounts of 
the methyl ester CILa were identified, which were subsequently hydrolyzed to cilazaprilat 
(Figure 3.59). 
On incubation with primary human hepatocytes 19 % of cilazapril and 13 % of cilazaprilat 
were found after one hour. Finally, after an incubation period of six hours the amount of 
cilazapril decreased to 10 %, whereas the amount of cilazaprilat increased to 72 % (data 
not shown). 
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Figure 3.59. Kinetics of hydro-
lysis of 3.7 in buffered porcine 
liver esterase. 
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The kinetics of hydrolysis of cilazapril (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester (3.12) 
in the presence of porcine skin homogenate, porcine liver esterase and human plasma is 
shown in Figure 3.60 to Figure 3.62. In all cases cilazapril (CIL) and cilazaprilat (3.29) 
were found to be the only products of hydrolysis of 3.12. 
In the incubation mixture containing porcine skin homogenate as well as in the presence 
of porcine liver esterase the same half-life for 3.12 was determined (t1/2 = 1.8 h). As this 
value is lower than the calculated half-life in buffer (3.7 h) the hydrolysis of the (5-methyl-
2-oxo-1,3-dioxol-4-yl)methyl ester pro-moiety must be partly enzymatically catalyzed. 
Thereby it remains unclear, whether the esterases in porcine skin homogenate and 
carboxylesterase from porcine liver brake down the pro-moiety at the 5-methyl-2-oxo-1,3-
dioxol-4-yl group or directly cleave the ester bond adjacent to the heterocyclic cilazapril 
core structure. The time, in which 50 % of cilazaprilat were formed, was estimated to be 
10.4 h in porcine skin homogenate and 4.3 h in the presence of porcine liver esterase. 
Figure 3.60. Examples of 
HPLC chromatograms depic-
ting the kinetics of hydrolysis 
of 3.12 in porcine skin homo-
genate. 
 
Figure 3.61. Examples of 
HPLC chromatograms showing 
the kinetics of hydrolysis of 
3.12 in the presence of porcine 
liver esterase. 
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According to the results for candesartan (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester 
3.33 the hydrolysis of 3.12 in human plasma yielding cilazapril was extraordinarily fast 
(t1/2 = 5 min). Presumably, this can be attributed to the high activity of human serum 
paraoxonase. However, the subsequent conversion to cilazaprilat turned out to be rather 
slow (f50% = 250 h). 
Figure 3.62. Kinetics of hydro-
lysis of 3.12 in human plasma. 
Incubation of 3.12 with primary human hepatocytes resulted in the formation of 66 % 
cilazapril and 34 % cilazaprilat within one hour. After six hours 15 % cilazapril and 85 % 
cilazaprilat were detected (data not shown). 
Cilazapril (5-tert-butyl-2-oxo-1,3-dioxol-4-yl)methyl 
ester (3.13) was completely hydrolyzed to cilazapri-
lat (3.29) by porcine skin homogenate (t1/2 = 1.3 h, 
f50% cilazaprilat = 12.8 h) and porcine liver esterase 
(t1/2 = 4.2 h, f50% cilazaprilat = 5.5 h) within 72 h (cf. 
Figure 3.63 and Figure 3.64). In contrast to 3.12 
cilazapril was not detected as an intermediate pro-
duct, instead a compound (3.13a) resulting from the 
cleavage of the ethyl ester appeared to be the 
exclusive intermediate (cf. Scheme 3.22). 
The exchange of the methyl group against a bulkier tert-butyl residue in the (5-alkyl-2-
oxo-1,3-dioxol-4-yl)methyl pro-moiety led to a 4-fold increase in stability against enzy-
matic hydrolysis in human plasma (t1/2 = 0.35 h) (Figure 3.65). In contrast to the hydro-
lysis in porcine skin homogenate and in buffered porcine liver esterase cilazapril (CIL) 
was detected as the main intermediate. The conversion to cilazaprilat was still compa-
rably slow (f50% = 186 h). Also the enzymes present in primary human hepatocytes were 
capable of cleaving both ester functions to yield cilazaprilat (data not shown). After an 
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Scheme 3.22. Structure of 3.13 and the 
putative metabolite 3.13a. 
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incubation period of one hour 24 % cilazapril and 42 % cilazaprilat were detected, where-
as after six hours the hydrolysis to cilazaprilat was almost complete (cilazapril: 6 %, 
cilazaprilat: 94 %). 
Figure 3.63. Kinetics of hydro-
lysis of 3.13 in porcine skin 
homogenate. 
 
Figure 3.64. Examples of 
HPLC chromatograms showing 
the kinetics of hydrolysis of 
3.13 in buffered porcine liver 
esterase. 
 
Figure 3.65. Examples of 
HPLC chromatograms show-
ing the kinetics of hydrolysis of 
3.13 in human plasma. 
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The kinetics of hydrolysis of the N-aryl-N-alkyloxycarbonylaminomethyl (NArNAOCAM) 
derivatives of cilazapril (3.25-3.27) could not be analyzed using the simplified model 
described at the beginning of this chapter. Determination of the half-life by linearization of 
the data failed in most of the cases, because the crucial step for the break-down of these 
pro-moieties is supposed to be based on chemical hydrolysis, whereas, simultaneously, 
present ethyl ester groups are cleaved enzymatically. Hence, the observed total hydro-
lysis is composed of the respective fractions of chemical and enzymatic hydrolysis. 
Moreover, the NArNAOCAM prodrugs turned out to be highly prone to hydrolysis in 
acidic medium. As the samples taken from the respective incubation mixtures were 
diluted with mobile phase (MeCN/ 0.05 % TFA) prior to HPLC analysis, it was necessary 
to perform the chromatographic separation immediately after dilution. Preparation without 
the addition of 0.05 % TFA resulted in the formation of broad double peaks due to 
insufficient protonation of the analyte. 
In the following, the behavior of the cilazapril NArNAOCAM prodrugs (3.25-3.27) on 
incubation with porcine skin homogenate, human plasma and porcine liver esterase is 
presented. In all three incubation mixtures 3.25, 3.26 and 3.27 were hydrolyzed to yield 
cilazapril and cilazaprilat. Special effort was put on the identification of unexpected peaks 
in the chromatograms be means of LC-MS coupling. 
In porcine skin homogenate 3.25 was hydrolyzed to cilazapril (tR ~ 9.4 min) and 
cilazaprilat (tR ~ 4.6 min) (Figure 3.66). A third peak at tR ~ 13.9 min was afterwards 
identified as ethyl phenylcarbamate (EPC) by LC-MS. The half-life of 3.25 could not be 
calculated by linear regression, but was estimated to be 28 h. Similar results were 
obtained for the incubation in the presence of porcine liver esterase (t1/2 ~ 4 h, cf. 
appendix, Figure 9.5). 
Figure 3.66. Kinetics of hydro-
lysis of 3.25 in porcine skin 
homogenate. 
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Also in human plasma cilazapril and cilazaprilat were observed as products of hydrolysis 
(Figure 3.67). In this case the data for the kinetics of degradation of 3.25 could be 
linearized resulting in a calculated t1/2 value of 4.1 h. 
Figure 3.67. Kinetics of hydro-
lysis of 3.25 in human plasma. 
Besides cilazapril and cilazaprilat two 
additional products were detected and 
further characterized by LC-MS (data not 
shown). The peak at tR ~ 13.9 min corre-
sponded to a pseudomolecular ion 
(MH+) at m/z 166, presumably referring 
to ethyl phenylcarbamate (EPC), which 
is a degradation product of the 
NArNAOCAM pro-moiety. The interme-
diately formed product 3.25a, detected at tR ~ 15.3 min and corresponding to a 
pseudomolecular ion (MH+) at m/z 567, supposedly resulted from the hydrolysis of the 
homophenylalanine ethyl ester in 3.25. Cleavage of the ethyl carbamate would give the 
same molecular mass, but result in a highly unstable and therefore most probably 
undetectable carbamic acid. 
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Scheme 3.23. Structures and exact masses of 3.25 and 
potential metabolites of 3.25. 
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Incubation of the cilazapril 
NArNAOCAM prodrug 3.26 with 
porcine skin homogenate (Figure 
3.68) and porcine liver esterase (cf. 
appendix, Figure 9.6), respectively, 
gave cilazaprilat (tR ~ 4.6 min), 
whereas on incubation with human 
plasma (Figure 3.69) both cilaza-
prilat and cilazapril (tR ~ 9.4 min) 
could be detected. Furthermore, in 
all three incubation mixtures a 
compound was detected at tR ~ 7.7 min, corresponding to a molecular ion of 453 Da in 
LC-MS analysis. This compound could only be poorly ionized in the MS resulting in very 
low signal intensity. Unfortunately, this peak could not be referred to any imaginable 
degradation product. However, on incubation with human plasma two additional species 
(tR ~ 15.2 min and tR ~ 17.6 min) with the same corresponding pseudomolecular ion 
(MH+) at m/z 639 were detected. On incubation with porcine skin homogenate and 
porcine liver esterase, respectively, only one of these molecular species (tR ~ 17.6 min) 
was found. Presumably, the formation of these compounds can be explained by 
enzymatic hydrolysis of the homophenylalanine ethyl ester, resulting in 3.26a, or the 
benzoic acid ethyl ester yielding 3.26b. Furthermore, at tR ~ 18.9 min small amounts of a 
compound were detected, which possessed a pseudomolecular ion (MH+) at m/z 238, 
probably corresponding to ethyl 4-(ethoxycarbonylamino)benzoate (3.26c) formed by 
hydrolysis of the NArNAOCAM pro-moiety (cf. Scheme 3.24). 
The half-life of 3.26 in human plasma was calculated to be 5.6 h. In porcine skin 
homogenate and in the presence of porcine liver esterase the respective t1/2 was 
estimated to be 4 h and 5 h, respectively. 
Figure 3.68. Kinetics of 
hydrolysis of 3.26 in porcine 
skin homogenate. 
 
0 5 10 15 20 25 30
-0.2
0.0
0.2
0.4
0.6
0.8
1.0
t i[
h]
72.00
blank
0.17
1.32
23.67
3.00
0.02
0.50
6.00
48.58
retention time [min]
ab
so
rb
an
ce
 [A
U]
N
N
O O
O
N
H
OO
R1
N
O
O
No R1
3.26
3.26a
CH2CH3
H
mass
666.3
638.3
3.26c, 237.1 Da
O O
R23.26b 638.3
R2
CH2CH3
H
CH2CH3
CH2CH3
R2 = CH2CH3
 
Scheme 3.24. Structures and exact masses of 3.26 and of 
potential metabolites of 3.26. 
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Figure 3.69. Kinetics of hydro-
lysis of 3.26 in human plasma. 
The methyl carbamate analogue 3.27 
was found to be hydrolyzed analo-
gously to 3.26 (cf. appendix, Figure 
9.7-Figure 9.9). Besides cilazaprilat 
and cilazapril two compounds having 
the same molecular mass (625 Da, 
MH+) were identified by LC-MS as 
intermediates resulting from the 
hydrolysis of the homophenylalanine 
ethyl ester (3.27a) or the benzoic 
acid ethyl ester (3.27b) (cf. Scheme 
3.25). Moreover, LC-MS of a sample of 3.27 incubated for 24 h with human plasma 
revealed small amounts of the degradation product 3.27c (224 Da, MH+). 
For the degradation in human plasma the half-life of 3.27, calculated by linear 
regression, amounted to 5.2 h. For incubation with porcine skin homogenate and porcine 
liver esterase the half-life of 3.27 was estimated to be 16 h and 3 h, respectively. 
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Scheme 3.25. Structures and exact masses of 3.27 and of 
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Cilazapril morpholinoethyl ester (3.14) was 
completely hydrolyzed in all three enzyme-
containing incubation mixtures (Figure 3.70 to 
Figure 3.72). However, in contrast to chemical 
hydrolysis in buffer enzymatic hydrolysis of 3.14 
was found to mainly take place at the ethyl ester 
instead of the morpholinoethyl ester. Hence, during 
the incubation with porcine skin homogenate 
cilazapril could not be detected as an intermediate. 
Only very small amounts of cilazapril (tR ~ 22.2 min) 
were detectable in the incubation mixtures con-
taining human plasma and porcine liver esterase, 
respectively. In all three incubation mixtures 
compound 3.14a (tR ~ 4.7 min) was found as the main intermediate of hydrolysis, which 
was supposed to derive from 3.14 by cleavage of the ethyl ester. Minor amounts of 
3.14b, supposedly the methyl ester of 3.14, most likely formed by transesterification of 
the ethyl ester in 3.14 with methanol, were detected, when methanol-containing stock 
solutions were used (i.e. human plasma, porcine liver esterase). To further corroborate 
these assumptions LC-MS studies were performed (cf. appendix, Figure 9.10). 
In porcine skin homogenate a fast hydrolysis of 3.14 to 3.14a was observed (t1/2 = 0.50 h) 
followed by conversion of 3.14a to cilazaprilat (f50% = 6.3 h) (Figure 3.70). On incubation 
with human plasma the half-life of 3.14 was estimated to be 1.3 h. 50 % of cilazaprilat 
were formed after 10.8 h (Figure 3.71). 
Figure 3.70. Examples of 
HPLC chromatograms showing 
the kinetics of hydrolysis of 
3.14 in porcine skin homo-
genate. 
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Scheme 3.26. Exact masses of 3.14 and 
of its presumable metabolites observed in 
different incubation mixtures. 
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Figure 3.71. Examples of 
HPLC chromatograms showing 
the kinetics of hydrolysis of 
3.14 in human plasma. 
 
Figure 3.72. Examples of 
HPLC chromatograms showing 
the kinetics of hydrolysis of 
3.14 in buffered porcine liver 
esterase. 
The half-life of 3.14 in the presence of porcine liver esterase was calculated by global 
fitting of the data using the least square method by Levenberg-Marquardt43-44 (Figure 
3.73). The t1/2 value amounted to 0.95 h. The f50% value of cilazaprilat was estimated to 
be 7.5 h. 
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Figure 3.73. Reaction kinetics of 3.14 on 
incubation with buffered porcine live resterase. 
Results from global fitting of the data. A: 3.14, B: 
cilazapril, C: 3.14a, D: cilazaprilat. 
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Also primary human hepatocytes initially cleaved the ethyl ester instead of the 
morpholinoethyl ester (data not shown). After an incubation period of one hour 6 % of 
cilazapril and 56 % of 3.14a were detected. After six hours the amounts of cilazapril and 
3.14a were calculated to 1 % and 54 %, respectively. However, the amount of cilazaprilat 
increased from 9 % after one hour to 45 % after six hours of incubation. 
HPLC-analysis of cilazapril 1-(2-morpholinoacetoxy)ethyl ester (3.18) subjected to 
enzymatic cleavage revealed four different, molecular species (cf. Scheme 3.27). 
Besides two peaks (tR ~ 16.1, 16.3 min) 
referring to the two diastereomers of the pro-
drug 3.18 and two peaks at tR ~ 11.7 min and 
12.0 min, cilazapril (CIL, tR ~ 18.6 min) as well 
as cilazaprilat (3.29, tR ~ 13.0 min) were detec-
ted. LC-MS analysis (data not shown) of a 
sample of 3.18 incubated for 30 min with por-
cine liver esterase revealed a pseudomolecular 
ion (MH+) at m/z 561 for the compounds detec-
ted at tR ~ 11.7 min and tR ~ 12.0 min, which 
were identified as the diastereomeric pair of 
structure 3.18a resulting from the hydrolysis of 
the ethyl ester in 3.18. 
In porcine skin homogenate a fast hydrolysis of the ethyl ester in 3.18 resulting in 3.18a 
was observed followed by successive conversion to cilazaprilat (Figure 3.74). Cilazapril 
was only detected as a minor intermediate. 
Figure 3.74. Kinetics of hydro-
lysis of 3.18 in porcine skin 
homogenate. 
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After global fitting of the incubation data using the least square method by Levenberg-
Marquardt43-44 (Figure 3.75) the half-life of 3.18 was estimated to be 0.33 h, whereas the 
f50% cilazaprilat amounted to 24.3 h. 
Figure 3.75. Reaction kinetics of 3.18 on 
incubation with porcine skin homogenate. 
Results from global fitting of the data. A: 3.18, B: 
cilazapril, C: 3.18a, D: cilazaprilat. 
In human plasma the hydrolysis of 3.18 was slower (t1/2 = 0.83 h) (Figure 3.76). The 
diastereomer of 3.18 detected at shorter retention time seemed to be hydrolyzed pre-
ferably. In contrast to the incubation with porcine skin homogenate cilazapril was found 
as the main intermediate, whereas only one diastereomer of 3.18a was formed in small 
amounts. The subsequent conversion to cilazaprilat turned out to be very slow 
(f50% = 132 h). The half-life of 3.18 in the presence of porcine liver esterase (Figure 3.77) 
was slightly shorter than in human plasma (t1/2 = 0.77 h). 50 % cilazaprilat were formed 
after 29.3 h. Primary human hepatocytes hydrolyzed 3.18 to cilazapril and cilazaprilat 
(data not shown). Within one hour 19 % of cilazapril and 38 % of cilazaprilat were 
formed. After an incubation period of six hours the percentage of cilazapril decreased to 
1%, whereas that of cilazaprilat increased to 79 %. 
Figure 3.76. Kinetics of hydro-
lysis of 3.18 in human plasma. 
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Figure 3.77. Kinetics of hydro-
lysis of 3.18 in buffered porcine 
liver esterase. 
Cilazapril ethylester (3.28) was completely degraded on 
incubation with porcine skin homogenate, human plasma, 
porcine liver esterase or primary human hepatocytes 
resulting exclusively in a compound detected at a 
retention time of 16.7 min. As confirmed by spiking, this 
product is not identical with cilazapril, which eluted at 
tR ~ 17.7 min (Figure 3.78). Hence, the compound 
presumably corresponds to the monoethyl ester 3.28a 
resulting from selective hydrolysis of the homophenyl-
alanine ethyl ester group in 3.28. 
Figure 3.78. HPLC chromatogram of 3.28 
incubated for 24 h in porcine skin homo-
genate spiked with cilazapril (CIL). 
In Figure 3.79 the formation of 3.28a is exemplarily shown in an incubation mixture 
containing porcine skin homogenate. The incubation of 3.28 in human plasma and in the 
presence of porcine liver esterase provided similar results (cf. appendix, Figure 9.11, 
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Figure 9.12). The half-lives of 3.28 in porcine skin homogenate, human plasma and in 
the presence of porcine liver esterase, respectively, were estimated to be 0.35 h, 11.9 h 
and 0.69 h. Also primary human hepatocytes were not able to cleave the desired ethyl 
ester. 3.28a was found to be the only metabolite amounting to 35 % after an incubation 
period of one hour and to 99 % after six hours. 
3.5.4 Summary: Hydrolytic stability of prodrugs of candesartan and 
cilazapril 
In the following the results of the bioanalytical studies described in chapter 3.5.2 and 
chapter 3.5.3 are summarized (Table 3.9 to Table 3.12). The half-lives of the respective 
prodrugs in different incubation media are depicted as well as the observed hydrolysis by 
primary human hepatocytes. 
Table 3.9. Half-lives (t1/2) of candesartan prodrugs in porcine skin homogenate, human plasma, buffered porcine 
liver esterase and phosphate buffer at 37 °C. 
prodrug 
porcine skin 
homogenate 
human 
plasma 
porcine liver 
esterase 
phosphate buffer 
(pH 7.4) 
 t1/2 (h) t1/2 (h) t1/2 (h) t1/2 (h) 
candesartan 
cilexetil 0.27 35.0 < 0.05 1385 
3.31 0.13 47.5 0.10 331 
3.32 0.45 32.2 0.03 780 
3.33 0.95 < 0.02 2.2 2.3 
3.34 15.9 0.82 15.7 14.2 
3.35 146 ---a 18.0 146 
a No hydrolysis detectable within an incubation period of 72 h. 
Figure 3.79. Examples of HPLC 
chromatograms showing the kine-
tics of hydrolysis of 3.14 in porcine 
skin homogenate. 
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Table 3.10. Hydrolysis of several candesartan prodrugs by primary human hepatocytes. The percentage of 
candesartan formed after an incubation period (ti) of 1 h and 6 h, respectively, is indicated. 
prodrug candesartan (%) 
 ti = 1 h ti = 6 h 
3.31 47 100 
3.32 22 72 
3.35 ---a ---a 
a No conversion detectable. 
Table 3.11. Rate of hydrolysis of cilazapril and cilazapril prodrugs in porcine skin homogenate, human plasma, 
buffered porcine liver esterase and phosphate buffer at 37 °C. 
prodrug 
porcine skin 
homogenate human plasma 
porcine liver 
esterase 
phosphate buffer 
(pH 7.4) 
 t1/2 (h) f50% (h)a t1/2 (h) f50% (h) t1/2 (h) f50% (h) t1/2 (h) 
cilazapril 9.4 9.4 88.8 88.8 3.3 3.3 183 
3.1 0.43 b 13.0 0.58 154 0.67 23.5 75.0 
3.2 1.4 8.6 3.2 228 4.2 62.2 ---c 
3.3 1.0 11.3 1.9 108 1.5 14.2 75.7 
3.6 0.50 / 0.52 b,d 14.0 0.68 91.2 0.63 9.7 40.3 
3.7 1.0 11.5 5.1 33.6 3.8 16.3 ---c 
3.12 1.8 10.4 0.08 250 1.8 4.3 3.7 
3.13 1.3 12.8 0.35 186 4.2 5.5 7.1 
3.14 0.50 6.3 1.3 10.8 0.95 c 7.5 14.0 
3.18 0.33 c 24.3 0.83 132 0.77 29.3 18.6 
3.25 ~ 28 ---e 4.1 ---e ~ 4 ---e ~ 12 
3.26 ~ 4 ---e 5.6 ---e ~ 5 ---e ---f 
3.27 ~ 16 ---e 5.2 ---e ~ 3 ---e ---f 
3.28 0.35 ---g 11.9 ---g 0.69 ---g 403 
a f50% is the time by which 50 % of total cilazaprilat has been formed. b t1/2 calculated after global fitting of the data 
using the least square method by Levenberg-Marquardt43-44. c No hydrolysis detectable within an incubation 
period of 72 h. d Two separate half-lives were obtained due to two different starting conditions of the global fit.  
e Could not be calculated due to unknown reaction kinetics. f Not determined because of low solubility in buffer.  
g No conversion to cilazaprilat detectable. 
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Table 3.12. Hydrolysis of cilazapril and cilazapril prodrugs by pri-
mary human hepatocytes. Percentage of cilazapril and cilazaprilat 
formed after an incubation period (ti) of 1 h and 6 h, respectively. 
prodrug cilazapril (%) cilazaprilat (%) 
 ti = 1 h ti = 6 h ti = 1 h ti = 6 h 
cilazapril 74 11 26 89 
3.1 29 36 6 86 
3.2 40 42 19 81 
3.3 33 28 6 89 
3.6 38 24 7 82 
3.7 19 13 10 72 
3.12 66 34 15 85 
3.13 24 42 6 94 
3.14 6 9 1 45 
3.18 19 38 1 79 
3.28 ---a ---a ---a ---a 
a No conversion to cilazapril or cilazaprilat detectable. 
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3.6 Pharmacological investigation of candesartan prodrugs using a 
spectrofluorimetric Ca2+-assay 
Activation of the angiotensin II AT1 receptor leads to an increase of the intracellular Ca2+ 
concentration ([Ca2+]i) by a Gαq protein coupled signal transduction pathway. Thus, AT1 
receptor antagonists such as candesartan cause an inhibition of the increase in [Ca2+]i. A 
subject of previous work was the determination of antagonistic activity at the AT1 
receptor of a small set of candesartan prodrugs in a fura-2 calcium assay with rat 
glomerular mesangial cells.45 
In brief, rat mesangial cells were loaded with fura-2 acetoxymethyl ester. After 
intracellular enzymatic ester cleavage the Ca2+-sensitive dye fura-2 coordinates cytosolic 
Ca2+ ions and [Ca2+]i can be determined by a ratiometric measurement of the 
fluorescence according to the Grynkiewicz equation46 (Equation 3.6). 
ሾCaଶାሿ୧ ൌ KD ·
ሺR െ R୫୧୬ሻ
ሺR୫ୟ୶ െ Rሻ · SFB 
Equation 3.6. The Grynkiewicz equation for calculation of the intracellular Ca2+ concentration. KD: dissociation 
constant of the fura-2-Ca2+ complex; R: ratio of fluorescence intensity at 510 nm after excitation at 340 and 
380 nm; Rmin: fluorescence ratio in absence of free Ca2+; Rmax: fluorescence ratio in presence of a saturating Ca2+ 
concentration; SFB: correction factor. 
Treatment of the rat cells with 
angiotensin II causes an increase in 
[Ca2+]i. This signal can be inhibited 
by angiotensin II AT1 receptor antag-
onists such as candesartan (Figure 
3.80). After preincubation with vari-
able concentrations of antagonist 
the [Ca2+]i signal was induced by 
addition of 100 nM angiotensin II 
(approximate agonist concentration 
inducing about 80 % of the maximal 
response). Using antagonist con-
centrations reducing the angiotensin 
II-induced fluorescence signal to 
20 % - 80 % the percental inhibition (P) relative to control (no antagonist) was 
determined by Equation 3.7. 
Percentage inhibition ሾ%ሿ ൌ P ൌ ቆ100 െ ሾCa
ଶାሿ୧ െ slope ሺcompound ൅ 100 nM angiotensin IIሻሾµMሿ
ሾCaଶାሿ୧ െ slope ሺcontrolሻሾµMሿ ቇ 
Equation 3.7. Calculation of the percental inhibition P. 
 
Figure 3.80. AT1 receptor mediated mobilization of intracel-
lular Ca2+ in rat glomerular mesangial cells induced by stimu-
lation with 1 µM angiotensin II (blue curve); inhibition of mobi-
lization of intracellular Ca2+ by 1 µM candesartan (red curve). 
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After logit-transformation following Equation 3.8 and plotting of the resulting logit (P) 
values versus the logarithm of the corresponding compound concentration the log (IC50) 
value was obtained as intersection point of the regression line with the x-axis. 
logitሺPሻ ൌ log ൬ P100 െ P൰ 
Equation 3.8. Logit-log Transformation 
A logit-log-plot is shown in Figure 3.81 for candesartan as an example. 
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Figure 3.81. Logit-log-plot of candesartan. 
The calculated IC50 values were converted to dissociation constants (Kb) according to the 
Cheng-Prusoff equation47 (Equation 3.9) using an EC50 value of 19.7 nM for angiotensin 
II (mean value from 2 independently determined concentration-effect curves on rat 
glomerular mesangial cells). 
Kୠ ൌ ICହ଴ ·
ECହ଴
ECହ଴ ൅ ሾLሿ 
Equation 3.9. Cheng-Prusoff equation for functional assays. Kb: dissociation constant; EC50: angiotensin II 
concentration which induces 50 % of the maximal effect (determined to 19.7 nM); [L]: angiotensin II concentration 
(100 nM). 
The results from the fura-2 calcium assay for candesartan and the candesartan prodrugs 
are summarized in Table 3.13. 
All investigated candesartan derivatives were able to antagonize the effect of the agonist 
angiotensin II on rat glomerular mesangial cells with IC50 values in the one- to two-digit 
nanomolar range (4.8 nM – 47.2 nM) and corresponding Kb values ranging from 0.8 nM 
to 7.8 nM. The parent compound candesartan showed an IC50 of 3.2 nM and a 
corresponding Kb of 0.5 nM, which is in good correlation with results reported in literature 
(Ki = 0.64 nM)48. Surprisingly, besides candesartan the synthesized prodrugs, in 
particular the 1-(2,2-dimethylpropanoyl)ethyl ester 3.32 (IC50 = 4.8 nM, Kb = 0.8 nM) as 
well as the morpholinoethyl ester 3.35 (IC50 = 6.0 nM, Kb = 1.0 nM), turned out to be 
potent antagonists. Whereas 3.32 and 3.35 were about as potent as candesartan, the 
antagonistic activities of the (oxodioxolyl)methyl ester prodrugs 3.33 and 3.34 were 
approximately four to five times lower, and the 1-(alkyloxycarbonyloxy)ethyl esters 3.31 
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and candesartan cilexetil were about 12 to 15 times less potent. From these data a clear 
structure-activity-relationship is not evident. However, a sterically more demanding ester 
moiety such as the cilexetil group seems to decrease the antagonistic activity more 
strongly than smaller ester moieties. Comparing the compounds with similar type of ester 
side chains (3.31 and candesartan cilexetil as well as 3.33 and 3.34) the bulkier 
substituent leads to a weaker antagonistic activity. Since there is only a slight difference 
between the IC50 values of candesartan and the prodrug esters 3.32 or 3.35 it is likely, 
that the affinity for the AT1 receptor is mainly caused by the tetrazolylbiphenylmethyl 
partial structure and the benzimidazole ring. The introduction of certain ester pro-
moieties seems to have a rather insignificant impact on the antagonistic activity. 
Table 3.13. Antagonistic activity at the AT1 receptor of candesartan and candesartan prodrugs in a spectrofluori-
metric Ca2+-assay (fura-2 assay) on rat glomerular mesangial cells given as mean values ± SEM from 3-5 inde-
pendent experiments. 
 No. R IC50 [nM] Kb [nM] 
 
Candesartan H 3.2 ± 0.5 0.5 ± 0.1 
3.31 38.6 ± 17.0 6.4 ± 2.8 
3.32 4.8 ± 0.4 0.8 ± 0.1 
3.33 11.7 ± 4.2 1.9 ± 0.7 
3.34 15.4 ± 2.1 2.5 ± 0.3 
3.35 6.0 ± 0.6 1.0 ± 0.1 
Candesartan 
cilexetil 47.2 ± 21.8 7.8 ± 3.6 
However, the most important conclusion from the pharmacological studies is that the 
investigated candesartan derivatives due to their partly high potency at the AT1 receptor 
must not be considered as inactive prodrugs. In fact, they represent new chemical 
entities. 
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3.7 Summary and conclusion 
Inspired by structures of therapeutically well-established or promising experimental 
carrier-prodrugs, a set of potential candesartan and cilazapril prodrugs, which should 
fulfill the requirements for application via a transdermal therapeutic system (TTS), was 
synthesized. Starting from candesartan and cilazapril, respectively, the desired com-
pounds were accessible by esterification. In terms of physicochemical properties, in 
particular with respect to lipophilicity (log P, log D), the synthesized candesartan and 
cilazapril prodrugs are considered suitable for skin permeation. Especially, compounds 
containing an ionizable morpholine moiety (3.14, 3.18, 3.35) are interesting candidates 
due to balanced lipophilicity and water solubility. 
Candesartan prodrugs: The candesartan double ester prodrugs (candesartan cilexetil, 
3.31 and 3.32) as well as the candesartan morpholinoethyl ester (3.35) exhibited 
excellent solid state stabilities at long-term storage conditions. The candesartan double 
ester prodrugs were also sufficiently stable against spontaneous, non-enzymatic 
hydrolysis in buffer pH 7.4. On the contrary, the prodrugs were enzymatically converted 
to candesartan in the presence of porcine skin homogenate, human plasma, porcine liver 
esterase and upon incubation with primary human hepatocytes. In contrast, enzymatic 
hydrolysis of 3.33 and 3.34 to candesartan was only observed in the presence of human 
plasma. Moreover, the (oxodioxolyl)methyl moiety appeared to be highly prone to non-
enzymatic hydrolysis. Surprisingly, the morpholinoethyl ester of candesartan (3.35) was 
only hydrolyzed in the presence of porcine skin homogenate and porcine liver esterase, 
whereas high stability was observed in human plasma and upon incubation with primary 
human hepatocytes. Thus, it can be assumed that hydrolysis is impaired due to the short 
distance between the core structure and the cleavage site. Surprisingly, in a spectro-
fluorimetric Ca2+-assay (fura-2 assay) on rat glomerular mesangial cells both, the 1-(2,2-
dimethylpropanoyl)ethyl ester 3.32 (Kb = 0.8 nM) and the morpholinoethyl ester 3.35 
(Kb = 1.0 nM) turned out to be potent angiotensin II AT1 receptor antagonists. Therefore, 
these candesartan derivatives must not be considered as inactive prodrugs, but as new 
pharmacologically active chemical entities. 
Cilazapril prodrugs: The investigation of the solid state stability of a selection of cilazapril 
prodrugs (3.1-3.3, 3.6, 3.7, 3.14, 3.28) revealed high stabilities of all compounds at 
5 °C/65 % rel. h. Except for the simple ethyl ester (3.28), which was found to be 
remarkably stable at all storage conditions, the stabilities of 3.1-3.14 were considerably 
decreasing at long-term as well as at accelerated storage conditions. In contrast to 
prodrugs of the ACE inhibitor trandolapril (previous in-house investigations), the chemical 
stability of cilazapril prodrugs is increased, as the intramolecular formation of 
diketopiperazine is precluded due to the more rigid structure of cilazapril. Moreover, 
there was no intermolecular formation of diketopiperazine. The cilazapril double ester 
prodrugs 3.1-3.3, 3.6 and 3.7 showed high to moderate stabilities towards non-enzymatic 
hydrolysis in buffer. Enzyme-containing incubation mixtures as well as primary human 
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hepatocytes led to a fast degradation of the prodrugs and to the formation of cilazaprilat 
as the final metabolite. Interestingly, double ester prodrugs, containing a stereogenic 
center in the pro-moiety, were stereoselectively cleaved in most cases, when used as a 
mixture of two diastereomers. In accordance to the candesartan prodrugs 3.33 and 3.34, 
the (oxodioxolyl)methyl prodrugs of cilazapril (3.12, 3.13) showed strikingly fast 
hydrolysis in human plasma, but insufficient stability in buffer pH 7.4. Furthermore, fast 
reaction kinetics concerning enzymatic hydrolysis and moderate stability towards non-
enzymatic hydrolysis were observed for compounds 3.14 and 3.18, which contain an 
ionizable morpholinoethyl and 1-(2-morpholinoacetoxy)ethyl moiety, respectively. In view 
of their application via a TTS, N-aryl-N-alkyloxycarbonylaminomethyl (NArNAOCAM) 
esters of cilazapril are considered rather unsuitable, since they are prone to hydrolysis at 
low pH values and kinetics of hydrolysis is complex. The ethyl ester of cilazapril (3.28) 
turned out to be completely stable against enzymatic cleavage of the additional ethyl 
carboxylate group, whereas hydrolysis occurred exclusively at the homophenylalanine 
ethyl ester moiety. This result corroborates previous findings from our laboratory on the 
cleavage of trandolapril ethyl ester. 
In conclusion, several promising prodrugs of candesartan and cilazapril were 
synthesized. Their physicochemical properties are presumably adequate for transdermal 
application, as they are enzymatically hydrolyzed, yielding the active principles cande-
sartan and cilazaprilat. 
3.8 Experimental section 
3.8.1 General experimental conditions 
Commercially available chemicals and reagents were purchased from Acros Organics 
(Geel, Belgium), Alfa Aesar GmbH & Co. KG (Karlsruhe, Germany), Merck KGaA 
(Darmstadt, Germany), Sigma-Aldrich Chemie GmbH (München, Germany) or Wako 
Pure Chemical Industries (Osaka, Japan). Cilazapril and candesartan were kindly provi-
ded by Hexal AG (Holzkirchen, Germany). All solvents used were of analytical grade or 
distilled before use. Reactions were usually monitored by thin layer chromatography 
(TLC) on Merck silica gel F254 aluminium sheets and spots were visualized with UV light 
at 254 nm or ammonium molybdate/cerium (IV) sulfate solution. For flash column chro-
matography Merck silica gel 60 (0.040-0.063 mm) was used. Purification by preparative 
HPLC was performed on a RP-column (Nucleodur 100-5 C18 ec, 250 x 21 mm, 5 µm; 
Machery-Nagel, Düren, Germany) with a system consisting of two K-1800 pumps 
(Knauer, Berlin, Germany) and a UV-VIS detector model K-2000 (Knauer). UV-detection 
was done at 220 nm, the temperature was 30 °C and the flow rate 22 ml/min. Melting 
points (mp) were determined with a Büchi 510 melting point apparatus and are 
uncorrected. Nuclear Magnetic Resonance (1H-NMR and 13C-NMR) spectra were recor-
ded on an Avance 300 (1H: 300 MHz), an Avance 600 (1H: 600 MHz) or an Avance III 
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600 spectrometer (1H: 600 MHz) (Bruker BioSpin GmbH, Rheinstetten, Germany) with 
per-deuterated solvents (Deutero GmbH, Kastellaun, Germany). The chemical shift δ is 
given in parts per million (ppm) with reference to the chemical shift of the residual protic 
solvent compared to tetramethylsilane (δ = 0). Multiplicities are specified with the 
following abbreviations: s (singlet), d (doublet), t (triplet), q (quartet), sept (septet), m 
(multiplet) and bs (broad singlet). The multiplicity of carbon atoms was determined by 
DEPT 135 (distortionless enhancement by polarization transfer) and is indicated as 
follows: “+” for primary and tertiary carbon atoms (positive DEPT 135 signal), “-“ for 
secondary carbon atoms (negative DEPT 135 signal), “quat” for quaternary carbon 
atoms. 2D-NMR techniques (COSY, TOCSY, HSQC, HMBC) were partially per-
formed to support interpretation of 1D spectra. Mass spectrometry analysis (MS) was 
performed on a Finnigan MAT 95 (EI-MS 70eV, HR-MS), a Finnigan SSQ 710A (EI-MS 
70 eV, CI-MS (NH3)) and on a Finnigan ThermoQuest TSQ 7000 (ES-MS) spectrometer. 
The peak-intensity in % relative to the strongest signal is given in parenthesis. Elemental 
analysis was carried out in the Department of Microanalysis, University of Regensburg. 
Analytical HPLC analysis was performed on a system from Thermo Separation Products 
(Thermo Scientific) consisting of a SN400 controller, a P4000 pump, an AS3000 
autosampler, a Spectra Focus UV-VIS detector and a RP-column (Luna C18-2, 150 x 4.6 
mm, 3 μm; Phenomenex, Aschaffenburg, Germany) at a flow rate of 0.75 mL/min and a 
column temperature varying between 25 to 60 °C. Absorbance was detected at 210 nm. 
The mobile phase consisted of MeCN and 0.05 % trifluoroacetic acid (TFA) in Millipore 
water. All samples were filtered prior to injection using 0.2 µm Phenex-NY Syringe Filters 
(0.2 µm pore size, 4 mm diameter) (Phenomenex, Aschaffenburg, Germany). For the 
determination of compound purity following gradients were used: Gradient a: 0 min: 
MeCN/0.05% TFA/aq 10/90, 25 min: 90/10, 26-31 min: 95/5; Gradient b: 0 min: 
MeCN/0.05% TFA/aq 10/90, 20 min: 90/10, 21-29 min: 95/5. The retention (capacity) 
factor k was calculated from the retention time tR and the hold-up time t0 according to k = 
(tR - t0)/t0 with t0 = 2.88 min for Luna C18-2, 150 x 4.6 mm, 3 μm. Millipore water was 
used throughout for the preparation of buffers and HPLC eluents. The loading buffer for 
the fura-2 assay on rat mesangial cells consisted of 7.013 g/l NaCl, 0.373 g/l KCl, 0.407 
g/l MgCl2·6 H2O, 0.221 g/l CaCl2·2 H2O, 5.958 g/l HEPES, 1.802 g/l glucose. The pH was 
adjusted to 7.4 with NaOH followed by sterile filtration. 
3.8.2 Chemistry: Experimental protocols and analytical data 
In the following the correlation of 1H and 13C nuclear magnetic reso-
nance signals of the (1S,9S)-10-oxooctahydro-1H-pyridazino-[1,2-
a][1,2]diazepine-1-carboxylic acid core structure will be reported ac-
cording to the atom numbering depicted on the right side. That 
means that the signal C-x refers to carbon atom no. x and the signal 
x-H refers to the hydrogen atom/atoms connected to the carbon atom no. x. 
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3.8.2.1 General procedure for the synthesis of 1-(alkyloxycarbonyloxy)ethyl esters 
(3.1-3.3) and 1-(acyloxy)ethyl esters (3.6-3.7) 
K2CO3 (1.2 eq) was added to a solution of cilazapril (1eq) in DMF (H2O < 0.01 %) and 
the solution was stirred for 10 min. The corresponding 1-(alkyloxycarbonyloxy)ethyl 
chloride or 1-chloroethyl alkanoate (cf. 3.8.2.2) (1.3 eq) was added dropwise at 0 °C. 
After stirring at room temperature overnight the reaction mixture was poured into water 
and extracted three times with ethyl acetate. The combined organic layers were washed 
with water, dried over anhydrous MgSO4, filtered and evaporated under reduced 
pressure. The crude product was purified by flash chromatography. 
(1S,9S)-1-(Ethoxycarbonyloxy)ethyl 9-((S)-1-ethoxy-1-oxo-4-phenylbutan-2-ylami-
no)-10-oxooctahydro-1H-pyridazino[1,2-a][1,2]diazepine-1-carboxylate (3.1): The 
title compound was prepared from cilazapril (2.4 mmol, 1.00 g), K2CO3 (2.9 mmol, 0.40 
g) and 1-chloroethyl(ethyl)carbonate (3.1 mmol, 0.48 g) in DMF (H2O < 0.01 %) (5 ml) 
following the general procedure 3.8.2.1. The desired product was obtained after flash 
chromatography (PE/EtOAc 3/2 v/v) as a yellowish oil (0.80 g, 62 %). 1H-NMR (CDCl3) δ 
ppm: 1.27 (m, 3H, CH3CH2OCOO), 1.30 (m, 3H, CH3CH2OCOCH), 1.37 and 1.72 (m, 
2H, 3-H2), 1.48 and 2.03 (m, 2H, 8-H2), 1.53 (m, 3H, OCHCH3O), 1.72 and 1.85 (m, 2H, 
7-H2), 1.82 and 2.23 and 2.35 (m, 2H, 2-H2), 2.03 (m, 2H, PhCH2CH2), 2.50 (bs, 1H, NH), 
2.50 and 3.27 and 3.44 (m, 2H, 6-H2), 2.73 (m, 2H, PhCH2), 2.94 and 3.07 (m, 2H, 4-H2), 
3.37 (m, 1H, PhCH2CH2CH), 4.17 (m, 1H, 9-H), 4.18 (m, 2H, CH3CH2OCOCH), 4.20 (m, 
2H, CH3CH2OCOO), 5.01 and 5.08 (m, 1H, 1-H), 6.73 and 6.80 (m, 1H, OCHCH3O), 7.17 
(m, 3H, PhH), 7.25 (m, 2H, PhH). 13C-NMR (CDCl3) δ ppm: 14.08 (+, CH3CH2OCOO), 
14.29 (+, CH3CH2OCOCH), 15.81 and 16.21 (-, C-3), 19.41 and 19.47 (+, OCHCH3O), 
24.82 and 24.89 (-, C-2), 24.99 and 25.26 (-, C-7), 29.83 and 29.98 (-, C-8), 32.17 (-, 
PhCH2), 34.99 and 35.05 (-, PhCH2CH2), 49.30 and 49.94 (+, C-1), 51.08 (-, C-6), 51.62 
and 51.81 (-, C-4), 57.17 and 57.30 (+, C-9), 60.49 and 60.55 (+, PhCH2CH2CH), 60.62 
(-, CH3CH2OCOCH), 64.48 and 64.52 (-, CH3CH2OCOO), 91.96 and 92.04 (+, 
OCHCH3O), 125.84 (+, PhC), 128.25 and 128.30 (2C, +, PhC), 128.37 (2C, +, PhC), 
141.48 (quat, PhC), 152.91 and 152.09 (quat, CH3CH2OCOO), 169.46 and 169.50 (quat, 
C-1-COO), 174.37 (quat, CH3CH2OCOCH), 174.88 and 174.96 (quat, C-10). HRMS: EI-
MS: m/z for (C27H39N3O8) calcd. 533.2737, found: 533.27304. Analytical HPLC: purity 
100 %, tR = 15.61 min (gradient a), k = 4.42. C27H39N3O8 (547.61). 
(1S,9S)-1-(Cyclohexyloxycarbonyloxy)ethyl 9-((S)-1-ethoxy-1-oxo-4-phenylbutan-2-
ylamino)-10-oxooctahydro-1H-pyridazino[1,2-a][1,2]diazepine-1-carboxylate (3.2): 
The title compound was prepared according to the general procedure 3.8.2.1 using 
cilazapril (0.6 mmol, 0.25 g), K2CO3 (0.7 mmol, 0.10 g) and 1-chloroethyl(cyclohexyl)car-
bonate (0.8 mmol, 0.16 g) in DMF (H2O < 0.01 %) (3 ml) and was obtained after flash 
chromatography (PE/EtOAc 3/2 v/v) as a yellowish oil (0.26 g, 74 %). 1H-NMR (CDCl3) δ 
ppm: 1.27 (m, 3H, CH3CH2), 1.27 and 1.52 (m, 2H, cy-4-H2), 1.35 and 1.73 (m, 4H, cy-3-
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H2, cy-5-H2), 1.35 and 1.73 (m, 2H, 3-H2), 1.47 and 1.90 (m, 4H, cy-2-H2, cy-6-H2), 1.47 
and 2.03 (m, 2H, 8-H2), 1.52 (m, 3H, OCHCH3O), 1.73 and 1.90 (m, 2H, 7-H2), 1.90 and 
2.26 and 2.35 (m, 2H, 2-H2), 2.02 (m, 2H, PhCH2CH2), 2.35 (bs, 1H, NH), 2.50 and 3.27 
and 3.44 (m, 2H, 6-H2), 2.73 (m, 2H, PhCH2), 2.94 and 3.06 (m, 2H, 4-H2), 3.37 (m, 1H, 
PhCH2CH2CH), 4.16 (m, 1H, 9-H), 4.18 (m, 2H, CH3CH2), 5.01 and 5.08 (m, 1H, 1-H), 
6.73 and 6.80 (m, 1H, OCHCH3O), 7.17 (m, 3H, PhH), 7.25 (m, 2H, PhH). 13C-NMR 
(CDCl3) δ ppm: 14.35 (+, CH3CH2), 15.84 and 16.21 (-, C-3), 19.42 and 19.49 (+, 
OCHCH3O), 23.51 (2C, -, cy-C-4), 24.81 and 24.89 (-, C-2), 25.04 and 25.27 (-, C-7), 
25.09 (4C, -, cy-C-3, cy-C-5), 29.88 and 30.06 (-, C-8), 31.32 (4C, -, cy-C-2, cy-C-6), 
32.18 (-, PhCH2), 35.04 and 35.09 (-, PhCH2CH2), 49.30 and 49.95 (+, C-1), 51.08 (-, C-
6), 51.63 and 51.81 (-, C-4), 57.16 and 57.28 (+, C-9), 60.51 (+, PhCH2CH2CH), 60.59 (-, 
CH3CH2), 77.47 and 77.50 (+, cy-C-1), 91.85 and 91.97 (+, OCHCH3O), 125.84 (+, PhC), 
128.30 (2C, +, PhC), 128.37 (2C, +, PhC), 141.50 (quat, PhC), 152.43 and 152.60 (quat, 
cy-OCOO), 169.46 and 169.52 (quat, C-1-COO), 174.43 (quat, CH3CH2OCO), 175.00 
(quat, C-10). HRMS: EI-MS: m/z for (C31H45N3O8) calcd. 587.3207, found: 587.32002. 
Analytical HPLC: purity 100 %, two diastereomeres, tR = 18.41, 18.65 min (gradient a), k 
= 5.39, 5.48. C31H45N3O8 (587.70). 
(1S,9S)-1-(Isopropyloxycarbonyloxy)ethyl 9-((S)-1-ethoxy-1-oxo-4-phenylbutan-2-
ylamino)-10-oxooctahydro-1H-pyridazino[1,2-a][1,2]diazepine-1-carboxylate (3.3): 
The title compound was prepared from cilazapril (0.6 mmol, 0.25 g), K2CO3 (0.7 mmol, 
0.10 g) and 1-chloroethyl(isopropyl)carbonate (0.8 mmol, 0.13 g) in DMF (H2O < 0.01 %) 
(3 ml) according to the general procedure 3.8.2.1 and was obtained after flash 
chromatography (PE/EtOAc 1/1 v/v) as a yellowish oil (0.28 g, 84 %). 1H-NMR (CDCl3) δ 
ppm: 1.27 (m, 3H, CH3CH2), 1.29 (m, 6H, CH(CH3)2), 1.36 and 1.72 (m, 2H, 3-H2), 1.48 
and 2.03 (m, 2H, 8-H2), 1.52 (m, 3H, OCHCH3O), 1.72 and 1.85 (m, 2H, 7-H2), 1.82 and 
2.26 and 2.35 (m, 2H, 2-H2), 2.03 (m, 2H, PhCH2CH2), 2.43 (bs, 1H, NH), 2.50 and 3.27 
and 3.44 (m, 2H, 6-H2), 2.73 (m, 2H, PhCH2), 2.94 and 3.07 (m, 2H, 4-H2), 3.37 (m, 1H, 
PhCH2CH2CH), 4.17 (m, 1H, 9-H), 4.19 (m, 2H, CH3CH2), 4.87 (m, 1H, CH(CH3)2), 5.01 
and 5.08 (m, 1H, 1-H), 6.73 and 6.80 (m, 1H, OCHCH3O), 7.17 (m, 3H, PhH), 7.25 (m, 
2H, PhH). 13C-NMR (CDCl3) δ ppm: 14.32 (+, CH3CH2), 15.82 and 16.21 (-, C-3), 19.42 
and 19.49 (+, OCHCH3O), 21.58 and 21.62 (2C, +, CH(CH3)2), 24.82 and 24.89 (-, C-2), 
25.03 and 25.25 (-, C-7), 29.86 and 30.03 (-, C-8), 32.18 (-, PhCH2), 35.02 and 35.08 (-, 
PhCH2CH2), 49.33 and 49.95 (+, C-1), 51.10 (-, C-6), 51.64 and 51.80 (-, C-4), 57.17 and 
57.29 (+, C-9), 60.51 and 60.56 (+, PhCH2CH2CH), 60.61 (-, CH3CH2), 72.73 and 72.78 
(+, CH(CH3)2), 91.83 and 91.94 (+, OCHCH3O), 125.84 (+, PhC), 128.31 (2C, +, PhC), 
128.38 (2C, +, PhC), 141.49 (quat, PhC), 152.42 and 152.61 (quat, (CH3)2CHOCOO), 
169.46 and 169.52 (quat, C-1-COO), 174.41 (quat, CH3CH2OCO), 174.99 (quat, C-10). 
HRMS: EI-MS: m/z for (C28H41N3O8) calcd. 547.2894, found: 547.28848. Analytical 
HPLC: purity 100 %, two diastereomeres, tR = 16.56, 16.72 min (gradient a), k = 4.75, 
4.81. C28H41N3O8 (547.64). 
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3.8.2.2 General procedure for the synthesis of 1-chloroethyl alkanoates 3.4, 3.520 
A catalytic amount of ZnCl2 was added to the corresponding acid chloride (1 eq). Under 
stirring acetaldehyde (1.04 eq) was added dropwise at -20 °C. The reaction mixture was 
stirred below 0 °C for 1 h and then at room temperature for 1-3 h. The resulting reaction 
mixture was poured into cold water and extracted three times with diethylether. The 
pooled organic layers were washed with saturated sodium hydrogen carbonate solution 
and twice with brine, dried over anhydrous MgSO4, filtered and evaporated under 
reduced pressure. The resulting brown liquid was purified by distillation under reduced 
pressure (57 mm Hg). 
1-Chloroethyl acetate (3.4): The title compound was prepared according to general 
procedure 3.8.2.2 using acetyl chloride (171 mmol, 12.17 ml) and acetaldehyde (177 
mmol, 10 ml). Distillation under reduced pressure yielded the desired product as a 
colorless liquid (12.57 g, 60 %). Bp: 32-34 °C/ 57 mmHg. 1H-NMR (CDCl3) δ ppm: 1.79 
(d, 3H, 3J = 5.8 Hz, ClCHCH3), 2.12 (s, 3H, OCOCH3), 6.53 (q, 1H, 3J = 5.8 Hz, 
ClCHCH3). 13C-NMR (CDCl3) δ ppm: 20.92 (OCOCH3), 25.19 (ClCHCH3), 80.67 
(ClCHCH3), 168.63 (C=O). CI-MS (NH3) m/z (%): 140 (100) [M+NH4]+. C4H7ClO2 
(122.55). 
1-Chloroethyl-2,2-dimethyl propanoate (3.5): The title compound was prepared from 
pivaloyl chloride (171 mmol, 20.98 ml) and acetaldehyde (177 mmol, 10 ml) according to 
the general procedure 3.8.2.2. Distillation under reduced pressure yielded the desired 
product as a colorless liquid (14.92 g, 53 %). Bp: 50-53 °C/ 57 mmHg. 1H-NMR (CDCl3) δ 
ppm: 1.22 (s, 9H, C(CH3)3), 1.79 (d, 3H, 3J = 5.8 Hz, ClCHCH3), 6.54 (q, 1H, 3J = 5.8 Hz, 
ClCHCH3). 13C-NMR (CDCl3) δ ppm: 25.07 (+, ClCHCH3), 26.73 (3C, +, C(CH3)3), 38.66 
(quat, C(CH3)3), 80.87 (+, ClCHCH3), 176.06 (quat, C=O). CI-MS (NH3) m/z (%): 182 
(100) [M+NH4]+. C7H13ClO2 (164.63). 
(1S,9S)-1-Acetoxyethyl 9-((S)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)-10-oxo-
octahydro-1H-pyridazino[1,2-a][1,2]diazepine-1-carboxylate (3.6): The title com-
pound was prepared according to the general procedure 3.8.2.1 using cilazapril (0.6 
mmol, 0.25 g), K2CO3 (0.7 mmol, 0.10 g) and 3.4 (0.8 mmol, 0.11 g) in DMF (H2O < 0.01 
%) (3 ml) and was obtained after flash chromatography (PE/EtOAc 5/4 to 1/2 v/v) as a 
pale yellow oil (0.18 g, 70 %). 1H-NMR (CDCl3) δ ppm: 1.27 (m, 3H, CH3CH2), 1.37 and 
1.72 (m, 2H, 3-H2), 1.48 (d, 3H, 3J = 5.5 Hz, OCHCH3O), 1.48 and 2.02 (m, 2H, 8-H2), 
1.72 and 1.89 (m, 2H, 7-H2), 1.83 and 2.23 and 2.34 (m, 2H, 2-H2), 2.02 (m, 2H, 
PhCH2CH2), 2.03 and 2.07 (2 s, 3H, CH3COO), 2.50 and 3.26 and 3.43 (m, 2H, 6-H2), 
2.73 (m, 2H, PhCH2), 2.93 and 3.06 (m, 2H, 4-H2), 3.37 (m, 1H, PhCH2CH2CH), 4.15 (m, 
1H, 9-H), 4.18 (m, 2H, CH3CH2), 5.00 and 5.06 (m, 1H, 1-H), 6.81 and 6.89 (m, 1H, 
OCHCH3O), 7.17 (m, 3H, PhH), 7.25 (m, 2H, PhH). 13C-NMR (CDCl3) δ ppm: 14.30 (+, 
CH3CH2), 15.79 and 16.15 (-, C-3), 19.35 and 19.41 (+, OCHCH3O), 20.70 and 20.75 (+, 
CH3COO), 24.76 and 24.91 (-, C-2), 25.00 and 25.28 (-, C-7), 29.91 and 30.06 (-, C-8), 
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32.17 (-, PhCH2), 35.04 and 35.10 (-, PhCH2CH2), 49.24 and 49.86 (+, C-1), 51.02 and 
51.55 (-, C-6), 51.62 and 51.80 (-, C-4), 57.15 and 57.26 (+, C-9), 60.52 (+, 
PhCH2CH2CH), 60.59 (-, CH3CH2), 89.21 and 89.27 (+, OCHCH3O), 125.83 and 125.84 
(+, PhC), 128.30 (2C, +, PhC), 128.36 (2C, +, PhC), 141.48 and 141.51 (quat, PhC), 
168.70 and 169.02 (quat, CH3COO), 169.46 and 169.52 (quat, C-1-COO), 174.46 (quat, 
CH3CH2OCO), 174.94 and 175.02 (quat, C-10). HRMS: EI-MS: m/z for (C26H37N3O7) 
calcd. 503.2632, found: 503.26416. Analytical HPLC: purity 99 %, tR = 14.65 min 
(gradient a), k = 4.09. C26H37N3O7 (503.59). 
(1S,9S)-1-(2,2-Dimethylpropanoyl)ethyl 9-((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl-
amino)-10-oxooctahydro-1H-pyridazino[1,2-a][1,2]diazepine-1-carboxylate (3.7): 
The title compound was prepared from cilazapril (0.6 mmol, 0.25 g), K2CO3 (0.7 mmol, 
0.10 g) and 3.5 (0.8 mmol, 0.14 g) in DMF (H2O < 0.01 %) (3 ml) according to the 
general procedure 3.8.2.1 and was obtained after flash chromatography (PE/EtOAc 1/1 
v/v) as a pale yellow oil (0.29 g, 87 %). 1H-NMR (CDCl3) δ ppm: 1.16 and 1.19 (2s, 9H, 
C(CH3)3), 1.27 (m, 3H, CH3CH2), 1.36 and 1.71 (m, 2H, 3-H2), 1.45 and 2.02 (m, 2H, 8-
H2), 1.48 (d, 3H, 3J = 5.5 Hz, OCHCH3O), 1.71 and 1.82 (m, 2H, 7-H2), 1.83 and 2.21 
and 2.33 (m, 2H, 2-H2), 2.01 (m, 2H, PhCH2CH2), 2.44 (bs, 1H, NH), 2.50 and 3.31 and 
3.44 (m, 2H, 6-H2), 2.72 (m, 2H, PhCH2), 2.93 and 3.06 (m, 2H, 4-H2), 3.36 (m, 1H, 
PhCH2CH2CH), 4.15 (m, 1H, 9-H), 4.19 (m, 2H, CH3CH2), 5.00 and 5.06 (m, 1H, 1-H), 
6.81 and 6.85 (m, 1H, OCHCH3O), 7.17 (m, 3H, PhH), 7.25 (m, 2H, PhH). 13C-NMR 
(CDCl3) δ ppm: 14.30 (+, CH3CH2), 15.78 and 16.19 (-, C-3), 19.21 and 19.38 (+, 
OCHCH3O), 24.79 and 24.92 (-, C-2), 25.11 and 25.38 (-, C-7), 26.79 and 26.82 (3C, +, 
C(CH3)3), 29.99 and 30.26 (-, C-8), 32.17 and 32.20 (-, PhCH2), 35.10 and 35.17 (-, 
PhCH2CH2), 38.59 and 38.64 (quat, C(CH3)3), 49.24 and 49.84 (+, C-1), 51.08 and 51.57 
(-, C-6), 51.64 and 51.82 (-, C-4), 57.11 and 57.22 (+, C-9), 60.52 (-, CH3CH2), 60.64 (+, 
PhCH2CH2CH), 89.19 and 89.63 (+, OCHCH3O), 125.81 and 125.82 (+, PhC), 128.28 
(2C, +, PhC), 128.36 (2C, +, PhC), 141.53 and 141.56 (quat, PhC), 169.44 and 169.65 
(quat, C-1-COO), 174.58 (quat, CH3CH2OCO), 175.02 and 175.14 (quat, C-10), 176.20 
and 176.46 (quat, C(CH3)3COO). HRMS: EI-MS: m/z for (C29H43N3O7) calcd. 545.3101, 
found: 545.30947. Analytical HPLC: purity 99 %, two diastereomers, tR = 17.26, 17.64 
min (gradient a), k = 4.99, 5.13. C29H43N3O7 (545.67). 
2-tert-Butyl-1,3-dithiane (3.8a)21: Propane-1,3-dithiol (1 eq, 0.18 mol, 19.4 g) was 
added dropwise to a mixture of pivaldehyde (1.3 eq, 0.24 mol, 20.3 g) and lithium 
tetrafluoroborate (0.1 eq, 0.018 mol, 1.0 g). The reaction mixture was allowed to stir 
overnight. Excess pivaldehyde was removed by distillation at atmospheric pressure. The 
desired product was obtained by distillation under reduced pressure as a light yellowish 
liquid (25.92 g, 82%). Bp.: 58-60 °C/ 0.2 mbar (ref.49: 108-110 °C/ 12 torr). 1H-NMR 
(CDCl3) δ ppm: 1.11 (s, 9H, (CH3)3), 1.80 and 2.07 (m, 2H, 1,3-dithiane-5-H2), 2.89 (m, 
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4H, 1,3-dithiane-4-H2 and 1,3-dithiane-6-H2), 3.99 (s, 1H, 1,3-dithiane-2-H). CI-MS (NH3) 
m/z (%): 177 (100) [M+H]+. C8H16S2 (176.34). 
1-(2-tert-Butyl-1,3-dithian-2-yl)ethanol (3.8b)22: 3.8a (1 eq, 108 mmol, 19.11 g) was 
dissolved in 217 ml THF/abs to give a 0.5 mol/l solution. A 1.6 mol/l solution of 
butyllithium in hexane (1.05 eq, 114 mmol, 71.1 ml) was added dropwise to the stirred 
reaction mixture under nitrogen at -25 °C. The reaction mixture was kept stirring for 5 h 
at -25 °C, cooled down to -78 °C and acetaldehyde (1.5 eq, 163 mmol, 9.2 ml) was 
added dropwise. The mixture was stirred overnight and allowed to warm to room 
temperature, poured into 600 ml H2O and extracted three times with CHCl3. The pooled 
organic layers were washed twice with 10 % potassium hydroxide solution and once with 
H2O, dried over anhydrous MgSO4 and filtered. The volatiles were rotary evaporated. 
The resulting material was fractionally distilled under reduced pressure to yield a light 
yellowish liquid (14.59 g, 61 %). Bp.: 92-95 °C/ 0.2 mbar. 1H-NMR (CDCl3) δ ppm: 1.23 
(s, 9H, (CH3)3), 1.57 (d, 3H, 3J = 6.5 Hz, CHCH3), 1.82 and 2.02 (m, 2H, 1,3-dithiane-5-
H2), 2.65 and 2.95 (m, 4H, 1,3-dithiane-4-H2, 1,3-dithiane-6-H2), 3.12 (d, 1H, 3J = 2.0 Hz, 
OH), 4.36 (dq, 1H, 3J = 2.7 Hz, 3J = 6.6 Hz, CH). 13C-NMR (CDCl3) δ ppm: 19.69 (+, 
CHCH3), 23.80 (-, 1,3-dithiane-C-5), 25.88 and 26.78 (-, 2C, 1,3-dithiane-C-4 and 1,3-
dithiane-C-6), 28.26 (+, C(CH3)3), 41.31 (quat, C(CH3)3), 67.49 (+, CH), 70.76 (quat, 1,3-
dithiane-C-2). CI-MS (NH3) m/z (%): 238 (100) [M+NH4]+. C10H20OS2 (220.40). 
4-Hydroxy-2,2-dimethylpentan-3-one (3.8)22: HgCl2 (2.5 eq, 166 mmol, 44.93 g) and 
HgO (1.5 eq, 99 mmol, 21.51 g) were added to a solution of 3.8b (1 eq, 66 mmol, 14.59 
g) in MeOH/H2O (9/1 v/v). The reaction mixture was heated to reflux for 5 h. Solids were 
removed by filtration and washed with little amounts of diethylether. The filtrate was 
diluted with ca. 700 ml H2O and extracted with diethylether three times. The pooled 
organic layers were successively washed with H2O, saturated ammonium chloride 
solution and H2O, dried over anhydrous MgSO4 and concentrated under reduced 
pressure. The resulting material was objected to fractional distillation to yield the desired 
product as a colorless liquid (3.83 g, 44.4 %). Bp.: 35-38 °C/ 0.2 mbar. 1H-NMR (CDCl3) 
δ ppm: 1.21 (s, 9H, C(CH3)3), 1.35 (d, 3H, 3J = 6.8 Hz, CH3), 2.83 (bs, 1H, OH), 4.60 (q, 
1H, 3J = 6.8 Hz, CH). 13C-NMR (CDCl3) δ ppm: 21.68 (+, CH3), 26.74 (+, C(CH3)3), 42.63 
(quat, C(CH3)3), 68.57 (+, CH), 218.43 (quat, C=O). CI-MS (NH3) m/z (%): 148 (100) 
[M+NH4]+. C7H14O2 (130.18). 
4-tert-Butyl-5-methyl-1,3-dioxol-2-one (3.9)23: A solution of triphosgene (0.75 eq, 22.1 
mmol, 6.55 g) in 15 ml of DCM to a mixture of 3.8 (1 eq, 29.4 mmol, 3.83 g) and 
dimethylaniline (1.5 eq, 44.1 mmol, 5.57 ml) in 60 ml of DCM was added over a period of 
30 min. The reaction mixture was stirred at room temperature for 2 h. The solvent was 
rotary evaporated, and the residue was heated to reflux at 160 °C for 4 h. The crude 
product was purified by fractional distillation under reduced pressure. The product 
containing fractions were pooled, dissolved in diethylether and washed with 1 mol/l HCl 
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solution. The organic phase was dried over anhydrous MgSO4, filtered and evaporated 
under reduced pressure to yield the title compound as a colorless liquid (1.84 g, 40 %). 
Bp.: 39-43 °C/ 0.2 mbar (ref.23: 108-112 °C/ 1 torr). 1H-NMR (CDCl3) δ ppm: 1.24 (s, 9H, 
C(CH3)3), 2.13 (s, 3H, CH3). 13C-NMR (CDCl3) δ ppm: 10.52 (+, CH3), 28.22 (+, C(CH3)3), 
31.54 (quat, C(CH3)3), 132.85 (quat, CH3C=CtBu), 145.03 (quat, CH3C=CtBu), 152.96 
(quat, C=O). EI-MS (70 eV) m/z (%): 192 (8) [M+.]. EI-MS (70 eV) m/z (%): 156 (21) [M+.]. 
C8H12O3 (156.18). 
4-(Bromomethyl)-5-methyl-1,3-dioxol-2-one (3.10): N-bromosuccinimide (1.1 eq, 9.7 
mmol, 1.72 g) and azobisisobutyronitrile (0.02 eq, 0.1 mmol, 22 mg) were added to a 
solution of 4,5-dimethyl-1,3-dioxol-2-one (1 eq, 8.8 mmol, 1.00 g) in ca. 40 ml CCl4. The 
reaction mixture was carefully heated to reflux. After the reaction started with vigorous 
boiling the reaction mixture was heated to reflux for 1 h. Solids were removed by filtration 
and the filtrate was concentrated under reduced pressure. The resulting material was 
subjected to distillation under reduced pressure to yield the title compound as a yellow 
liquid (1.12 g, 66 %). Bp: 90 °C/ 1 mbar (ref.50:115-120 °C/ 5 torr). 1H-NMR (CDCl3) δ 
ppm: 2.13 (s, 3H, CH3), 4.18 (s, 2H, CH2). 13C-NMR (CDCl3) δ ppm: 9.49 (+, CH3), 17.78 
(-, CH2), 134.46 (quat, CH3C=CCH2), 136.57 (quat, CH3C=CCH2), 137.89 (quat, C=O). 
EI-MS (70 eV) m/z (%): 192 (8) [M+.]. C5H5BrO3 (193.00). 
4-(Bromomethyl)-5-tert-butyl-1,3-dioxol-2-one (3.11): The title compound was pre-
pared following the procedure described for the synthesis of 3.10, using 3.9 (1 eq, 6.4 
mmol, 1.0 g), N-bromosuccinimide (1.1 eq, 7.0 mmol, 1.25 g) and azobisisobutyronitrile 
(0.05 eq, 0.5 mmol, 87 mg) in ca. 50 ml CCl4, and was obtained after distillation under 
reduced pressure as a pale yellow liquid (1.29 g, 86%). Bp.: 60-64 °C/ 0.2 mbar (ref.51: 
112-115 °C/ 4 torr). 1H-NMR (CDCl3) δ ppm: 1.31 (s, 9H, C(CH3)3), 4.29 (s, 2H, CH2). 
13C-NMR (CDCl3) δ ppm: 19.54 (-, CH2), 27.76 (+, C(CH3)3), 32.30 (quat, C(CH3)3), 
133.01 (quat, CH2C=CtBu), 148.09 (quat, CH2C=CtBu), 151.42 (quat, C=O). EI-MS (70 
eV) m/z (%): 234 (10) [M+.]. C8H11BrO3 (235.08). 
3.8.2.3 General procedure for the synthesis of (5-alkyl-2-oxo-1,3-dioxol-4-yl)me-
thyl esters (3.12, 3.13) 
K2CO3 (1.5 eq) was added to a solution of cilazapril (1 eq) in DMF (H2O < 0.01 %). A 
solution of the appropriate 4-(bromomethyl)-5-alkyl-1,3-dioxol-2-one (1.4 eq) in DMF 
(H2O < 0.01 %) was added dropwise at 0 °C. The reaction mixture was warmed to room 
temperature and stirred overnight. The solvent was evaporated under reduced pressure 
and the residue was taken up in EtOAc/H2O 1/1 v/v. The layers were separated and the 
aqueous phase was extracted twice with EtOAc. The combined organic phases were 
washed with brine, dried over anhydrous MgSO4, filtered and evaporated to dryness. 
Flash chromatography of the crude material yielded the title cilazapril derivatives. 
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(1S,9S)-(5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 9-((S)-1-ethoxy-1-oxo-4-phenylbu-
tan-2-ylamino)-10-oxooctahydro-1H-pyridazino[1,2-a][1,2]diazepine-1-carboxylate 
(3.12): The title compound was prepared according to the general procedure 3.8.2.3, 
using cilazapril (1.2 mmol, 0.50 g), K2CO3 (1.8 mmol, 0.25 g) and 3.10 (1.48 eq, 
1.8 mmol, 0.34 g) in DMF (H2O < 0.01 %) (5 ml), and was obtained after flash 
chromatography (PE/EtOAC 2/1 to 1/1 v/v) as a yellow oil (0.36 g, 61 %). 1H-NMR 
(CDCl3) δ ppm: 1.27 (t, 3H, 3J = 7.2 Hz, CH3CH2), 1.39 and 1.68 (m, 2H, 3-H2), 1.44 and 
2.02 (m, 2H, 8-H2), 1.72 and 1.84 (m, 2H, 7-H2), 1.85 and 2.29 (m, 2H, 2-H2), 2.01 (m, 
2H, PhCH2CH2), 2.16 (s, 3H, CH3C=C), 2.51 and 3.24 (m, 2H, 6-H2), 2.72 (m, 2H, 
PhCH2), 2.94 and 3.08 (m, 2H, 4-H2), 3.34 (m, 1H, PhCH2CH2CH), 4.13 (m, 1H, 9-H), 
4.17 (m, 2H, CH3CH2), 4.88 (s, 2H, OCH2C=C), 5.06 (m, 1H, 1-H), 7.17 (m, 3H, PhH), 
7.25 (m, 2H, PhH). 13C-NMR (CDCl3) δ ppm: 9.38 (+, CH3C=C), 14.28 (+, CH3CH2), 
15.93 (-, C-3), 24.87 (-, C-2), 24.95 (-, C-7), 29.98 (-, C-8), 32.16 (-, PhCH2), 35.13 (-, 
PhCH2CH2), 49.53 (+, C-1), 51.28 (-, C-6), 51.58 (-, C-4), 54.37 (-, OCH2C=C), 57.09 (+, 
C-9), 60.43 (+, PhCH2CH2CH), 60.58 (-, CH3CH2), 125.83 (+, PhC), 128.29 (2C, +, PhC), 
128.35 (2C, +, PhC), 133.00 (quat, CH3C=C), 140.35 (quat, CH3C=C), 141.49 (quat, 
PhC), 151.86 (quat, OC(O)O), 171.44 (quat, C-1-COO), 174.61 (quat, CH3CH2OCO), 
175.11 (quat, C-10). HRMS: EI-MS: m/z for (C27H35N3O8) calcd. 529.2424, found: 
529.24212. Analytical HPLC: purity 98 %, tR = 12.41 min (gradient b), k = 3.31. 
C27H35N3O8 (529.58). 
(1S,9S)-(5-tert-Butyl-2-oxo-1,3-dioxol-4-yl)methyl 9-((S)-1-ethoxy-1-oxo-4-phenylbu-
tan-2-ylamino)-10-oxooctahydro-1H-pyridazino[1,2-a][1,2]diazepine-1-carboxylate 
(3.13): The title compound was prepared from cilazapril (1.2 mmol, 0.50 g), K2CO3 (1.7 
mmol, 0.23 g) and 3.11 (1.7 mmol, 0.40 g) in DMF (H2O < 0.01 %) (5 ml) according to 
the general procedure 3.8.2.3 and was obtained after flash chromatography (PE/EtOAC 
3/1 v/v) as a yellow oil (0.42 g, 66 %). 1H-NMR (CDCl3) δ ppm: 1.28 (m, 3H, CH3CH2), 
1.29 (s, 9H, (CH3)3), 1.48 and 1.70 (m, 2H, 3-H2), 1.48 and 2.05 (m, 2H, 8-H2), 1.72 and 
1.85 (m, 2H, 7-H2), 1.85 and 2.30 (m, 2H, 2-H2), 2.05 (m, 2H, PhCH2CH2), 2.53 and 3.29 
(m, 2H, 6-H2), 2.73 (m, 2H, PhCH2), 2.94 and 3.08 (m, 2H, 4-H2), 3.39 (m, 1H, 
PhCH2CH2CH), 4.16 (m, 1H, 9-H), 4.20 (m, 2H, CH3CH2), 5.00 (m, 2H, OCH2C=C), 5.05 
(m, 1H, 1-H), 7.17 (m, 3H, PhH), 7.25 (m, 2H, PhH). 13C-NMR (CDCl3) δ ppm: 14.33 (+, 
CH3CH2), 16.01 (-, C-3), 25.03 (2C, -, C-2 and C-7), 27.92 (3C, +, C(CH3)3), 29.58 (-, C-
8), 32.17 (-, PhCH2), 34.86 (-, PhCH2CH2), 40.87 (quat, C(CH3)3), 49.82 (+, C-1), 51.42 (-
, C-6), 51.70 (-, C-4), 55.89 (-, OCH2C=C), 57.31 (+, C-9), 60.40 (+, PhCH2CH2CH), 
60.87 (-, CH3CH2), 125.96 (+, PhC), 128.38 (2C, +, PhC), 128.44 (2C, +, PhC), 131.13 
(quat, (CH3)3CC=C), 141.35 (quat, PhC), 150.17 (quat, (CH3)3CC=C), 151.72 (quat, 
OC(O)O), 170.80 (quat, C-1-COO), 174.02 (quat, CH3CH2OCO), 174.72 (quat, C-10). 
HRMS: EI-MS: m/z for (C30H41N3O8) calcd. 571.2894, found: 571.2890. Analytical HPLC: 
purity 97 %, tR = 14.11 min (gradient b), k = 3.90. C30H41N3O8 (571.66). 
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(1S,9S)-2-Morpholinoethyl 9-((S)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)-10-oxo-
octahydro-1H-pyridazino[1,2-a][1,2]diazepine-1-carboxylate (3.14): A catalytic 
amount of 4-(dimethylamino)pyridine and 4-(2-hydroxyethyl)morpholine (1 eq, 2.4 mmol, 
0.29 ml) were added to a solution of cilazapril (1 eq, 2.4 mmol, 1.00 g) in DCM/abs 
(5 ml). A solution of N,N’-dicyclohexylcarbodiimide (1.1 eq, 2.6 mmol, 0.55 g) in 
DCM/abs (2 ml) was added dropwise at 0 °C under an atmosphere of argon. The 
reaction mixture was stirred at 0 °C for 1 h and at room temperature overnight. Solids 
were removed by filtration. Rotary evaporation of the filtrate gave the crude product, 
which was subjected to flash chromatography (PE/EtOAc 1/3 + 0.5 % NEt3 v/v) to yield 
the desired product as a yellow oil (0.91 g, 72 %). 1H-NMR (CDCl3) δ ppm: 1.27 (t, 3H, 3J 
= 7.1 Hz, CH3CH2), 1.37 and 1.72 (m, 2H, 3-H2), 1.46 and 2.01 (m, 2H, 8-H2), 1.72 and 
1.85 (m, 2H, 7-H2), 1.85 and 2.31 (m, 2H, 2-H2), 2.01 (m, 2H, PhCH2CH2), 2.22 (bs, 1H, 
NH), 2.47 (m, 4H, mo-3-H2, mo-5-H2), 2.50 and 3.40 (m, 2H, 6-H2), 2.60 (m, 2H, 
OCOCH2CH2N), 2.73 (m, 2H, PhCH2), 2.94 and 3.08 (m, 2H, 4-H2), 3.52 (t, 1H, 3J = 6.6 
Hz, PhCH2CH2CH), 3.67 (m, 4H, mo-2-H2, mo-6-H2), 4.14 (m, 1H, 9-H), 4.18 (m, 2H, 
CH3CH2), 4.21 and 4.29 (m, 2H, OCOCH2CH2N), 5.03 (m, 1H, 1-H), 7.17 (m, 3H, PhH), 
7.25 (m, 2H, PhH). 13C-NMR (CDCl3) δ ppm: 14.29 (+, CH3CH2), 16.06 (-, C-3), 25.13 
(2C, -, C-2 and C-7), 30.15 (-, C-8), 32.19 (-, PhCH2), 35.16 (-, PhCH2CH2), 49.78 (+, C-
1), 51.38 (-, C-6), 51.74 (-, C-4), 53.67 (2C, -, mo-C-3, mo-C-5), 56.96 (-, 
OCOCH2CH2N), 57.13 (+, C-9), 60.50 (-, CH3CH2), 60.56 (+, PhCH2CH2CH), 61.81 (-, 
OCOCH2CH2N), 66.87 (2C, -, mo-C-2, mo-C-6), 125.80 (+, PhC), 128.28 (2C, +, PhC), 
128.35 (2C, +, PhC), 141.55 (quat, PhC), 171.34 (quat, C-1-COO), 174.61 (quat, 
CH3CH2OCO), 175.14 (quat, C-10). HRMS: EI-MS: m/z for (C28H42N4O6) calcd. 
530.3104, found: 530.31032. Analytical HPLC: purity 100 %, tR = 8.49 min (gradient b), k 
= 1.95. C28H42N4O6 (530.66). 
Chlorosulfuric acid 1-chloroethyl ester (3.15)24: Chlorosulfuric acid (1.08 eq, 45 mmol, 
3.00 ml) was added dropwise to 1-chloroethyl chloroformate (1 eq, 42 mmol, 4.57 ml) at 
0 °C. The reaction mixture was stirred for 4 h until gas evolution ceased and was then 
poured into a mixture of ice water and DCM (1/1 v/v). The phases were separated and 
the aqueous layer was extracted with DCM twice. The pooled organic layers were 
washed twice with saturated NaHCO3 solution and once with brine, dried over anhydrous 
MgSO4 and filtered. The volatiles were rotary evaporated and the residue was purified by 
distillation under reduced pressure to yield the title compound as a colorless liquid (4.15 
g, 55 %). Bp.: 63-65 °C/ 57 mmHg (ref.24: 49-50 °C/ 10 torr). 1H-NMR (CDCl3) δ ppm: 
1.99 (d, 1H, 3J = 5.8 Hz, CH), 6.48 (q, 3H, 3J = 5.8 Hz, CH3). 13C-NMR (CDCl3) δ ppm: 
26.31 (+, CH3), 90.98 (+, CH). C2H4Cl2O3S (179.02). 
(1S,9S)-1-Chloroethyl 9-((S)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)-10-oxoocta-
hydro-1H-pyridazino[1,2-a][1,2]diazepine-1-carboxylate (3.16)24: Compound 3.15 
(2 eq, 2.9 mmol, 0.52 g) was added dropwise to a mixture of cilazapril (1 eq, 1.4 mmol, 
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0.60 g), NaHCO3 (3.9 eq, 5.6 mmol, 0.47 g) and tetrabutylammonium hydrogensulfate 
(0.1 eq, 0.14 mmol, 49 mg) in DCM/H2O (1/1 v/v). The reaction mixture was vigorously 
stirred under reflux for 4 h and at room temperature overnight. The phases were 
separated and the aqueous layer was extracted with DCM twice. The combined organic 
layers were washed twice with saturated NaHCO3 solution and once with brine, dried 
over anhydrous MgSO4, filtered and evaporated to dryness. The title compound was 
obtained after flash chromatography (PE/EtOAC 2/1 v/v) as a yellow oil (0.44 g, 63 %). 
1H-NMR (CDCl3) δ ppm: 6.52 (m, 1H, CHCl). 13C-NMR (CDCl3) δ ppm: 25.03 and 25.25 
(+, CH3CHCl), 81.47 and 81.37 (+, CH3CHCl). ES-MS (DCM/MEOH + 10 mM NH4OAc) 
m/z (%): 480 (100) [M+H]+. C24H34ClN3O5 (480.00). 
tert-Butyl 2-morpholinoacetate (3.17a)25: To a solution of tert-butyl bromoacetate 
(1 eq, 28.5 mmol, 5.56 g) in THF a mixture of morpholine (1 eq, 28.5 mmol, 2.50 g) and 
triethylamine (1 eq, 28.5 mmol, 4 ml) was added dropwise at 0 °C. The reaction mixture 
was heated to reflux for 2 h and then cooled down to 0 °C again. The resulting 
suspension was filtered and the filtrate was evaporated to dryness. The oily residue was 
dissolved in ethyl acetate and washed with H2O. After the organic phase was dried over 
anhydrous MgSO4 and filtered the solvent was removed under reduced pressure to yield 
the desired product as a yellow oil (5.17 g, 90 %). 1H-NMR (CDCl3) δ ppm: 1.39 (s, 9H, 
C(CH3)3), 2.50 (m, 4H, mo-3-H2, mo-5-H2), 3.03 (s, 2H, CH2), 3.68 (m, 4H, mo-2-H2, mo-
6-H2). C10H19NO3 (201.26). 
2-Morpholinoacetic acid (3.17)25: TFA (1.6 eq, 42 mmol, 32 ml) was added dropwise to 
a solution of 3.17a (1 eq, 26 mmol, 5.17 g) in DCM at 0 °C. The reaction mixture was 
stirred at room temperature overnight and was afterwards evaporated to dryness. 
Treatment of the residue with diisopropylether resulted in crystallization of the product, 
which was filtered off and dried under reduced pressure. The off-white crystalline product 
was obtained as a non-stoichiometric salt with TFA (6.16 g). 1H-NMR (DMSO-d6) δ ppm: 
3.26 (m, 4H, mo-3-H2, mo-5-H2), 3.83 (m, 4H, mo-2-H2, mo-6-H2), 4.08 (s, 2H, CH2), 
10.68-14.10 (bs, 2H, OH). ES-MS (DCM/MEOH + 10 mM NH4OAc) m/z (%): 146 (100) 
[M+H]+. C6H11NO3 (145.16). 
(1S,9S)-1-(2-Morpholinoacetoxy)ethyl 9-((S)-1-ethoxy-1-oxo-4-phenylbutan-2-ylami-
no)-10-oxooctahydro-1H-pyridazino[1,2-a][1,2]diazepine-1-carboxylate (3.18): 
Cs2CO3 (4 eq, 3.76 mmol, 1.23 g) was added to a solution of the 3.17 (2 eq, 1.88 mmol, 
0.49 g) in DMF (H2O < 0.01 %) (6 ml). A solution of 3.16 (1 eq, 0.94 mmol, 0.45 g) in 
DMF (H2O < 0.01 %) (1 ml) was added dropwise. The mixture was stirred for 7 h at 40 °C 
and overnight at room temperature. The solvent was evaporated under reduced pressure 
and the residue was taken up in EtOAc/H2O 1/1 v/v. The layers were separated and the 
aqueous phase was extracted with EtOAc twice. The pooled organic phases were 
washed with brine, dried over anhydrous MgSO4, filtered and evaporated to dryness. 
Flash chromatography (PE/EtOAc 1/1 + NH3 to 1/2 + NH3 v/v) of the crude material 
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yielded the target compound as a yellow oil (0.17 g, 31 %). 1H-NMR (CDCl3) δ ppm: 1.27 
(t, 3H, 3J = 7.1 Hz, CH3CH2), 1.36 and 1.71 (m, 2H, 3-H2), 1.44 and 2.00 (m, 2H, 8-H2), 
1.50 (d, 3H, 3J = 5.5 Hz, OCHCH3O), 1.70 and 1.85 (m, 2H, 7-H2), 1.85 and 2.22 and 
2.30 (m, 2H, 2-H2), 2.01 (m, 2H, PhCH2CH2), 2.49 and 3.28 and 3.39 (m, 2H, 6-H2), 2.56 
(m, 4H, mo-3-H2, mo-5-H2), 2.71 (m, 2H, PhCH2), 2.93 and 3.06 (m, 2H, 4-H2), 3.18 and 
3.22 (2 s, 2H, mo-CH2CO), 3.34 (m, 1H, PhCH2CH2CH), 3.71 (m, 4H, mo-2-H2, mo-6-
H2), 4.14 (m, 1H, 9-H), 4.17 (m, 2H, CH3CH2), 5.00 and 5.05 (m, 1H, 1-H), 6.85 and 6.91 
(2 q, 1H, 3J = 5.4 Hz, OCHCH3O), 7.17 (m, 3H, PhH), 7.25 (m, 2H, PhH). 13C-NMR 
(CDCl3) δ ppm: 14.28 (+, CH3CH2), 15.77 and 16.04 (-, C-3), 19.37 and 19.47 (+, 
OCHCH3O), 24.79 and 24.94 (-, C-2), 24.85 and 25.13 (-, C-7), 29.88 and 30.04 (-, C-8), 
32.15 (-, PhCH2), 35.08 and 35.12 (-, PhCH2CH2), 49.29 and 49.74 (+, C-1), 51.10 and 
51.50 (-, C-6), 51.54 and 51.66 (-, C-4), 52.94 and 53.00 (2C, -, mo-C-3, mo-C-5), 57.06 
and 57.12 (+, C-9), 58.98 and 59.12 (-, mo-CH2CO), 60.48 and 60.52 (+, PhCH2CH2CH), 
60.54 (-, CH3CH2), 66.65 and 66.66 (2C, -, mo-C-2, mo-C-6), 89.28 and 89.38 (+, 
OCHCH3O), 125.81 and 125.82 (+, PhC), 128.28 (2C, +, PhC), 128.33 (2C, +, PhC), 
141.46 and 141.48 (quat, PhC), 167.92 and 168.17 (mo-CH2CO), 169.42 and 169.55 
(quat, C-1-COO), 174.52 (quat, CH3CH2OCO), 174.97 and 175.07 (quat, C-10). HRMS: 
EI-MS: m/z for (C30H44N4O8) calcd. 588.3159, found: 588.31599. Analytical HPLC: purity 
98 %, tR = 10.49 min (gradient a), k = 2.64. C30H44N4O8 (588.69). 
Ethyl phenylcarbamate (3.19)26: Triethylamine (1 eq, 20 mmol, 1.44 g) and aniline 
(1 eq, 20 mmol, 1.86 g) were added dropwise to a solution of ethyl chloroformate (1 eq, 
20 mmol, 2.17 g) in DCM at 0 °C. The reaction mixture was allowed to warm to room 
temperature and was stirred overnight. The solution was washed with brine three times. 
The organic layer was dried over MgSO4, filtered and concentrated under reduced 
pressure to yield the title compound as a yellow solid (2.79 g, 84 %). 1H-NMR (CDCl3) δ 
ppm: 1.30 (t, 3H, 3J = 7.1 Hz, CH3), 4.23 (q, 2H, 3J = 7.1 Hz, CH2), 6.87 (bs, 1H, NH), 
7.05 (m, 1H, PhH), 7.29 (m, 2H, PhH), 7.40 (m, 2H, PhH). C9H11NO2 (165.19). 
Ethyl 4-(ethoxycarbonylamino)benzoate (3.20)26: The title compound was prepared 
following the procedure described for the synthesis of 3.19 using ethyl 4-aminobenzoate 
(1 eq, 20 mmol, 3.30 g), triethylamine (1 eq, 20 mmol, 2.77 ml) and ethyl chloroformate 
(1 eq, 20 mmol, 2.17 g) and was obtained as a yellow solid (2.45 g, 52 %). EI-MS 
(70 eV) m/z (%): 237 (73) [M+.]. C12H15NO4 (237.25). 
Ethyl 4-(methoxycarbonylamino)benzoate (3.21)26: The title compound was prepared 
following the procedure described for the synthesis of 3.19 using ethyl 4-aminobenzoate 
(1 eq, 20 mmol, 3.30 g), triethylamine (1 eq, 20 mmol, 2.77 ml) and methyl chloroformate 
(1 eq, 20 mmol, 1.55 ml) and was obtained as a yellow solid (2.35 g, 53 %). EI-MS 
(70 eV) m/z (%): 223 (56) [M+.]. C11H13NO4 (223.23). 
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Ethyl chloromethyl(phenyl)carbamate (3.22)26: A mixture of 3.19 (1 eq, 17 mmol, 
2.79 g), paraformaldeyde (1.7 eq, 29 mmol, 0.86 g) and trimethylsilyl chloride (13 eq, 
219 mmol, 28 ml) was heated to reflux for 2.5 h. The reaction mixture was diluted with 
DCM and the solids were filtered off. The filtrate was concentrated under reduced 
pressure and the resulting oily residue was triturated with hexane overnight. The 
suspension was filtered and evaporated to dryness to give the desired product as a 
yellow oil (3.03 g, 84 %). 1H-NMR (CDCl3) δ ppm: 1.25 (t, 3H, 3J = 7.1 Hz, CH3), 4.25 (q, 
2H, 3J = 7.1 Hz, CH3CH2), 5.57 (s, 2H, ClCH2), 7.28-7.45 (m, 5H, PhH). CI-MS (NH3) m/z 
(%): 231 (71) [M+NH4]+. C10H12ClNO2 (213.66). 
4-[(Chloromethyl)(ethoxycarbonyl)amino]benzoate (3.23)27: A suspension of 3.20 
(1 eq, 10 mmol, 2.38 g), paraformaldehyde (1.1 eq, 11 mmol, 0.36 g), trimethylsilyl chlo-
ride (5 eq, 50 mmol, 6.3 ml) and 10 g of anhydrous MgSO4 in toluol was stirred at room 
temperature for 2.5 d. After the solids were removed by filtration the filtrate was concen-
trated under reduced pressure to yield the title compound as yellow oil (1.41 g, 49 %). 
1H-NMR (CDCl3) δ ppm: 1.26 (t, 3H, 3J = 7.1 Hz, CH3CH2OCON), 1.39 (t, 3H, 3J = 7.1 
Hz, CH3CH2OCOPh), 4.26 (q, 2H, 3J = 7.1 Hz, CH3CH2OCON), 4.38 (q, 2H, 3J = 7.1 Hz, 
CH3CH2OCOPh), 5.57 (s, 2H, ClCH2), 7.43 (m, 2H, aminobenzoate-3-H, aminobenzoate-
5-H), 8.07 (m, 2H, aminobenzoate-2-H, aminobenzoate-6-H). 13C-NMR (CDCl3) δ ppm: 
14.33 (2C, +, CH3CH2OCON, CH3CH2OCOPh), 61.19, 61.46 (-, ClCH2, CH3CH2OCOPh), 
63.21 (-, CH3CH2OCON), 126.19 (+, 2C, aminobenzoate-C-2, aminobenzoate-C-6), 
129.45 (quat, aminobenzoate-C-4), 130.53 (+, 2C, aminobenzoate-C-3, aminobenzoate-
C-5), 144.28 (quat, aminobenzoate-C-1), 154.05 (quat, OCON), 165.81 (quat, OCOPh). 
CI-MS (NH3) m/z (%): 303 (100) [M+NH4]+. C13H16ClNO4 (285.72). 
4-[(Chloromethyl)(methoxycarbonyl)amino]benzoate (3.24)27: The title compound 
was prepared following the procedure for the synthesis of 3.23 using 3.21 (1 eq, 
8.2 mmol, 1.82 g), paraformaldehyde (1.7 eq, 14 mmol, 0.46 g), trimethylsilyl chloride 
(10 eq, 82 mmol, 10.4 ml) and 10 g of anhydrous MgSO4 and was obtained as yellow oil 
(0.95 g, 43 %). 1H-NMR (CDCl3) δ ppm: 1.39 (t, 3H, 3J = 7.1 Hz, CH3CH2), 3.79 (s, 3H, 
CH3OCO), 4.38 (q, 2H, 3J = 7.1 Hz, CH3CH2), 5.56 (s, 2H, ClCH2), 7.43 (m, 2H, 
aminobenzoate-3-H, aminobenzoate-5-H), 8.08 (m, 2H, aminobenzoate-2-H, amino-
benzoate-6-H). 13C-NMR (CDCl3) δ ppm: 14.33 (+, CH3CH2), 53.96 (+, CH3O), 61.21, 
61.44 (-, ClCH2, CH3CH2), 126.34 (+, 2C, aminobenzoate-C-2, aminobenzoate-C-6), 
129.67 (quat, aminobenzoate-C-4), 130.60 (+, 2C, aminobenzoate-C-3, aminobenzoate-
C-5), 144.10 (quat, aminobenzoate-C-1), 154.57 (quat, OCON), 165.74 (quat, OCOPh). 
CI-MS (NH3) m/z (%): 303 (100) [M+NH4]+. C12H14ClNO4 (271.70). 
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3.8.2.4 General procedure for the synthesis of cilazapril derivatives 3.25-3.27 
K2CO3 (1.8 eq) was added to a solution of cilazapril (1 eq) in DMF (H2O < 0.01 %). A 
solution of ethyl chloromethyl(phenyl)carbamate (1.5 eq) or the appropriate ethyl 4-
((chloromethyl)(alkyloxycarbonyl)amino)benzoate (1.8 eq) in DMF (H2O < 0.01 %) was 
added dropwise at 0 °C. The reaction mixture was warmed to room temperature and 
stirred overnight. The solvent was evaporated under reduced pressure and the residue 
was taken up in EtOAc/H2O 1/1 v/v. The layers were separated and the aqueous phase 
was extracted twice with EtOAc. The combined organic phases were washed with brine, 
dried over anhydrous MgSO4, filtered and evaporated to dryness. Flash chromatography 
of the crude material yielded the title cilazapril derivatives. 
(1S,9S)-[Ethoxycarbonyl(phenyl)amino]methyl 9-((S)-1-ethoxy-1-oxo-4-phenylbu-
tan-2-ylamino)-10-oxooctahydro-1H-pyridazino[1,2-a][1,2]diazepine-1-carboxylate 
(3.25): The title compound was prepared according to the general procedure 3.8.2.4 
from cilazapril (0.36 mmol, 0.15 g), K2CO3 (1.5 eq, 0.54 mmol, 75 mg) and 3.22 
(0.54 mmol, 115 mg) in DMF (H2O < 0.01 %) (3 ml) and was obtained after flash 
chromatography (PE/EtOAc 2/1 v/v) as a pale yellow oil (60 mg, 28 %). 1H-NMR (CDCl3) 
δ ppm: 1.22 (t, 3H, 3J = 6.9 Hz, CH3CH2OCON), 1.27 (t, 3H, 3J = 7.1 Hz, 
CH3CH2OCOCH), 1.37 and 1.67 (m, 2H, 3-H2), 1.37 and 1.98 (m, 2H, 8-H2), 1.67 and 
1.81 (m, 2H, 7-H2), 1.81 and 2.30 (m, 2H, 2-H2), 2.02 (m, 2H, PhCH2CH2), 2.48 and 3.31 
(m, 2H, 6-H2), 2.74 (m, 2H, PhCH2), 2.93 and 3.07 (m, 2H, 4-H2), 3.36 (t, 1H, 3J = 6.6 Hz, 
PhCH2CH2CH), 4.14 (m, 1H, 9-H), 4.18 (m, 4H, CH3CH2OCON and CH3CH2OCOCH), 
5.07 (m, 1H, 1-H), 5.63 and 5.74 (m, 2H, OCH2N), 7.18 (m, 3H, PhH), 7.26 (m, 5H, 
aniline-H, PhH), 7.36 (m, 2H, aniline-H). 13C-NMR (CDCl3) δ ppm: 14.28 (+, 
CH3CH2OCOCH), 14.33 (+, CH3CH2OCON), 16.02 (-, C-3), 24.96 (-, C-2), 25.11 (-, C-7), 
30.06 (-, C-8), 32.20 (-, PhCH2), 35.17 (-, PhCH2CH2), 49.64 (+, C-1), 51.25 (-, C-6), 
51.79 (-, C-4), 57.11 (+, C-9), 60.60 (+, PhCH2CH2CH), 60.63 (-, CH3CH2OCOCH), 62.52 
(-, CH3CH2OCON), 75.33 (-, OCH2N), 125.82 (+, PhC), 126.80 (+, aniline-C), 127.32 (2C, 
+, aniline-C), 128.29 (2C, +, PhC), 128.36 (2C, +, PhC), 129.05 (2C, +, aniline-C), 
140.63 (quat, aniline-C), 141.55 (quat, PhC), 155.02 (quat, CH3CH2OCON), 170.78 
(quat, C-1-COO), 174.59 (quat, CH3CH2OCOCH), 175.19 (quat, C-10). HRMS: LSI-MS: 
m/z for (C32H42N4O7 + H+) calcd. 595.3126, found: 595.31148. Analytical HPLC: purity 96 
%, tR = 13.63 min (gradient b), k = 3.73. C32H42N4O7 (594.70). 
(1S,9S)-{Ethoxycarbonyl[4-(ethoxycarbonyl)phenyl]amino}methyl 9-((S)-1-ethoxy-
1-oxo-4-phenylbutan-2-ylamino)-10-oxooctahydro-1H-pyridazino[1,2-a][1,2]diaze-
pine-1-carboxylate (3.26): The title compound was prepared from cilazapril (0.48 mmol, 
0.20 g), K2CO3 (0.86 mmol, 0.12 g) and 3.23 (0.86 mmol, 0.25 g) in DMF (H2O < 0.01 %) 
(5 ml) according to the general procedure 3.8.2.4 and was obtained after flash 
chromatography (PE/EtOAc 5/2 to 2/1 v/v) as a pale yellow oil (0.19 g, 59 %). 1H-NMR 
(CDCl3) δ ppm: 1.26 (m, 6H, CH3CH2OCON and CH3CH2OCOPh), 1.37 (m, 3H, 
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CH3CH2OCOCH), 1.37 and 1.67 (m, 2H, 3-H2), 1.37 and 2.02 (m, 2H, 8-H2), 1.67 and 
1.81 (m, 2H, 7-H2), 1.81 and 2.30 (m, 2H, 2-H2), 2.02 (m, 2H, PhCH2CH2), 2.02 (m, 1H, 
NH), 2.49 and 3.31 (m, 2H, 6-H2), 2.74 (m, 2H, PhCH2), 2.93 and 3.07 (m, 2H, 4-H2), 
3.36 (t, 1H, 3J = 6.6 Hz, PhCH2CH2CH), 4.14 (m, 1H, 9-H), 4.18 (m, 2H, 
CH3CH2OCOCH), 4.21 (m, 2H, CH3CH2OCON), 4.36 (m, 2H, CH3CH2OCOC6H5) 5.07 
(m, 1H, 1-H), 5.71 (m, 2H, OCH2N), 7.18 (m, 3H, PhH), 7.26 (m, 2H, PhH), 7.35 (m, 2H, 
EtOOCPhH), 8.05 (m, 2H, EtCOOPhH). 13C-NMR (CDCl3) δ ppm: 14.07 (+, 
CH3CH2OCON), 14.26 (+, CH3CH2OCOPh), 14.29 (+, CH3CH2OCOCH), 16.00 (-, C-3), 
24.96 (-, C-2), 25.14 (-, C-7), 30.08 (-, C-8), 32.21 (-, PhCH2), 35.19 (-, PhCH2CH2), 
49.68 (+, C-1), 51.33 (-, C-6), 51.78 (-, C-4), 57.09 (+, C-9), 60.52 (+, PhCH2CH2CH), 
60.55 (-, CH3CH2OCOCH), 61.07 (-, CH3CH2OCOPh), 62.86 (-, CH3CH2OCON), 74.81  
(-, OCH2N), 125.83 (+, PhC), 126.08 (2C, +, EtCOOPhC), 128.30 (2C, +, PhC), 128.37 
(2C, +, PhC), 129.05 (quat, EtCOOPhC), 130.44 (2C, +, EtCOOPhC), 141.54 (quat, 
PhC), 144.64 (quat, EtCOOPhC), 154.46 (quat, CH3CH2OCON), 165.79 (quat, 
CH3CH2OCOPh), 170.75 (quat, C-1-COO), 174.61 (quat, CH3CH2OCOCH), 175.24 
(quat, C-10). HRMS: LSI-MS: m/z for (C35H46N4O9 + H+) calcd. 667.3338, found: 
676.33251. Analytical HPLC: purity 95 %, tR = 14.33 min (gradient b), k = 3.98. 
C35H46N4O9 (666.76). 
(1S,9S)-{[4-(Ethoxycarbonyl)phenyl](methoxycarbonyl)amino}methyl 9-((S)-1-eth-
oxy-1-oxo-4-phenylbutan-2-ylamino)-10-oxooctahydro-1H-pyridazino[1,2-a][1,2]di-
azepine-1-carboxylate (3.27): The title compound was prepared from cilazapril 
(0.48 mmol, 0.20 g), K2CO3 (0.86 mmol, 0.12 g) and 3.24 (0.86 mmol, 0.23 g) in DMF 
(H2O < 0.01 %) (5 ml) according to the general procedure 3.8.2.4 and was obtained after 
flash chromatography (PE/EtOAc 5/2 to 1/1 v/v) as a pale yellow oil (0.25 g, 80 %). 1H-
NMR (CDCl3) δ ppm: 1.27 (t, 3H, 3J = 7.1 Hz, CH3CH2OCOCH), 1.37 (m, 3H, 
CH3CH2OCOPh), 1.37 and 1.67 (m, 2H, 3-H2), 1.37 and 2.02 (m, 2H, 8-H2), 1.67 and 
1.80 (m, 2H, 7-H2), 1.80 and 2.30 (m, 2H, 2-H2), 2.02 (m, 2H, PhCH2CH2), 2.49 and 3.30 
(m, 2H, 6-H2), 2.74 (m, 2H, PhCH2), 2.93 and 3.07 (m, 2H, 4-H2), 3.36 (t, 1H, 3J = 6.6 Hz, 
PhCH2CH2CH), 3.75 (s, 3H, CH3OCO), 4.14 (m, 1H, 9-H), 4.18 (m, 2H, 
CH3CH2OCOCH), 4.36 (m, 2H, CH3CH2OCOC6H5) 5.07 (m, 1H, 1-H), 5.70 (m, 2H, 
OCH2N), 7.18 (m, 3H, PhH), 7.26 (m, 2H, PhH), 7.35 (m, 2H, EtOOCPhH), 8.05 (m, 2H, 
EtCOOPhH). 13C-NMR (CDCl3) δ ppm: 14.26 (+, CH3CH2OCOPh), 14.29 (+, 
CH3CH2OCOCH), 16.00 (-, C-3), 24.94 (-, C-2), 25.16 (-, C-7), 30.09 (-, C-8), 32.21 (-, 
PhCH2), 35.19 (-, PhCH2CH2), 49.67 (+, C-1), 51.34 (-, C-6), 51.79 (-, C-4), 53.65 (+, 
CH3OCO), 57.10 (+, C-9), 60.52 (+, PhCH2CH2CH), 60.54 (-, CH3CH2OCOCH), 61.09 (-, 
CH3CH2OCOPh), 74.83 (-, OCH2N), 125.83 (+, PhC), 126.25 (2C, +, EtCOOPhC), 
128.30 (2C, +, PhC), 128.38 (2C, +, PhC), 129.29 (quat, EtCOOPhC), 130.52 (2C, +, 
EtCOOPhC), 141.56 (quat, PhC), 144.49 (quat, EtCOOPhC), 155.00 (quat, CH3OCO), 
165.74 (quat, CH3CH2OCOPh), 170.77 (quat, C-1-COO), 174.62 (quat, 
CH3CH2OCOCH), 175.27 (quat, C-10). HRMS: LSI-MS: m/z for (C34H44N4O9+ H+) calcd. 
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653.3181, found: 653.31693. Analytical HPLC: purity 97 %, tR = 13.72 min (gradient b), k 
= 3.76. C34H44N4O9 (652.73). 
(1S,9S)-Ethyl 9-((S)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)-10-oxooctahydro-1H-
pyridazino[1,2-a][1,2]diazepine-1-carboxylate (3.28): Trimethylsilyl chloride (2.2 eq, 
0.79 mmol, 0.1 ml) was added to a solution of cilazapril (1 eq, 0.36 mmol, 0.15 g) in 
EtOH/abs (5 ml). The reaction mixture was heated at reflux for 4 h. The solution was 
evaporated to dryness. The resulting residue was taken up in EtOAc and the organic 
layer was washed with saturated NaHCO3 solution twice. The organic layer was dried 
over anhydrous MgSO4, filtered and rotary evaporated. The crude product was submitted 
to flash chromatography (PE/EtOAc 1/1 v/v) to obtain the title compound as a pale yellow 
oil (0.12 g, 73 %). 1H-NMR (CDCl3) δ ppm: 1.27 (m, 6H, CH3CH2OCOCHNH, 
CH3CH2OCOCHN<), 1.36 and 1.72 (m, 2H, 3-H2), 1.46 and 2.02 (m, 2H, 8-H2), 1.72 and 
1.85  (m, 2H, 7-H2), 1.85 and 2.31 (m, 2H, 2-H2), 2.01 (m, 2H, PhCH2CH2), 2.21 (bs, 
1H, NH), 2.50 and 3.35 (m, 2H, 6-H2), 2.73 (m, 2H, PhCH2), 2.94 and 3.08 (m, 2H, 4-H2), 
3.36 (m, 1H, PhCH2CH2CH), 4.14 (m, 1H, 9-H), 4.17 (m, 4H, CH3CH2OCOCHNH, 
CH3CH2OCOCHN<), 5.02 (m, 1H, 1-H), 7.17 (m, 3H, PhH), 7.25 (m, 2H, PhH). 13C-NMR 
(CDCl3) δ ppm: 14.08 (+, CH3CH2OCOCHN<), 14.29 (+, CH3CH2OCOCHNH), 16.05  
(-, C-3), 25.05 (2C, -, C-2 and C-7), 30.11 (-, C-8), 32.21 (-, PhCH2), 35.16  
(-, PhCH2CH2), 49.78 (+, C-1), 51.30 (-, C-6), 51.74 (-, C-4), 57.17 (+, C-9), 60.53  
(-, CH3CH2OCOCHNH), 60.60 (+, PhCH2CH2CH), 61.30 (-, CH3CH2OCOCHN<), 125.81 
(+, PhC), 128.29 (2C, +, PhC), 128.36 (2C, +, PhC), 141.57 (quat, PhC), 171.44 (quat, 
C-1-COO), 174.61 (quat, CH3CH2OCOCHNH), 175.11 (quat, C-10). HRMS: EI-MS: m/z 
for (C24H35N3O5) calcd. 445.2577, found: 445.25801. Analytical HPLC: purity 97 %, tR = 
12.08 min (gradient b), k = 3.19. C24H35N3O5 (445.56). 
(1S,9S)-9-((S)-1-carboxy-3-phenylpropylamino)-10-oxooctahydro-1H-pyridazino-
[1,2-a][1,2]diazepine-1-carboxylic acid (3.29): A mixture of cilazapril (1 eq, 0.31 mmol, 
0.13 g) and LiOH (3 eq, 0.93 mmol, 22 mg) in methanol was stirred for 6 d at room 
temperature. The reaction mixture was acidified by addition of TFA (10%). Subsequently, 
the volatiles were removed in vacuo and the residue was purified by preparative HPLC 
yielding the title compound as a white solid (0.11 g, 67 %). Mp.: 144-146 °C. 1H-NMR 
(CD3OD) δ ppm: 1.42 and 1.74 (m, 2H, 3-H2), 1.79 and 2.18 (m, 2H, 8-H2), 1.86 and 2.13 
(m, 2H, 7-H2), 2.13 and 2.38 (m, 2H, 2-H2), 2.25 (m, 2H, PhCH2CH2), 2.59 and 3.48 (m, 
2H, 6-H2), 2.83 (m, 2H, PhCH2), 3.03 and 3.15 (m, 2H, 4-H2), 3.96 (t, 1H, 3J = 5.9 Hz, 
PhCH2CH2CH), 4.84 (t, 1H, 3J = 7.8 Hz, 9-H), 4.92 (m, 1H, 1-H), 7.20 (m, 1H, PhH), 7.25 
(m, 2H, PhH), 7.28 (m, 2H, PhH). 13C-NMR (CD3OD) δ ppm: 16.99 (-, C-3), 25.79 (-, C-
2), 25.82 (-, C-7), 26.64 (-, C-8), 32.21 (-, PhCH2), 33.43 (-, PhCH2CH2), 51.57 (+, C-1), 
51.81 (-, C-6), 52.64 (-, C-4), 60.20 (+, C-9), 60.73 (+, PhCH2CH2CH), 127.51 (+, PhC), 
129.44 (2C, +, PhC), 129.67 (2C, +, PhC), 141.44 (quat, PhC), 169.71 (quat, C-10), 
171.47 (quat, NHCHCOOH), 173.69 (quat, C-1-COO). HRMS: EI-MS: m/z for 
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(C20H27N3O5) calcd. 389.1951, found: 389.19426. Prep. HPLC: MeCN/0.05% TFA/aq 
25/75, 10 min: 45/55, 10.1-20 min: 95/5. Analytical HPLC: purity 100 %, tR = 8.49 min 
(gradient b), k = 1.95. Anal. (C20H27N3O5·C2HF3O2·0.75H2O) C, H, N. C20H27N3O5 · 1 TFA 
(503.47). 
2-Ethoxy-1-{[2’-(1-triphenylmethyl-1H-tetrazole-5-yl)biphenyl-4-yl]methyl}benzimi-
dazole-7-carboxylic acid (3.30)52: 2-Ethoxy-1-[[2’-(1H-tetrazole-5-yl)biphenyl-4-yl]me-
thyl]benzimidazole-7-carboxylic acid (1 eq, 11.4 mmol, 5.00 g) was suspended in 22 ml 
of DCM. After addition of triethylamine (1.2 eq, 13.7 mmol, 1.92 ml) a solution of trityl 
chloride (1.2 eq, 13.7 mmol, 3.81 g) in 10 ml of DCM was added dropwise. The reaction 
mixture was stirred at room temperature for one hour and washed with water. The 
organic layer was dried over anhydrous MgSO4, filtered and concentrated under reduced 
pressure. The crude product was purified by flash chromatography (PE/EtOAC 2/1 to 2/3 
+ 0.1 % acetic acid v/v) to give colorless crystals (4.43 g, 57 %). Mp: 166-169 °C (ref.52: 
168-170 °C). 1H NMR (DMSO-d6) δ ppm: 1.28 (t, 3H, 3J = 7.0 Hz, OCH2CH3), 4.50 (q, 
2H, 3J = 7.0 Hz, OCH2CH3), 5.64 (s, 2H, NCH2-p-phenylene), 6.86 (m, 8H, CPh3, p-
phenylene-2-H, p-phenylene-6-H), 6.96 (d, 2H, 3J = 8.2 Hz, p-phenylene-3-H, p-
phenylene-5-H), 7.13 (t, 1H, 3J = 7.8 Hz, ArH), 7.34 (m, 10H, CPh3, ArH), 7.54 (m, 4H, 
CPh3, ArH), 7.76 (m, 1H, ArH), 13.12 (br s, COOH). ES-MS (DCM/MEOH + 10 mM 
NH4OAc) m/z (%): 683 (100) [M+H+]. C43H34N6O3 (682.77). 
3.8.2.5 General procedure for the esterification of 3.30 
The corresponding alkyloxycarbonyloxyethylchloride, acyloxyethylchloride or 4-(bromo-
methyl)-5-alkyl-1,3-dioxol-2-one (1.5 eq) was added dropwise to a mixture of 3.30 (1 eq) 
and K2CO3 (1.5 eq) in DMF (H2O < 0.01 %) at 0 °C. The reaction mixture was stirred 
overnight at room temperature and concentrated in vacuo. The residue was distributed 
between water and ethyl acetate. The organic layer was separated and the aqueous 
layer was extracted two times with ethyl acetate. The combined organic phases were 
washed with water, dried over anhydrous MgSO4, filtered and evaporated to dryness. 
The crude product was subjected to flash chromatography. 
1-(Isopropyloxycarbonyloxy)ethyl 2-ethoxy-1-{[2'-(1-triphenylmethyl-1H-tetrazole-5-
yl)biphenyl-4-yl]methyl}benzimidazole-7-carboxylate (3.31a): The title compound 
was prepared according to the general procedure 3.8.2.5, using 3.30 (1 eq, 3.2 mmol, 
2.18 g), K2CO3 (1.5 eq, 4.8 mmol, 0.66 g) and 1-chloroethyl(isopropyl)carbonate (1.5 eq, 
4.8 mmol, 0.80 g), and was obtained after flash chromatography (PE/EtOAc 2/1 v/v) as 
colorless crystals (2.16 g, 83 %). ES-MS (DCM/MEOH + 10 mM NH4OAc) m/z (%): 813 
(100) [M+H+]. C49H44N6O6 (812.91). 
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1-(2,2-Dimethylpropanoyloxy)ethyl 2-ethoxy-1-[[2'-(1-triphenylmethyl-1H-tetrazole-
5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate (3.32a): The title compound 
was prepared according to the general procedure 3.8.2.5, using 3.30 (1 eq, 5.3 mmol, 
3.62 g), K2CO3 (1.5 eq, 8.0 mmol, 1.11 g) and 3.5 (1.5 eq, 8.0 mmol, 1.32 g), and was 
obtained after flash chromatography (PE/EtOAc 2/1 v/v) as colorless crystals (4.30 g, 80 
%). ES-MS (DCM/MEOH + 10 mM NH4OAc) m/z (%): 811 (100) [M+H+]. C50H46N6O5 
(810.94). 
(5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-1-{[2'-(1-triphenylmethyl-1H-tetra-
zole-5-yl)biphenyl-4-yl]methyl}benzimidazole-7-carboxylate (3.33a): The title com-
pound was prepared according to the general procedure 3.8.2.5, using 3.30 (1 eq, 0.3 
mmol, 0.20 g), K2CO3 (1.5 eq, 0.4 mmol, 60 mg) and 3.10 (1.5 eq, 0.4 mmol, 77 mg), and 
was obtained after flash chromatography (PE/EtOAc 2/1 v/v) as colorless crystals (0.20 
g, 87 %). 1H NMR (CDCl3) δ ppm: 1.42 (t, 3H, 3J = 7.1 Hz, OCH2CH3), 4.62 (q, 2H, 3J = 
7.1 Hz, OCH2CH3), 4.73 (s, 2H, OCH2C=C), 5.58 (s, 2H, NCH2-p-phenylene), 6.73 (m, 
2H, ArH), 6.93-7.03 (m, 8H, ArH), 7.20-7.28 (m, 6H, ArH), 7.15-7.25 (m, 6H, ArH), 7.29-
7.37 (m, 4H, ArH), 7.39-7.56 (m, 3H, ArH), 7.79 (m, 2H, ArH). ES-MS (DCM/MEOH + 10 
mM NH4OAc) m/z (%): 795 (100) [M+H+]. C48H38N6O6 (794.85). 
(5-tert-Butyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-1-{[2'-(1-triphenylmethyl-1H-te-
trazole-5-yl)biphenyl-4-yl]methyl}benzimidazole-7-carboxylate (3.34a): The title 
compound was prepared from 3.30 (1 eq, 0.7 mmol, 0.50 g), K2CO3 (1.5 eq, 1.1 mmol, 
0.15 g) and 3.11 (1.5 eq, 1.1 mmol, 0.26 g) according to the general procedure 3.8.2.5 
and was obtained after flash chromatography (PE/EtOAc 2/1 v/v) as colorless crystals 
(0.54 g, 88 %). 1H NMR (CDCl3) δ ppm: 1.23 (s, 9H, C(CH3)3), 1.43 (t, 3H, 3J = 7.1 Hz, 
OCH2CH3), 4.66 (q, 2H, 3J = 7.0 Hz, OCH2CH3), 4.90 (s, 2H, OCH2C=C), 5.58 (s, 2H, 
NCH2-p-phenylene), 6.72 (m, 2H, ArH), 6.94 (m, 6H, ArH), 6.99 (m, 2H, ArH), 7.20-7.28 
(m, 6H, ArH), 7.32 (m, 5H, ArH), 7.45 (m, 2H, ArH), 7.57 (m, 1H, ArH), 7.83 (m, 2H, 
ArH). ES-MS (DCM/MEOH + 10 mM NH4OAc) m/z (%): 837 (100) [M+H+]. C51H44N6O6 
(836.93). 
3.8.2.6 General procedure for the deprotection of the trityl-protected compounds 
3.31a-3.34a to generate the compounds 3.31-3.34 
The corresponding compound 3.31a-3.34a was dissolved in a mixture of methanol and 
tetrahydrofurane. After addition of 1M hydrochloric acid the reaction mixture was stirred 
at room temperature for 2 to 5 h (DC control). The solution was neutralized with 1 M 
NaOH and evaporated to dryness. The residue was taken up in ethyl acetate and H2O. 
The phases were separated and the aqueous layer was extracted two times with ethyl 
acetate. The combined organic phases were dried over anhydrous MgSO4, and the 
solvent was evaporated. The crude product was purified by flash chromatography. The 
product containing fractions were neutralized by washing with saturated NaHCO3 
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solution and dried over MgSO4. After filtration and removal of the solvents under reduced 
pressure the resulting solid was recrystallized. 
1-(Isopropoxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazole-5-yl)biphenyl-4-yl]me-
thyl]benzimidazole-7-carboxylate (3.31): The title compound was prepared according 
to the general procedure 3.8.2.6 by stirring of 3.31a (5 mmol, 4.06 g) in 70 ml 
MeOH/THF 1/1 v/v under addition of 15 ml of 1M HCl for 5 h. After workup, flash 
chromatography (PE/EtOAc 3/2 + 0.1% acetic acid v/v) and recrystallization from ethanol 
the desired product was obtained as a white solid (1.80 g, 63 %). Mp: 92-94 °C. 1H NMR 
(CDCl3) δ ppm: 1.19 (t, 6H, 3J = 6.0 Hz, (CH3)2CH), 1.33 (d, 3H, 3J = 5.4 Hz, OCHCH3O), 
1.43 (t, 3H, 3J = 7.1 Hz, OCH2CH3), 4.16-4.52 (m, 2H, OCH2CH3), 4.77 (sept, 1H, 3J = 
6.3 Hz, (CH3)2CH), 5.62 (s, 2H, NCH2-p-phenylene), 6.67 (q, 1H, 3J = 5.4 Hz, 
OCHCH3O), 6.75 (d, 2H, 3J = 8.0 Hz, p-phenylene-2-H, p-phenylene-6-H), 6.87 (d, 2H, 3J 
= 8.2 Hz, p-phenylene-3-H, p-phenylene-5-H), 6.99 (m, 2H, ArH), 7.31 (m, 1H, ArH), 7.50 
(m, 1H, ArH), 7.58 (m, 2H, ArH), 8.01 (m, 1H, ArH), 15.08 (bs, tetrazole-H). 13C-NMR 
(CDCl3) δ ppm: 14.56 (+, OCH2CH3), 19.25 (+, OCHCH3O), 21.53, 21.57 (+, (CH3)2CH), 
46.93 (-, NCH2-p-phenylene), 67.73 (-, CH3CH2OCO), 72.99 (+, (CH3)2CH), 91.86 (+, 
OCHCH3O), 115.28 (quat, benzim-C-7), 121.19, 121.29 (+, ArC), 123.30 (quat, ArC), 
124.27 (+, ArC), 125.30 (+, 2C, p-phenylene-C-2, p-phenylene-C-6), 128.34 (+, ArC), 
129.48 (+, 2C, p-phenylene-C-3, p-phenylene-C-5), 130.58 (+, ArC), 130.72 (quat, ArC), 
131.20, 131.30 (+, ArC),136.62, 138.16, 140.04, 140.90 (quat, ArC), 152.41 (quat, 
(CH3)2CHOCO), 154.66 (quat, benzim-C-2), 158.01 (quat, tetrazole), 163.35 (quat, OCO-
benzim). ES-MS (DCM/MEOH + 10 mM NH4OAc) m/z (%): 571 (100) [M+H+]. Anal. 
(C30H30N6O6·H2O) C, H, N. C30H30N6O6 (570.60). 
1-(2,2-Dimethylpropanoyloxy)ethyl 2-ethoxy-1-{[2'-(1H-tetrazole-5-yl)biphenyl-4-yl]-
methyl}benzimidazole-7-carboxylate (3.32): The title compound was prepared 
according to the general procedure 3.8.2.6 by stirring of 3.32a (10.4 mmol, 8.43 g) in 150 
ml MeOH/THF 1/1 v/v under addition of 35 ml of 1M HCl for 3.5 h. Workup, followed by 
flash chromatography (PE/EtOAc 2/1 + 0.1% acetic acid v/v) and recrystallization from 
ethanol gave the desired product as a white solid (3.96 g, 67 %). Mp: 100-102 °C. 1H 
NMR (CDCl3) δ ppm: 1.11 (s, 9H, (CH3)3C), 1.23 (d, 3H, 3J = 5.4 Hz, OCHCH3O), 1.41 (t, 
3H, 3J = 7.1 Hz, OCH2CH3), 4.28 (m, 2H, OCH2CH3), 5.61 (s, 2H, NCH2-p-phenylene), 
6.71 (m, 3H, OCHCH3O, ArH), 6.82 (m, 2H, ArH), 6.90 (t, 1H, 3J = 7.8 Hz, ArH), 7.28 (m, 
1H, ArH), 7.42 (d, 1H, 3J = 7.7 Hz, ArH), 7.59 (m, 2H, ArH), 7.99 (m, 1H, ArH), 15.98 (bs, 
tetrazole-H). 13C-NMR (CDCl3) δ ppm: 14.55 (+, OCH2CH3), 19.11 (+, OCHCH3O), 26.78 
(3C, +, (CH3)3C), 38.65 (quat, (CH3)3C), 46.97 (-, NCH2-p-phenylene), 67.73 (-, 
OCH2CH3), 89.28 (+, OCHCH3O), 115.46 (quat, benzim-C-7), 121.10, 121.28 (+, ArC), 
123.35 (quat, ArC), 124.14 (+, ArC), 125.32 (+, 2C, p-phenylene-C-2, p-phenylene-C-6), 
128.31 (+, ArC), 129.44 (+, 2C, p-phenylene-C-3, p-phenylene-C-5), 130.08 (quat, ArC), 
130.54, 131.20, 131.27 (+, ArC), 136.77, 138.17, 140.05, 140.90 (quat, ArC), 154.82 
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(quat, benzim-C-2), 158.01 (quat, tetrazole-H), 163.42 (quat, OCO-benzim), 176.81 
(quat, (CH3)3COO). ES-MS (DCM/MEOH + 10 mM NH4OAc) m/z (%): 569 (100) [M+H+]. 
Anal. (C31H32N6O5·H2O) C, H, N. C31H32N6O5 (568.62). 
(5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-1-{[2'-(1H-tetrazole-5-yl)biphenyl-4-
yl]methyl}benzimidazole-7-carboxylate (3.33): Following the general procedure 
3.8.2.6 3.33a (0.25 mmol, 0.20 g) was stirred in 7 ml MeOH/THF 5/2 v/v under addition 
of 1 ml of 1M HCl for 2.25 h the title compound was obtained after workup, followed by 
flash chromatography (PE/EtOAc 1/1 to 1/2 + 0.1% acetic acid v/v) and recrystallization 
from cyclohexane/ tert-butyl methylether/ hexane as a white solid (53 mg, 38 %). Mp: 98-
100 °C. 1H NMR (CD3OD) δ ppm: 1.45 (t, 3H, 3J = 7.1 Hz, OCH2CH3), 2.16 (s, 3H, 
CH3C=C), 4.60 (q, 2H, 3J = 7.1 Hz, OCH2CH3), 5.03 (s, 2H, OCH2C=C), 5.61 (s, 2H, 
NCH2-p-phenylene), 6.87 (m, 2H, ArH), 6.99 (m, 2H, ArH), 7.21 (t, 1H, 3J = 7.9 Hz, ArH), 
7.52 (m, 2H, ArH), 7.61 (m, 3H, ArH), 7.68 (m, 1H, ArH). 13C-NMR (CD3OD) δ ppm: 9.38 
(+, CH3C=C), 14.93 (+, OCH2CH3), 48.05 (-, NCH2-p-phenylene), 55.85 (-, OCH2C=C), 
68.50 (-, OCH2CH3), 116.47 (quat, benzim-C-7), 122.44, 123.10 (+, ArC), 124.51 (quat, 
CH3CC=C), 125.51 (+, ArC), 127.65 (+, 2C, p-phenylene-C-2, p-phenylene-C-6), 129.02 
(+, ArC), 130.43 (+, 2C, p-phenylene-C-3, p-phenylene-C-5), 131.59, 131.97, 132.50 (+, 
ArC), 132.67 (quat, ArC), 135.05 (quat, CH3CC=C), 138.19, 140.00, 142.08, 142.74, 
143.04 (quat, ArC), 153.84 (quat, OCOO), 156.90 (quat, benzim-C-2), 160.20 (quat, 
tetrazole), 166.83 (quat, OCO-benzim). ES-MS (DCM/MeOH + 10 mM NH4OAc) m/z (%): 
553 (100) [M+H+]. Anal. (C29H24N6O6·0.5 C5H12O·0.5 H2O) C, H, N. C29H24N6O6 (552.54). 
(5-tert-Butyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-1-{[2'-(1H-tetrazole-5-yl)biphe-
nyl-4-yl]methyl}benzimidazole-7-carboxylate (3.34): The title compound was prepared 
according to the general procedure 3.8.2.6 by stirring of 3.34a (0.65 mmol, 0.54 g) in 30 
ml MeOH/THF 2/1 v/v under addition of 7.5 ml of 1M HCl for 3 h and was obtained after 
workup and flash chromatography (PE/EtOAc 1/2 + 0.5% acetic acid v/v) as a white solid 
(0.63 g, 16 %). Mp: 103-105 °C. 1H NMR (CDCl3) δ ppm: 1.20 (s, 9H, (CH3)3C), 1.41 (t, 
3H, 3J = 7.1 Hz, OCH2CH3), 4.28 (q, 2H, 3J = 6.9 Hz, OCH2CH3), 4.80 (s, 2H, 
OCH2C=C), 5.58 (s, 2H, NCH2-p-phenylene), 6.70 (m, 2H, ArH), 6.85 (m, 3H, ArH), 6.93 
(t, 1H, 3J = 7.8 Hz, ArH), 7.34 (m, 1H, ArH), 7.45 (m, 1H, ArH), 7.60 (m, 2H, ArH), 7.97 
(m, 1H, ArH), 15.64 (bs, tetrazole-H). 13C-NMR (CDCl3) δ ppm: 14.55 (+, OCH2CH3), 
27.89 (3C, +, (CH3)3C), 32.12 (quat, (CH3)3C), 46.98 (-, NCH2-p-phenylene), 56.09 (-, 
OCH2C=C), 67.88 (-, OCH2CH3), 115.09 (quat, benzim-C-7), 121.32, 121.55 (+, ArC), 
123.11 (quat, ArC), 124.24 (+, ArC), 125.52 (+, 2C, p-phenylene-C-2, p-phenylene-C-6), 
128.45 (+, ArC), 129.50 (+, 2C, p-phenylene-C-3, p-phenylene-C-5), 130.39 (quat, ArC), 
130.89 (+, ArC), 131.06 (quat, (CH3)3CC=C), 131.17, 131.49 (+, ArC), 136.35, 138.49, 
139.99, 140.69 (quat, ArC), 150.08 (quat, (CH3)3CC=C), 151.88 (quat, OCOO), 154.80 
(quat, benzim-C-2), 158.00 (quat, tetrazole), 165.11 (quat, OCO-benzim). ES-MS 
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(DCM/MeOH + 10 mM NH4OAc) m/z (%): 595 (100) [M+H+]. Anal. (C32H30N6O6·1.1 
C2H4O2) C, H, N. C32H30N6O6 (594.62). 
2-Morpholinoethyl 1-{[2'-(1H-tetrazole-5-yl)biphenyl-4-yl]methyl}-2-ethoxy-benzimi-
dazole-7-carboxylate (3.35): 3.30 (1 eq, 3.4 mmol, 1.50 g) was dissolved in DMF (H2O 
< 0.01 %) (8 ml). A catalytic amount of 4-(dimethylamino)pyridine and 4-(2-hydroxyethyl)-
morpholine (1 eq, 3.4 mmol, 0.41 ml) were added. A solution of N,N’-dicyclohexylcarbo-
diimide (1.1 eq, 3.8 mmol, 0.78 g) in DMF (H2O < 0.01 %) (15 ml) was added dropwise at 
0 °C. The reaction mixture was stirred for 1 h at 0 °C and overnight at room temperature. 
The solids were removed by filtration and the solvent was rotary evaporated. The 
resulting crude solid was purified by recrystallization from ethyl acetate/hexane to yield 
the title compound as pale beige crystals (0.96 g, 51 %). Mp: 181-183 °C. 1H NMR 
(CDCl3) δ ppm: 1.47 (t, 3H, 3J = 7.1 Hz, OCH2CH3), 2.61 (m, 4H, mo-3-H, mo-5-H), 2.97 
(m, 2H, NCH2CH2O), 3.39 (m, 4H, mo-2-H, mo-6-H), 4.10 (m, 2H, NCH2CH2O), 4.64 (q, 
2H, 3J = 7.1 Hz, OCH2CH3), 5.55 (s, 2H, NCH2-p-phenylene), 6.74 (d, 2H, 3J = 8.3 Hz, p-
phenylene-2-H, p-phenylene-6-H), 6.97 (d, 2H, 3J = 8.3 Hz, p-phenylene-3-H, p-
phenylene-5-H), 7.19 (t, 1H, 3J = 7.9 Hz, ArH), 7.49 (m, 2H, ArH), 7.73 (m, 4H, ArH), 
9.22 (bs, tetrazole-H). 13C-NMR (CDCl3) δ ppm: 14.62 (+, OCH2CH3), 46.69 (-, NCH2-p-
phenylene), 53.07 (-, 2C, mo-C-2, mo-C-6), 56.34 (-, NCH2CH2O), 62.31 (-, NCH2CH2O), 
65.31 (-, 2C, mo-C-3, mo-C-5), 67.01 (-, OCH2CH3), 116.01 (quat, benzim-C-7), 121.08, 
121.78, 122.49 (+, ArC), 124.89 (quat, ArC), 125.60 (+, 2C, p-phenylene-C-2, p-
phenylene-C-6), 128.11 (+, ArC), 129.09 (+, 2C, p-phenylene-C-3, p-phenylene-C-5), 
130.25 (+, ArC), 130.69 (quat, ArC), 130.98, 131.35 (+, ArC), 136.55, 138.25, 140.31, 
141.60 (quat, ArC), 156.87 (quat, benzim-C-2), 158.51 (quat, tetrazole), 165.65 (quat, 
OCO-benzim). ES-MS (DCM/MeOH + 10 mM NH4OAc) m/z (%): 554 (100) [M+H+]. Anal. 
(C30H31N7O4·0.5 H2O) C, H, N. C30H31N7O4 (553.61). 
3.8.3 Bioanalytical investigations 
Solid state stability of cilazapril and candesartan prodrugs (3.1-3.3, 3.6, 3.7, 3.14, 
3.28, 3.31-3.35). A few milligrams of each substance were stored at 5 °C/ 65 % rel. h., 25 
°C/ 60 % rel. h. and 40 °C/ 75 % rel. h., respectively. After respective storage periods of 
6, 10 or 16 months the compounds were dissolved in methanol to yield 10 mM stock 
solutions, diluted to 100 µM with mobile phase and subsequently analyzed by analytical 
HPLC using following gradients. 3.1: 0 min: MeCN/0.05% TFA/aq 25/75, 23 min: 39/61, 
27 min: 43/57, 28-34 min: 95/5, 35-43 min: 25/75. 3.2: 0 min: MeCN/0.05% TFA/aq 
25/75, 36 min: 47/53, 42 min: 53/47, 43-49 min: 95/5, 50-58 min: 25/75. 3.3: 0 min: 
MeCN/0.05% TFA/aq 25/75, 23 min: 39/61, 33 min: 49/51, 34-40 min: 95/5, 41-49 min: 
25/75. 3.6: 0 min: MeCN/0.05% TFA/aq 22/78, 35 min: 36/64, 36-42 min: 95/5, 43-51 
min: 22/78. 3.7: 0 min: MeCN/0.05% TFA/aq 25/75, 36 min: 49/51, 37-43 min: 95/5, 44-
52 min: 25/75. 3.14: 0 min: MeCN/0.05% TFA/aq 18/82, 27 min: 33/67, 29-35 min: 95/5, 
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36-44 min: 18/82. 3.28: 0 min: MeCN/0.05% TFA/aq 22/78, 25 min: 32/68, 30 min: 40/60, 
31-37 min: 95/5, 38-46 min: 22/78. 3.31-3.35: 0 min: MeCN/0.05% TFA/aq 30/70, 20 
min: 85/15, 21-36 min: 95/5, 27-35 min: 30/70. 
Preparation of porcine skin homogenate. From fresh full-thickness porcine skin the 
subcutaneous fatty tissue was removed and the skin was cut in thin slices. 50 g 
(25 % w/w) of porcine skin were added to 150 ml of PBS and homogenized with an ultra-
turrax under cooling.53 The resulting homogenate was centrifuged at 35000 g for 20 min 
at 5 °C. After removal of the upper fatty layer the homogenate was aliquoted and stored 
at -78 °C. 
Determination of esterase activity in porcine skin homogenate, human CPD 
plasma and of porcine liver esterase.54 Esterase activity was determined by a 
continuous spectrophotometric rate measurement using 2-nitrophenyl butyrate as a 
substrate. In acryl cuvettes suitable volumina of potassium phosphate buffer (0.1 M, pH 
7.4, 1.42-1.48 ml) and of a 100 mM stock solution of 2-nitrophenyl butyrate in DMSO (15-
30 µl) were mixed and equilibrated to 25 °C in a Cary 100 UV/VIS spectrophotometer 
(Varian Inc., Palo Alto, USA). After addition of a suitable volume of enzyme solution (5-
50 µl) and mixing by inversion the increase in the absorption of 2-nitrophenol at 414 nm 
was recorded for approximately 5 min. A sample containing the same volume of 
phosphate buffer instead of enzyme solution was measured simultaneously as a 
reference. The maximum linear rate of ΔA414nm vs. time was used to determine the 
volume activity VA according to Equation 3.10. 
VA ൌ
∆Aସଵସ୬୫t · V
ε · d · v  
Equation 3.10. Volume activity VA. V = total volume (ml), ε = molar extinction coefficient of 2-nitrophenol = 3190 
l·mol-1·cm-1 55, d = path length (cm), v = volume of enzyme solution (ml). 
The results from the determination of esterase activity in porcine skin homogenate and 
different batches of human CPD plasma and of porcine liver esterase are listed below. 
 VA (U/ml) 
porcine skin homogenate 0.65 
human CPD plasma (charge a (07/1999)) 2.17 
human CPD plasma (charge b (01/2004)) 3.82 
porcine liver esterase a 2369 
a (EC 3.1.1.1.), suspension in 3.2 M (NH4)2SO4 solution, pH 8, Lot 67H7175 (Sigma-Aldrich Chemie GmbH 
(München, Germany)).  
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Determination of the stability of cilazapril and candesartan prodrugs in different 
incubation media. A defined volume of the respective prodrug stock solution or the 
same volume of solvent was added to potassium phosphate buffer (0.1 M, pH 7.4), 
porcine skin homogenate (PSH), human plasma and buffered porcine liver esterase 
(PLE), respectively. All samples were incubated in a water bath at 37 °C. Over a period 
of up to 72 h samples of the prodrug containing incubation mixtures (200 µl) were 
collected. To all samples 400 µl of ice-cold acetonitrile were added. After vortex mixing 
the samples were allowed to stand in a refrigerator for approx. 30 min. The samples 
were then centrifuged at 13000 g for 5 min. The supernatants were collected and stored 
at -78 °C until HPLC analysis. To 200 µl of each supernatant 400 µl of aqueous 0.05 % 
TFA were added prior to injection. Samples containing 3.25, 3.26 or 3.27 were partially 
diluted 1:1:1 with MeCN and 0.05 % TFA. 
 
In Table 3.14 the compositions of the respective incubation mixtures for all studied 
cilazapril and candesartan prodrugs are summarized. 
Table 3.14. Incubation mixtures used for bioanalytical studies of cilazapril and candesartan prodrugs. 
 
incubation 
mixture 
volume (µl)
No. 
phosphate 
buffer 
porcine skin 
homogenate
human 
plasmaa 
porcine liver 
esterase dilutionb
stock solution in 
MeOH 
stock solution 
in DMSO 
      conc. (mM) 
µl conc. 
(mM) 
µl 
Cila-
za-
pril 
buffer 1960 - - - - - 100 40 
PSH - 1960 - - - - 100 40 
human plasma - - 1960 - - - 100 40 
buffered PLE 1920 - - 40 - - 100 40 
3.1 buffer 1960 - - - 50 40 - - 
 PSH - 1960 - - - - 50 40 
 human plasma - - 1960 - 50 40 - - 
 buffered PLE 1920 - - 40 50 40 - - 
3.2 buffer 1960 - - - - - 50 40 
 PSH - 1960 - - - - 50 40 
 human plasma - - 1960 - 50 40 - - 
 buffered PLE 1920 - - 40 50 40 - - 
3.3 buffer 1960 - - - 50 40 - - 
 PSH - 1960 - - - - 50 40 
 human plasma - - 1960 - 50 40 - - 
 buffered PLE 1920 - - 40 50 40 - - 
3.6 buffer 1960 - - - 50 40 - - 
 PSH - 1960 - - - - 50 40 
 human plasma - - 1960 - 50 40 - - 
 buffered PLE 1920 - - 40 50 40 - - 
3.7 buffer 1960 - - - 50 40 - - 
 PSH - 1960 - - - - 50 40 
 human plasma - - 1960 - 50 40 - - 
 buffered PLE 1920 - - 40 50 40 - - 
3.12 buffer 1960 - - - - - 100 40 
 PSH - 1960 - - - - 100 40 
 human plasma - - 1960 - - - 100 40 
 buffered PLE 1920 - - 40 - - 100 40 
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Table 3.14 continued       
3.13 buffer 1960 - - - 50 40 - - 
 PSH - 1960 - - - - 50 40 
 human plasma - - 1960 - 50 40 - - 
 buffered PLE 1920 - - 40 50 40 - - 
3.14 buffer 1960 - - - 50 40 - - 
 PSH - 1960 - - - - 50 40 
 human plasma - - 1960 - 50 40 - - 
 buffered PLE 1920 - - 40 50 40 - - 
3.18 buffer 1960 - - - - - 50 40 
 PSH - 1960 - - - - 50 40 
 human plasma - - 1960 - - - 50 40 
 buffered PLE 1920 - - 40 - - 50 40 
3.25 buffer 1960 - - - - - 50 40 
 PSH - 1960 - - - - 50 40 
 human plasma - - 1960 - - - 50 40 
 buffered PLE 1920 - - 40 - - 50 40 
3.26 buffer 1960 - - - - - 50 40 
 PSH - 1960 - - - - 50 40 
 human plasma - - 1960 - - - 50 40 
 buffered PLE 1920 - - 40 - - 50 40 
3.27 buffer 1960 - - - - - 50 40 
 PSH - 1960 - - - - 50 40 
 human plasma - - 1960 - - - 50 40 
 buffered PLE 1920 - - 40 - - 50 40 
3.28 buffer 1960 - - - 50 40 - - 
 PSH - 1960 - - - - 50 40 
 human plasma - - 1960 - 50 40 - - 
 buffered PLE 1920 - - 40 50 40 - - 
CAN
-CILc 
buffer 1960 - - - 10 40 - - 
PSH - 1960 - - - - 10 40 
human plasma - - 1960 d - 10 40 - - 
buffered PLE 1955 - - 5 e 10 40 - - 
3.31 buffer 1960 - - - 10 40 - - 
 PSH - 1960 - - - - 10 40 
 human plasma - - 1960 d - 10 40 - - 
 buffered PLE 1953 - - 7 10 40 - - 
3.32 buffer 1960 - - - 10 40 - - 
 PSH - 1960 - - - - 10 40 
 human plasma - - 1960 - 10 40 - - 
 buffered PLE 1959 - - 0.75 e 10 40 - - 
3.33 buffer 1960 - - - 10 40 - - 
 PSH - 1960 - - - - 10 40 
 human plasma - - 1960 - 10 40 - - 
 buffered PLE 1950 - - 10 10 40 - - 
3.34 buffer 1960 - - - - - 50 40 
 PSH - 1960 - - - - 50 40 
 human plasma - - 1960 - - - 50 40 
 buffered PLE 1920 - - 40 - - 50 40 
3.35 buffer 1960 - - - 10 40 - - 
 PSH - 1960 - - - - 10 40 
 human plasma - - 1960 d - 10 40 - - 
 buffered PLE 1955 - - 5 e 10 40 - - 
a Human CPD plasma batch b (01/2004) unless otherwise indicated. b Porcine liver esterase was diluted with 
phosphate buffer 1:100 (v:v) prior to incubation unless otherwise indicated. c Candesartan cilexetil. d Human CPD 
plasma batch b (07/1999) e Porcine liver esterase was used undiluted. 
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The following analytical HPLC gradients were applied: 
Cilazapril: 0 min: MeCN/0.05% TFA/aq 20/80, 5 min: 30/70, 8 min: 55/45, 9-15 min: 
95/5, 16-24 min: 20/80. 3.1: 0 min: MeCN/0.05% TFA/aq 25/75, 23 min: 39/61, 27 min: 
43/57, 28-34 min: 95/5, 35-43 min: 25/75. 3.2: 0 min: MeCN/0.05% TFA/aq 25/75, 36 
min: 47/53, 42 min: 53/47, 43-49 min: 95/5, 50-58 min: 25/75. 3.3: 0 min: MeCN/0.05% 
TFA/aq 25/75, 23 min: 39/61, 33 min: 49/51, 34-40 min: 95/5, 41-49 min: 25/75. 3.6: 0 
min: MeCN/0.05% TFA/aq 22/78, 35 min: 36/64, 36-42 min: 95/5, 43-51 min: 22/78. 3.7: 
0 min: MeCN/0.05% TFA/aq 25/75, 36 min: 49/51, 37-43 min: 95/5, 44-52 min: 25/75. 
3.12: 0 min: MeCN/0.05% TFA/aq 25/75, 18 min: 51/49, 19-25 min: 95/5, 26-34 min: 
25/75. 3.13: 0 min: MeCN/0.05% TFA/aq 25/75, 20 min: 50/50, 21-27 min: 95/5, 28-36 
min: 25/75. 3.14: 0 min: MeCN/0.05% TFA/aq 18/82, 27 min: 33/67, 29-35 min: 95/5, 36-
44 min: 18/82. 3.18: 0 min: MeCN/0.05% TFA/aq 10/90, 20 min: 40/60, 21-28 min: 95/5, 
29-37 min: 10/90. 3.25-3.27: 0 min: MeCN/0.05% TFA/aq 25/75, 10 min: 38/62, 20 min: 
55/45, 21-27 min: 95/5, 28-36 min: 25/75. 3.28: 0 min: MeCN/0.05% TFA/aq 22/78, 25 
min: 32/68, 30 min: 40/60, 31-37 min: 95/5, 38-46 min: 22/78. Candesartan cilexetil: 0 
min: MeCN/0.05% TFA/aq 20/80, 24 min: 80/20, 25-29 min: 95/5, 31-39 min: 20/80. 3.31: 
0 min: MeCN/0.05% TFA/aq 20/80, 24 min: 73/27, 25-30 min: 95/5, 32-42 min: 20/80. 
3.32: 0 min: MeCN/0.05% TFA/aq 20/80, 24 min: 77/23, 25-29 min: 95/5, 31-39 min: 
20/80. 3.33: 0 min: MeCN/0.05% TFA/aq 20/80, 21 min: 66/34, 22-26 min: 95/5, 27-35 
min: 20/80. 3.34: 0 min: MeCN/0.05% TFA/aq 25/75, 20 min: 80/20, 21-27 min: 95/5, 28-
36 min: 25/75. 3.35: 0 min: MeCN/0.05% TFA/aq 20/80, 24 min: 43/57, 27-31 min: 95/5, 
32-40 min: 20/80. 
Preparation of primary human liver cell culture. Tissue samples were obtained and 
experimental procedures were performed according to the guidelines of the charitable 
state controlled foundation HTCR, with the informed patient's consent.56-57 Briefly, 
primary human liver cells (hepatocytes) were seeded in a 96-well plate coated with rat 
tail collagen type I (Biocoat Cell Environments Collagen I Cellware 96-well plate, Becton 
Dickinson Labware, Bedford, USA) at a density of 0.15 ·106 cells/cm2 (0.48 ·105 
cells/well). The medium consisted of DMEM with 5 % fetal calf serum (FCS) and the 
following supplements: 125 mU/ml insulin, 60 ng/ml hydrocortisone, 10 ng/ml glucagon, 
100 mg/ml streptomycin, 100 mU/ml penicillin. After 24 h the culture medium was 
replaced by fresh medium. 
Protocol for determination of the stability of cilazapril and candesartan prodrugs 
in different incubation media. The test compounds were dissolved in DMSO (stock 
solution, 50 mM) and prior to use diluted with hepatocyte culture medium yielding a final 
concentration of 150 µM. 48 h after seeding, four wells each were treated with 200 µl of 
fresh culture medium containing the respective test compound or DMSO as a control. 
After incubation periods (37 °C) of one and six hours, respectively, 150 µl were collected 
in duplicate and immediately stored at -78 °C. Prior to analysis to each sample (150 µl) 
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300 µl of MeCN were added. Prior to HPLC analysis, the samples were thawed and 
300 µl of MeCN were added to each sample. After vortex mixing the samples were 
stored in a refrigerator for approx. 30 min, then vortexed again and centrifuged at 13000 
g for 5 min. The supernatants were evaporated to dryness using a speed vac. The 
resulting residues were dissolved in 450 µl of mobile phase, shortly sonicated and 
analyzed by HPLC applying the following gradient: 0 min: MeCN/0.05% TFA/aq 10/90, 
15 min: 30/70, 30 min: 75/25, 31-36 min: 95/5, 37-45 min: 10/90. For the HPLC analysis 
of samples containing candesartan prodrugs the following gradient was used: 0 min: 
MeCN/0.05% TFA/aq 30/70, 20 min: 85/15, 21-26 min: 95/5, 27-35 min: 30/70. 
3.8.4 Investigation for AT1 receptor antagonism on rat mesangial cells 
Fura-2 assay on rat mesangial cells. Glomerular rat mesangial cells (kindly provided 
by the work group of Prof. Dr. A Kurtz, Institute of Physiology, University of Regensburg) 
were passaged 4-5 days prior to the experiment, and the content of a confluent 25 cm2 
culture flask was divided to four 175 cm2 culture flasks. The cells were cultured in 
RPMI1640 medium supplemented with 10 % FCS and 0.24 mg/l insulin at 37 °C and 5 % 
CO2 in a saturated humidity atmosphere. On the day of the experiment the cells were 
trypsinized, suspended in medium and centrifuged (7 min, 200 g). The cells were re-
suspended in 40 ml of loading buffer and 30 µl of fura-2/AM (1 mM in DMSO), 37.5 µl 
Pluronic F-127 (20 % in DMSO) and 200 mg of BSA were added. After an incubation 
period of 30 min at ambient temperature under exclusion of light the cells were 
centrifuged, transferred to fresh loading buffer und incubated for additional 60 min. The 
cells were washed with loading buffer, suspended in 25 ml of loading buffer and were 
allowed to stand for at least 15 min under light protection. 200-fold concentrated 
solutions of the test compounds were prepared by dilution of the respective stock 
solutions (10 mM in DMSO) with DMSO/H2O (1:1 v:v). One ml of cell suspension and 
10 µl of the appropriate substance concentration were added to 1 ml of loading buffer in 
an acryl cuvette equipped with a small stirring bar. After incubation for 1 min at 25 °C, the 
Ca2+-signal was stimulated by addition of angiotensin II (100 nM in DMSO). The 
fluorescence intensity was recorded using a Perkin-Elmer LS50 B spectrofluorometer 
(Perkin Elmer, Überlingen, Germany) with following settings: λex = 340 and 380 nm 
(alternating), slit = 10 nm; λem =510 nm, slit = 10 nm. For each concentration a 
sample containing 10 µl of loading buffer instead of test substance was measured 
simultaneously and gave the uninhibited control value. The maximal fluorescence 
signal was detected by adding 10 µl of digitonin solution (2 % in H2O) instead of 10 µl 
of test substance and the minimal fluorescence signal resulted from the subsequent 
addition of 50 µl of EGTA solution (600 mM in 1 M tris buffer, pH 8.7). 
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 Chapter 4  
Novel Transdermal Therapeutic Systems 
Containing Prodrugs of Candesartan or 
Cilazapril: Making and Characterization 
4.1 Introduction 
Transdermal therapeutic systems (TTS), also known as transdermal drug delivery 
systems (TDDS), are drug-loaded adhesive patches, designed to deliver a thera-
peutically effective amount of drug across a patient’s skin.1-2 Common transdermal drug 
delivery typically involves passive diffusion of a drug through the skin, whereas novel 
strategies intend to improve transdermal delivery by using e.g. chemical enhancers, 
electrically-assisted approaches (iontophoresis, electroporation), ultrasound (sonopho-
resis), heat or strategies for increasing permeability of the skin (microneedles, micro-
dermabrasion).3 
Typical designs of passive trans-
dermal therapeutic systems are shown 
in Figure 4.1. In the simplest form, the 
adhesive matrix or drug-in-adhesive 
design (Figure 4.1 a), the drug is 
dissolved, dispersed or suspended in 
a pressure-sensitive adhesive (PSA) 
polymer matrix, which provides skin 
adhesion, storage of the drug, and 
control over the drug delivery rate.2 
The adhesive matrix is supported on 
the topside by an impermeable 
backing film, and on the side that 
faces the skin, it is laminated with a 
removable release liner. The liquid re-
servoir design (Figure 4.1 c) consists 
of a liquid reservoir compartment containing the drug and a permeation enhancer either 
in solution or dispersed. It is positioned between a backing film and a rate-controlling 
membrane adjacent to a skin-contacting PSA layer and a release liner. For both designs 
the release liner usually consists of a layer of release coating (e.g. fluoro-polymer, 
silicone) applied to a carrier substrate (e.g. polyester).4 Also copolymers such as 
 
Figure 4.1. Typical designs of passive transdermal thera-
peutic systems. Reprinted from Tan and Pfister2 with per-
mission from Elsevier. 
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ethylene vinyl acetate, coated papers or aluminium foil are used.5 The backing layer is 
often prepared from polyethylene, polypropylene, polyester, polyurethane or less 
occlusive polyvinylchloride.5 
Three classes of PSA polymers are widely used in TTS development: polyisobutylene 
(PIB)-based adhesives, acrylics and silicone-based PSAs. Ideally, the PSA should 
provide solubility and long-term stability of the drug and potential excipients.  
Furthermore, it should be biologically inert, non-irritating and non-sensitizing to the skin, 
exhibit strong adhesion for the prescribed 
application period, easily removable without 
any residues on the skin and comfortable to 
wear.1-2 
Silicone PSAs (Scheme 4.1) are well 
established adhesives for application in 
TTS devices. They have a highly flexible 
and extremely open macromolecular archi-
tecture with a high void volume resulting in 
a high permeability to vapor, gases and a 
variety of therapeutic molecules.2 To avoid 
condensation reactions of reactive silanol 
end groups with basic drugs, the residual 
SiOH groups are end-capped to yield an 
amine-compatible silicone PSA.6 
4.2 Selection of most promising prodrug candidates for TTS 
development 
In the previous chapter synthesis and physicochemical properties of potential prodrugs of 
candesartan and cilazapril are presented. Furthermore, the compounds were characte-
rized in terms of solid state stability, enzymatic and non-enzymatic (spontaneous) 
cleavage as well as pharmacological activity in case of the candesartan prodrugs. 
According to these criteria a set of the three most promising candidates each had to be 
selected for upscaling of the synthesis to manufacture TTS. Adequate lipophilicity and 
preferably fast enzymatic hydrolysis to the active metabolite are classified as crucial 
criteria. Since prodrug activation ideally takes place in the viable epidermis, and because 
porcine skin shows similarities to the integument of humans in terms of enzyme activity 
and distribution7, hydrolysis in porcine skin homogenate was considered the most 
predictive criterion. 
Among the candesartan prodrugs the cascade esters 3.31 and 3.32 as well as the 
morpholinoethyl ester 3.35 (Table 4.1) were chosen for development of TTS. 3.31 and 
3.32 showed high stability against non-enzymatic hydrolysis, short half-lives in porcine 
skin homogenate and similar experimentally determined octanol/water partition 
 
Scheme 4.1. Processing of silicone pressure 
sensitive adhesive. Adapted from Tan and Pfister.2 
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coefficients as the reference candesartan cilexetil. The hydrolysis of 3.35 in porcine skin 
homogenate was found to be rather slow, but the possibility of salt formation and the fact 
that the putative prodrugs 3.35 and 3.32 are potent AT1 receptor antagonists led to the 
decision to short-list 3.35 as a third potential development candidate. 
Similar considerations led to the selection of the cilazapril cascade prodrugs 3.1, 3.2 and 
the morpholinoethyl ester 3.14 as TTS development candidates (cf. Table 4.1). These 
compounds are characterized by ease of synthesis, adequate lipophilicity, high to 
moderate stability against non-enzymatic hydrolysis and fast cleavage in porcine skin 
homogenate. (5-alkyl-2-oxo-1,3-dioxol-4-yl)methyl esters (3.12, 3.13) and N-aryl-N-alkyl-
oxycarbonylaminomethyl esters (3.25-3.27) of cilazapril do not fulfill the criteria, because 
they are prone to spontaneous hydrolysis. By contrast, the simple ethyl ester 3.28 was 
disregarded due to very high resistance against enzymatic hydrolysis. 
 
Subsequently, approximately 5 g of each selected prodrug (Table 4.1) were synthesized 
for further TTS development. 
Table 4.1. Prodrugs of candesartan and cilazapril chosen for TTS development. 
  
 candesartan prodrugs   cilazapril prodrugs 
compound structure  compound structure 
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4.3 Manufacturing of transdermal therapeutic systems 
For the preparation of monolithic drug-in-adhesive type transdermal patches used for 
analytical studies and permeation experiments the respective prodrug was dissolved in 
an appropriate amount of organic solvent (ethyl acetate), and the required amount of a 
silicone pressure-sensitive adhesive (PSA) in organic solvent (ethyl acetate) was added. 
After homogenizing, the resulting mixture was coated on a fluorosiliconized polyester-
based film laminate serving as the release liner by means of a motorized film applicator. 
The solvent was removed in a drying cabinet. Subsequently, the adhesive coating was 
covered with a thin PET backing foil and round patches with an area of 10 cm2 or 2.5 cm2 
were punched out using appropriate cutting tools. The TTS were then separately packed 
in sachets and vacuum sealed. 
 
TTS batches with different intended drug dosages were prepared, aiming at masses per 
unit area in the range between 60 to 80 g/m2. The resulting drug dose per TTS is 
assumed to provide adequate permeability to reach therapeutic levels. Table 4.2 
summarizes the produced TTS batches for analytical studies and permeation 
experiments containing either a candesartan prodrug (3.31, 3.32, 3.35) or a cilazapril 
prodrug (3.1, 3.2, 3.14). Additionally, batches of TTS containing candesartan cilexetil and 
cilazapril, respectively, were produced for the purpose of comparative studies. 
Table 4.2. Manufactured TTS batches containing candesartan prodrugs, cilazapril prodrugs or cilazapril. 
TTS batch compound intended 
conc. 
[%] 
calculated 
drug 
conc.a [%] 
intended mass 
per unit area 
[g/m2] 
actual matrix mass 
per unit areab 
[g/m2] 
drug dose 
per 10 cm2 
TTS 
[mg/TTS] 
PCAN0001TTS 3.31 5 4.68 80 131.93 6.18 
PCAN0002TTS 3.32 5 4.79 80 141.13 6.76 
PCAN0003TTS 3.35 5 4.90 80 171.93 8.42 
PCAN0004TTS 3.31 10 9.82 80 70.01 6.87 
PCAN0005TTS 3.32 10 9.94 80 71.14 7.07 
PCAN0006TTS 3.35 10 9.42 80 49.74 4.68 
PCAN0009TTS 3.31 10 10.09 60 66.82 6.74 
PCAN0010TTS 3.32 10 9.76 60 63.62 6.21 
PCAN0011TTS 3.35 10 10.08 60 65.90 6.64 
CAN0043TTS CAN-CIL 10 9.52 80 72.25 6.88 
CAN0044TTS CAN-CIL 10 9.94 60 60.00 5.96 
PCIL0002TTS 3.1 10 10.12 80 74.07 7.49 
PCIL0003TTS 3.2 10 10.70 80 74.76 8.00 
PCIL0004TTS 3.14 10 9.79 80 75.18 7.36 
PCIL0011TTS 3.1 10 9.71 70 62.92 6.11 
PCIL0012TTS 3.2 10 10.39 70 63.98 6.65 
PCIL0013TTS 3.14 10 10.28 70 63.88 6.57 
CIL0025TTS cilazapril 10 9.76 75 96.57 9.42 
CIL0027TTS cilazapril 10 10.17 70 65.18 6.63 
a Calculated from the weight of added compound and PSA. b Theoretical mass per unit area of the TTS matrix 
calculated from the weight of TTS samples by subtraction of the weights of release liner and backing foil. 
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As the initial formulations of candesartan prodrug TTS batches with intended drug 
concentrations of 5 % (PCAN0001TTS – PCAN0003TTS) were successful, loading was 
increased to 10 %. Thereby, the apparent difference between intended and actual drug 
concentration can be attributed to the fact that, with respect to the small batch size, the 
exact manual addition of a small amount of semi-solid PSA was challenging. The 
calculated drug concentration represents only a theoretical value. Because of inequalities 
of the coating mixture, variations of the true drug concentration of each TTS cannot be 
excluded. High discrepancies between the intended and the actual TTS matrix mass 
were mainly caused by an unsuitable gap width of the film applicator during coating, 
which led to thicker and heavier patches, when the gap width was adjusted too broad. 
The TTS matrix mass at the edges of the laminate is generally smaller due to a reduced 
thickness of the coating mass. Regarding the solubility of the respective prodrugs in ethyl 
acetate and in the resulting coating mixture, it became apparent that the 1-(2,2-
dimethylpropanoyloxy)ethyl ester 3.32 was most soluble in ethyl acetate and showed 
only slight turbidity after addition of the PSA. The solubility of the 1-(isopropyloxy-
carbonyloxy)ethyl ester 3.31 and candesartan cilexetil in ethyl acetate turned out to be 
dependent on the amount of solvent added. The prodrugs became insoluble, when 
slightly decreased amounts of ethyl acetate were used. The resulting suspension was 
then mixed with PSA and intensively stirred to obtain a homogeneous coating mixture. 
The candesartan morpholinoethyl ester 3.35 turned out to be the least soluble prodrug. 
In the case of PCAN0003TTS a clear prodrug stock solution in ethyl acetate was 
obtained after addition of a larger solvent volume and heating, but the addition of PSA 
led to precipitation of the prodrug. Since a high solvent content can affect the properties 
of the resulting laminate, 3.35 was only suspended in ethyl acetate and homogeneously 
distributed in the coating mixture for following TTS batches. 
The manufacturing of cilazapril prodrug-containing TTS batches was very promising. The 
intended drug concentrations of 10 % were successfully achieved, as all prodrugs were 
highly soluble in ethyl acetate resulting in clear prodrug stock solutions. Addition of 
silicone PSA did not compromise the properties of the coating mixtures, which stayed 
clear and homogeneous. Furthermore, the semi-solid nature of the prodrugs was 
considered rather beneficial than disadvantageous for the formulation. However, the 
preparation of TTS batches with a drug concentration of 12.5 % failed, due to 
inhomogeneity of the matrix after coating and drying (data not shown). Cilazapril is poorly 
soluble in ethyl acetate. Therefore, it was suspended and mixed after addition of PSA 
until a homogeneous coating mixture was obtained. 
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4.4 Characterization of transdermal therapeutic systems 
In the following, examples of TTS batches containing candesartan prodrugs, cilazapril 
prodrugs and cilazapril, respectively are characterized in terms of quality including 
evaluation of the visual and microscopic appearance and relevant properties like ease of 
release (removal from the release liner), adhesive strength and cold flow. Furthermore, 
the stabilities of the individual TTS batches were studied visually as well as by means of 
HPLC for determination of drug content. 
4.4.1 TTS quality 
The relevant quality features of the respective candesartan and cilazapril prodrug-
containing TTS batches, determined immediately after manufacturing, are summarized in 
Table 4.3 and Table 4.4. The release was determined by the ease of removal of the 
release liner. The adhesive strength was assayed by categorizing the power needed to 
remove the TTS from a plane surface. For the characterization of the cold flow, the 
tendency of the TTS to form matrix strings during cutting and to stick to the sachet was 
evaluated. 
Table 4.3. Properties of candesartan prodrug TTS batches. 
TTS batch visual appearance release adhesive 
strength 
cold flow 
PCAN0001TTS turbid, homogenous good good not present 
PCAN0002TTS turbid, homogenous good good not present 
PCAN0003TTS turbid, inhomogeneous, particles/ 
crystals visible 
good good not present 
PCAN0004TTS turbid, homogenous easy and complete very good not present 
PCAN0005TTS turbid, homogenous easy and complete moderate not present 
PCAN0006TTS clear, homogeneous, particles/ 
crystals visible 
easy and complete good not present 
PCAN0009TTS turbid, homogenous good moderate hardly present 
PCAN0010TTS turbid, homogenous good moderate hardly present 
PCAN0011TTS turbid, particles/ crystals visible good moderate hardly present 
CAN0043TTS turbid, homogenous easy and complete moderate not present 
CAN0044TTS turbid, homogenous easy and complete moderate hardly present 
Almost all TTS batches had a turbid and milky, but still homogeneous appearance after 
removal of the solvents (Table 4.3). Regarding batches containing the prodrug 3.35, 
unsolved prodrug particles or crystals were visible, caused by the use of 3.35 as 
suspension in the coating mixture. The release of all batches was convincing, as the 
release liner could be removed easily and without any residual matrix. The adhesive 
strength was adequate, too. Furthermore, no or hardly any cold flow was identified. 
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Table 4.4. Properties of cilazapril and cilazapril prodrug TTS batches. 
TTS batch visual appearance release adhesive 
strength 
cold flow
PCIL0002TTS turbid, homogenous easy and complete good hardly present 
PCIL0003TTS turbid, homogenous easy and complete good hardly present 
PCIL0004TTS turbid, homogenous easy and complete good hardly present 
PCIL0011TTS turbid, homogenous bad, matrix sticks on the RL, 
BF was removed instead 
moderate hardly present 
PCIL0012TTS turbid, homogenous easy and complete moderate hardly present 
PCIL0013TTS turbid, homogenous bad at the edges moderate hardly present 
CIL0025TTS turbid, homogenous easy and complete good hardly present 
CIL0027TTS turbid, homogenous good moderate hardly present 
All batches of cilazapril prodrugs depicted in Table 4.4 were characterized showing turbid 
and homogenous visual appearance, moderate to good adhesive strength and hardly 
any cold flow. In most of the cases the release liner could be removed easily and 
completely without any residual matrix. Only in case of batch PCIL0011TTS, removal of 
the release liner from the matrix was impossible, but the backing foil was removed quite 
easily instead. A rather difficult release at the edges of each TTS was observed for 
PCIL0013TTS. 
 
For further characterization of the TTS matrix-structures microscopic images of 
exemplary TTS batches were taken directly after manufacturing (cf. Figure 4.2 A-H). 
Regarding the batches PCAN0004TTS, PCAN0005TTS and PCAN0010TTS homo-
geneous matrices with dispersed emulsion droplets were visible. For CAN0043TTS 
single crystals distributed in a homogeneous matrix were found, whereas the matrices of 
PCAN0009TTS and CAN0044TTS appeared to be more crystalline, containing scattered 
drug agglomerates. The images of PCAN0006TTS and PCAN0011TTS revealed crystals 
and small particles, which were either embedded in clear (PCAN0006TTS) or turbid 
(PCAN0011TTS) matrices. In summary, homogeneous matrices containing emulsion 
droplets were only found, when the drug was dissolved in the coating mixture. However, 
when the drug was processed as a suspension, particles and crystals of the drug were 
clearly visible in the TTS matrix. 
Images taken from examples of cilazapril prodrug TTS batches (Figure 4.3 A-H) showed 
very homogeneous, finely structured matrices with scattered emulsion droplets. The 
matrices of cilazapril containing TTS batches appeared to be slightly more inhomo-
geneous due to comparatively more voluminous (CIL0027TTS) or rather amorphous 
(CIL0025TTS) emulsion droplets. Although cilazapril was used as a suspension in the 
coating mixture, particles or crystals of the drug were not detected in the TTS, indicating 
that the suspension was resolved after coating on the release liner. 
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A: PCAN0004TTS, objective: 10 x B: PCAN0005TTS, objective: 10 x 
C: PCAN0006TTS, objective: 10 x D: CAN0043TTS, objective: 10 x 
E: PCAN0009TTS, objective: 25 x 
 
F: PCAN0010TTS, objective: 25 x 
 
G: PCAN0011TTS, objective: 25 x H: CAN0044TTS, objective: 25 x 
Figure 4.2 A-H. Microscopic images of candesartan prodrug TTS batches, provided by Hexal AG. 
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A: PCIL0002TTS, objective: 40 x B: PCIL0003TTS, objective: 40 x 
 
C: PCIL0004TTS, objective: 40 x D: CIL0025TTS, objective: 40 x 
 
E: PCIL0011TTS, objective: 25 x 
 
F: PCIL0012TTS, objective: 25 x 
G: PCIL0013TTS, objective: 25 x H: CIL0027TTS, objective: 25 x 
Figure 4.3 A-H. Microscopic images of cilazapril and cilazapril prodrug TTS batches, provided by Hexal AG. 
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4.4.2 TTS stability 
The stability of the different TTS formulations was determined after storage for different 
periods of time at various temperatures and humidities (rel. h.) by extraction of examples 
of the respective TTS batches with an organic solvent and subsequent analysis by HPLC 
using the 100 % method. Furthermore, visible changes of the TTS quality were controlled 
by light microscopy. 
 
The stability of TTS batches containing candesartan prodrugs in a silicone PSA matrix at 
different conditions is summarized in Table 4.5 and illustrated in Figure 4.4. It became 
obvious that all candesartan prodrugs remained stable during storage at 5 °C/65 % rel. h. 
for eight months. Storage at 25 °C/60 % rel. h. over a period of eight months led to a 
slight decrease in drug content of the batches PCAN0004TTS, PCAN0005TTS and 
CAN0043TTS. Furthermore, storage over a period of two months under accelerated 
storage conditions (40 °C/75 % rel. h.) resulted in a significant decrease in the content of 
the double ester prodrugs 3.31, 3.32 and candesartan cilexetil. With respect to the initial 
value (0 months, promptly determined after TTS preparation), degradation of 3.32 and 
candesartan cilexetil was comparable. By contrast, 3.31 revealed the lowest stability in 
the accelerated stability test. Regarding the morpholinoethyl ester 3.35, excellent stability 
was observed, irrespective of the storage conditions. However, 3.35 was not dissolved in 
the TTS matrix. In contrast to PCAN0004TTS, PCAN0005TTS and CAN0043TTS, 
PCAN0006TTS contained the prodrug in a crystalline form. 
Surprisingly, in all TTS batches candesartan was either not detectable or present only in 
negligible amounts as impurity. For 3.31, 3.32 and candesartan cilexetil two major 
impurities each were detected (highlighted in italics in Table 4.5 and indicated by black 
arrows in Figure 4.4), one with shorter, one with longer retention time compared to the 
respective prodrug. Since each pair of impurities showed a ΔtR ~ 8 min the correspon-
ding decomposition reaction might have occurred at the same positions in the respective 
prodrugs but not at the pro-moiety. 
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Table 4.5. Stability of candesartan prodrugs in a silicone PSA matrix after different storage periods at different 
temperatures and humidities.a 
  content [%] content (Δ)b [%] content (Δ)b [%] 
batch/ 
prodrug 
prodrug 
or impurity (I)c, d 
0 months 
2 months 
25 °C/ 
60 % rel. h. 
2 months 
40 °C/ 
75 % rel. h. 
8 months 
5 °C/ 
65 % rel. h. 
8 months 
25 °C/ 
60 % rel. h. 
PCAN0004TTS/ 
3.31 
3.31 92.8 93.3 (-0.5) 53.3 (39.5) 95.3 (-2.5) 90.7 (2.1) 
I_133 3.4 3.7 18.8 2.8 5.0 
I_156 0.1 0.1 2.3 0.0 0.2 
I_178 0.1 0.1 8.9 0.0 0.3 
I_198 0.9 0.9 3.9 0.7 1.1 
I_221 2.0 1.8 12.8 1.2 2.6 
I_rest e 0.7 0.1 0.0 0.0 0.1 
PCAN0005TTS/ 
3.32 
3.32 93.2 93.2 (0) 79.4 (13.8) 95.6 (-2.4) 91.0 (2.2) 
I_152 3.1 3.5 9.9 2.6 4.7 
I_198 0.2 0.2 1.9 0.0 0.3 
I_217 0.6 0.6 1.9 0.6 0.9 
I_238 1.3 1.7 5.7 1.1 2.3 
I_rest e 1.6 0.8 1.2 0.1 0.8 
PCAN0006TTS/ 
3.35 
3.35 99.0 99.5 (-0.5) 99.4 (-0.4) 100.0 (-1.0) 100.0 (-1.0) 
I_rest e 1.0 0.5 0.6 0.0 0.0 
CAN0043TTS/ 
candesartan 
cilexetil 
(CAN-CIL) 
CAN-CIL 94.9 94.4 (0.5) 82.3 (12.6) 97.3 (-2.4) 92.8 (2.1) 
I_165 2.5 3.0 8.9 1.8 3.9 
I_209 0.0 0.1 1.3 0.0 0.3 
I_228 0.3 0.5 1.5 0.0 0.6 
 I_245 1.0 1.6 5.4 0.8 2.3 
 I_rest e 1.3 0.4 0.6 0.1 0.1 
a Mean values of two independently analyzed TTS samples. b decrease of prodrug content with respect to the 0 
months value c Not further characterized impurities (I) with > 1 % abundance are listed separately and are 
highlighted in italics. d I_xxx stands for impurity eluting at tR ~ xx.x min. d I_rest: sum of all impurities not 
separately listed. 
 
Figure 4.4. Examples of 
HPLC chromatograms 
illustrating the analysis of 
candesartan prodrug contai-
ning TTS batches after two 
different storage periods (1 
and 8 months) and at dif-
ferent conditions. Black ar-
rows indicate major impu-
rities. Asterisk refers to an 
impurity from the used or-
ganic solvent. 
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In Table 4.6 the stabilities of cilazapril and cilazapril prodrugs in silicone PSA matrices 
are summarized and illustrated in Figure 4.4. Surprisingly, masking of the free carboxylic 
acid group in cilazapril with a promoiety seemed to be beneficial in terms of drug stability 
in a silicone PSA matrix, since the prodrugs 3.1 and 3.2 showed a slightly better stability 
at long-term stability conditions (25 °C, 60 % rel. h.) and were clearly superior to 
cilazapril under accelerated conditions (40 °C, 75 % rel. h.) over nine months. By 
contrast, the presence of a basic group in the pro-moiety as in 3.14 led to accelerated 
degradation compared to cilazapril, although the stability at 25 °C/60 % rel. h. over nine 
months was still satisfactory and comparable to cilazapril. It becomes obvious from Table 
4.6 and Figure 4.4 that (apart from small amounts of cilazaprilat and not further charac-
terized impurities) cilazapril was the major degradation product of 3.1, 3.2 and 3.14, 
whereas the major degradation product of cilazapril was cilazaprilat. 
Table 4.6. Stability of cilazapril and cilazapril prodrugs in a silicone PSA matrix 
after different storage periods at different temperatures and humidities.a, b 
   content (Δ)c [%] 
batch/ 
prodrug 
molecular 
species 
0 months 9 months 
25 °C/60 % rel. h. 
9 months 
40 °C/75 % rel. h. 
PCIL0002TTS/ 
3.1 
3.1 99.7 98.0 (1.7) 94.1 (5.6) 
cilazapril 0.3 0.4 3.5 
cilazaprilat 0.0 0.0 0.2 
 I_restd 0.0 1.6 2.2 
PCIL0003TTS/ 
3.2 
3.2 100.0 98.3 (1.7) 95.9 (4.1) 
cilazapril 0.0 0.2 1.9 
cilazaprilat 0.0 0.0 0.1 
 I_restd 0.0 1.5 2.1 
PCIL0004TTS/ 
3.14 
3.14 98.0 94.7 (3.3) 69.1 (28.9) 
cilazapril 0.6 0.6 21.5 
cilazaprilat 0.0 0.0 1.7 
 I_restd 1.4 4.7 7.7 
CIL0025TTS/ 
cilazapril 
cilazapril 100.0 97.0 (3.0) 76.8 (23.2) 
cilazaprilat 0.0 2.1 21.2 
I_restd 0.0 0.9 2.0 
a Data represent values from the respective “worst case chromatograms” of two 
analyzed TTS. b Data provided from Hexal AG. c decrease of prodrug content with 
respect to the 0 months value. d I_rest: sum of all not further characterized impurities or 
degradation products not separately listed. 
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Figure 4.5. HPLC chromatograms of PCIL0002TTS (A), PCIL0003TTS (B), PCIL0004TTS (C) and CIL0025TTS 
(D) stored at given conditions and periods of time. Raw data was provided from Hexal AG and processed by M. 
Ertel. 
 
After a storage period of five months at 25 °C/60 % rel. h. and 40 °C/75 % rel. h., 
respectively, the TTS batches PCAN0004TTS, PCAN0005TTS, PCAN0006TTS and 
CAN0043TTS were inspected and documented by microscopic images in order to detect 
potential alterations in the TTS matrix structures. From Figure 4.6 it becomes obvious, 
that compared to long-term stability conditions storage under accelerated conditions led 
to considerable changes in the appearance of the TTS batches PCAN0004TTS, 
PCAN0005TTS and CAN0043TTS, which were characterized by a grainier matrix and an 
increase in the size of present emulsion droplets. This became particularly obvious for 
PCAN0005TTS by determination of the diameter of randomly chosen spherical emulsion 
droplets by means of an image processing software (ImageJ 1.43u). Comparing two 
samples stored at 25 °C/60 % rel. h. and 40 °C/75 % rel. h., respectively, the average 
diameter increased from ~18 µm to ~71 µm under accelerated storage conditions. 
The TTS batch PCAN0006TTS seemed not to be affected during storage in the 
accelerated stability test, showing single drug crystals or agglomerates and some 
bubbles. However, the patches revealed a strong tendency to cake, resulting in a 
considerably more difficult release of the release liner. 
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A: PCAN0004TTS, 25 °C, 60 % rel. h., objective: 10 x B: PCAN0004TTS, 40 °C, 75 % rel. h., objective: 10 x 
C: PCAN0005TTS, 25 °C, 60 % rel. h., objective: 10 x D: PCAN0005TTS, 40 °C, 75 % rel. h., objective: 10 x 
E: PCAN0006TTS, 25 °C, 60 % rel. h., objective: 4 x, 
polarized light 
F: PCAN0006TTS, 40 °C, 75 % rel. h., objective: 4 x, 
polarized light 
 
G: CAN0043TTS, 25 °C, 60 % rel. h., objective: 10 x H: CAN0043TTS, 40 °C, 75 % rel. h., objective: 10 x 
Figure 4.6 A-H. Microscopic images of candesartan prodrug TTS batches stored for five months at given 
temperature and humidity conditions. 
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Microscopic studies of examples of the cilazapril and cilazapril prodrug containing TTS 
batches PCIL0002TTS, PCIL0003TTS, PCIL0004TTS and CIL0025TTS after a storage 
period of 26 months at 25 °C/60 % rel. h. and 40 °C/75 % rel. h., respectively, revealed 
promising results for the prodrug containing systems (Figure 4.7). Even over a relatively 
long storage period at 25 °C/60 % rel. h. no crystallization was observed for 
PCIL0002TTS, PCIL0003TTS and PCIL0004TTS, and the appearance of the respective 
matrices was quite satisfactory. As also noticed for candesartan prodrug TTS batches, 
storage under accelerated storage conditions led to a decrease in homogeneity resulting 
in a grainier matrix. In PCIL0004TTS yellowish emulsion drops were detected. However, 
it should be kept in mind that, irrespective of the storage conditions, degradation of all 
prodrugs took place to a certain degree; this might contribute to the changes in the 
appearance of the TTS. Investigation of the cilazapril containing TTS CIL0025TTS 
showed a generally more homogeneous matrix with numerous randomly shaped emul-
sion structures, which tended to agglomerate under accelerated conditions. 
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A: PCIL0002TTS, 25 °C, 60 % rel. h., objective: 10 x 
 
B: PCIL0002TTS, 40 °C, 75 % rel. h., objective: 10 x 
C: PCIL0003TTS, 25 °C, 60 % rel. h., objective: 10 x 
 
D: PCIL0003TTS, 40 °C, 75 % rel. h., objective: 10 x 
E: PCIL0004TTS, 25 °C, 60 % rel. h., objective: 10 x F: PCIL0004TTS, 40 °C, 75 % rel. h., objective: 10 x 
G: CIL0025TTS, 25 °C, 60 % rel. h., objective: 20 x H: CIL0025TTS, 40 °C, 75 % rel. h., objective: 20 x 
 
Figure 4.7 A-H. Microscopic images of cilazapril and cilazapril prodrug TTS batches stored for 26 months at 
given temperature and humidity conditions. 
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4.5 Summary 
In consideration of synthesis, physicochemical properties as well as bioanalytical and 
pharmacological studies of a set of candesartan and cilazapril prodrugs, respectively, i.e. 
the three most promising candidates of each group, was selected for TTS development. 
Regarding the candesartan prodrugs candesartan 1-(isopropyloxycarbonyloxy)ethyl ester 
(3.31), candesartan 1-(2,2-dimethylpropanoyloxy)ethyl ester (3.32) and candesartan 
morpholinoethyl ester (3.35), TTS batches based on silicone PSA with drug con-
centrations of 10 % were successfully manufactured. The formulate-ability of 3.31 and 
3.32 was comparable or even superior to that of candesartan cilexetil. By contrast, the 
use of 3.35 resulted in inhomogeneous TTS matrices with scattered drug crystals, made 
visible by microscopy. The manufactured TTS exhibited comparable properties as the 
candesartan cilexetil containing TTS in terms of release (removal of the release liner), 
adhesive strength and cold flow. HPLC analysis of examples of TTS batches revealed 
promising stabilities of all prodrugs at low temperatures and under long-term stability 
conditions. Moreover, alterations of the matrix structure during storage were controlled 
by microscopic studies. 
Among the selected cilazapril prodrugs, cilazapril 1-(ethoxycarbonyloxy)ethyl ester (3.1), 
cilazapril 1-(cyclohexyloxycarbonyloxy)ethyl ester (3.2) and cilazapril morpholinoethyl 
ester (3.14) turned out to be very promising in terms of formulate-ability. The semi-solid 
prodrugs proved to have favorable properties to successfully manufacture TTS based on 
silicone PSA with drug concentrations of 10 %, showing homogeneous matrices with 
finely dispersed emulsion droplets. At low temperature the stability of 3.1, 3.2 and 3.14 in 
these TTS was very good, and, surprisingly, under accelerated storage conditions the 
double esters 3.1 and 3.2 were significantly more stable than cilazapril. Furthermore, 
microscopic studies of such TTS showed no tendency for crystallization over 26 months. 
 
In summary, the prodrugs 3.31, 3.32, 3.35 and 3.1, 3.2, 3.14 were found to be 
comparable or even superior to the reference compounds candesartan cilexetil and 
cilazapril with respect to formulate-ability, TTS quality and stability in a silicone PSA 
matrix. Thus, the selected prodrugs are considered suitable for permeation experiments. 
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4.6 Experimental section 
4.6.1 General experimental conditions 
Commercially available chemicals and reagents were purchased from Acros Organics 
(Geel, Belgium), Merck KGaA (Darmstadt, Germany) or Sigma-Aldrich Chemie GmbH 
(München, Germany). All solvents used were of analytical grade or HPLC grade. 
Analytical HPLC analysis was performed on a system from Thermo Separation Products 
(Thermo Scientific) consisting of a SN400 controller, a P4000 pump, an AS3000 
autosampler, a Spectra Focus UV-VIS detector and a RP-column (Luna C18-2, 150 x 4.6 
mm, 3 μm; Phenomenex, Aschaffenburg, Germany) at a flow rate of 0.75 mL/min and a 
column temperature varying between 45 to 60 °C. Absorbance was detected at 210 nm. 
The mobile phase consisted of MeCN and 0.05 % trifluoroacetic acid (TFA) in Millipore 
water. All samples were filtered prior to injection using 0.2 µm Phenex-NY Syringe Filters 
(0.2 µm pore size, 4 mm diameter) (Phenomenex, Aschaffenburg, Germany). TTS 
manufacturing was performed at Hexal AG (Holzkirchen, Germany) in a separate 
laboratory area (“Technikum”, part of the GMP area). Microscopic images were taken by 
means of a Leitz Laborlux S microscope (Leitz, Stuttgart, Germany) equipped with a SIS 
ColorView12 CCD camera (Soft Imaging System GmbH, Münster, Germany) or an 
Olympus BH-2 microscope (Olympus, Tokyo, Japan) equipped with a Digital Mikroskop 
DCM-500 Ocular microscope camera. 
4.6.2 Production of transdermal therapeutic systems 
4.6.2.1 General procedure for manufacturing transdermal therapeutic systems 
Exact amounts of drug and ethyl acetate were weighed into a small glass vessel and 
mixed by stirring until, if possible, a clear stock solution was obtained. The required 
amount of silicone PSA (Bio PSA 4302, Dow Corning, Wiesbaden, Germany, solids 
content: 71.13 %, solvent: ethyl acetate) was added and the mixture was homogenized 
by stirring. The resulting coating mass was distributed on a release liner (PET-foil, 
fluorosiliconized, transparent, thickness: 75 µM Scotchpak 3M 1022, 3M Drug Delivery 
Systems, St. Paul, USA) by means of an motorized film applicator (Coatmaster 509/MC-
I, Erichsen, Hemer, Germany) with adjusted gap width and coating speed followed by 
successively drying at ambient temperature and in a drying cabinet. Subsequently, the 
coating was laminated with PET backing foil (thickness: 15 µM, Hostaphan RN 15, 
Mitsubishi Polyester Film GmbH, Wiesbaden, Germany) and round patches with an area 
of 10 cm2 or 2.5 cm2 were cut out by means of a circle cutter. The TTS were separately 
packed in sachets, vacuum sealed and stored. 
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Manufacturing of candesartan prodrug containing TTS batches 
PCAN0004TTS: The TTS batch was prepared according to the general procedure 
4.6.2.1, using 0.4006 g of 3.31 and 3.57 g of ethyl acetate. To the resulting clear solution 
5.1729 g of silicone PSA were added yielding a slightly turbid, homogeneous coating 
mixture, which was distributed with a gap width of 320 µm and a coating speed of 
10 mm/s on the release liner. After drying for 5 min at ambient temperature and for 
60 min at 60 °C the matrix was laminated and TTS were cut out and stored. 
PCAN0005TTS: The TTS batch was prepared according to the general procedure 
4.6.2.1, using 0.3999 g of 3.32 and 3.50 g of ethyl acetate. To the resulting clear solution 
5.0935 g of silicone PSA were added yielding a slightly turbid, homogeneous coating 
mixture. The release liner was coated adjusting the gap width to 320 µm and the coating 
speed to 10 mm/s. After drying for 5 min at ambient temperature and for 60 min at 60 °C 
the matrix was laminated and TTS were cut out and stored. 
PCAN0006TTS: The TTS batch was manufactured according to the general procedure 
4.6.2.1, using 0.3998 g of 3.35 and 3.51 g of ethyl acetate. Despite extensive stirring and 
slight heating 3.35 remained undissolved. To the suspension 5.4072 g of silicone PSA 
were added yielding a clear mass with homogeneously distributed drug particles. The 
release liner was coated adjusting the gap width to 320 µm and the coating speed to 
10 mm/s. After drying for 5 min at ambient temperature and for 60 min at 60 °C the 
matrix was laminated and TTS were cut out and stored. 
PCAN0009TTS: According to the general procedure 4.6.2.1, 0.30 g of 3.31 were 
suspended in 2.23 g of ethyl acetate. To the suspension 4.39 g of silicone PSA were 
added and the coating mixture was distributed on the release liner using a gap width of 
180 µm and a coating speed of 10 mm/s. After drying for 5 min at ambient temperature 
and for 60 min at 60 °C the matrix was laminated and TTS were cut out and stored. 
PCAN0010TTS: The TTS batch was prepared according to the general procedure 
4.6.2.1, using 0.297 g of 3.32 and 2.15 g of ethyl acetate. To the resulting clear solution 
4.51 g of silicone PSA were added. The release liner was coated adjusting the gap width 
to 180 µm and the coating speed to 10 mm/s. After drying for 5 min at ambient 
temperature and for 60 min at 60 °C the matrix was laminated and TTS were cut out and 
stored. 
PCAN0011TTS: The TTS batch was manufactured according to the general procedure 
4.6.2.1, using 0.301 g of 3.35 as a suspension in 2.14 g of ethyl acetate. To the resulting 
suspension 4.41 g of silicone PSA were added. The release liner was coated adjusting 
the gap width to 180 µm and the coating speed to 10 mm/s. After drying for 5 min at 
ambient temperature and for 60 min at 60 °C the matrix was laminated and TTS were cut 
out and stored. 
CAN0043TTS: The TTS batch was prepared according to the general procedure 4.6.2.1, 
using 0.4021 g of candesartan cilexetil and 3.50 g of ethyl acetate. To the resulting clear 
solution 5.3367 g of silicone PSA were added yielding a slightly turbid, homogeneous 
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coating mixture, which was distributed with a gap width of 320 µm and a coating speed of 
10 mm/s on the release liner. After drying for 5 min at ambient temperature and for 
60 min at 60 °C the matrix was laminated and TTS were cut out and stored. 
CAN0044TTS: According to the general procedure 4.6.2.1, 0.303 g of candesartan 
cilexetil were suspended in 2.11 g of ethyl acetate. 4.51 g of silicone PSA were added 
and the coating mixture was distributed on the release liner using a gap width of 180 µm 
and a coating speed of 10 mm/s. After drying for 5 min at ambient temperature and for 
60 min at 60 °C the matrix was laminated and TTS were cut out and stored. 
Manufacture of cilazapril or cilazapril prodrug containing TTS batches 
PCIL0002TTS: The TTS batch was prepared according to the general procedure 4.6.2.1 
using 0.329 g of 3.1 and 2.06 g of ethyl acetate. To the resulting clear solution 4.11 g of 
silicone PSA were added yielding a clear coating mixture. The release liner was coated 
adjusting the gap width to 235 µm and the coating speed to 10 mm/s. After drying for 
5 min at ambient temperature and for 90 min at 60 °C the matrix was laminated and TTS 
were cut out and stored. 
PCIL0003TTS: The TTS batch was manufactured according to the general procedure 
4.6.2.1 using 0.347 g of 3.2 and 2.18 g of ethyl acetate. To the resulting clear stock 
solution 4.07 g of silicone PSA were added yielding a clear coating mixture, which was 
distributed on the release liner with a gap width of 235 µm and a coating speed of 
10 mm/s. After drying for 5 min at ambient temperature and for 90 min at 60 °C the 
matrix was laminated and TTS were cut out and stored. 
PCIL0004TTS: The TTS batch was manufactured according to the general procedure 
4.6.2.1 using 0.338 g of 3.14 and 2.20 g of ethyl acetate. To the resulting clear solution 
4.38 g of silicone PSA were added yielding a clear coating mixture. The release liner was 
coated adjusting the gap width to 235 µm and the coating speed to 10 mm/s. After drying 
for 5 min at ambient temperature and for 90 min at 60 °C the matrix was laminated and 
TTS were cut out and stored. 
PCIL0011TTS: The TTS batch was manufactured according to the general procedure 
4.6.2.1 using 0.281 g of 3.1 and 2.01 g of ethyl acetate. To the resulting clear solution 
4.29 g of silicone PSA were added yielding a clear coating mixture. The release liner was 
coated adjusting the gap width to 185 µm and the coating speed to 10 mm/s. After drying 
for 5 min at ambient temperature and for 60 min at 60 °C the matrix was laminated and 
TTS were cut out and stored. 
PCIL0012TTS: The TTS batch was manufactured according to the general procedure 
4.6.2.1 using 0.293 g of 3.2 and 2.00 g of ethyl acetate. After addition of 4.15 g of 
silicone PSA and homogenizing the clear coating mass was distributed on the release 
liner adjusting the gap width to 185 µm and the coating speed to 10 mm/s. After drying 
for 5 min at ambient temperature and for 60 min at 60 °C the matrix was laminated and 
TTS were cut out and stored. 
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PCIL0013TTS: The TTS batch was manufactured according to the general procedure 
4.6.2.1 using 0.293 g of 3.14 and 1.99 g of ethyl acetate. After addition of 4.20 g of 
silicone PSA and homogenizing the clear coating mass was distributed on the release 
liner adjusting the gap width to 185 µm and the coating speed to 10 mm/s. After drying 
for 5 min at ambient temperature and for 60 min at 60 °C the matrix was laminated and 
TTS were cut out and stored. 
CIL0025TTS: The TTS batch was manufactured according to the general procedure 
4.6.2.1 using 0.529 g of cilazapril and 3.52 g of ethyl acetate. Because only little amounts 
of cilazapril could be dissolved after 2 h of stirring additional 0.97 g of ethyl acetate were 
added. As most of the compound remained undissolved 6.84 g of silicone PSA were 
added and 0.60 g of ethyl acetate were removed under a stream of nitrogen. The 
resulting crystals-containing, homogeneous coating mixture was distributed on the 
release liner using a gap width of 310 µm and the coating speed to 10 mm/s. After drying 
for 5 min at ambient temperature and for 120 min at 60 °C the matrix was laminated and 
TTS were cut out and stored. 
CIL0027TTS: The TTS batch was manufactured according to the general procedure 
4.6.2.1 using 0.354 g of cilazapril suspended in 2.69 g of ethyl acetate. To the 
suspension 5.11 g of silicone PSA were added and the coating mixture was distributed 
on the release liner using a gap width of 190 µm and a coating speed of 10 mm/s. After 
drying for 5 min at ambient temperature and for 60 min at 60 °C the matrix was laminated 
and TTS were cut out and stored. 
4.6.3 Determination of TTS stability 
The stability of the candesartan prodrugs 3.31, 3.32, 3.35 and candesartan cilexetil in a 
silicone adhesive layer after various storage periods under different storage conditions 
was studied in our laboratory. The analytical investigation of cilazapril and cilazapril 
prodrug (3.1, 3.2, 3.14) containing TTS was performed at Hexal AG (Holzkirchen, 
Germany). 
4.6.3.1 Procedure for the determination of the stability of candesartan prodrug 
containing TTS by HPLC 
For determination of stability two TTS each (2 x 10 cm2 or 2 x 2.5 cm2) of the 
candesartan prodrug containing TTS batches PCAN0004TTS, PCAN0005TTS, 
PCAN0006TTS and CAN0043TTS were analyzed promptly after manufacturing as well 
as after storage for two and eight months, respectively, at 5 °C/ 65 % rel. h., 25 °C/ 60 % 
rel. h. and 40 °C/ 75 % rel. h. The release liner was removed and each patch was put 
into a small glass vessel. After addition of THF (10 cm2: 10.0 ml, 2.5 cm2: 5.0 ml) the 
adhesive matrix was dissolved by sonication (15 min) and mixing on a shaker (30 min). 
The samples were diluted with mobile phase (10 cm2: 1:10, 2.5 cm2: 1:5) and filtrated. 
For HPLC analysis 25 µl of each sample were injected using the following gradient: 
0 min: MeCN/0.05% TFA/aq 30/70, 20 min: 85/15, 21-26 min: 95/5, 27-35 min: 30/70. 
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 Chapter 5  
Permeation of Prodrugs of Candesartan and 
Cilazapril Through Animal and Human Skin 
5.1 Introduction 
In order to exert a therapeutic effect, a dermally administered antihypertensive drug must 
overcome the various layers of the skin and reach the systemic circulation. This 
absorption process can be divided into three steps: 
- penetration, which is the entry of a substance into a particular layer or structure such as 
the entrance of a compound into the stratum corneum; 
- permeation, which is the penetration through one layer into another, where both layers 
are functionally and structurally different from each other; 
- resorption, which is the uptake of a substance into the vascular system, which acts as 
the central compartment.1 
 
Figure 5.1. Schematic of skin and its appendages that shows the epidermis, dermis, and subcu-
taneous tissue. Netter illustration from www.netterimages.com. © Elsevier Inc. All rights reserved. 
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As interface between the body and the environment one of the most important functions 
of the skin is its ability to act as a protective barrier against noxious physical, chemical 
and mechanical harm and the loss of excessive endogenous material such as water. 
Basically, the skin can be divided into three layers: epidermis, dermis and hypodermis 
(cf. Figure 5.1). Whereas the hypodermis mainly comprises fatty tissue, the dermis is 
composed of collagen, elastin, salts, water, and a gel of glycosaminoglycans. The dermis 
is highly vascularized and also includes skin appendages as eccrine and apocrine sweat 
glands, sebaceous glands and hair follicles.2-3 The upper part of the dermis, which is 
referred to as papillary dermis, is characterized by ridges and folds of papillae and a 
more widely dispersed arrangement of elastin and collagen fibers. In the reticular dermis, 
the subjacent thicker counterpart of the papillary dermis, the collagen fibers are arranged 
in an interwoven, crisscross pattern in a plane parallel with the skin.3 
The uppermost part of the skin, the epidermis, can be divided into 4 to 5 distinct layers, 
which are (from deep to superficial) the stratum basale, stratum spinosum, stratum gra-
nulosum, stratum lucidum (only apparent at palms and soles of the feet) and the stratum 
corneum (Figure 5.2). 
The stratum basale is 
composed of a single 
layer of epidermal stem 
cells having the ability to 
undergo mitosis and 
thus, regenerating the 
epidermal tissue. Cells 
deriving from dividing 
cells of the stratum ba-
sale, the keratinocytes, 
migrate superficially into 
the stratum spinosum, 
where they begin to dif-
ferentiate. They flatten 
and elongate, while a 
formation of lipid-en-
riched lamellar bodies and an increase in intracellular keratin filaments is noticeable. The 
stratum granulosum consists of 2-5 layers of cells containing keratohyalin granules. 
While these granules are released by exocytosis, the keratinocytes face cell death, turn 
into corneocytes and move to the surface, where they get sloughed by abrasion. The 
uppermost layer, the stratum corneum, consists of 18-21 layers of corneocytes.2 Its 
architecture is probably best described by the ‘brick and mortar’ model by Elias 
suggesting that the keratin-enriched corneocytes resemble the bricks and are embedded 
in the mortar consisting of extracellular hydrophobic lipids.5 According to an improved 
Figure 5.2. Schematic representation of the epidermis. Modified from 
Benninghoff.4 
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model proposed by Barry, the intercellular “mortar” is considered as stacks of 
intercellular lipid bilayers with an aqueous phase in between (cf. section 3.4).6 
The average overall thickness of human skin is between 2-3 mm.3 However, depending 
on the body part, the thickness varies considerably. The average diameter of the 
epidermis is indicated as 100-150 µm, of which 20-40 µm are attributed to the stratum 
corneum.2 
To reach the viable cells, three different diffusion pathways for a permeant through the 
stratum corneum are discussed: a tortuous intercellular pathway through the extracellular 
lipids, a transcellular pathway through the corneocytes and the extracellular lipids and an 
appendageal pathway along sweat ducts or hair follicles. As the appendages cover only 
0.1 % of the surface area of the skin, this route contributes negligibly to permeation, but 
may be important for ions and large polar molecules.6 Due to the relative impermeability 
of the corneocytes, the major pathway for permeation through the stratum corneum is 
assumed to be the intercellular route (cf. section 3.4).7 
As drug transport across the stratum corneum is a passive diffusion process, it can be 
described by Fick’s Law8 (Equation 5.1), stating that the flux of a compound (J) per unit 
path length (δx) is proportional to the concentration gradient (δc) and the diffusion 
coefficient or diffusivity (D). 
J ൌ െD · δcδx 
Equation 5.1. Fick’s Law. J = flux [mol·cm-2·s-1], D = diffusivity [cm2·s-1], δc = concentration gradient [mol·cm-3], 
δx = path length [cm]. 
The steady-state flux Jss results from the integrated form of Equation 5.1 according to 
Equation 5.2. 
Jୱୱ ൌ
K୫ · D · ∆c
x ൌ K୮ · ∆c 
Equation 5.2. Jss = steady-state flux [mol·cm-2·s-1], Km = partition or distribution coefficient between the stratum 
corneum and the vehicle, D = diffusivity [cm2·s-1], Δc = concentration difference [mol·cm-3], x = path length [cm], 
Kp = permeability constant [cm·s-1]. 
Typically, the steady-state flux Jss is assessed from an in vitro permeation experiment, in 
which the donor concentration of the permeant is kept (more or less) constant (infinite 
dose conditions), while the receiver phase provides sink conditions and is calculated 
from the slope of the linear portion of the graph of the cumulative amount permeated vs. 
time. Back-extrapolation of the latter plot to the x-axis yields the so-called lag time tlag, 
which designates the time needed for the permeated compound to reach steady-state. 
For the development of a novel transdermal therapeutic system the assessment of 
reliable skin absorption data is indispensable. Usually, percutaneous absorption is 
studied in vivo by means of various animal models or by different in vitro methods. In 
2004 a guideline for in vitro skin absorption methods was designed by the OECD 
(Organisation for Economic Co-operation and Development) describing procedures and 
methods with the objective of ensuring the reliability of obtained skin absorption results.9 
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The principle of the described method comprises the application of a test substance to 
the surface of a skin sample, separating the donor and receptor reservoir of a diffusion 
cell. At appropriate periods of time the receptor fluid is sampled and analyzed for the test 
compound and/or metabolites. Two different designs of diffusion cells are used – the 
static cell (usually a Franz cell10) and the flow-through design11. Conventionally, the test 
substance is applied to the skin on the donor side as a reservoir solution or as a suitable 
formulation (e.g. a TTS). For transdermal in vitro absorption studies the most relevant 
barrier is of course human skin. However, since its availability is limited, a multitude of 
animal substitutes, ranging from snake, mouse, rat, guinea pig over pig to primates is 
used. Especially, porcine ear skin, which is readily obtainable from abattoirs and which 
has similar biochemical properties as human skin, is accepted to be particularly well-
suited for permeation studies and to give results comparable to human skin.12 
Furthermore, the use of artificial skin such as Testskin™, Epiderm™ or Skinethic™ has 
been described.13-15 However, due to rather constricted barrier function of these model 
systems, the use of artificial membranes is not recommended for in vitro permeation 
studies.16 The OECD suggests the use of epidermal membranes (separated by heat, 
chemically or enzymatically), full-thickness skin or split-thickness skin (typically 200-
400 μm) prepared with a dermatome.9 Regarding the comparability of permeation 
results, particularly the anatomical site should be taken into consideration due to varying 
thickness of the epidermis depending on the body part. The age of the skin donors is 
known to affect skin permeation.17 Furthermore, gender-related differences in skin phy-
siology were reported. 18 By contrast, no statistical difference in percutaneous absorption 
was found between different human ethnicities (Caucasian, Asian, black).19 
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5.2 Selection of experimental design and conditions for in vitro 
permeation studies 
As a suitable test system for permeation studies with candesartan and cilazapril prodrugs 
a static Franz diffusion cell system was chosen (cf. Figure 5.3). With this system, both, 
the permeation of substances from a reservoir solution, filled into the donor chamber, 
and from transdermal therapeutic systems directly stuck on top of the membrane, 
clamped between donor and receptor chamber, can be investigated. Each Franz cell has 
a donor chamber volume of 12.5 ml and a permeation area of 1.77 cm2. 
Figure 5.3. Assembly of a vertically arranged 
Franz diffusion cell. 1: donor chamber, 2: plug 
for donor chamber, 3: clamp for fixing donor 
and receptor chamber, 4: membrane contact 
surface, 5: sampling port, 6: receptor chamber, 
7: water jacket, 8: connection to a thermostat. 
The use of a Franz cell stirrer (Figure 5.4) allows parallel measurement of nine 
permeation samples. Each diffusion chamber is connected to a thermostat ensuring a 
constant receptor fluid and membrane temperature of 32 °C in accordance with the 
physiological skin temperature. 
Figure 5.4. Nine-station Franz cell stirrer 
connected to a thermostat. 
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A prerequisite for the correct determination of dermal permeation is an adequate 
solubility of the permeant and its metabolites in the receptor fluid. In case of poor 
solubility, the receptor fluid acts as a barrier to permeation by inhibiting steady-state 
fluxes, when the permeant reaches its saturation concentration. Thus, it is necessary to 
make sure that the sink conditions are fulfilled. Normally, this is guaranteed in a volume 
of receptor fluid amounting to at least the 3-10-fold of the saturation volume.20 
In addition, the receptor fluid should not affect skin integrity and the enzymatic activity in 
the skin should be maintained. Thus, the use of buffered aqueous solutions seems 
obvious. If maintenance of the viability of the skin is needed, solutions of “physiological” 
buffers are commonly used. In case of low aqueous solubility, compounds enhancing 
solubility should be added in order to provide sink conditions. As these additives should 
not affect skin integrity, high amounts of organic solvents like ethanol are unsuited. 
However, as an alternative, the usage of aqueous solutions containing cyclodextrins as 
solubility enhancers appeared to be favorable. Cyclodextrins consist of cyclic (α-1,4-)-
linked α-D-glycopyranose units with a hydrophilic outer surface forming a central cavity, 
the lipophilicity of which is comparable to an aqueous ethanolic solution.21 Substituted 
cyclodextrins such as 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) are highly soluble in 
water and are able to form non-covalent inclusion complexes with rather lipophilic 
moieties of molecules, leading to an increase in the aqueous solubility of the guest 
molecules.22 
Since the skin is capable of metabolic reactions like ester hydrolysis, not only the 
solubility of the candesartan and cilazapril prodrugs, but also that of the reaction 
products (candesartan and cilazapril/cilazaprilat) should be taken into account. In view of 
an appropriate receptor fluid for permeation studies, the equilibrium solubility (i.e. the 
concentration of a compound in saturated solution when excess of solid is present and 
solution and solid are at equilibrium)23 of all relevant species was determined by means 
of HPLC. 
As an appropriate receptor fluid for the rather lipophilic candesartan prodrugs an 
aqueous solution containing 10 % (w/v) HP-β-CD was considered. From Table 5.1 it is 
obvious that the equilibrium solubility of the prodrugs candesartan cilexetil, 3.31, 3.32 
and 3.35 was satisfactory with values between 0.16 mg/ml and 0.76 mg/ml. Although a 
rather low (0.02 mg/ml) equilibrium solubility of candesartan was determined, overall, 
10 % HP-β-CD solution was regarded a promising receptor fluid. 
Table 5.1. Equilibrium solubility of candesartan and candesartan prodrugs in 10 % HP-β-CD. 
equilibrium solubility [mg/ml]
candesartan CAN-CIL 3.31 3.32 3.35
0.02 0.23 0.16 0.22 0.76 
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The experimentally determined log Poct/H2O values of all cilazapril prodrugs indicate a 
lower lipophilicity with respect to their candesartan analogues (cf. section 3.4). Hence, 
sufficient solubility in buffer solution devoid of solubility enhancers was assumed. 
Table 5.2 shows the equilibrium solubility values of cilazapril and of the cilazapril 
prodrugs 3.1, 3.2 and 3.14 in 50 mM phosphate buffer, pH 7.4. Whereas the equilibrium 
solubility of 3.14, due to its protonatable morpholine, was convincing, only moderate to 
low values for 3.1 and 3.2 were determined. Nevertheless, taking into account that 
equilibrium solubility is known to be strongly influenced by parameters such as 
temperature or sedimentation time, 50 mM phosphate buffer, pH 7.4 was considered an 
acceptable receptor fluid particularly due to its low costs and compatibility with HPLC 
analysis. Furthermore, a fast enzymatic degradation of the cilazapril prodrugs in the skin, 
leading to the formation of the highly hydrophilic and therefore well water-soluble species 
cilazapril and cilazaprilat, was expected. The equilibrium solubility of cilazapril amounted 
to 15.43 mg/ml and the value for cilazaprilat was assumed to be even higher. 
Table 5.2. Equilibrium solubility of cilazapril and cilazapril prodrugs in 50 mM phosphate buffer, pH 7.4. 
equilibrium solubility [mg/ml]
cilazapril 3.1 3.2 3.14
15.43 0.06 0.00 2.75 
In order to determine steady-state fluxes, all permeation experiments were performed 
under conditions enabling the donor concentration of the permeant to be maintained 
more or less constant (infinite dose conditions). In an OECD guideline for the testing of 
chemicals via an in vitro skin absorption method9 a duration of 24 h is recommended for 
adequate characterization of the absorption profile. Longer sampling periods lead to 
increasing deterioration of skin integrity, but are required for slowly permeating 
substances with high lag times.9 In the present work, the permeation experiments were 
stopped after a period of at most 72 h independent of the permeated amount of drug. 
5.2.1 Choice of skin 
Due to the aforementioned similarities between porcine and human skin and its ready 
availability, dermatomized (500-800 µm) or full-thickness skin from pig ears was used for 
the majority of permeation experiments. Since excised human skin gives results more 
similar to the human in vivo situation, full- or split-thickness human skin was also used in 
exemplary permeation studies. In addition, permeability of selected compounds was 
investigated on nude mouse skin. 
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5.3 Permeation studies with candesartan prodrugs 
The permeability of the novel candesartan prodrugs 3.31, 3.32 and 3.35 as well as the 
standard reference candesartan cilexetil through porcine and human skin was investi-
gated. Permeation studies of compounds with unknown permeability profile are usually 
performed with compound solutions under infinite dose conditions before applying the 
relevant formulation, in this case a transdermal therapeutic system. Thus, the perme-
ability of the candesartan prodrugs through porcine ear skin was at first investigated 
using reservoir solutions, i.e. concentrated stock solutions of the respective prodrug, to 
avoid potential limitations of permeability by the dosage form. Subsequently, permeation 
experiments with prodrug containing TTS were performed. 
For oral application, the recommended starting dose and maintenance dose of 
candesartan cilexetil amount to 8-16 mg.24 The oral bioavailability has been cited as 
approximately 15 %.25 Thus, a resorbed amount of 1.2-2.4 mg daily would be necessary 
to achieve a therapeutic effect by transdermal application. 
5.3.1 Procedure 
Permeation from reservoir solution. Into the donor chambers of thermostated Franz 
cells, equipped with dermatomized porcine ear skin (provided by Hexal AG) and a stirred 
10 % HP-β-cyclodextrin solution serving as receptor fluid, solutions of the respective 
prodrugs in ethanol/propylene glycol 70/30 (v/v) were filled, at concentrations amounting 
to 90 % of the saturation concentration of the respective prodrug. At appropriate time 
periods, samples of 0.5 ml were withdrawn from the receptor chamber and directly 
analyzed by HPLC. The volume was replaced by fresh receptor fluid. 
Permeation from TTS. Permeation through dermatomized porcine ear skin (provided by 
Hexal AG) and full-thickness porcine and human skin from TTS was measured in Franz 
cells, equipped with a stirred 10 % HP-β-cyclodextrin solution serving as receptor fluid. A 
10-cm2 or 2.5-cm2 TTS was directly stuck on the epidermal side of a piece of thawed 
porcine ear or human skin, before a circle with a diameter of 27 mm was punched out, by 
which the area of the 10-cm2 TTs was reduced to 5.7 cm2. Skin and TTS were clamped 
between donor and receptor chamber. Essentially, the rest of the procedure was 
analogous to that described for the permeation from reservoir solution (see above). 
 
The cumulative permeated amount (sum of intact prodrug and metabolites) was plotted 
against time. The steady-state flux (Jss) was obtained from the slope of the linear 
regression line of this plot. The x-axis intercept of this regression line provided the 
corresponding lag time (tlag), which is the time needed for the permeated compound to 
reach the steady-state. 
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5.3.2 Permeation of candesartan prodrugs through dermatomized por-
cine skin from reservoir solution 
Permeation experiments using compound reservoir solutions were performed according 
to the procedure described in 5.3.1. 
Shortly after applying the prodrug reservoir solutions (11 mg/ml in ethanol/propylene 
glycol 70/30 (v/v)) on the dermatomized porcine ear skin surfaces, streaks of donor 
solvent in the receptor chambers and an increasing turbidity of the receptor fluids could 
were observed. The permeation experiment was aborted after 6 h due to obvious 
leakage of the membranes. 
Figure 5.5 depicts the cumulative permeated amount of each candesartan prodrug 
against time. The permeated amounts were found to increase very fast to approach 
saturation concentrations. Thus, sink conditions were not fulfilled, and steady-state fluxes 
could not be determined.Due to these unsatisfactory results, the approach studying 
permeation from prodrug reservoir solutions was not pursued any longer. 
Figure 5.5. Skin permeation profile of 
candesartan prodrugs across derma-
tomized porcine skin from reservoir 
solutions. Depicted are individual values 
from two independent experiments. 
5.3.3 Permeation of candesartan prodrugs through dermatomized por-
cine skin from TTS 
The permeation of candesartan prodrugs from TTS across dermatomized porcine ear 
skin was studied following the procedure described in 5.3.1. 
In Figure 5.6 and Figure 5.7 results from permeation experiments carried out with two 
differently sized patches (5.7-cm2 and 2.5-cm2 TTS) of the candesartan prodrug TTS 
batches PCAN0009TTS, PCAN0010TTS, PCAN0011TTS and CAN0043TTS are shown. 
Regarding the cumulative amount permeated, which was calculated as the sum of the 
respective prodrug and the parent drug candesartan, striking differences became 
obvious. Whereas the batches PCAN0009TTS and PCAN0011TTS containing the 
candesartan prodrugs candesartan 1-(isopropyloxycarbonyloxy)ethyl ester (3.31) and 
candesartan morpholinoethyl ester (3.35) show only moderate skin permeation  
(~ 40-73 µg/cm2), the values for the TTS batch PCAN0010TTS (3.32) containing 
candesartan 1-(2,2-dimethylpropanoyloxy)ethyl ester were found to be approx.  
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5 to 14-fold higher (388-559 µg/cm2). The reference compound, candesartan cilexetil 
(CAN0044TTS), showed rather low skin permeation (1-2 µg/cm2). 
Figure 5.6. Skin permeation profile of 
candesartan prodrugs across derma-
tomized porcine skin from 5.7-cm2 TTS. 
The data represent the sum of candesar-
tan prodrug and candesartan and is depic-
ted as mean ± SEM values (n=4). 
 
Figure 5.7. Skin permeation profile of 
candesartan prodrugs across derma-
tomized porcine skin from 2.5-cm2 TTS. 
The data represent the sum of candesar-
tan prodrug and candesartan and is depic-
ted as mean ± SEM values (n=4). 
As sink conditions for 3.32 were not fulfilled, steady-state fluxes were only calculated for 
3.31, 3.35 and candesartan cilexetil (cf. Figure 5.8 A+B). 
Figure 5.8. Permeation profiles (mean ± SEM, n = 3-6) for candesartan prodrugs 3.35 (■), 3.31 (▲) and cande-
sartan cilexetil (●) through dermatomized porcine ear skin from 5.7-cm2 (A) and 2.5-cm2 (B) TTS. 
The novel candesartan prodrugs 3.31 and 3.35 showed a 30 to 60-fold higher flux 
through porcine ear skin than candesartan cilexetil (Table 5.3). Although the permeation 
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area for each experiment was the same (1.77 cm2), the use of 2.5-cm2 patches led to a 
slight decrease in flux compared to 5.7-cm2 TTS, suggesting that diffusion processes 
from parts of the TTS outside of the permeation area play a role by increasing the 
concentration gradient and thus, directly leading to higher fluxes. Intersection of the 
linear regression line with the x-axis gave the corresponding lag times (Table 5.3), 
indicating almost instantaneous permeation of all prodrugs. 
Table 5.3. Steady-state fluxes and lag times (mean ± SEM, n = 3-6) of candesartan prodrugs from 5.7-cm2 
and 2.5-cm2 TTS through dermatomized porcine ear skin. 
compound TTS batch 
Jss
[µg·cm-2·h-1] 
tlag 
[h] 
  5.7-cm2 2.5-cm2 5.7-cm2 2.5-cm2 
3.31 PCAN0009TTS 1.12 ± 0.14 1.08 ± 0.13 -3.94 ± 1.88 -1.39 ± 1.26 
3.35 PCAN0011TTS 2.01 ± 0.18 1.86 ± 0.05 -0.73 ± 0.61 1.01 ± 0.51 
CAN-CIL CAN0044TTS 0.04 ± 0.01 0.03 ± 0.01 -0.05 ± 1.63 3.51 ± 0.58 
In case of compound 3.35, mostly intact prodrug was found in the receptor fluid, whereas 
for the double esters 3.31, 3.32 and candesartan cilexetil prodrug as well as increasing 
amounts of candesartan were determined. Surprisingly, all novel candesartan prodrugs 
permeated porcine ear skin very quickly. 
The enormous difference in skin permeation of 3.32 compared to 3.31, 3.35 and 
candesartan cilexetil, could presumably be explained by the different state of the 
prodrugs in the TTS matrix. In case of PCAN0010TTS, the prodrug 3.32 is present in 
dissolved form in individual emulsion droplets, whereas 3.31, 3.35 and candesartan 
cilexetil prevail as suspended crystals and agglomerates. Therefore, skin permeation 
seems to be favored, when dissolved drug is available in the TTS matrix. 
 
These findings were corroborated by results from permeation experiments with the TTS 
batches PCAN0004TTS, PCAN0005TTS, PCAN0006TTS and CAN0043TTS performed 
by Hexal AG (Figure 5.9), using automated sampling (AutoPlus MultiFill, Hanson 
Research, Chatsworth, USA). 
Figure 5.9. Skin permeation profile of 
candesartan prodrugs across derma-
tomized porcine skin from TTS. The data 
represent the sum of candesartan prodrug 
and candesartan and is given mean values 
± SEM (n=6). 
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Again, reliable steady-state fluxes could only be determined for 3.35 (PCAN0006TTS) 
and candesartan cilexetil (CAN0043TTS), due to the lack of sink conditions for 3.31 
(PCAN0004TTS) and 3.32 (PCAN0005TTS). In accordance with aforementioned results, 
the diffusion from TTS, in which the drug prevails as suspension in the PSA matrix 
(PCAN0006TTS, CAN0043TTS) rather than as a solution (PCAN0004TTS, 
PCAN0005TTS), appears to be hindered. The steady-state fluxes (Table 5.4) were 
determined to be between those obtained for the TTS batches PCAN0009TTS, 
PCAN0011TTS and CAN0044TTS. The lag times were rather short. 
Table 5.4. Steady-state fluxes and lag times (mean ± SEM, n = 6) of candesartan prodrugs from TTS through 
dermatomized porcine ear skin. 
compound TTS batch Jss
[µg·cm-2·h-1] 
tlag
[h] 
3.35 PCAN0006TTS 0.65 ± 0.11 0.57 ± 0.75 
CAN-CIL CAN0043TTS 0.50 ± 0.08 2.55 ± 0.54 
Overall, the unsatisfactory results from the permeation experiments using reservoir 
solutions, the extraordinarily high skin permeation of some candesartan prodrug 
containing TTS lots as well as the short lag times prompted us to examine the used 
porcine ear skin in detail. 
5.3.4 Histological studies on porcine ear skin 
In order to gain deeper insight in the status of the porcine skin used, histological studies 
were performed. Thin slices of tissue, embedded in paraffin, were prepared and studied 
by light microscopy. In brief, small pieces of the tissue were fixated, dehydrated, 
embedded in paraffin and cut into 6 µm thin slices by means of a microtome. Then, the 
sections were stained according to a Masson-Goldner trichrome protocol, modified by 
Jerusalem. As a result nuclei appear dark brown to black, collagen green and cytoplasm, 
muscle, fibrin and keratin red. 
 
When comparing images of thawed dermatomized porcine ear skin, which was stored at 
-20 °C, used for the past permeation experiments (Figure 5.10 A, C, E) and a reference 
section from fresh porcine skin (Figure 5.10 B, D, F), it became obvious that surprisingly, 
the whole epidermis of the experimentally used specimens was missing. Furthermore, 
dermis volume was apparently increased and the collagen matrix appeared swollen, 
allegedly a result of the process of freezing and thawing. 
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A: objective: 4x 
 
B: objective: 4x 
 
C: objective: 20x D: objective: 20x 
E: objective: 40x 
 
F: objective: 40x 
 
Figure 5.10. Micrographs of Masson-Goldner trichrome stained paraffin sections of dermatomized porcine ear 
skin (skin provided by Hexal AG) (A, C, E) and of intact porcine reference skin (B, D, F). The dermatomized 
porcine ear skin was stored at -20 °C and thawed prior to fixation in Bouin’s solution. a: stratum corneum, b: 
stratum granulosum, c: stratum spinosum, d: stratum basale. 
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The lack of epidermis seemed neither result from freezing and thawing nor from 
processing with a dermatome, as fresh, non-processed skin samples from the same 
source showed the same results (Figure 5.11 A+B). 
A: objective: 4x B: objective: 10x 
Figure 5.11 A+B. Masson-Goldner trichrome stained paraffin sections of fresh, dermatomized porcine ear skin 
(skin provided by Hexal AG). 
Consequentially, porcine ears obtained from the respective slaughterhouse were 
inspected under a stereo microscope and photographed using a macro lens. It became 
obvious that the slaughtered pigs were presumably treated in a way to deprive them of 
the epidermis. Pictures taken with a digital camera (Figure 5.12 A+B) and by means of a 
stereo microscope (Figure 5.13 A+B) revealed almost hairless skin with only residual 
pieces of epidermis. This gave rise to the presumption that the pigs went through a 
routine slaughter process with scalding and scraping, before their ears were resected. 
Residual hairs are commonly removed by singeing. 
A B 
Figure 5.12. Pictures from porcine ears (material provided by Hexal AG) taken with a digital camera (Nikon, 
Tokyo, Japan). A: upper side, B: lower side. 
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A 
 
B 
 
Figure 5.13 A+B. Images of the dorsal side of porcine ears (material provided by Hexal AG) taken with a stereo 
microscope. 
These findings prompted us to find a new source of untreated porcine ear skin with intact 
anatomy. A local butcher supplied porcine ears, of which the skin was carefully excised. 
Histological studies proved the flawless structure of epidermis and dermis (Figure 5.14 
A-C). The overall thickness was variable and estimated to be 1.0 – 1.7 mm, whereas the 
thickness of the epidermis amounted to 70 – 230 µm. 
A: objective: 4x 
 
B: objective: 10x 
 
C: objective: 40x 
 
Figure 5.14 A-C. Masson-Goldner trichrome 
stained histological sections of fresh, intact 
porcine ear skin. 
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5.3.5 Permeation of candesartan prodrugs through full-thickness por-
cine skin 
According to the procedure 5.3.1 permeation of candesartan prodrugs through full-
thickness porcine ear skin was studied using the candesartan prodrug TTS batches 
PCAN0009TTS, PCAN0010TTS, PCAN0011TTS and CAN0044TTS. Skin specimens 
were obtained from two female, 6-7 months old animals (crossbred Deutsche Landrasse 
x Pietrain). Shortly after slaughtering, skin samples were prepared and immediately 
stored at -20 °C. For permeation studies freshly thawed pieces of skin were used. 
Compared to the results obtained with epidermis-free (scalded and scraped) porcine skin 
a striking decrease in skin permeation was observed (Figure 5.15). Thus, the sampling-
time was extended to 72 h. Nevertheless, for the prodrugs 3.35 (PCAN0011TTS) and 
candesartan cilexetil (CAN0044TTS) no skin permeation over a period of 72 h was 
detectable. Still, 3.32 appeared to be the most permeable compound, but was only 
reaching at the best 1/30 (~ 19 µg/cm2 after 72 h) of the skin permeation obtained with 
epidermis-free skin. The skin permeation of 3.31 was low. Determination of the steady-
state flux was possible for 3.31 (PCAN0009TTS) and 3.32 (PCAN0010TTS), respec-
tively, for one of two experiments each. 3.31 revealed a very low flux of 0.12 µg·cm-2·h-1 
and a long lag time (44.68 h), whereas the flux of 3.32 was found to be nearly 3-fold 
higher (0.29 µg·cm-2·h-1) corresponding to a 3.5-fold shorter lag time of 12.62 h. 
Figure 5.15. Skin permeation profile of 
candesartan prodrugs across full-thickness 
porcine skin from TTS (n = 2) depicted as 
the sum of candesartan prodrug and can-
desartan. 
Obviously, the presence of an intact epidermis with the stratum corneum serving as a 
lipophilic barrier is the decisive factor for the low permeability. Presumably, only low 
amounts of the candesartan prodrugs are able to penetrate into the epidermis. Thereby, 
also the prodrug formulation (prodrug dissolved/ suspended) may influence the extent of 
drug penetration. However, the formation of a drug reservoir in the skin, presumably in 
the epidermis, leading to low receptor fluid levels should be taken into account, as this is 
postulated especially for compounds having low solubility in water and oil as well as a 
log Poct/H2O greater than 1.
26-27 Furthermore, the influence of the absence of physiological 
blood circulation and drug distribution should be considered, since this may lead to 
underestimation of the permeability. 
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5.3.6 Permeation of candesartan prodrugs through dermatomized and 
full-thickness human skin 
In the following, results from permeation experiments with candesartan prodrug con-
taining TTS batches using dermatomized or full-thickness human skin as in vitro model 
are shown. Excised human skin samples were obtained according to the guidelines of 
the charitable state controlled foundation HTCR, with the informed patient's consent. 
Dermatomized skin was prepared from male (51 years) abdominal tissue. Full-thickness 
skin was obtained from femoral or abdominal regions of two female patients (75 and 47 
years). Appropriately sized skin samples were prepared as soon as possible after 
surgery and were immediately stored at -20 °C. For permeation experiments freshly 
thawed skin samples were used. 
5.3.6.1 Histological studies of full-thickness human skin 
Prior to permeation experiments, histological analysis of the used full-thickness human 
skin before storage at -20 °C and after thawing was performed in order to verify the 
anatomical integrity. Figure 5.16 A-C confirm the intactness of epidermis and dermis of 
fresh skin before freezing as well as the nearly complete removal of the subcutaneous fat 
(Figure 5.16 A). The overall thickness of the skin was found to be quite varying and was 
estimated between 1.4-2.3 mm, of which approx. 30-90 µm are related to the epidermis. 
Furthermore, the process of freezing and thawing seems to lead to partly severing the 
stratum corneum (Figure 5.16 D). Notwithstanding, the residual epidermis appeared to 
be intact. 
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A: objective: 4x B: objective: 20x 
C: objective: 40x D: objective: 20x 
Figure 5.16 A-D. Masson-Goldner trichrome stained histological sections of full-thickness human femoral skin. 
A-C: prior to freezing, D: thawed. 
  
 Permeation of Prodrugs Through Animal and Human Skin 161 
5.3.6.2 Permeation of candesartan prodrugs through dermatomized human skin 
The following results were obtained from permeation experiments performed by Hexal 
AG (Holzkirchen, Germany) with dermatomized (500-800 µm) human abdominal skin, 
using the candesartan prodrug containing TTS batches PCAN0004TTS, PCAN0005TTS, 
PCAN0006TTS and CAN0043TTS by means of automated sampling (AutoPlus MultiFill, 
Hanson Research, Chatsworth, USA) and illustrated in Figure 5.17. In accordance with 
permeation results obtained with full-thickness porcine ear skin, very low fluxes between 
0.04 and 0.09 µg·cm-2·h-1 were determined for all candesartan prodrugs (Table 5.5). 
However, a significantly improved permeability compared to candesartan cilexetil was 
achieved by variation of the pro-moiety. 
Figure 5.17. Skin permeation profile of 
candesartan prodrugs across dermatomized 
human skin from TTS. Data represent mean 
values ± SEM of 3-4 individual experiments. 
Table 5.5. Steady-state fluxes and lag times (mean ± SEM, n = 3-4) of candesartan prodrugs from TTS through 
dermatomized human skin. 
compound TTS batch Jss
[µg·cm-2·h-1] 
tlag 
[h] 
3.31 PCAN0004TTS 0.05 ± 0.02 5.63 ± 1.78 
3.32 PCAN0005TTS 0.09 ± 0.05 4.04 ± 1.48 
3.35 PCAN0006TTS 0.04 ± 0.02 0.90 ± 2.21 
CAN-CIL CAN0043TTS 0.00 - 
5.3.6.3 Permeation of candesartan prodrugs through full-thickness human skin 
Using full-thickness human femoral skin very low skin permeation was observed for all 
candesartan prodrugs over a sampling period of 72 h (Figure 5.18). Thereby, only the 
active principle candesartan but no intact prodrug was detected. Due to the variations of 
the single permeation values and the limited number of experiments due to shortage of 
human skin reliable steady-state fluxes and lag times could not be generated. 
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Figure 5.18. Skin permeation profile of 
candesartan prodrugs across full-thickness 
human skin from TTS referring to two 
individual experiments. 
In order to investigate, if the prodrugs penetrated into the skin at all or if they were 
subjected to reservoir formation, concentrations of the prodrugs in the skin samples and 
in the TTS were determined. After termination of the permeation experiment, skin 
samples and TTS were removed from the Franz cells, separately extracted with organic 
solvent and analyzed by HPLC. In Table 5.6 absolute amounts of the candesartan 
prodrugs, extracted from the TTS and skin samples, and corresponding recoveries are 
summarized. Amounts between 35 µg and 353 µg were determined in the skin samples. 
The high value found for PCAN0011TTS in the skin (1063 µg) presumably results from 
residual matrix sticking to the skin after removal of the patch. The overall recovery values 
of the prodrugs range between 76 % and 106 %. In conclusion, these results indicate 
unequivocally that all candesartan prodrugs penetrate into the skin. It may be speculated 
that diffusion from the epidermis into the dermis is the permeation-limiting factor. 
Table 5.6. Mean recovery of candesartan prodrugs in skin and TTS (n = 2) after 72 h. 
 recovered 
amounts [µg] 
sum of recovered 
amounts [µg] 
theoretical 
amount [µg] 
recovery [%] 
prodrug/ batch TTS skin TTS + skin   
3.31/ 
PCAN0009TTS 
4502 60 4562 
5642 
81 
4271 35 4306 76 
3.32/ 
PCAN0010TTS 
4742 79 4821 
5049 
95 
4961 62 5023 99 
3.35/ 
PCAN0011TTS 
5865 276 6141 
5984 
103 
4480 1063 a 5543 93 
CANCILb/ 
CAN0044TTS 
4288 353 4641 
4393 
106 
4381 114 4495 102 
a: This value was considered an outlier with reference to the observed values. b CANCIL = candesartan cilexetil. 
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5.4 Permeation studies with cilazapril and cilazapril prodrugs 
The permeability of the novel cilazapril prodrugs 3.1, 3.2 and 3.14 as well as the 
reference standard cilazapril was investigated using nude mouse, porcine and human 
skin. The experiments were performed according to the procedure described in 5.3.1 
using 50 mM phosphate buffer pH 7.4 as receptor fluid. For permeation studies with 
nude mouse skin, dermatomized and full-thickness porcine skin as well as full-thickness 
human skin the following TTS batches were used: PCIL0011TTS, PCIL0012TTS, 
PCIL0013TTS and CIL0027TTS. Permeation studies with dermatomized human skin 
were performed with PCIL0002TTS, PCIL0003TTS, PCIL0004TTS and CIL0025TTS. 
For oral application the recommended starting dose and maintenance dose of cilazapril 
amount to 1.25 mg and 2.5 mg, respectively.24 The oral bioavailability of cilazapril is 
indicated as 57 % (range 45-75 %) and that of cilazaprilat as 19 % (range 8-40 %).28 
Hence, transdermal delivery of 0.7 mg would be sufficient as starting dose and 1.4 mg 
daily would be necessary to maintain the antihypertensive effect. 
5.4.1 Permeation of cilazapril and cilazapril prodrugs through nude 
mouse skin 
The suitability of nude (thymusaplastic) mice as a model of percutaneous penetration in 
man is discussed controversially.29 Transdermal delivery is highly dependent on the 
physicochemical properties of the investigated compound, but nude mouse skin shows 
generally higher permeation than human skin.12, 29 This could presumably be associated 
with the reduced thickness of the stratum corneum of nude mice, which is less than half 
as thick as that of the human integument.29 However, by the lack of a fur coat nude 
mouse skin better resembles human skin than that of furred animals.12 For the purpose 
of comparison and due to ready availability, the permeability of cilazapril and selected 
cilazapril prodrugs was studied on freshly excised full-thickness skin of nude (NMRI 
(nu/nu)) mice. 
5.4.1.1 Histological studies on nude mouse skin 
Histological studies of freshly excised nude mouse skin proved the integrity of the skin 
consisting of epidermis, dermis and subcutis (Figure 5.19 A-C). The overall thickness 
was estimated to be approximately 800-1000 µm, the epidermis to be 15-30 µm, 
rendering the full skin and the epidermis markedly thinner than pig or human tissue. 
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A: objective: 4x B: objective: 20x 
C: objective: 40x 
5.4.1.2 Results from permeation experiments with nude mouse skin 
The permeability of cilazapril and the cilazapril prodrugs 3.1, 3.2 and 3.14 through full-
thickness nude mouse skin was investigated using patches of the corresponding TTS 
batches CIL0027TTS, PCIL0011TTS, PCIL0012TTS and PCIL0013TTS as donor vehicle 
applied on the epidermal side of the skin samples (Figure 5.20). In the receptor fluid 
mainly cilazapril and cilazaprilat were detected. No intact prodrug was found for 3.1, 3.2 
and 3.14, but for 3.14 a metabolite resulting from the hydrolysis of the homophenyl-
alanine ethyl ester group could be observed. The sink conditions were fulfilled over the 
entire sampling period of 72 h. The resulting skin permeation profile of all cilazapril 
prodrugs was quite promising. 
Figure 5.20. Permeation profiles for 
cilazapril and cilazapril prodrugs through 
full-thickness nude mouse skin from TTS 
depicted as the sum of all compound 
related metabolites. 
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Figure 5.19 A-C. Masson-Goldner trichrome stained 
histological sections of full-thickness nude mouse 
skin. 
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As depicted in Table 5.7 the highest steady-state flux was detected for the morpholino-
ethyl ester of cilazapril (3.14) (7.10 µg·cm-2·h-1). Cilazapril and 3.1 showed a similar, 
moderate flux (4.05 and 3.16 µg·cm-2·h-1), whereas the skin permeation of 3.2 was rather 
low (0.64 µg·cm-2·h-1). The corresponding lag times varied between ~ 1.6 and 3.3 h. 
Table 5.7. Steady-state fluxes of cilazapril and cilazapril prodrugs from TTS through nude mouse skin. 
compound TTS batch 
Jss
[µg·cm-2·h-1] 
tlag
[h] 
3.1 PCIL0011TTS 3.16 3.21 
3.2 PCIL0012TTS 0.64 1.61 
3.14 PCIL0013TTS 7.10 2.47 
cilazapril CIL0027TTS 4.05 3.31 
For reasons of practicability, data were obtained from a single experiment. However, the 
results are considered plausible and reliable, because reproducibility is usually high, 
when data are acquired from tissues of animals of identical genetic background. As the 
skin of nude mice is thinner and generally more permeable than human skin, the 
obtained results must not be overestimated and may be considered at most “best case” 
results. 
5.4.2 Permeation of cilazapril and cilazapril prodrugs through derma-
tomized, scalded and scraped porcine skin 
Dermatomized, scalded and scraped porcine ear skin (provided by Hexal AG) was found 
to be permeable for cilazapril and the cilazapril prodrugs 3.1, 3.2 and 3.14. The most 
hydrophilic compounds, cilazapril and cilazapril morpholinoethyl ester (3.14), showed 
highest skin permeation (Figure 5.21 and Figure 5.22). In the receptor fluid mainly 
cilazapril and cilazaprilat were detected. Furthermore, regarding the cilazapril prodrugs 
3.1, 3.2 and 3.14 both intact prodrug and molecular species resulting from the hydrolysis 
of the homophenylalanine ethyl ester group were found. Thus, both findings led to the 
conclusion that the used porcine skin, despite the lack of the epidermis, was still capable 
of enzymatically hydrolyzing the present ester moieties. 
Figure 5.21. Permeation profiles 
for cilazapril and cilazapril 
prodrugs through dermatomized, 
scalded and scraped porcine ear 
skin from 5.7-cm2 TTS (mean ± 
SEM, n=3-4). The data represent 
the sum of parent drug and 
detected metabolites. 
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Figure 5.22. Permeation profiles for 
cilazapril and cilazapril prodrugs through 
dermatomized, scalded and scraped 
porcine ear skin from 2.5-cm2 TTS 
(mean ± SEM, n=4). The data represent 
the sum of parent drug and detected 
metabolites. 
In general, the use of 5.7-cm2 TTS led to higher permeation values compared to 2.5-cm2 
TTS (Table 5.8) indicating diffusion processes from outer parts of the TTS to the actual 
permeation area as suggested for 5.7-cm2 and 2.5-cm2 patches of candesartan prodrug 
TTS batches (cf. 5.3.3). 
Table 5.8. Skin permeation (sum of parent compound and metabolites) of cilazapril prodrugs and cilazapril after a 
period of 48 h (mean ± SEM, n = 3-4). 
  skin permeation
µg/cm2 
compound TTS batch 2.5-cm2 5.7-cm2 
3.1 PCIL0011TTS 128 ± 22 383 ± 25 
3.2 PCIL0012TTS 17 ± 4 61 ± 7 
3.14 PCIL0013TTS 548 ± 12 803 ± 23 
cilazapril CIL0027TTS 573 ± 8 877 ± 36 
Steady-state fluxes were determined by linear regression of the permeation data 
obtained with 5.7-cm2 (Figure 5.23 A) and 2.5-cm2 (Figure 5.23 B) patches for 3.1 
(PCIL0011TTS) and 3.2 (PCIL0012TTS) and amounted to 8.63 ± 0.69 µg·cm-2·h-1  
(5.7-cm2) vs. 2.73 ± 0.49 µg·cm-2·h-1 (2.5 cm2), respectively for 3.1 and 
1.34 ± 0.15 µg·cm-2·h-1 (10 cm2) vs. 0.36 ± 0.09 µg·cm-2·h-1 (2.5 cm2), respectively for 3.2 
(Table 5.9). In addition, the lag times were found to be short. Despite the lack of 
epidermis, the permeation of 3.2 was surprisingly low. This was presumably caused by 
inappropriate physicochemical properties such as an unsuitably high lipophilicity, which 
decelerated the penetration into the dermis. 
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Figure 5.23 A+B. Permeation profiles (mean ± SEM, n = 3-4) for cilazapril prodrugs 3.1 (PCIL0011TTS) and 3.2 
(PCIL0012TTS) through dermatomized, scalded and scraped porcine ear skin from 5.7-cm2 (A) and 2.5-cm2 (B) 
TTS. 
Table 5.9. Steady-state fluxes (mean ± SEM, n = 3-4) of cilazapril and cilazapril prodrugs from TTS through 
dermatomized, scalded and scraped porcine ear skin. 
compound TTS batch 
Jss
[µg·cm-2·h-1] 
tlag 
[h] 
  5.7-cm2 2.5-cm2 5.7-cm2 2.5-cm2 
3.1 PCIL0011TTS 8.63 ± 0.69 2.73 ± 0.49 -0.28 ± 0.13 0.48 ± 0.28 
3.2 PCIL0012TTS 1.34 ± 0.15 0.36 ± 0.09 1.25 ± 0.08 1.17 ± 0.65 
In summary, the lack of epidermis resulted in a drastic decrease of the barrier function of 
the skin. This was noticeable by high and fast skin permeation of cilazapril and 3.14. The 
compounds 3.1 and 3.2 showed lower but also almost immediate permeation. 
5.4.3 Permeation of cilazapril and cilazapril prodrugs through full-thick-
ness porcine skin 
The following results were obtained from skin permeation studies using intact full-
thickness porcine ear skin of two female, 6-7 months old animals (crossbred Deutsche 
Landrasse x Pietrain) (cf. 5.3.5). In Figure 5.24 A+B the cumulative permeated amounts 
as a sum of all detected metabolites of cilazapril, 3.1 (PCIL0011TTS), 3.2 
(PCIL0012TTS) and 3.14 (PCIL0013TTS) are depicted for two different porcine skin 
specimens. Mainly cilazapril and cilazaprilat were detected in the receptor fluid but no 
intact prodrug (3.1, 3.2, 3.14). Furthermore, in the case of 3.14 a metabolite resulting 
from the hydrolysis of the homophenylalanine ethyl ester group was observed. The sink 
conditions were fulfilled over the entire sampling period of 72 h. 
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Figure 5.24. A+B. Permeation profiles from TTS of 3.1 (PCIL0011TTS), 3.2 (PCIL0012TTS), 3.14
(PCIL0013TTS) and cilazapril (CIL0027TTS) through full-thickness porcine ear skin prepared from two different 
animals (A and B). The cumulative amount permeated is depicted as a sum of all compound related detected 
metabolites. 
In Table 5.10 steady-state fluxes and lag times for the cilazapril prodrugs 3.1, 3.2 and 
3.14 and for cilazapril are summarized. Although skin samples of two female pigs of the 
same race with similar age and body weight were used, the results for 3.1, 3.14 and 
cilazapril differ significantly, showing 1.4 to 3.3 fold higher skin permeation through skin 
sample A. In addition, except for 3.2, shorter lag times were found for skin sample A. 
Compared to scalded and scraped porcine skin, the skin permeation of all compounds 
was markedly decreased. The steady-state fluxes of 3.1 and 3.2 were reduced by a 
factor of approx. 5 to 7. Furthermore, lag times were notably increased. With respect to 
nude mouse skin, lower mean steady-state fluxes and higher lag times were observed, 
but the rank orders of the compounds were consistent. Concerning the thickness of 
porcine skin compared to that of nude mouse skin, the decrease in permeability (factor 
1.5 – 3.5) through full-thickness porcine skin was less pronounced than expected. 
Table 5.10. Steady-state fluxes of cilazapril and cilazapril prodrugs from 5.7-cm2 TTS through intact porcine ear 
skin (two different skin specimens used (A+B, referring to Figure 5.24 A+B)). 
compound TTS batch 
Jss
[µg·cm-2·h-1] 
tlag 
[h] 
  A B mean A B mean 
3.1 PCIL0011TTS 2.77 0.84 1.81 1.26 7.05 4.16 
3.2 PCIL0012TTS 0.17 0.20 0.19 10.52 8.35 9.44 
3.14 PCIL0013TTS 6.25 4.39 5.32 4.14 5.26 4.70 
cilazapril CIL0027TTS 4.57 1.41 2.99 1.56 6.53 4.05 
With regard to transdermal delivery of cilazapril, therapeutic doses of approximately 
1.3 mg could be reached within 24 h, assuming the application of a 10-cm2 TTS, 
containing prodrug 3.14. In the case of cilazapril, 3.1 and 3.2, possibly, either enlarged 
size or higher drug dose of the TTS would be needed to reach the desired effect. 
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5.4.4 Permeation of cilazapril and cilazapril prodrugs through human 
skin 
In the following, results obtained from Franz cell permeation experiments with human 
skin are depicted and discussed. As in vitro skin absorption studies with human tissue 
are regarded to have the highest predictive value, they should be considered as most 
relevant. 
5.4.4.1 Permeation of cilazapril and cilazapril prodrugs through dermatomized 
human skin 
The following permeation experiments were performed by Hexal AG (Holzkirchen, 
Germany) with dermatomized (500-800 µm) human abdominal skin using the cilazapril or 
cilazapril prodrug containing TTS batches PCIL0002TTS, PCIL0003TTS, PCIL0004TTS 
and CIL0025TTS by means of automated sampling (AutoPlus MultiFill, Hanson 
Research, Chatsworth, USA) The obtained results (personal communication) are shown 
in Table 5.11. The highest steady-state flux (3.32 ± 0.12 µg·cm-2·h-1) was observed for 
the cilazapril morpholinoethyl ester 3.14 (PCIL0004TTS). The double ester prodrugs 3.1 
(PCIL0002TTS) and 3.2 (PCIL0003TTS) showed approx. 2.5 to 3 fold lower skin 
permeation (1.42 ± 0.31 µg·cm-2·h-1 and 1.07 ± 0.42 µg·cm-2·h-1, respectively) than 3.14. 
Interestingly, the lowest flux was found for cilazapril (1.00 ± 0.39 µg·cm-2·h-1) confirming 
the working hypothesis that masking of the free carboxylic acid group in cilazapril with 
suitable prodrug moieties is key to improve skin permeation. Compared to the other 
investigated prodrugs, the introduction of the hydrophilic morpholinoethyl ester led to a 
lower log D value. This seems to be favorable for penetration into the epidermis and 
permeation across the dermis. The lag times of compounds 3.1, 3.2, 3.14 and cilazapril 
ranged from approximately 3 (3.1, 3.2) to 10 h. Remarkably, the prodrug 3.14 and 
cilazapril showed a big difference in skin permeation, regardless of similar lag times. 
Compared to the results obtained with porcine and nude mouse skin the permeability of 
cilazapril was significantly lower in human skin. It may me speculated that this is crucially 
depending on the different lipid composition of human, porcine and murine skin. Among 
all investigated cilazapril prodrugs compound 3.14 appeared most suitable for application 
by means of a TTS, since the achieved flux corresponds to an (estimated) transdermal 
resorption of 0.8 mg daily (assuming the use of a 10 cm2 patch), which is in the desired 
therapeutic range. 
Table 5.11. Steady-state fluxes (mean ± SEM, n = 2-4) of cilazapril and cilazapril prodrugs from TTS through 
dermatomized human skin (data provided from Hexal AG). 
compound TTS batch 
Jss
[µg·cm-2·h-1] 
tlag
[h] 
3.1 PCIL0002TTS 1.42 ± 0.31 3.05 ± 2.49 
3.2 PCIL0003TTS 1.07 ± 0.42 3.06 ± 0.26 
3.14 PCIL0004TTS 3.32 ± 0.12 9.07 ± 0.01 
cilazapril CIL0025TTS 1.00 ± 0.39 10.65 ± 0.58 
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5.4.4.2 Permeation of cilazapril and cilazapril prodrugs through full-thickness 
human skin 
For the permeation studies with full-thickness human skin, freshly thawed femoral or 
abdominal skin specimens from two female patients (75 and 47 years) were used (cf. 
5.3.6). In Figure 5.25 A+B the skin permeation profiles of cilazapril and cilazapril 
prodrugs from TTS obtained from each donor are depicted as a sum of all detected 
metabolites. 
Figure 5.25 A+B. Permeation profiles (n = 3) from 5.7-cm2 TTS of 3.1 (PCIL0011TTS), 3.2 (PCIL0012TTS), 3.14 
(PCIL0013TTS) and cilazapril (CIL0027TTS) through two different full-thickness human skin specimens. A: 
femoral skin, B: abdominal skin. The cumulative amount permeated is depicted as a sum of all compound related 
detected metabolites. 
Similar to the results obtained with dermatomized human skin, in both donor skin 
samples the highest permeability was found for prodrug 3.14 (PCIL0013TTS). However, 
markedly lower steady-state fluxes were estimated for compounds 3.1 (PCIL0011TTS), 
3.2 (PCIL0012TTS) and cilazapril (CIL0027TTS) (cf. Table 5.12), and the absolute skin 
permeation appeared to be lower as well. Considerable differences between the two 
donor skin samples became obvious: 3.1 and 3.14 showed approx. 2.5-fold higher 
permeation through femoral than through abdominal skin. Whereas 3.2 and cilazapril 
yielded very small fluxes through femoral skin, no compound or corresponding 
metabolites were detected in the receptor fluid of the abdominal skin sample over a 
sampling period of 72 h. Again rather long lag times between 4 and 12 h were estimated, 
whereby the corresponding lag times referring to the femoral skin sample were found to 
be shorter. In conclusion, 3.14 and to a smaller degree also 3.1 turned out to exhibit 
clear advantages compared to cilazapril in terms of permeability through human skin, 
3.14 being the most promising candidate. 
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Table 5.12. Steady-state fluxes (mean ± SEM, n = 3) of cilazapril and cilazapril prodrugs from 5.7-cm2 TTS 
through full-thickness human skin. 
compound TTS batch 
Jss
[µg·cm-2·h-1] 
tlag 
[h] 
  femoral skin abdominal skin femoral skin abdominal skin 
3.1 PCIL0011TTS 0.16 ± 0.02 0.06 ± 0.02 7.97 ± 0.40 11.91 ± 0.79 
3.2 PCIL0012TTS 0.02 ± 0.01 0.00 8.84 ± 0.19 - 
3.14 PCIL0013TTS 2.13 ± 0.59 0.91 ± 0.08 3.92 ± 0.30 6.21 ± 0.40 
cilazapril CIL0027TTS 0.09 ± 0.05 0.00 8.85 ± 2.13 - 
The use of full-thickness skin resulted in rather high variance, probably, due to non-
uniform skin samples. Thus, it appears reasonable to use dermatomized skin samples 
with more or less the same thickness. Moreover, factors such as anatomical, age and 
gender should be taken into consideration, when comparing results obtained with differ-
rent skin specimens. 
5.5 Summary 
The permeability of the novel candesartan prodrugs candesartan 1-(isopropyloxycarbo-
nyloxy)ethyl ester (3.31), candesartan 1-(2,2-dimethylpropanoyloxy)ethyl ester (3.32) and 
candesartan morpholinoethyl ester (3.35) as well as of the novel cilazapril prodrugs 
cilazapril 1-(ethoxycarbonyloxy)ethyl ester (3.1), cilazapril 1-(cyclohexyloxycarbonyloxy)-
ethyl ester (3.2) and cilazapril morpholinoethyl ester (3.14) and the reference compounds 
candesartan cilexetil and cilazapril, released from various TTS batches, through porcine, 
murine and human skin was investigated in vitro using static Franz diffusion cells. In the 
“receptor fluids” exclusively the corresponding active principle or other prodrug related 
metabolites were analyzed, indicating effective metabolism of all applied prodrugs during 
permeation through intact skin. 
The permeability of all candesartan prodrugs across full-thickness porcine ear skin as 
well as across dermatomized and full-thickness human skin was rather low. Neverthe-
less, modification of the pro-moiety improved the permeability with respect to candesar-
tan cilexetil. Probably, the skin permeation is affected by the kind of formulation (prodrug 
dissolved or suspended) resulting in different penetration rates or reservoir formation in 
certain layers of the skin due to inappropriate physicochemical properties. Furthermore, 
the lack of the physiological blood microcirculation in the dermis and the high inter-
individual variability of the used tissue in terms of thickness or age of donor should be 
taken into account when drawing conclusions from in vitro results with respect to in vivo 
conditions. 
Permeability of the cilazapril prodrugs and cilazapril across nude mouse skin was 
comparably high, presumably due to the rather low barrier function of mouse epidermis. 
Compared to cilazapril the morpholinoethyl ester 3.14 showed clear advantages in terms 
of skin permeation, whereas the double ester prodrugs 3.1 and 3.2 were found to be less 
permeable. On full-thickness porcine ear skin reduced steady-state fluxes were obtained 
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for all compounds. Surprisingly, the rank order of permeability was changed, when using 
human tissue. Across dermatomized human skin the steady-state flux of cilazapril was 
found to be ~1.5 fold and ~3 fold, respectively, lower than the fluxes of 3.1 and 3.14. Also 
with full-thickness human skin the best and most promising permeation profile was 
obtained for 3.14 (2.13 µg·cm-2·h-1, femoral skin) followed by 3.1 (0.16 µg·cm-2·h-1, 
femoral skin), whereas cilazapril and 3.2 appeared to be poorly permeable. 
In addition, histological studies of all used skin species were performed by preparing 
paraffin sections stained according to Masson and Goldner. Thereby, a lack of the 
epidermis of certain dermatomized batches of porcine ear skin was detected, which was 
likely caused by a standard cleaning procedure in the slaughterhouse, before the ears 
were resected. Comparable permeation experiments with intact porcine ear skin 
illustrated the importance of the epidermis and especially of the stratum corneum to 
achieve the full permeation barrier effect, since the permeability of all investigated 
compounds was markedly decreased, when the epidermis was missing. 
5.6 Perspectives 
Compared to studies on isolated animal tissue, in vitro skin permeation data from human 
tissue is known to correlate much better with the in vivo profile of the TTS in humans. 
Therefore, the utmost importance was attached to the results obtained from 
dermatomized and full-thickness human skin. It should be noted, that a considerable 
variability of the used porcine and human skin specimens regarding permeability was 
observed, which can presumably be attributed to various factors as different age, gender, 
or varying thickness of the epidermis depending on the body part.  
Candesartan prodrugs: Although an improved in vitro skin permeation for the novel 
candesartan prodrugs was observed, it is assumed that fluxes, required to produce 
therapeutic drug levels in vivo, are unlikely to be reached by application of present TTS. 
However, various approaches to the optimization of the formulation are conceivable, for 
instance, increase in drug loading of the TTS. Furthermore, a variation of the PSA should 
be considered. Optionally, the addition of drug solubilizers like polyvinylpyrrolidone (PVP) 
could be advantageous to prevent premature crystallization.30 Moreover, the use of 
permeation enhancers could be taken into consideration to affect the diffusion across the 
stratum corneum or to alter the distribution into the stratum corneum.31 A further 
approach could be the creation of a supersaturated system, i.e. a formulation containing 
a drug concentration higher than the saturation concentration, to improve the transder-
mal delivery.32 
Cilazapril prodrugs: Regarding human skin permeation at least two of three studied novel 
cilazapril prodrugs turned out to be superior to cilazapril. These findings corroborate the 
assumption that masking of the free carboxylic acid of cilazapril by using pro-moieties 
with appropriate physicochemical properties leads to a considerable gain in permeability. 
So far, besides the (ethoxycarbonyloxy)ethyl ester (3.1) the morpholinoethyl ester of 
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cilazapril (3.14) turned out to be the most promising candidate for preclinical proof-of-
concept studies. In addition, the (2-morpholinoacetoxy)ethyl ester (3.18) should be taken 
into consideration due to similar physicochemical properties of the promoiety. For further 
TTS development upscaling of the synthesis of the respective prodrugs in 
pharmaceutical quality is inevitable. Stability of the compounds as solids and after 
incorporation in the patch has to be determined again and a greater number of 
permeation experiments is required due to the high interindividual variations within the 
skin of donors to gain more reliable and predictive permeability data. In addition, the 
formulation should be optimized, and studies concerning the potential of the TTS for 
causing skin irritations should be carried out at an early stage. 
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5.7 Experimental section 
5.7.1 General experimental conditions 
Commercially available chemicals and reagents were purchased from Acros Organics 
(Geel, Belgium), Merck KGaA (Darmstadt, Germany) or Sigma-Aldrich Chemie GmbH 
(München, Germany). All solvents used were of analytical grade or HPLC grade. 
Analytical HPLC analysis was performed on a system from Thermo Separation Products 
(Thermo Scientific) consisting of a SN400 controller, a P4000 pump, an AS3000 
autosampler, a Spectra Focus UV-VIS detector and a RP-column (Luna C18-2, 150 x 4.6 
mm, 3 μm; Phenomenex, Aschaffenburg, Germany) at a flow rate of 0.75 mL/min and a 
column temperature varying between 45 to 60 °C. Absorbance was detected at 210 nm. 
The mobile phase consisted of MeCN and 0.05 % trifluoroacetic acid (TFA) in Millipore 
water. All samples were filtered prior to injection using 0.2 µm Phenex-NY Syringe Filters 
or 0.2 µm Phenex-RC Syringe Filters (each 0.2 µm pore size, 4 mm diameter) 
(Phenomenex, Aschaffenburg, Germany). Permeation experiments were performed, 
unless otherwise indicated, using customized Franz diffusion cells and a 9-station Franz 
cell stirrer (Crown Glass Company, Inc., Somerville, NJ, USA) equipped with a Lauda 
Ecoline 003/E100 heating water bath circulator (LAUDA DR. R. WOBSER GMBH & CO. 
KG, Lauda-Königshofen, Germany). Microscopic images were taken by means of an 
Olympus BH-2 microscope (Olympus, Tokyo, Japan) equipped with a Digital Mikroskop 
DCM-500 Ocular microscope camera. 
5.7.2 Determination of equilibrium solubility 
To a defined amount of substance in a small vessel a defined volume of receptor fluid 
was added resulting in a saturated solution with excess of solid present. The sample was 
stirred at room temperature for a specified time. After centrifugation the supernatant was 
collected and diluted with mobile starting phase to yield an appropriate concentration for 
HPLC analysis. The drug concentrations were determined on the analytical HPLC 
system described in the general experimental conditions (5.7.1) by applying following 
gradients: 3.31: 0 min: MeCN/0.05% TFA/aq 20/80, 24 min: 73/27, 25-33 min: 95/5, 34-
42 min: 20/80. 3.32, candesartan cilexetil: 0 min: MeCN/0.05% TFA/aq 20/80, 24 min: 
80/20, 25-33 min: 95/5, 34-42 min: 20/80. 3.35: 0 min: MeCN/0.05% TFA/aq 20/80, 24 
min: 43/57, 25-33 min: 95/5, 34-42 min: 20/80. 3.1, cilazapril: 0 min: MeCN/0.05% 
TFA/aq 25/75, 23 min: 39/61, 27 min: 43/57, 28-34 min: 95/5, 35-43 min: 25/75. 3.2: 0 
min: MeCN/0.05% TFA/aq 25/75, 36 min: 47/53, 42 min: 53/47, 43-49 min: 95/5, 50-58 
min: 25/75. 3.14: 0 min: MeCN/0.05% TFA/aq 25/75, 23 min: 39/61, 27 min: 43/57, 28-34 
min: 95/5, 35-43 min: 25/75. Determination of the corresponding equilibrium solubility 
was achieved by comparison with the respective calibration curve. 
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5.7.3 Preparation of skin membranes 
Porcine skin. Dermatomized (500-800 µm) porcine ear skin specimens were prepared 
using a Nouvag TCM3000 dermatome (Nouvag, Konstanz, Germany) and were provided 
by Hexal AG. The cooled skin samples were stored at -20 °C immediately after receipt 
and thawed prior to permeation experiments. 
Full-thickness porcine skin membranes were prepared from porcine ears, immediately 
obtained after slaughtering from a local abattoir. The ears were gently cleaned with water 
and the skin from the upper side was excised. The tissue was divided into several pieces 
of approximately 6-8 cm2, humidified with PBS and stored at -20 °C. 
Human skin. Tissue samples were obtained and experimental procedures were 
performed according to the guidelines of the charitable state controlled foundation 
HTCR, with the informed patient's consent.33 Human femoral or abdominal skin 
specimens were obtained from two female patients (75 and 47 years). As soon as 
possible after surgery, subcutis and fatty tissue were removed and the skin was divided 
in appropriately sized pieces (6-8 cm2), which were humidified with PBS and stored at -
20 °C. 
Nude mouse skin. After sacrifice the skin of two 74 d old NMRI (nu/nu) mice was 
excised and stored moistly on ice until prompt use. 
5.7.4 General procedure for in vitro skin permeation 
Reservoir solution. The receptor compartment of a Franz diffusion cell was filled with 
12.5 ml of 10 % (w/v) HP-β-CD solution or 50 mM phosphate buffer pH 7.4, respectively. 
Whilst the constantly stirred receptor fluid was allowed to equilibrate at 32 °C, frozen 
porcine, murine or human skin was thawed on a soaked paper tissue. A circle with a 
diameter of 27 mm was punched out and mounted on the receptor compartment with the 
epidermal side facing upwards. After adjustment of the donor compartment, 2.0 ml of a 
solution of the test compound in ethanol/propylene glycol 70/30 (v/v) were filled into the 
chamber. The cell was occluded and gently turned upside down to remove bubbles. At 
appropriate intervals, 500 µl aliquots of the receptor fluid were withdrawn and 
immediately replaced with an equal volume of fresh solution. The samples were filtrated 
and analyzed by HPLC. 
TTS. The receptor compartment of a Franz diffusion cell was filled with 12.5 ml of 10 % 
(w/v) HP-β-CD solution or 50 mM phosphate buffer pH 7.4, respectively. The receptor 
fluid was constantly stirred and allowed to equilibrate at 32 °C. A TTS was stuck on the 
epidermal side of a thawed animal or human skin sample, before a circle with a diameter 
of 27 mm was punched out and clamped between receptor and donor chamber. The cell 
was occluded and bubbles were removed by gently turning the cell upside down. 
Sampling and HPLC analysis were performed by analogy with the above described 
procedure. 
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The determination of drug concentrations in the receptor fluid samples was performed on 
the analytical HPLC system described in the general experimental conditions (5.7.1). The 
injection volume of each sample amounted to 25 µl. Candesartan prodrug containing 
samples were analyzed applying following gradient: 0 min: MeCN/0.05% TFA/aq 30/70, 
20 min: 85/15, 21-26 min: 95/5, 27-35 min: 30/70. For analysis of cilazapril and cilazapril 
prodrug containing samples the HPLC gradient was as follows: 0 min: MeCN/0.05% 
TFA/aq 15/85, 16-20 min: 35/65, 26 min: 70/30, 27-32 min: 95/5, 33-41 min: 15/85. 
5.7.4.1 Recovery 
At the end of the permeation experiment TTS and skin membranes were separated and 
positioned in small glass vessels. To vessels containing TTS samples 5 ml THF were 
added. The vessels were sonicated for 3 min and subsequently treated with a shaker for 
1 h. Skin samples were extracted with 10 ml MeOH by treatment in an ultrasonic bath for 
1 h and by shaking for 1.5 h. Each sample was diluted with mobile phase (TTS: 1:10, 
skin: 1:5), filtrated and analyzed by HPLC according to the HPLC method described in 
5.7.4. 
5.7.5 Preparation of paraffin sections for histological studies of animal 
and human skin 
Tissue samples (approx. 1x1 cm2) were fixed in approx. 25 ml of Bouin’s solution (300 ml 
sat. aq. picric acid solution, 100 ml formaldehyde 37 %, 20 ml glacial acetic acid) for at 
most 3 days, dehydrated, and embedded into paraffin. Serial 6-μm sections were 
prepared with a Leica RM2255 microtome (Leica, Bensheim, Germany), deparaffinated, 
and stained according to Masson and Goldner (modification by Jerusalem).34 
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 Chapter 6  
Exploring the Toxic Potential of NG-Acylated 
Hetarylpropylguanidines – Trapping of 
Reactive Metabolites 
6.1 Introduction 
6.1.1 Trapping of reactive metabolites 
Although the link between the formation of reactive drug metabolite-protein adducts and 
drug-induced toxicity is neither well-defined nor consistent, it is widely accepted that 
these processes may be causally related.1-2 Thus, a few strategies have been estab-
lished enabling the identification of compounds that bear the potential for bioactivation at 
an early stage of preclinical drug development to avoid economic risks associated with 
pursuing the development of a drug with apparent safety issues. Typically, these ap-
proaches involve the use of small molecule trapping agents capable of covalently binding 
to reactive metabolites generated by hepatic subcellular fractions in the presence of 
cytochrome P450 enzymes and cofactor NADPH. The resulting stable adduct should be 
amenable to analytical characterization.2 
 
Scheme 6.1. Examples of reactions of trapping agents with reactive metabolites: trapping of a quinoneimine by 
glutathione (GSH) (A), of an iminium ion by cyanide (B) and of an aldehyde by methoxylamine or semicarbazide 
(C). Adapted from Ma3 and Argikar4. 
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Due to the electrophilic nature of most reactive metabolites, appropriate nucleophilic 
trapping agents, espacially thiol-containing nucleophiles, as the endogenous tripeptide 
glutathione (GSH) (Scheme 6.2), are most frequently used and commonly applied for 
early screening. GSH is particularly useful for the reaction with various soft electrophiles 
(e.g. Michael acceptors or epoxides) (Scheme 6.1 A), 
but for trapping of hard nucleophiles like iminium ions 
or nitrons a hard nucleophile, such as cyanide, is more 
effective (Scheme 6.1 B).4-5 In addition, reactive alde-
hydes are capable of reacting with methoxylamine or 
semicarbazide via a Schiff base-reaction (Scheme 6.1 C).2 
Further screening for reactive metabolites may include the synthesis of a radiolabeled 
analogue of the compound to perform in vitro covalent binding studies in liver microsomal 
or hepatocyte preparations from laboratory animals and humans, or also in vivo, typically 
in the rat.2 
6.1.2 Glutathione (GSH) 
The tripeptide glutathione (γ-glutamylcysteinylglycine) is the most abundant intracellular 
small molecule thiol, reaching concentrations up to 10 mM6 in the liver.7 It is kept in its 
reduced thiol form by glutathione disulfide (GSSG) reductase.8 As a potent antioxidant it 
plays a major role in the maintenance of a reductive cellular environment. Furthermore, it 
is involved in the detoxification of a variety of endogenous and exogenous electrophilic 
compounds and peroxides. Its cysteine sulfhydryl group is capable of reacting with 
electrophilic species non-enzymatically or via catalysis by glutathione S-transferases 
(GST) and glutathione peroxidases (GPx). In addition, GSH is known to play a role in 
various cellular processes, including the regulation of protein and gene expression.7 
6.1.3 LC/MS analysis of reactive metabolite-GSH adducts 
The detection of reactive metabolite-GSH adducts is commonly based on the analysis by 
liquid chromatography/ tandem mass spectrometry (LC-MS). Traditionally, a triple quad-
rupole mass spectrometer is used, allowing the performance of several types of expe-
riments (Figure 6.1). 
Besides, a full scan to 
search for putative glu-
tathione adducts, a 
constant neutral loss 
(CNL) scanning for 129 
mass units in the po-
sitive ion mode proved 
to be particularly use-
ful, since glutathione 
conjugates, when frag-
HO
O
(S)
N
H
(R)
SH
O
O
H
N
O
OH
NH2  
Scheme 6.2. Chemical structure of 
glutathione (GSH). 
 
Scheme 6.3. Example of constant neutral loss for a glutathione conjugate of 
acetaminophene loosing a pyroglutamic acid moiety with the corresponding 
mass of 129 Da on CID.
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mented under collision induced dissociation (CID), can give a characteristic loss of a 
neutral fragment of 129 Da corresponding to the pyroglutamic acid moiety (Scheme 
6.3).9 Nevertheless, one should be aware that this technique suffers from poor selectivity, 
as on CID endogenous compounds present in biological matrices may undergo a loss of 
129 Da, which is not glutathione-conjugate related, resulting in the detection of false 
positive CNL signals.3 To enhance selectivity, multiple reaction monitoring (MRM) can be 
performed to follow either one or usually more specific mass transitions of a putative 
adduct induced by CID. Furthermore, a characteristic product ion scan (MS/MS 
spectrum) can provide additional information about the molecular structure of the trapped 
reactive metabolite. 
Figure 6.1. Schematic representation of 
common types of MS/MS experiments per-
formed on a triple quadrupole (TQ) MS. A: full 
scan (Q1-Q3: scan), B: product ion scan = 
MS/MS (Q1: selecting m/z, Q2: CID, Q3: 
scanning), C: precursor ion scan (Q1: scanning, 
Q2: CID, Q3: scanning selected m/z), D: 
constant neutral loss (CNL) scan (Q1: scanning, 
Q2: CID, Q3: scanning neutral loss), E: multiple 
reaction monitoring (MRM) (Q1: selecting m/z, 
Q2: CID, Q3: scanning selected m/z). 
Other LC-MS/MS-based techniques for the identification of GSH adducts include 
precursor ion scanning of an anion fragment at m/z 272 in the negative ionization 
mode10, the use of stable isotope labeled GSH11 and the use of high resolution mass 
spectrometry-based mass defect filtering12. 
  
Quadrupole 1 Quadrupole 2 Quadrupole 3
A
B
C
D
E
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6.2 Reactive metabolites of NG-acylated hetarylpropylguanidines 
NG-acylated hetarylpropylguanidines as NG-acylated imidazolylpropylguanidines and NG-
acylated 2-aminothiazolylpropylguanidines are potent histamine H2 receptor agonists. 
 
Scheme 6.4. General mechanism of oxidative ring opening of azoles. Adapted from Dalvie.13 
Due to their improved pharmacokinetic properties (oral bioavailability, CNS penetration) 
relative to the corresponding strongly basic NG-alkylated analogues the acylguanidines 
are valuable pharmacological tools for in vitro and potential in vivo studies.14 Hence, the 
identification of their toxic potential is obvious. It is known that biotransformation of 
heterocycles such as imidazole and thiazole through cytochrome P450-mediated 
oxidative ring opening can result in toxic metabolites (e.g. thioamide) and compounds 
capable of generating covalent adducts with biological nucleophiles (Scheme 6.4).13 
Furthermore, there is strong evidence that the bioactivation of the 2-aminothiazole ring 
results in highly reactive intermediates capable of forming adducts with critical 
biomacromolecules (Scheme 6.5).15 
 
Scheme 6.5. Proposed mechanism for the bioactivation of the 2-aminothiazole motif. NuH refers to e.g. a protein 
nucleophile or GSH. Adapted from Kalgutkar.15 
In view of the great potential of NG-acylated hetarylpropylguanidines with regard to 
pharmacological studies and potential therapeutic use, representative NG-acylated 2-
aminothiazol-5-ylpropylguanidines are studied with respect to the formation of reactive 
intermediates by incubation of the respective substance with rat liver microsomes in the 
presence of GSH as a trapping agent for electrophilic reactive metabolites. 
Subsequently, putative covalent GSH adducts are analyzed by appropriate LC-MS/MS 
experiments such as CNL scanning, MRM and product ion scanning. 
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In order to explore the suitability of this method for determination of unknown GSH 
adducts a proof of concept study was performed using diclofenac as model substrate. 
6.2.1 Proof of concept study – Determination of reactive metabolites of 
diclofenac by GSH trapping and LC-MS/MS analysis 
Diclofenac, a non-steroidal anti-inflammatory drug, causes rare, but severe cases of 
hepatotoxicity. It is known that P450-mediated oxidative metabolism of diclofenac leads 
to the formation of highly reactive 1’,4’-quinone imine and 2,5-quinone imine inter-
mediates capable of covalently binding to proteins causing liver injury.16 
The purpose of this study was to detect reactive metabolites from a GSH trapping assay 
in rat liver microsomes by applying a triple quadrupole LC-MS/MS system. So far, four 
GSH adducts from diclofenac are reported in the literature (Scheme 6.6).16-17 
 
Scheme 6.6. Proposed bioactivation pathway of diclofenac, showing the formation of reactive quinone imine 
intermediates and GSH conjugates. 
6.2.1.1 Method 
In brief, diclofenac was incubated in 0.1 M potassium phosphate buffer, pH 7.4, in the 
presence of rat liver microsomes, GSH and a NADPH regenerating system for 17 h at 
37 °C. After quenching of the reaction with ice cold acetonitrile, precipitated proteins 
were removed by centrifugation. The supernatant was concentrated, reconstituted in 
mobile LC phase and analyzed by LC-MS/MS. 
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6.2.1.2 Results 
Four GSH-containing adducts of diclofenac are reported in the literature: 4’-OH-2’-
glutathion-deschloro-diclofenac (4‘-OH-2‘-GS-DDF, exact mass: 582)16 as well as three 
constitutional isomers 5-OH-4-GS-DF, 5-OH-6-GS-DF and 4’-OH-3’-GS-DF (exact mass: 
616)18 (cf. Scheme 6.6). Figure 6.2 shows a full scan of a microsomal incubation mixture 
containing diclofenac. In accordance with the literature, the extracted ion chromatograms 
at m/z 583 and m/z 617 revealed the presence of four distinct GSH adducts (A1-A4), all 
of them exhibiting the characteristic one-chlorine or two-chlorine isotope cluster (MS not 
shown). Furthermore, a potential diclofenac phase-I metabolite (A5), presumably derived 
from ring oxidation in 5 or 4’-position, was detected showing a corresponding m/z 312 
(Figure 6.2 D). Unfortunately, CNL scanning at m/z 129 for the characteristic loss of 
pyroglutamic acid failed to yield the expected corroboration of the full scan results (cf. 
Figure 6.3), as the intensity of the obtained CNL signals was too weak to selectively 
detect all proposed GSH-containing adducts A1-A4. However, selectivity as well as 
sensitivity could be remarkably increased by an LC-MRM/MS experiment monitoring 
specific mass transitions of putative GSH adducts (Figure 6.4). Besides the observation 
of the loss of pyroglutamic acid (-129 Da), CID induced fragmentation of glycine from the 
GSH residue corresponding to a loss of 75 Da turned out to be a useful marker of GSH-
containing adducts. Thus, by monitoring two discrete mass transitions characteristic of 
GSH-derived metabolites the presence of the glutathionyl moiety in A1 to A4 becomes 
very likely. 
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Figure 6.2. Full scan TIC of a microsomal incubation mixture containing diclofenac, GSH and a NADPH-
regenerating system (A). Extracted ion chromatograms (MH+) of GSH-containing adducts A1 at m/z 583 (B) and 
of A2, A3 and A4 at m/z 617 (C) and of the oxidized diclofenac metabolite A5 at m/z 312 (D). 
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Further confirmation of the proposed reactive metabolites trapped by glutathione could 
be achieved by product ion scans. Thus, CID of A1 produced product ions at m/z 508 by 
loss of glycine, at m/z 454 by fragmentation of pyroglutamate and m/z 436 by 
subsequent loss of water (Figure 6.5 A). Beside the characteristic elimination of glycine 
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Figure 6.4. TIC of the LC-MRM/MS of four GSH-containing metabolites of diclofenac (A1-A4) generated by 
microsomal incubation with GSH and a NADPH-generating system (A). MRM chromatograms for m/z 617→542 
(B), m/z 617→488 (C), m/z 583→508 (D) and m/z 583→454 (E). 
Figure 6.3. CNL scanning (129 Da) of GSH adducts generated by microsomal incubation of diclofenac with GSH 
and a NADPH-generating system on a triple quadrupole instrument. A: TIC of the CNL scanning of a diclofenac 
incubation sample. B, C: Extracted ion chromatograms (MH+) at m/z 583 and 617, respectively. 
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and pyroglutamate the MS/MS spectrum of A4 showed product ions at m/z 313 and 342, 
respectively, derived from the fragmentation of the complete glutathionyl moiety and  
γ-glutamyl-dehydroalanyl-glycine, respectively (Figure 6.5 B). 
6.2.1.3 Conclusion 
In summary, four GSH adducts of diclofenac formed, in a rat microsomal incubation 
mixture in vitro, were identified by triple quadrupole LC-MS/MS. The combination of full 
scan, constant neutral loss scanning, multiple reaction monitoring and product ion 
scanning proved to be a successful strategy for the identification of GSH adducts. Thus, 
the method is considered appropriate for detection of GSH adducts formed by trapping of 
potential reactive intermediates of NG-acylated 2-aminothiazolylpropylguanidines. 
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Figure 6.5. TQ LC-MS/MS product ion spectra of GSH adducts A1 (A) and A4 (B) detected in microsomal
incubation mixture of diclofenac supplemented with GSH. The proposed origins of key fragment ions are indicated
and refer to monoprotonated species. 
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6.2.2 Determination of reactive metabolites of 3-(2-aminothiazol-5-yl)-
propylguanidines and 3-(2-amino-4-methylthiazol-5-yl)propylguani-
dines by GSH trapping and LC-MS/MS analysis 
6.2.2.1 Aminothiazolylpropylguanidines 
For the investigation of the potential bioactivation of 2-aminothiazolylpropylguanidines 
two compounds of rather “simple” chemical structures (6.1 and 6.2, synthesized in our 
laboratory by Dr. A. Kraus19) were chosen as examples to minimize the probability of 
metabolic attacks at moieties other than the heterocycle (Scheme 6.7). The initial 
consideration to use the free guanidine (1-[3-(2-aminothiazol-5-yl)propyl]guanidine) as a 
model substrate for microsomal incubation was not pursued, since the lower polarity of 
acylguanidines entailed marked advantages in terms of analyzability on a RP-LC column. 
The analyte is detected at longer retention times, where less noise (e.g. caused by buffer 
salts) is present. 
SN
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Scheme 6.7. Structures of two 2-aminothiazolylpropylguanidines used for bioactivation studies. 
Method 
The incubation of the substances 6.1 and 6.2 was carried out according to procedure 
6.2.1.1, but the incubation period was reduced to 2 h. 
Results 
Figure 6.6 A displays the full scan base peak chromatogram of the supernatant of a 
microsomal incubation of 6.1 containing GSH and a NADPH-regenerating system. A re-
corded UV profile at 210 nm did not provide any additional information due to insufficient 
sensitivity, and is therefore not shown. Interestingly, no parent compound was detected 
after 2h of microsomal incubation. LC-MS/MS screening for potential GSH-containing 
adducts was performed by CNL scanning for the loss of 129 Da upon CID and in fact, led 
to the detection of a putative GSH adduct (B1, tR ~ 24.9 min) at m/z 637 (MH+) (Figure 
6.6 B+C). Besides B1 a second CNL signal was detected at tR ~ 11.1 min corresponding 
to oxidized glutathione (glutathione disulfide, GSSG, m/z 613 (MH+)), which derived from 
GSH during incubation and/or sample preparation. 
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The susceptibility of the 2-aminothiazole ring to bioactivation and subsequent GSH 
addition is known from the literature.15, 20 Therefore, in case of the bioactivated histamine 
H2 receptor agonists, the GSH moiety is most likely attached to the aminothiazole, 
although the exact regiochemistry of the addition is unknown. The proposed bioactivation 
pathway for 6.1 is shown in Scheme 6.8 and is assumed to involve either a cytochrome 
P450-mediated epoxidation (A) or a ring oxidation resulting in an electrophilic reactive 
intermediate (B). Both intermediates are assumed to readily undergo nucleophilic 
trapping reactions with glutathione. Epoxide ring opening by GSH in 4-position of the 
aminothiazole is supposed to be preferred, since nucleophilic attack in 5-position is 
sterically hindered and does not lead to an energetically favored aromatic ring system. 
Thus, pathway B is also assumed to be rather unlikely. 
 
Scheme 6.8. Proposed bioactivation pathway of the 2-aminothiazolylpropylguanidine 6.1. 
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Figure 6.6. TQ LC-MS/MS analysis of a microsomal incubation mixture containing 6.1, GSH and a NADPH-rege-
nerating system. A: Full scan base peak chromatogram. B: CNL scanning of m/z 129. C: Full scan extracted ion 
chromatogram of B1 at m/z 637 (MH+). 
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Further characterization of the proposed GSH adduct B1 was achieved by subsequent 
product ion scanning of the MH+ ion at m/z 637 and revealed two major fragment ions at 
m/z 508 and 364 corresponding to a neutral loss of 129 Da, consistent with the loss of 
pyroglutamic acid, and to the fragmentation of γ-glutamyl-dehydroalanyl-glycine, res-
pectively (Figure 6.7). 
 
Additionally, four potential phase I metabolites (B2-B5) were detected with ions at 
m/z 348 consistent with monohydroxylated metabolites of 6.1 (cf. Figure 6.8). Unfortu-
nately, product ion scans of B2-B5 did not provide more detailed information about the 
attachment site of the OH group. However, oxidation in various positions of the phenyl 
ring seems plausible. 
 
To explore the dependence of bioactivation on the presence of cytochrome P450 
enzymes, an incubation sample of 6.1 was analyzed, in which rat liver microsomes were 
replaced with a respective volume of phosphate buffer (Figure 6.9). In fact, in the 
absence of rat liver microsomes biotransformation of 6.1 (tR ~ 24.3 min) was not 
observed. Hence, neither the GSH adduct B1 nor the putative hydroxylated metabolites 
B2-B5 were detected, suggesting that their formation is P450-dependent. 
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Figure 6.8. Full scan extracted ion chromatogram of a microsomal incubation mixture containing 6.1, GSH and a 
NADPH-regenerating system at m/z 348 (MH+) depicting four potential oxidized metabolites (B2-B5) of 6.1. 
Unlabeled peaks do not exhibit a molecular ion at m/z 348. 
Figure 6.7. TQ LC-MS/MS product ion spectrum of the proposed GSH adduct B1 derived from a microsomal 
incubation of 6.1 supplemented with GSH. The proposed origins of key fragment ions are as indicated and refer to
monoprotonated species. The exact regiochemistry of the GSH addition is unknown. 
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Strikingly, the sum of the peak areas of all potential 6.1-derived metabolites in Figure 
6.6 A turned out to be considerably smaller than the peak area of 6.1 detected in an 
incubation sample devoid of microsomes (Figure 6.9 A). This may be caused by high 
unspecific or covalent protein binding of 6.1 and/or 6.1-derived metabolites, presumably 
resulting in a loss of (detectable) substance during protein precipitation and separation. 
Plasma protein binding (PPB) studies with various NG-acylated hetarylpropylguanidines 
using bovine serum albumin indeed indicated a high unspecific PPB, which amounted to 
79 % for 6.1 (in-house communication). 
In Figure 6.10 the base peak chromatogram of a microsomal incubation sample of 6.2 
containing GSH and a NADPH-regenerating system (A) as well as the TIC of a control 
sample devoid of microsomes (B) are shown. Apparently, the recovery of 6.2 compared 
to 6.1 was higher, although the experimentally determined PPB was actually increased 
(87 %, in-house communication). 
0 5 1 0 1 5 20 25 3 0 3 5 4 0 45 50
Tim e  (m in )
0
1 0
2 0
3 0
4 0
5 0
6 0
7 0
8 0
9 0
1 00
0
1 0
2 0
3 0
4 0
5 0
6 0
7 0
8 0
9 0
1 00
R
el
at
iv
e 
A
bu
nd
an
ce
0
1 0
2 0
3 0
4 0
5 0
6 0
7 0
8 0
9 0
1 00
2 4 .2 9
8 .0 0
7 .9 0
8 .4 0
1 1 .0 6
10 .3 8
1 7 .5 8
3 .5 5 3 .7 8 26 .6 916 .7 7 2 3 .1417 .8 5 3 3 .3 612 .0 4 3 0 .0 8 3 4 .1 03 .2 8 43 .3 93 6 .1 1 46 .0 6 5 0 .073 9 .2 5
4 .1 43 .5 9
4 .3 8
1 8 .55
6 .2 6
3 .5 0
1 2 .8 9 24 .4 2
1 4 .4 38 .2 8 30 .9 828 .3 01 0 .0 4 34 .7 37 .7 0 27 .6 72 2 .5 7 32 .5 72 1 .8 31 1 .0 1 1 6 .0 93 .0 5 2 8 .9 0
1 1 .04
23 .8 5
7 .7 1
8 .5 1
3 .4 9 8 .8 6 1 9 .9 4 2 6 .732 2 .8 23 .6 8 12 .0 9 27 .1 516 .8 0 2 1 .23 3 3 .8213 .4 7 29 .2 36 .8 26 .6 1 34 .0 83 .1 7
N L :
3 .8 0 E6
Ba s e  Pe a k 
 MS 
a n s a tz2 _ 2
N L :
1 .4 2 E4
m /z= 
6 3 6 .7 -
6 3 7 .7   MS 
a n s a tz2 _ 2
N L :
7 .3 7 E4
m /z= 
3 4 7 .6 -
3 4 8 .6   MS 
a n s a tz2 _ 2
6.1A
B
C
Figure 6.9. TQ LC-MS/MS analysis of an incubation mixture of 6.1 devoid of rat liver microsomes, supplemented 
with GSH and a NADPH-regenerating system. A: Full scan base peak chromatogram showing the parent 
compound 6.1 at tR ~ 24.3 min. B, C: Full scan extracted ion chromatograms at m/z 637 and 348, respectively 
confirming the absence of B1-B5. 
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Screening of the full scan data set of the 6.2-containing microsomal incubation mixture 
for trapping of reactive intermediates by GSH revealed the presence of a potential GSH 
adduct (C1) at tR ~ 26.0 min with a pseudomolecular ion (MH+) at m/z 665, which is 
consistent with the addition of one molecule of GSH to 6.2 (Figure 6.11 A, B, D). This 
addition is assumed to take place by analogy with the formation of the 6.1-derived GSH 
adduct B1. 
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Figure 6.10. A: Full scan base peak chromatogram of 6.2 coincubated with GSH and a NADPH-regenerating 
system in rat liver microsomes. B: Full scan TIC of the negative control sample devoid of rat liver microsomes. 
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More detailed information on the proposed structure of C1 was obtained by using the 
MRM mode to follow specific fragmentation pathways known for the glutathionyl moiety. 
Moreover, the MRM mode is superior to CNL scanning in terms of sensitivity, which is of 
particular interest in cases of low analyte levels. Three distinct mass transitions were 
chosen as criteria for the presence of a glutathionyl moiety in C1: the loss of pyrogluta-
mic acid (-129 Da), glycine (-75 Da) and γ-glutamyl-dehydroalanyl-glycine (-273 Da). As 
depicted in Figure 6.12, C1 showed corresponding MRM signals for all three characte-
ristic mass transitions and is therefore suggested to be a GSH adduct of 6.2. 
Analogously to 6.1, various species with a mass difference of +16 Da, consistent with 
monohydroxylation, were detected after microsomal incubation showing corresponding 
ions at m/z 376 (cf. Figure 6.11 C). The appearance of an enlarged number of proposed 
hydroxylated species (C2-C7) compared to 6.1 (B2-B5) could be due to the introduction 
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Figure 6.11. TQ LC-MS/MS analysis of a microsomal incubation mixture of 6.2 supplemented with GSH and a 
NADPH-regenerating system. A: Detailed representation of a full scan base peak chromatogram of the 6.2-
containing microsomal incubation mixture. B: Extracted ion chromatogram at m/z 665 showing the proposed 
structure of the GSH adduct C1 eluting at tR ~ 26.0 min. C: Extracted ion chromatogram at m/z 376 depicting the 
presence of six potential monohydroxylated metabolites of 6.2 (C2-C7). D: Full scan mass spectrum of C1 at tR
~26.0 min. As the exact regiochemistry of hydroxylation and the attachment point of the glutathionyl moiety are
not known, the structures are only drawn for illustrative purpose. 
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of an additional ethyl group, which may also serve as potential point of attack in phase I 
oxidation. The seemingly increased amount of monohydroxylated species gives rise to 
the speculation that the ethyl substitution shifts the metabolic pathway to enhanced alkyl 
and aryl oxidation instead of formation of reactive intermediates by bioactivation of the 
aminothiazole ring. This could lead to less protein binding and hence, to higher recovery. 
LC-MS/MS analysis of a control sample of 6.1 containing GSH and a NADPH-regene-
rating system incubated in the absence of rat liver microsomes revealed neither the 
formation of the GSH adduct C1 nor of the hydroxylated metabolites C2-C7. This corro-
borates the P450 dependence of these reactions. 
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Figure 6.12. TIC of the LC-MRM/MS of the 6.2-derived GSH-containing metabolite C1 generated by microsomal 
incubation with GSH and a NADPH-generating system (A). MRM chromatograms for m/z 665→536 (B), m/z
665→590 (C) and m/z 665→392 (D). All mass transitions are assumed to take place as indicated in the drawn 
structure. 
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6.2.2.2 NG-Acylated 3-(2-amino-4-methylthiazol-5-yl)propylguanidines 
Recently, Kalgutkar et al. published a chemical intervention strategy to reduce the bio-
activation liability of the 2-amino-4-arylthiazole motif.15 The authors showed that replace-
ment of the thiazole against a 1,2,4-thiadiazole analogue or blocking of the C5-position 
by introduction of a fluorine atom abolished the liability for GSH adduct formation. Based 
on a predictive in silico model and subsequent screening for GSH adducts, Subramanian 
et al. observed that introduction of a methyl substituent in C4-position of a 5-(2-amino-
thiazol-5-yl)indolin-2-one motif prevented GSH conjugation.20 In our workgroup the intro-
duction of a methyl group in position 4 of the thiazole ring as in the H2R agonist amtha-
mine (2-amino-4-methylthiazol-5-ethanamine) was investigated in the course of struc-
ture-activity studies of H2R agonists.21 Considering these results, it seems reasonable to 
investigate the role of 4-methyl substitution with regard to GSH adduct formation. Thus, 
the bioactivation potential of the 4-methyl analogues 6.3 and 6.4 (Scheme 6.9, 
synthesized in our laboratory by Dr. A. Kraus19, 21) of the 2-aminothiazolylpropylguani-
dines 6.1 and 6.2 was explored in a GSH trapping assay using rat liver microsomes. 
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Scheme 6.9. Structure of two 2-amino-4-methylthiazolylpropylguanidines used for bioactivation studies. 
Method 
The incubation of the substances 6.3 and 6.4 was carried out according to the procedure 
described in section 6.2.2.1 for the incubation of 2-aminothiazolylpropylguanidines. 
Results 
There is evidence from the literature that by introduction of a methyl group in 4-position 
of the 2-aminothiazole epoxidation and subsequent GSH conjugation becomes unlikely 
due to sterical hindrance.20 However, GSH addition after ring oxidation according to 
Scheme 6.8, pathway B seems theoretically possible (Scheme 6.10). Thereby, the 
addition is assumed to take place in 5-position in structure (I), as the contribution of 
structure (II) to resonance is negligible due to highly unfavorable distribution of charges. 
 
Scheme 6.10. Proposed mechanism for GSH conjugation at the 2-amino-4-methylthiazolylpropylguanidine 6.3. 
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Full scan LC-MS/MS analysis of the supernatants of an incubation mixture containing 
6.3, GSH, NADPH-regenerating system and rat liver microsomes as well as of the 
control sample devoid of microsomes revealed a very low recovery of the parent 
compound 6.3 after microsomal incubation (Figure 6.13). According to the results for the 
demethylated analogue 6.1 this finding is in agreement with a high degree of unspecific 
protein binding. 
 
Screening of the full scan data set of a 6.3-containing microsomal incubation mixture 
supplemented with GSH and a NADPH-regenerating system for potential GSH adducts 
of 6.3, formed by the bioactivation pathway proposed in Scheme 6.10, yielded two 
separate signals at tR ~ 23.7 min (D1) and 23.8 min (D2), respectively, both showing a 
corresponding pseudomolecular ion (MH+) at m/z 651 (Figure 6.14). D1 and D2 are 
considered potential diastereomers derived from GSH addition in C5-position, which 
could yield the (R) or (S)-configured stereocenter. However, relative abundance of both 
putative GSH adducts was very low. Thus, CNL scanning of 129 Da gave no corres-
ponding CNL signals. Furthermore, two potentially monohydroxylated species with ions 
at m/z 362 were detected at tR ~ 21.7 min and 22.4 min, respectively, that have apparent 
masses consistent with the formal addition of an oxygen atom (Figure 6.15). 
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Figure 6.13. A: Full scan base peak chromatogram of 6.3 coincubated with GSH and a NADPH-regenerating 
system in rat liver microsomes. B: Full scan base peak chromatogram of a control sample without microsomes. 
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Figure 6.15. A: Detailed representation of a full scan base peak chromatogram of a microsomal incubation
mixture containing 6.3, GSH and a NADPH-regenerating system. B: Extracted ion chromatogram at m/z 362 
showing two potential monohydroxylated metabolites (D3, D4) of 6.3. 
Figure 6.14. A: Detailed representation of a full scan TIC chromatogram of a microsomal incubation mixture
containing 6.3, GSH and a NADPH-regenerating system. B: Extracted ion chromatogram at m/z 651 showing two
potential diastereomeric GSH adducts (D1, D2) and their corresponding proposed structure with undefined
stereochemistry at C5. C, D: Full scan mass spectra of the MH+ ions at 651 Da of D1 and D2 at tR ~23.7 min and
tR ~ 23.8 min. 
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In Figure 6.16 the results of full scan analyses of incubation mixtures containing 6.4, 
GSH and a NADPH-regenerating system in the absence (A) and in the presence (B) of 
rat liver microsomes are depicted. In accordance with the results for the demethylated 
analogue 6.2 the recovery of 6.4 after microsomal incubation was higher than for 
compound 6.3 lacking the ethyl substituent in the acyl part. 
 
By analogy with the analysis of 6.3, the full scan data set of the microsomal incubation 
sample was scanned for a GSH adduct, formed by the postulated bioactivation pathway 
depicted in Scheme 6.10, having a molecular weight, which is consistent with the 
proposed structure shown in Figure 6.17 A. Apparently, compound E1, detected at 
tR ~ 26.1 min, suggests the addition of a GSH molecule, as it shows a corresponding 
pseudomolecular ion at m/z 679. However, beside the pseudomolecular ion MH+ at m/z 
679 a sodium adduct ion ([M+Na]+) at m/z 701 and a potassium adduct ion ([M+K]+) at 
m/z 717 were detected, which were not observed with other GSH adducts. Moreover, the 
CID fragmentation pattern obtained by a product ion scan of the MH+ ion at m/z 679 did 
not confirm the formation of an GSH adduct, as characteristic fragment ions of the 
glutathionyl moiety due to the loss of glycine (-75 Da) or γ-glutamyl-dehydroalanyl-glycine 
(-273 Da) were missing. In addition, the required collision energy (45 eV) for adequate 
fragmentation was unusually high in contrast to product ion scans of other GSH adducts, 
which only required 22-30 eV. Furthermore, in incubation mixtures containing 6.2 and 
6.3, respectively, corresponding peaks at tR ~ 26.1 min were detected. Thus, the forma-
tion of a specific 6.4-derived GSH adduct seems rather unlikely. 
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Figure 6.16. A: Full scan base peak chromatogram of a 6.4-containing incubation mixture co-incubated with GSH 
and a NADPH-regenerating system in the absence of rat liver microsomes. B: Full scan base peak chromatogram
of an analogous incubation mixture with rat liver microsomes. 
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However, the generation of monohydroxylated metabolites of 6.4 seemed possible, as 
the extracted ion chromatogram for m/z 390 revealed two species at tR ~ 24.5 min and 
25.4 min, respectively, consistent with the formal addition of one oxygen atom (Figure 
6.18). 
 
6.2.2.3 Metabolite identification 
In order to gain further information about the metabolic fate of NG-acylated hetarylpropyl-
guanidines the metabolite profiles of compounds 6.1 and 6.3 were investigated. The 
studies were carried out in cooperation with Dr. A. Rottmann and coworkers at the 
department of Drug Metabolism and Pharmacokinetics at Bayer Schering Pharma AG 
(Berlin, Germany). The substances were incubated in the presence of rat and human 
liver microsomes as well as rat hepatocytes. For microsomal incubations a NADPH-
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Figure 6.18. Extracted ion chromatogram at m/z 390 showing the presence of two putative monohydroxylated 
metabolites of 6.4 (E2, E3). 
Figure 6.17. A: Extracted ion chromatogram at m/z 679 showing the presence of a putative GSH adduct of 6.4
(E1) with corresponding possible structure. B: Mass spectrum of E1 (tR ~ 26.1 min). C: Product ion scan of E1 at
tR ~ 26.1 min. 
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regenerating system was added or omitted (negative control sample). Furthermore, the 
incubation samples were not supplemented with GSH. 
Subsequent LC-MS analysis yielded poor recoveries for both substances possibly due to 
high unspecific or covalent protein binding. Incubation of 6.1 and 6.3 in the presence of 
rat hepatocytes led to the detection of 1-[3-(2-aminothiazol-5-yl)propyl]guanidine and 1-
[3-(2-amino-4-methylthiazol-5-yl)propyl]guanidine, respectively by cleavage of the amide 
bond. However, no GSH adducts were detected. Thus, bioactivation of 6.1 and 6.3 to 
reactive intermediates could not be verified. Furthermore, in all incubation samples 
various potential mono- as well as dihydroxylated metabolites of 6.1 and 6.3 were 
detected, but not further characterized. 
6.3 Modification of the trapping agent – fluorescence-labeled GSH 
In order to increase the sensitivity of GSH adduct detection and to improve specificity, 
the possibility of using a fluorescence-based detection method was explored. Gan et al. 
reported a LC-MS/MS method that exploits the fluorescent signal of a dansylated gluta-
thione derivative.22 Dansyl chloride is a widely applied derivatizing agent for compounds 
bearing hydroxyl or amino groups. Thus, it is applied especially for amino acid and 
peptide analysis23-24, but also for the determination of pharmaceutical compounds in 
pharmaceutical preparations and biological fluids25. In the following the synthesis of 
dansylated glutathione (dGSH) and its use for trapping of reactive intermediates is 
presented. 
6.3.1 Chemistry 
The synthesis of dansylated glutathione (dGSH) was performed according to described 
procedures22, 26 with several modifications. Since reaction of dansyl chloride with the free 
thiol group in GSH must be avoided, oxidized glutathione (glutathione disulfide, GSSG) 
was used as starting material. Derivatization of the γ-glutamyl amino moieties was 
accomplished under basic reaction conditions in a mixture of carbonate buffer, pH 9.0, 
and acetone. Subsequent reduction of the disulfide bond of double dansylated GSSG 
(ddGSSG) was achieved by addition of dithiothreitol (DTT) to yield dGSH (Figure 6.19). 
6.3.2 Trapping reactions with test substances 
To prove the trapping efficiency of dGSH towards reactive intermediates, adduct 
formation was investigated using test compounds exhibiting an intrinsic tendency for 
reaction with nucleophiles like thiols. As an indicative model reaction, the addition of 
dGSH to acrolein and N-ethylmaleimide, respectively (Figure 6.20), was followed by 
means of HPLC using fluorescence detection. Dansyl-related fluorescence was moni-
tored at 525 nm after excitation at 340 nm. 
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Figure 6.19. Synthesis of dansylated glutathione (6.5). Reagents and conditions: (i) dansyl chloride (3 eq), 
sodium carbonate buffer pH 9/ acetone, rt, 3 h, protection from light (ii) dithiothreitol (5 eq), 0.1 M TRIS buffer 
pH 8, rt, 1.5 h protection from light. 
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Figure 6.20. Examples of trapping reactions with dGSH using acrolein and N-ethylmaleimide. 
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Michael addition of dGSH (6.5) to acrolein yielded the fluorescent adduct 6.6 (cf. Figure 
6.20). Apparently, 6.5 and 6.6 showed overlapping retention times under chosen chro-
matographic conditions resulting in the detection of one broad fluorescence signal for 6.5 
and 6.6 (Figure 6.21). Nevertheless, LC-MS analysis of the reaction mixture yielded suffi-
cient separation of both species to determine a clean mass spectrum for 6.6, which cor-
roborates the formation of the acrolein-dGSH adduct consistent with the pseudo-
molecular ion (MH+) at m/z 597 (Figure 6.22). A second distinct fluorescence signal at tR 
~ 18.9 min (Figure 6.21) was observed, which was identified by LC-MS as double dansy-
lated glutathione disulfide (ddGSSG) (Figure 6.22) formed by oxidation of excess dGSH. 
Figure 6.21. Chromatograms of a reaction 
mixture of acrolein and dGSH. The 
fluorescent acrolein-dGSH adduct (6.6) and 
residual dGSH (6.5) appear to overlap. A: 
fluorescence trace. B: UV trace (210 nm).  
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Figure 6.22. A: Full scan TIC chromatogram of a reaction mixture containing acrolein and dGSH. The
trapped acrolein-dGSH adduct (6.6, tR = 8.96 min) and dGSH (6.5, tR = 9.06 min) was not completely
resolved under present chromatographic conditions. B: Mass spectrum of 6.6 at tR = 8.91 min. 
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By analogy with acrolein the reaction of dGSH with an excess of N-ethylmaleimide 
(NEM) led to the formation of adduct 6.7. However, since dGSH is a chiral compound 
Michael addition to NEM yielded two diastereomers, which could be resolved with the 
applied chromatographic method and showed two distinct fluorescence signals (Figure 
6.23). A faster HPLC gradient used for LC-MS resulted in merging of the two dia-
stereomers of 6.7 (Figure 6.24 A). Nevertheless, a mass spectrum of 6.7 recorded at tR = 
9.56 min revealed the presence of a pseudomolecular ion (MH+) at m/z 666 and a mono-
protonated cluster ion (2M+H+) at m/z 1331 consistent with the addition of one molecule 
of dGSH to NEM (Figure 6.24 B). 
Figure 6.23. Chromatograms of a reaction 
mixture of N-ethylmaleimide (NEM) and 
dGSH depicting the formation of two 
diastereomeric NEM-dGSH adducts (6.7). 
A: fluorescence trace. B: UV trace (210 
nm).  
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Figure 6.24. A: Full scan TIC chromatogram of a reaction mixture containing N-ethylmaleimide and
dGSH. Diastereomeric separation of the dGSH adduct 6.7 (tR = 9.56 min) was not achieved under
present chromatographic conditions. B: Mass spectrum of 6.7 at tR = 9.56 min. 
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In summary, dansylated glutathione reacted with the chosen Michael acceptors to give 
adducts, which could be identified by HPLC using fluorescence detection. Thus, dGSH 
could be a suitable trapping reagent for the identification of unknown reactive 
intermediates. 
6.3.3 Trapping of reactive metabolites of NG-acylated hetarylpropyl-
guanidines with dGSH 
The suitability of dansylated glutathione (6.5) for trapping of reactive metabolites was 
studied using the 2-aminothiazolylpropylguanidine 6.1, which had already provided evi-
dence of being bioactivated to reactive intermediates on incubation with rat liver 
microsomes. 
Method 
6.1 was co-incubated with rat liver microsomes, dGSH and a NADPH regenerating 
system in 0.1 M potassium phosphate buffer, pH 7.4, for 2 h at 37 °C. After quenching of 
the reaction with ice cold acetonitrile, precipitated proteins were removed by centrifu-
gation. The supernatant was concentrated, reconstituted in mobile LC phase and ana-
lyzed by LC-MS/MS. Unfortunately, simultaneous fluorescence detection could not be 
carried out with the available LC-MS/MS system. 
Results 
Derivatization of GSH with the dansyl fluorophore enabled sensitive fluorescence 
detection, but also improved the signal to noise ratio using UV detection. In Figure 6.25 
the UV trace as well as the base peak chromatogram of a microsomal incubation mixture 
of 6.1 coincubated with 6.5 and a NADPH-regenerating system is depicted revealing a 
very prominent and sharp eluting signal of 6.5 at tR ~ 13.3 min and a smaller peak 
referring to ddGSSG formed by oxidation of 6.5. A product ion scan of 6.5 at 
tR ~ 13.3 min was performed to assess the typical CID-induced fragmentation pattern of 
6.5 (Figure 6.25 C). Besides the loss of glycine, fragmentation of the dansylated γ-
glutamyl moiety as well as dissociation of the sulfonamide bond between GSH and the 
dansyl moiety was observed. Therefore, fragmentation of dGSH appeared to proceed by 
analogy with the fragmentation of GSH. Scanning of the full scan data set for potential 
dGSH adducts of 6.1 led to the detection of the species F1 (tR ~ 14.6 min) at m/z 870 
(MH+) (Figure 6.26). The corresponding molecular weight of 869 Da suggests the 
addition of one molecule of dGSH to 6.1. However, F1 showed only a very low relative 
abundance. Hence, product ion scan and CNL scanning failed due to insufficient 
sensitivity. Though, using the MRM mode the characteristic loss of glycine (m/z 870 → 
795) as well as the dansylated γ-glutamyl fragment (m/z 870 → 363) could be monitored 
corroborating the formation of a dGSH adduct of 6.1 (Figure 6.27). 
Generally, dGSH can be considered a useful alternative trapping agent for the screening 
of compounds for reactive intermediate formation, especially because it allows sensitive 
and quantitative analysis. However, by introduction of the rather bulky dansyl group to 
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GSH the recognition of the (modified) cofactor by glutathione S-transferases (GST) could 
be impaired. This, in turn, might increase the percentage of non-enzymatic adduct 
formation.22 
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Figure 6.25. Triple quadrupole LC-MS/MS analysis of 6.1 coincubated with dGSH (6.5) and a NADPH-
regenerating system in rat liver microsomes. A: UV trace recorded at 210 nm. B: Full scan base peak chromato-
gram. C: Product ion spectrum of 6.5 at tR = 13.27 min. The proposed origins of key fragment ions are as
indicated. 
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Figure 6.26. A: Detailed representation of a TIC chromatogram of a microsomal incubation mixture containing
6.1, dGSH (6.5) and a NADPH-regenerating system. B: Extracted ion chromatogram at m/z 870 showing a 
potential dGSH adduct (F1) of 6.3 with proposed structure. C: Mass spectrum of F1 at tR = 14.62 min. 
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Figure 6.27. TIC of the LC-MRM/MS of the 6.1-derived dGSH-containing metabolite F1 generated by microsomal 
incubation with dGSH and a NADPH-generating system (A). MRM chromatograms for m/z 870→795 (B) and m/z
870→363 (C). All mass transitions are assumed to take place as indicated in the drawn structure. The signal at 
tR ~ 13.8 min does not correspond to a pseudomolecular ion at m/z 870, but indicates an isotope peak of a 
different molecular species. 
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6.4 Summary 
Previously, strong evidence was arising concerning a toxic potential of 2-aminothiazoles 
due to bioactivation of the heterocycle resulting in electrophilic intermediates capable of 
covalently binding to proteins.15, 20 In view of future pharmacological in vivo investigations 
of NG-acylated 2-aminothiazol-5-ylpropylguanidines, developed in our workgroup as 
highly potent and selective H2 agonists19, the bioactivation potential of examples of NG-
acylated 3-(2-aminothiazol-5-yl)propylguanidines and NG-acylated 3-(2-amino-4-methyl-
thiazol-5-yl)propylguanidines was investigated in vitro by coincubation with rat liver 
microsomes and glutathione to trap putative reactive intermediates. A suitable method 
for the detection of GSH adducts based on liquid chromatography/tandem mass 
spectrometry (LC-MS) was developed, which was successfully applied for identification 
of GSH-containing metabolites of the model compound diclofenac by combination of 
appropriate MS/MS experiments as full scan, constant neutral loss scanning, multiple 
reaction monitoring and product ion scanning. Application of this method to bioactivation 
studies with NG-acylated 3-(2-aminothiazol-5-yl)propylguanidines revealed P450-
mediated formation of putative GSH adducts, presumably generated by oxidation or 
epoxidation of the heterocycle followed by trapping with GSH. Concerning the 
bioactivation of NG-acylated (2-amino-4-methylthiazol-5-yl)propylguanidines the epoxida-
tion pathway was assumed to be rather unlikely due to steric hindrance by the 4-methyl 
group. The addition of GSH in 5-position of the 2-aminothiazole was still conceivable, but 
could not be unequivocally confirmed by LC-MS/MS analysis. Further metabolic 
investigations with human liver microsomes and rat hepatocytes suggested that cleavage 
of the amide bond resulting in the free guanidine and oxidation of phenyl and alkyl 
substituents were the preferred metabolic pathways for NG-acylated 3-(2-aminothiazol-5-
ylpropyl)guanidines and 3-(2-amino-4-methylthiazol-5-yl)propylguanidines. Aiming at 
increased sensitivity of GSH adduct detection and improved selectivity, dansyl 
glutathione (dGSH), a fluorescence-labeled glutathione derivative, was synthesized. Its 
benefit in terms of trapping of reactive species was demonstrated using the Michael 
acceptors acrolein and N-ethylmaleimide as examples. The reaction was investigated by 
HPLC-fluorescence detection and LC-MS analysis of resulting dGSH adducts. Indeed, 
also dansylated glutathione proved to be suitable for detecting trapped reactive 
intermediates derived from bioactivation of 2-aminothiazolylpropylguanidines, since a 
dGSH adduct of 6.1 was identified by LC-MS/MS. 
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6.5 Discussion and outlook 
Apparently, the detection of GSH adducts of NG-acylated 2-aminothiazolylpropyl-
guanidines indicates a certain potential of 2-aminothiazoles for bioactivation resulting in 
reactive intermediates. Although these GSH adducts appeared to be rather low level 
metabolites, the possibility of their formation should not be neglected, but the 2-amino-
thiazole ring should rather be considered a structural alert. As it is extremely difficult to 
predict a correlation between formation of reactive intermediates and the incidence of 
adverse drug reactions, a lot more information about the proposed GSH adducts should 
be collected. Firstly, structural elucidation is required to identify the exact point of 
attachment of the glutathionyl moiety and to allow conclusions on the pathway of 
bioactivation. This could be achieved by means of LC-NMR analysis. However, as the 
NMR technique suffers from relatively low sensitivity27, the amounts of putative GSH 
adducts will have to be increased. Thus, upscaling of the microsomal incubation samples 
followed by solid phase extraction should be considered. Furthermore, more sophistica-
ted MS techniques, especially high resolution mass spectrometry (HR-MS), could pro-
vide more detailed structural information and help to exclude false positives.9 If the 
suspicion of reactive intermediate formation was confirmed, the synthesis of a radio-
labeled test compound would be reasonable to investigate covalent protein binding by 
means of liquid scintillation counting.2 Moreover, a radiolabeled compound might help to 
enlighten the phenomenon of low recovery of all tested NG-acylated hetarylpropyl-
guanidines, which was assumed to be caused by high unspecific protein binding. 
Thereby, also the possibility of an increased binding affinity to precipitated protein 
(occurring during sample preparation) should be taken into account. 
Based on the results obtained from GSH trapping assays with NG-acylated 2-amino-4-
methylthiazolylpropylguanidines, blocking of the 4-position of the 2-aminothiazole by 
methyl substitution seems to be a successful chemical intervention strategy to prevent 
bioactivation of the heterocycle by epoxidation. Thus, the 2-amino-4-methylthiazole 
moiety presents a safer alternative to the non-methylated 2-aminothiazole in terms of 
potential bioactivation. Hence, it should be taken into consideration as a suitable struc-
tural replacement, as long as desired pharmacological and pharmacokinetic properties 
can be retained. 
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6.6 Experimental section 
6.6.1 General experimental conditions 
Commercially available chemicals and reagents were purchased from Acros Organics 
(Geel, Belgium), Alfa Aesar GmbH & Co. KG (Karlsruhe, Germany), Merck KGaA 
(Darmstadt, Germany) or Sigma-Aldrich Chemie GmbH (München, Germany). All 
solvents used were of analytical grade or distilled before use. Melting points (mp) were 
determined with a Büchi 510 melting point apparatus and are uncorrected. Nuclear 
Magnetic Resonance (1H-NMR and 13C-NMR) spectra were recorded on an Avance 300 
(1H: 300 MHz) or an Avance 600 (1H: 600 MHz) (Bruker BioSpin GmbH, Rheinstetten, 
Germany) with per-deuterated solvents (Deutero GmbH, Kastellaun, Germany). The 
chemical shift δ is given in parts per million (ppm) with reference to the chemical shift of 
the residual protic solvent compared to tetramethylsilane (δ = 0). Multiplicities are 
specified with the following abbreviations: s (singlet), d (doublet), t (triplet), q (quartet), 
sept (septet), m (multiplet) and bs (broad singlet). The multiplicity of carbon atoms was 
determined by DEPT 135 (distortionless enhancement by polarization transfer) and is 
indicated as follows: “+” for primary and tertiary carbon atoms (positive DEPT 135 
signal), “-“ for secondary carbon atoms (negative DEPT 135 signal), “quat” for quaternary 
carbon atoms. 2D-NMR techniques (COSY, TOCSY, HSQC, HMBC) were performed to 
support interpretation of 1D spectra. Mass spectrometry analysis (MS) was performed on 
a Finnigan MAT 95 (EI-MS 70eV, HR-MS) and on a Finnigan ThermoQuest TSQ 7000 
(ES-MS) spectrometer. The peak-intensity in % relative to the strongest signal is given in 
parenthesis. Purification by preparative HPLC was performed on a RP-column 
(Nucleodur 100-5 C18 ec, 250 x 21 mm, 5 µm; Machery-Nagel, Düren, Germany) with a 
system consisting of two K-1800 pumps (Knauer, Berlin, Germany) and a UV-VIS 
detector model K-2000 (Knauer). UV-detection was done at 220 nm, the temperature 
was 30 °C and the flow rate 20 ml/min. Analytical HPLC analysis was performed on a 
system from Thermo Separation Products or a system from Merck Hitachi. The Thermo 
Separation Products system consisted of a SN400 controller, a P4000 pump, an AS3000 
autosampler, a Spectra Focus UV-VIS detector and a RP-column (Luna C18-2, 150 x 4.6 
mm, 3 μm; Phenomenex, Aschaffenburg, Germany) at a flow rate of 0.75 mL/min and a 
column temperature of 30 °C. Absorbance was detected at 210 nm. The retention 
(capacity) factor k was calculated from the retention time tR and the hold-up time t0 
according to k = (tR - t0)/t0 with t0 = 2.88 min for Luna C18-2, 150 x 4.6 mm, 3 μm. The 
Merck Hitachi system consisted of a 655A‐12 pump, a 655A‐40 autosampler, a 655A-52 
column oven, a L‐4250 UV‐VIS detector, a F1000 Fluorescence Spectrophotometer and 
a RP-column (Eurosphere C18, 250mm, 4.6 mm, 5 μm; Knauer, Berlin, Germany). The 
system was operated at a flow rate of 0.7 ml/min and a column temperature of 30 °C. 
UV-absorbance was detected at 210 nm and fluorescence emission was monitored at 
525 nm after excitation at 340 nm. The mobile phases were MeCN and 0.05 % 
trifluoroacetic acid (TFA) in Millipore water (Thermo Scientific system) or MeOH + 0.05 % 
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TFA and 0.05 % TFA in Millipore water (Merck system). All samples were filtered prior to 
injection using 0.2-µm Phenex-NY Syringe Filters (0.2 µm pore size, 4 mm diameter) 
(Phenomenex, Aschaffenburg, Germany). Millipore water was used throughout for the 
preparation of buffers and HPLC eluents. The NADPH regenerating system used for in 
vitro microsomal incubations was purchased from Promega (Madison, USA) consisted of 
two separate solutions (A + B). Solution A contained 26 mM NADP+, 66 mM glucose-6-
phosphate and 66 mM MgCl2. Solution B contained 40 U/ml glucose-6-phophate 
dehydrogenase in 5 mM sodium citrate (pH 5.5). Liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) was carried out on a Finnigan ThermoQuest TSQ 7000 
(Thermo Scientific, Waltham, USA) mass spectrometer interfaced to an Agilent HP1100 
(Santa Clara, USA) HPLC system consisting of autosampler, binary pump, DAD and 
heater. The mobile phases consisted of 0.1 % formic acid in Millipore water (A) and 
MeCN + 0.1 % formic acid (B). The column temperature was 25 °C and UV-detection 
was performed at 210 nm. LC-MS/MS analyses were operated in the positive ion 
electrospray mode. The spray voltage was set at 4.0 kV, and the capillary temperature 
was set at 300 °C. Argon was used as the collision gas with a pressure of approximately 
2 mtorr in the collision cell. 
6.6.2 Chemistry: Experimental protocols and analytical data 
6.6.2.1 NG-acylated hetarylpropylguanidines 
Used 2-aminothiazolylpropylguanidines (6.1, 6.2) and 2-amino-4-methylthiazolylpropyl-
guanidines (6.3, 6.4) were synthesized by Dr. A. Kraus and T. Birnkammer as reported 
elsewhere and kindly provided.19, 21 
6.6.2.2 Synthesis and analytical data of (S)-5-[(R)-1-(carboxymethylamino)-3-
mercapto-1-oxopropan-2-ylamino]-2-[5-(dimethylamino)naphthalene-1-sul-
fonamido]-5-oxopentanoic acid (6.5)22 
A solution of dansyl chloride (3 eq, 1.01 mmol, 0.28 g) in acetone (3.5 ml) was added 
dropwise to a solution of glutathione disulfide (1 eq, 0.34 mmol, 0.21 g) in 4 ml of sodium 
carbonate buffer pH 9. The reaction mixture was stirred for 3 h at room temperature 
under exclusion of light and was extracted with diethylether twice. The aqueous layer 
was separated and lyophilized. The resulting crude solid was resolved in 0.1 M TRIS 
buffer pH 8 (15 ml) followed by addition of dithiothreitol (5 eq, 1.72 mmol, 0.27 g). The 
reaction mixture was stirred for 1.5 h at room temperature under protection from light and 
lyophilized. The title compound was obtained as a white powder after purification by 
preparative HPLC (73 mg, 20 %). Mp.: 112-113 °C. 1H-NMR (D2O) δ ppm: 1.70 and 1.89 
(m, 2H, γ-Glu-Cβ-H2), 2.24 (m, 2H, γ-Glu-Cγ-H2), 2.76 (m, 2H, Cys-Cβ-H2), 3.40 (s, 6H, 
dimethylamino), 3.76 (m, 1 H, γ-Glu-Cα-H), 3.87 (s, 2H, Gly-CH2), 4.37 (t, 1H, 3J = 6.0 Hz, 
Cys-Cα-H), 7.77 (m, 2H, naphthalene-H), 7.98 (m, 1H, naphthalene-H), 8.25 (m, 1H, 
naphthalene-H), 8.32 (m, 1H, naphthalene-H), 8.68 (m, 1H, naphthalene-H). 13C-NMR 
(D2O) δ ppm: 25.41 (-, Cys-Cβ), 27.37 (-, γ-Glu-Cβ), 30.85 (-, γ-Glu-Cγ), 41.07 (-, Gly-
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CH2), 46.79 (2C, +, dimethylamino), 55.17 (+, γ-Glu-Cα), 55.30 (+, Cys-Cα), 119.44 (+, 
naphthalene-C), 125.41 (quat, naphthalene-C), 125.85 (+, naphthalene-C), 126.58 (+, 
naphthalene-C), 126.85 (+, naphthalene-C), 127.99 (+, naphthalene-C), 128.70 (quat, 
naphthalene-C), 130.87 (+, naphthalene-C), 134.94 (quat, naphthalene-C), 138.37 (quat, 
naphthalene-C), 172.29 (quat, Cys-CO), 172.92 (quat, Gly-COOH), 174.16 (quat, γ-Glu-
COOH), 174.67 (γ-Glu-CO). HRMS: EI-MS: m/z for (C22H28N4O8S2) calcd. 541.1427, 
found: 541.14255. Prep. HPLC: 0 min: MeCN/0.05% TFA/aq 5/95, 20 min: 50/50, 20.1-
30 min: 95/5. Analytical HPLC (Thermo Scientific system): 0 min: MeCN/0.05% TFA/aq 
10/90, 25 min: 40/60, 35 min: 10/90, 36-42 min: 95/5, purity 99 %, tR = 11.93 min, k = 
3.14. Anal. (C22H28N4O8S2·C2HF3O2·2 H2O) C, H, N, S. C22H28N4O8S2 · 1 TFA (654.63). 
6.6.2.3 Preparation and HPCL-fluorescence detection of (S)-5-[(R)-1-(carboxy-
methylamino)-1-oxo-3-(3-oxopropylthio)propan-2-ylamino]-2-[5-(dimethyl-
amino)naphthalene-1-sulfonamido]-5-oxopentanoic acid (6.6) 
A reaction mixture containing 6.5 (1 mM) and acrolein (5 mM) in 200 µl 0.1 M potassium 
phosphate buffer pH 7.4 was stirred for 1 h at room temperature. The reaction was 
monitored by analytical HPLC with fluorescence detection (Merck system) after dilution 
(1:10) with mobile phase (MeOH+0.05 % TFA / 0.05 % TFA/aq 20/80). Following gra-
dient was applied: 0 min: MeOH+0.05 % TFA / 0.05 % TFA/aq 20/80, 20-30 min 80/20; tR 
(6.6) ~ 15.4 min. ES-MS (DCM/MEOH + 10 mM NH4OAc) m/z (%): 597 (100) [M+H]+. 
6.6.2.4 Preparation and HPCL-fluorescence detection of (S)-5-[(R)-1-(carboxy-
methylamino)-3-(1-ethyl-2,5-dioxopyrrolidin-3-ylthio)-1-oxopropan-2-ylami-
no]-2-[5-(dimethylamino)naphthalene-1-sulfonamido]-5-oxopentanoic acid 
(6.7) 
A solution of 6.5 (1 mM) and N-ethylmaleimide (2 mM) in 200 µl 0.1 M potassium 
phosphate buffer pH 7.4 was stirred for 1 h at room temperature. The reaction was moni-
tored by analytical HPLC with fluorescence detection (Merck system) after dilution (1:10) 
with mobile phase (MeOH+0.05 % TFA / 0.05 % TFA/aq 20/80). Following gradient was 
applied: 0 min: MeOH+0.05 % TFA / 0.05 % TFA/aq 20/80, 20-30 min 98/2; tR (6.7) ~ 
16.8 min + 17.2 min (diasteromers). ES-MS (DCM/MEOH + 10 mM NH4OAc) m/z (%): 
666 (100) [M+H]+. 
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6.6.3 Bioanalytics: Experimental protocols and instrument settings 
6.6.3.1 Preparation of phenobarbital-induced rat liver microsomes 
To obtain liver microsomes with metabolically activated CYP enzymes, a male Sprague 
Dawley rat received 50 mg/kg per day phenobarbital sodium (solution in 0.9 % NaCl 
solution) intraperitoneally over three days. Then the rat was killed, the liver was excised 
and immediately cooled on ice. The liver was cut into small pieces with scissors, divided 
onto two Potter-Elvehjem homogenizer tubes, each filled with 30 ml of cooled 0.15 M 
potassium phosphate buffer (pH 7.4) and homogenized under ice cooling by 25 heaves 
at 100 RPM. After every 5 heaves a break of 30 seconds was kept to avoid overheating. 
The resulting homogenates were centrifuged for 30 min at 9000 g and 4 °C. Subse-
quently, the lipid layer was discarded, the supernatants (S9-fraction) were removed and 
subjected to centrifugation at 105000 g for 1 h at 4 °C. Each resulting microsome pellet 
was suspended in 880 µl 0.15 M phosphate buffer (pH 7.4) containing 17 mM KCl and 
stored in aliquots á 100 µl at -78 °C. The amount of microsomal protein was determined 
according to the method of Bradford to 80 mg protein/ml. 
6.6.3.2 In vitro microsomal incubation conditions 
In vitro incubations of test compounds contained the following: 5 mM GSH or dGSH (6.5) 
(stock: 50 mM in phosphate buffer), 2 mg protein/ml phenobarbital-induced rat liver 
microsomes (stock: 4 mg protein/ml in phosphate buffer) and 50 µM test compound 
(stock: 5 mM in phosphate buffer (diclofenac) or 10 mM in 70 % ethanol (6.1-6.4). This 
mixture was pre-incubated at 37 °C for 5 min. Then, 50 µl of NADPH regenerating 
system solution A and 10 µl of solution B were added to obtain a total incubation volume 
of 1 ml. Incubations that contained buffer instead of microsomes served as control. After 
incubation for 16.5 h (diclofenac) and 2 h (6.1-6.4) the reaction was quenched by 
addition of 3 ml of ice-cold MeCN. The mixture was vortex mixed, allowed to stand in the 
refrigerator for approximately 30 min, again vortex mixed and centrifuged for 5 min at 
13000 rpm (13000 g) and 4 °C. The supernatant was collected, evaporated to dryness 
using a speed vac and stored at -20 °C. 
6.6.3.3 Detection of GSH containing metabolites of diclofenac 
Samples from microsomal incubation of diclofenac were reconstituted in 500 µl of a 
water-acetonitrile mixture (90/10, v/v) and aliquots of 10-20 µl were injected for LC-
MS/MS analysis. A Luna C18-2 HPLC column (100 x 2.0 mm, 3 μm; Phenomenex, 
Aschaffenburg, Germany) was used at a flow rate of 0.3 ml/min. For LC-separation 
following gradient was applied (for mobile phases see 6.6.1): 0 min: A/B = 90/10, 16 min: 
40/60, 17-22 min: 2/98, 23-27 min: 90/10. For MS analysis of GSH adducts full scan MS 
analysis in a range from 250 to 700 Da and product ion scanning over a mass range of 
160 to 900 Da were performed in the positive ion electrospray mode with a collision 
energy of 26 eV. In the MRM mode (collision energy 26 eV) following mass transitions 
were monitored: m/z 617 → 542, 617 → 488, 583 → 508 and 583 → 454. 
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6.6.3.4 Detection of GSH containing metabolites of 6.1, 6.2, 6.3 and 6.4 
For analysis of GSH adducts samples of microsomal incubation were reconstituted in 
500 µl of a water-acetonitrile mixture (90/10, v/v) and aliquots (5-20 µl) were subjected to 
HPLC separation using a Synergi Hydro RP HPLC column (250 x 4.6 mm, 4 μm; 
Phenomenex, Aschaffenburg, Germany) at a flow rate of 0.6 ml/min. Potential GSH 
adducts were separated by applying following gradient: 0 min: A/B = 98/2, 15 min: 85/15, 
30 min: 25/75, 31-39 min: 5/95, 40-52 min: 98/2. In the full scan MS mode a mass range 
from 145-1200 Da (6.1) and from 200-1400 Da (6.2, 6.3, 6.4) was measured. 
Fragmentation by CID was induced at a collision energy of 30 eV. The mass range for 
CNL scans of 6.1 for loss of 129 Da was set to 350-800 Da. Product ions of 6.1 and 6.2 
were scanned between 100-700 Da. For identification of potential GSH adducts of 6.2 
following mass transitions were monitored using the MRM mode: m/z 665 → 536, 665 → 
590 and 665 → 392. 
6.6.3.5 Detection of dGSH containing metabolites of 6.1 
Samples from microsomal incubation of 6.1 with dGSH were reconstituted in 500 µl of a 
water-acetonitrile mixture (90/10, v/v) and aliquots of 0.5-1.0 µl were injected for LC-
MS/MS analysis. For used HPLC column and flow rate see 6.6.3.3. LC-separation was 
achieved by applying following gradient: 0 min: A/B = 90/10, 30-35 min: 20/80, 36-40 
min: 90/10. Full scan over a mass range of 200-1400 Da and product ion scanning of 
dGSH over a mass range of 50-600 Da (collision energy: 25 eV) were performed. 
Furthermore, specific mass transitions of the putative dGSH adduct of 6.1 were followed, 
namely: m/z 870 → 795 and 870 → 363. 
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 Chapter 7  
Unspecific Toxicity of NG-Acylated 
Hetarylpropylguanidines 
7.1 Introduction 
In contrast to drug toxicity arising from enzymatic bioactivation of drugs to reactive 
metabolites, toxic effects can be elicited by the parent compound per se. As a prere-
quisite for application as pharmacological tools for in vivo or cell based in vitro studies, 
representative NG-acylated hetarylpropylguanidines were tested with respect to their 
potential to induce the rupture of erythrocytes (hemolysis) and toxicity in cells (cyto-
toxicity). Hemolysis results in the release of hemoglobin from erythrocytes. Due to the 
characteristic absorption maximum of hemoglobin at 580 nm the hemolytic effect of a 
substance can be determined spectrophotometrically. Cytotoxicity was studied in a 
standard crystal violet based chemosensitivity assay with long-term exposure of test 
compounds on HT-29 colon carcinoma cells.1 Furthermore, short-term cytotoxic effects 
were assessed in a lactate dehydrogenase (LDH) assay using HT-29 cells and cultured 
primary human hepatocytes (PHH). The cytotoxic effect is proportional to the release of 
LDH activity, which is determined spectrophotometrically, measuring the LDH-catalyzed 
reduction of pyruvate to lactate under consumption of NADH.2 
Selected substances out of a set of NG-acylated imidazolylpropylguanidines and NG-
acylated 2-aminothiazolylpropylguanidines shown in Table 7.1 were used for hemolysis 
and cytotoxicity studies. These compounds were synthesized in our workgroup and 
provided by Dr. A. Kraus and T. Birnkammer.3-4 
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Table 7.1. NG-acylated imidazolylpropylguanidines and NG-acylated 2-aminothiazolylpropylguanidines used for 
hemolysis and cytotoxicity studies. 
 
7.2 Hemolytic potential of selected NG-acylated hetarylpropylguanidines 
In Figure 7.1 the percentage of hemolysis of selected NG-acylated hetarylpropyl-
guanidines (cf. Table 7.1 for structures) is shown compared to the reference compound 
digitonin, which is known to induce strong hemolysis.5 At a concentration of 100 µM 
severe hemolysis (60-100 %) was observed for 7.4, 7.6, 7.8 and 7.11. In addition, 7.2 
exhibited a significant hemolytic effect (~20 %). For all other investigated compounds the 
hemolytic effect was rather weak. Strikingly, 7.2, 7.4, 7.6, 7.8 and 7.11 have a cyclohexyl 
ring at the end of the acyl chain in common. It is known from literature that interactions of 
certain substances with the erythrocyte membrane can lead to hemolysis by inducing 
osmotic pressure followed by cell swelling or by partial solubilization of membrane lipids 
and proteins, e.g by formation of mixed micelles.6 These mechanisms are typical for 
amphiphilic substances such as surfactants. Regarding the investigated NG-acylated 
hetarylpropylguanidines, the introduction of a highly lipophilic cyclohexyl moiety 
obviously resulted in a marked increase in compromising the erythrocyte membrane. 
Presumably, the amphiphilic character of the compounds became more distinct, as, in 
contrast to the cyclohexyl moiety, the acylguanidine represents the more polar partial 
structure in the respective molecules due to protonation at physiological pH. 
Furthermore, the imidazole and 2-aminothiazole heterocyles are considered more polar 
as well. On the other hand, compounds bearing a less lipophilic acyl chain seemed to 
have a decreased tendency for solubilization of the cell membrane due to reduced 
amphiphilicity. At a test concentration of 30 µM the hemolytic effect especially of 
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compounds 7.2, 7.4, 7.6, 7.8 and 7.11 was drastically decreased. Only 7.6 and 7.8 still 
caused weak hemolysis, whereas the effect of all other compounds was marginal 
(< 5 %). Probably, at 30 µM the concentration of these compounds was below the critical 
micellar concentration to effectively damage the erythrocyte membrane. 
Taken together, in view of cellular in vivo experiments, concentrations higher than 30 µM 
of amphiphilic NG-acylated hetarylpropylguanidines, especially those bearing lipophilic 
residues such as cyclohexyl, should be avoided. Less “tenside-like” compounds were 
found to induce only minor hemolytic effects up to a concentration of 100 µM. 
Figure 7.1. Mean percentage of hemolysis (n=2) induced by NG-acylated hetarylpropylguanidines at 100 µM (A) 
and 30 µM (B). 
7.3 Cytotoxicity of selected NG-acylated hetarylpropylguanidines in the 
crystal violet assay 
In order to investigate the potential cytotoxic effects of NG-acylated hetarylpropyl-
guanidines, selected compounds (6.1, 7.1, 7.6, 7.9, 7.11; cf. Table 7.1) were investigated 
in a crystal violet based chemosensitivity assay1 on proliferating human HT-29 colon 
carcinoma cells over a period of approximately 200 h. Cisplatin was taken as a reference 
compound. The results are presented as plots of corrected T/C values (cf. Equation 7.2 
in the experimental part) vs. time of incubation to distinguish cytotoxic (T/Ccorr > 0 %) and 
cytocidal (T/Ccorr < 0 %) drug effects (Figure 7.2 A-F). 
All tested compounds showed more or less distinct cytotoxicity in the concentration 
range of 3-100 µM. In addition, after 200 h cytocidal effects were detected for 7.1 at 
100 µM, for 7.6 at 10 µM and 100 µM and for 7.11 at 10 µM, 30 µM and 100 µM. Thus, 
7.6 and 7.11 were considered the compounds with the highest cytotoxicity. This obser-
vation confirms the results from the hemolysis studies, in which the compounds, compri-
sing a cyclohexyl moiety and assumably the highest extent of amphiphilicity, produced 
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the most pronounced cell-damaging effects. In conclusion, one should be aware of 
potential cytotoxicity of NG-acylated hetarylpropylguanidines at micromolar concentra-
tions with respect to cell based in vitro or in vivo studies. 
Figure 7.2 continued on page 221  
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Figure 7.2. Effects of 6.1 (A), 7.1 (B), 7.6 (C), 7.9 (D) and 7.11 (E) on proliferating HT-29 cells upon long-term 
exposure. Following concentrations were used: 3 µM (●), 10 µM (■), 30 µM (▲), 100 µM (▼). Cisplatin (F) was 
used as positive control in following concentrations: 1 µM (), 2.5 µM (), 5 µM (△). 
7.4 Cytotoxicity of selected NG-acylated hetarylpropylguanidines in the 
lactate dehydrogenase assay 
In order to assess the cytotoxicity of NG-acylated hetarylpropylguanidines upon short-
term exposure (24 h), selected compounds (cf. Table 7.1 for structures) were tested in a 
lactate dehydrogenase (LDH) assay on HT-29 colon carcinoma cells. To take a potential 
impact of metabolism on the toxification into account, the same compounds were also 
exposed to cultured primary human hepatocytes (PHH), as PHH generally have a higher 
metabolical capacity and activity. 
The extent of LDH release, which positively correlates with the percentage of cell death, 
was determined relative to the effect of the detergent Triton X-100, which strongly 
induces cell lysis. In Figure 7.3 the effect of representative compounds on HT-29 cells at 
test concentrations of 30 µM and 100 µM, respectively (exception: 7.6, 30 and 50 µM) 
are depicted. Compared to the control, all compounds except for 7.6 and 7.11 at 50 µM 
and 100 µM, respectively, induced no more than a slight increase in LDH release over an 
incubation period of 24 h. However, incubation of HT-29 cells with 7.6 at a concentration 
of 50 µM led to approximately 55 % cell death, and 7.11, the most cytotoxic compound 
among the investigated acylguanidines, killed 100 % of the cells at a concentration of 
100 µM. These findings are in accordance with the results from the crystal violet based 
chemosensitivity assay and from hemolysis studies. Again, 7.6 and 7.11 proved to 
drastically affect membrane integrity at concentrations in the upper micromolar range. 
Incubation of the same set of test compounds with cultured PHHs revealed an overall 
higher sensitivity of PHHs compared to HT-29 cells (cf. Figure 7.4). This effect may be 
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caused by the absence of FCS in the culture medium. As NG-acylated hetarylpropylgua-
nidines are known to exhibit strong plasma protein binding, in medium devoid of FCS, 
the concentration of “free” compound, that can exert a cytotoxic effect, is higher. Except 
for 6.1, 6.3 and 6.9, all investigated compounds caused high percentage (up to 100 %) of 
cell death. Compound 7.11 even showed a relatively strong cytotoxic effect at both 
30 µM and 100 µM. Obviously, lowering the lipophilicity of the acyl chain (6.1) or intro-
duction of polar substituents such as a hydroxy group (7.9) resulted in reduced cytotoxi-
city. Regarding the compounds 6.1 and 6.3 as well as 6.2 and 6.4, no significant differ-
ence in LDH release was detectable. Hence, introduction of a 4-methyl residue at the 2-
aminothiazole ring does not alter the cytotoxic properties. Again, an increase in amphi-
philicity by introduction of alkyl moieties at the acyl side chain, seemed to have a more 
distinct impact on the cytotoxic properties, presumably, by increasing the tendency for 
formation of micelles. 
 
Figure 7.3. Effects of selected NG-acylated hetarylpropylguanidines on HT-29 cells depicted as percent LDH 
release, respectively cell death, relative to Triton X-100 (n=3). 
 
Figure 7.4. Effects of selected NG-acylated hetarylpropylguanidines on cultured primary human hepatocytes 
depicted as percent LDH release, respectively cell death, relative to Triton X-100 (n=3). 
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7.5 Summary 
With respect to their use in cell based in vitro studies or future in vivo experiments, 
selected NG-acylated hetarylpropylguanidines were characterized regarding their 
hemolytic and cytotoxic properties. At a concentration of 30 µM only weak hemolytic 
effects were observed, whereas at 100 µM strong hemolysis was induced by compounds 
bearing a cyclohexyl residue-containing acyl chain. Obviously, the increase in acyl chain 
lipophilicity and overall amphiphilicity led to an enhanced damage of the erythrocyte 
membrane, presumably by solubilization of membrane lipids and proteins through 
formation of mixed micelles. In the crystal violet chemosensitivity assay all tested 
compounds showed a more or less distinct cytotoxic effect in the concentration range of 
3-100 µM over an incubation period of 200 h. Cytocidal effects were detected for 
compounds containing a 4-cyclohexyl-3-methylbutanoyl chain at 10 µM to 100 µM. 
Furthermore, selected compounds were incubated for 24 h in a lactate dehydrogenase 
assay on HT-29 colon carcinoma cells and cultured primary human hepatocytes (PHH). 
In accordance to the results obtained from hemolysis and long-term chemosensitivity 
assay, compounds bearing lipophilic cyclohexyl residues, tested at a concentration of 
100 µM, revealed the most pronounced compromising effect on membrane integrity. A 
concentration of 30 µM was generally well tolerated by HT-29 cells. However, PHHs 
were observed to have a higher sensitivity when incubated with NG-acylated hetaryl-
propylguanidines. 
In summary, NG-acylated hetarylpropylguanidines revealed considerable hemolytic and 
cytotoxic effects in the micromolar range, particularly when the acyl part of the 
compounds contained highly lipophilic moieties such as a cyclohexyl ring. These findings 
must be taken into account, when the compounds are used for cell based in vitro assays 
or in in vivo studies. 
7.6 Experimental section 
7.6.1 Determination of hemolytic properties of NG-acylated hetarylpropyl-
guanidines using mouse erythrocytes 
Isotonic saline (2 ml) was added to fresh citrated mouse blood (1 ml). After centrifugation 
(70 g, 15 min, 4 °C) the supernatant plasma and the leukocyte-layer were removed. The 
resulting erythrocytes were re-suspended in isotonic saline (1 ml) and centrifuged 
(2000 g, 10 min, 4 °C). The supernatant was discarded and the washing procedure was 
repeated twice. Subsequently, the erythrocytes were stored on ice before use on the 
same day. 
500 µl of freshly prepared erythrocytes were diluted with 9.5 ml of isotonic saline and 
aliquots á 50 µl were filled into each well of a microtiter plate (Greiner, Frickenhausen, 
Germany). Then, 1 µl of respective test compound stock solutions (1.5 mM and 5 mM, 
respectively in 70 % EtOH) was added to obtain the final concentration of the test 
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compounds (30 µM and 100 µM, respectively). For control experiments 1 µl of 70 % 
EtOH was added (0 % hemolysis) and 1 µl of digitonin solution (2 %, w/v) was added as 
a reference to induce 100 % hemolysis. Each sample was prepared in duplicate. After 
careful mixing, the plate was incubated for 1 h at 37 °C and shaken every 20 min. The 
plate was centrifuged at 2000 g for 3 min and 30 µl of each well were transferred to a 
new microtiter plate. After addition of 100 µl of isotonic saline into each well, the 
absorbance was measured at 580 nm (λhemoglobin, max) and at 485 nm (λhemoglobin, min) using 
a GENios Pro microplate reader (Tecan Deutschland GmbH, Crailsheim, Germany). The 
percentage hemolysis was calculated according to Equation 7.1. 
% Hemolysis ൌ ቆAହ଼଴ ୬୫Aସ଼ହ ୬୫ െ
Aହ଼଴ ୬୫ ሺ଴ %ሻ
Aସ଼ହ ୬୫ ሺ଴ %ሻቇ ቆ
Aହ଼଴ ୬୫ ሺଵ଴଴ %ሻ
Aସ଼ହ ୬୫ ሺଵ଴଴ %ሻ െ
Aହ଼଴ ୬୫ ሺ଴ %ሻ
Aସ଼ହ ୬୫ ሺ଴ %ሻቇ · 100൘  
Equation 7.1. A580 nm, A485 nm = measured absorbance of the sample at 580 nm and 485 nm, respectively; 
A580 nm (0 %), A485 nm (0 %) = measured absorbance of the control at 580 nm and 485 nm, respectively; A580 nm (100 %), 
A485 nm (100 %) = measured absorbance of the reference containing digitonin at 580 nm and 485 nm, respectively 
7.6.2 Crystal violet chemosensitivity assay 
The assay was performed according to the procedure described by Bernhardt et al.1 In 
brief, tumor cells were seeded into flat-bottomed 96-well plates (Greiner, Frickenhausen, 
Germany) at a density of ca. 15 cells per microscopic field (magnification: 320-fold). After 
48-72 h of incubation at 37 °C / 5 % CO2, the culture medium was replaced by fresh 
medium containing the test compounds at various concentrations. Cells treated with 
medium containing the respective solvent used for the test compounds served as control. 
After various incubation periods, medium was discarded, the cells were fixed with 1 % 
glutardialdehyde solution in PBS and stored at 4 °C. At the end of the experiment the 
mass of viable cells was determined by simultaneous staining of all plates with 0.02 % 
aqueous crystal violet (Serva, Heidelberg, Germany) solution. Subsequently, excess dye 
was removed with water and cell-bound crystal violet was re-dissolved with 70 % 
ethanol. The absorbance was measured at 578 nm using a BioTek 309 Autoreader 
(Tecnomara, Fernwald, Germany) or at 580 nm using a GENios Pro microplate reader 
(Tecan Deutschland GmbH, Crailsheim, Germany). 
The effects of the test compounds on the proliferating cells were presented as corrected 
T/C values according to Equation 7.2. 
T/Cୡ୭୰୰ ሺ%ሻ ൌ
ሺT െ C଴ሻ
ሺC െ C଴ሻ · 100 
Equation 7.2. T = mean absorbance of treated cells, C = mean absorbance of controls, C0 = mean absorbance at 
the time when test compounds were added (t = 0). 
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7.6.3 Lactate dehydrogenase assay 
HT-29 colon carcinoma cells were cultured in McCoy’s medium supplemented with 5 % 
FCS. Two days prior to addition of test compounds, tumor cells were seeded into flat-
bottomed 96-well plates (Greiner, Frickenhausen, Germany) at a density of ca. 60 cells 
per microscopic field (magnification: 320-fold) and incubated for 48 h at 37 °C / 5 % CO2. 
Stock solutions (30 mM) of test compounds were prepared in 70 % EtOH. The culture 
medium was removed and replaced by fresh medium (200 µl per well) containing test 
compounds at concentrations of 30 µM and 100 µM, respectively. Cells treated with 
medium containing 70 % EtOH served as control. After incubation for 24 h, 2 µl each of a 
10 % aqueous Triton X-100 solution were added to 8 untreated wells and were incubated 
for 30 min to achieve 100 % LDH release. Subsequently, the microtiter plates were 
centrifuged at 120 g for 3 min. 50 µl of each supernatant were transferred into fresh 
microtiter plates. After addition of 110 µl of 0.1 M KH2PO4/K2HPO4 buffer pH 7.00 
supplemented with 1 mM EDTA and 0.1 mM DTE and 10 µl of a freshly prepared 7 mM 
solution of NADH (Roche Diagnostics) in buffer, the reaction was started by addition of 
20 µl of a 10.5 mM solution of pyruvate in Millipore water using a GENios Pro microplate 
reader (Tecan Deutschland GmbH, Crailsheim, Germany). The reaction was monitored 
by measuring the decrease in absorbance at 340 nm caused by the oxidation of NADH 
over a period of ca. 9 min. The slope of the linear part of the absorbance vs. reaction 
time plot was used for determination of the LDH release, which corresponds to the 
percentage of cell death. Thereby, the mean slope obtained from wells treated with 
Triton X-100 is set to 100 % cell death. 
Primary human hepatocytes were isolated and cultured as described in section 3.8.3. 
One day after isolation the culture medium was replaced by fresh culture medium devoid 
of FCS. 24 h later, the culture medium was removed and fresh medium (devoid of FCS) 
containing the test compounds was added. Further steps were performed according to 
the assay procedure described above for HT-29 cells. 
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 Chapter 8 Summary 
Figuratively, drug metabolism can be considered as two sides of the same coin; one lea-
ding to desired, beneficial effects, e.g. by activation of prodrugs, whereas the other one 
results in adverse side effects due to toxic metabolites. In this work both aspects were 
explored more closely. 
 
Transdermal therapeutic systems (TTS) are known as drug formulations providing 
constant and sustained drug plasma levels at reduced application frequency. Therefore, 
TTS are particularly advantageous for the treatment of disorders requiring long-term 
pharmacotherapy as, e.g., cardiovascular diseases. By now, hypertension is recognized 
as one of the leading risk factors for cardiovascular morbidity and mortality. However, 
there is a strong discrepancy between the high incidence of hypertension and the 
availability of transdermally applicable antihypertensive drugs. 
Thus, one part of this thesis aimed at novel derivatives of the angiotensin II AT1 receptor 
antagonist candesartan and the angiotensin-converting enzyme inhibitor (ACEi) cilaza-
pril, suitable for administration via a TTS. The prodrug approach was pursued to design 
and synthesize various ester-based candesartan and cilazapril prodrugs with physico-
chemical properties considered suitable to overcome the barrier function of the skin. The 
novel compounds were bioanalytically characterized with respect to solid-state stability, 
susceptibility for enzymatic hydrolysis, and stability against non-enzymatic hydrolysis. All 
candesartan and cilazapril prodrugs except for a simple ethyl ester of cilazapril were 
enzymatically hydrolyzed to release the active principle. By contrast to other ACEi, 
decomposition by diketopiperazine formation was not observed during synthesis and 
storage, due to the conformationally constrained structure of the cilazapril scaffold. Addi-
tionally, the potential candesartan prodrugs turned out to be potent angiotensin II AT1 
receptor antagonists (Kb = 0.8 – 6.4 nM) in a fura-2 Ca2+-assay on rat glomerular mesan-
gial cells. 
The three most promising candidates of each group were selected for TTS development, 
namely candesartan 1-(isopropyloxycarbonyloxy)ethyl ester, candesartan 1-(2,2-di-
methylpropanoyloxy)ethyl ester and candesartan morpholinoethyl ester as well as cilaza-
pril 1-(ethoxycarbonyloxy)ethyl ester, cilazapril 1-(cyclohexyloxycarbonyloxy)ethyl ester 
and cilazapril morpholinoethyl ester. These new chemical entities were found to be com-
parable or even superior to the reference compounds candesartan cilexetil and cilazapril, 
respectively, in terms of formulate-ability, TTS quality and stability in a silicone PSA 
matrix. 
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Furthermore, the manufactured TTS containing the new prodrugs were superior to the 
respective candesartan cilexetil and cilazapril formulations, when investigated for trans-
dermal permeation through animal and human skin using Franz diffusion cells. 
 
The second part of this thesis addressed the adverse side of drug metabolism, namely 
toxic effects due to the formation of reactive metabolites/intermediates capable of cova-
lent protein binding. In our workgroup highly potent NG-acylated hetarylpropylguanidine-
type H2R agonists, comprising either an imidazole ring or a 2-aminothiazole group, were 
developed, which could serve as valuable pharmacological tools for in vitro and potential 
in vivo studies. There is strong evidence that cytochrome P450-mediated bioactivation of 
the 2-aminothiazole ring results in highly reactive intermediates. 
Thus, the aim of this project was the detection and identification of reactive intermediates 
by co-incubating NG-acylated 3-(2-aminothiazol-5-yl)propylguanidines with rat liver micro-
somes and glutathione (GSH) to trap putative reactive molecules. By means of liquid 
chromatography/tandem mass spectrometry (LC-MS) and appropriate MS/MS experi-
ments such as full scan, constant neutral loss scanning, multiple reaction monitoring and 
product ion scanning, GSH adducts of reactive intermediates of NG-acylated 3-(2-amino-
thiazol-5-yl)propylguanidines were detected. Benefitting from the selectivity of fluores-
cence detection, these results were corroborated by using dansylated GSH as a trapping 
agent. Interestingly, blocking of the 4-position of the 2-aminothiazole by methyl substi-
tution seemed to be a successful strategy to prevent bioactivation of the heterocycle. 
 
Finally, unspecific toxicity of NG-acylated hetarylpropylguanidines was investigated, 
revealing considerable hemolysis and cytotoxicity in the micromolar range, particularly 
when the acyl part of the compounds contained highly lipophilic moieties. 
 
In summary, the ambivalent character of drug metabolism was highlighted in this thesis. 
Novel synthesized prodrugs of cilazapril and candesartan turned out to be enzymatically 
convertible to the active drug and to be superior to the reference drugs in terms of stabi-
lity, formulate-ability and skin permeability, thus representing promising compounds for 
transdermal antihypertensive therapy via TTS. By contrast, the identification of reactive 
intermediates of NG-acylated hetarylpropylguanidines demonstrated that one should be 
aware of the potential risk of bioactivation residing in structural moieties such as amino-
thiazoles to avoid toxification. 
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9.1 Appendix 1: Abbreviations 
ACE angiotensin-converting enzyme 
ACEi angiotensin-converting enzyme inhibitor 
ADR adverse drug reaction 
Ang II angiotensin II 
aq. aqueous 
ARB angiotensin II AT1 receptor antagonist / blocker 
AT1R, AT2R angiotensin II receptor subtypes 
BSA bovine serum albumine 
[Ca2+]i intracellular calcium ion concentration 
CID collision-induced dissociation 
CNL constant neutral loss 
CPD citrate phosphate dextrose 
cy cyclohexyl 
CYP cytochrome P450 enzyme 
d day 
Da Dalton 
DCC N,N’-dicyclohexylcarbodiimide 
DCM dichloromethane 
DMAP p-dimethylaminopyridine 
DMF dimethylformamide 
DMSO dimethyl sulfoxide 
DTE dithioerythritol 
DTT dithiothreitol 
EC50 agonist concentration which induces 50 % of the maximal effect 
EDTA ethylenediaminetetraacetic acid 
EGTA ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid 
EI-MS electron impact mass spectrometry 
Eq equivalent 
ESI electrospray ionisation 
EtOAc ethyl acetate 
EtOH ethanol 
f50% time at which 50 % of the active principle have been formed 
FCS fetal calf serum 
GI gastrointestinal tract 
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GSH reduced glutathione 
GSSG glutathione disulfide, oxidized glutathione 
h hour 
HPLC high performance liquid chromatography 
HR-MS high resolution mass spectrometry 
HT-29 human colon carcinoma cell line 
IC50 antagonist concentration which suppresses 50 % of an agonist induced 
effect 
iPr isopropyl 
Jss steady state flux 
k retention (capacity) factor 
Kb dissociation constant derived from a functional assay 
LC-MS liquid chromatography tandem mass spectrometry 
log P partition coefficient 
log D distribution coefficient 
log D5.5 distribution coefficient at pH 5.5 
M mol/L 
MeCN acetonitrile 
MeOH methanol 
min minute 
mo morpholine 
mp melting point 
MRM multiple reaction monitoring 
m/z mass-to-charge ratio 
NADH nicotinamide adenine dinucleotide (reduced form) 
NADPH nicotinamide adenine dinucleotide phosphate (reduced form) 
n-BuLi n-butyllithium 
n.d. not determined 
NMR nuclear magnetic resonance 
PBS phosphate buffered saline 
PE petroleum ether 
PHH primary human hepatocytes 
pKa acid dissociation constant 
PPB plasma protein binding 
ppm parts per million 
PSA pressure-sensitive adhesive 
rel. h. relative humidity 
RP-LC reversed-phase liquid chromatography 
rt room temperature 
sat. saturated 
SEM standard error of the mean 
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t1/2 half-live 
tBu tert-butyl 
TFA trifluoroacetic acid 
THF tetrahydrofuran 
ti incubation period 
tlag lag time 
tR retention time 
TQ triple quadrupole 
TTS transdermal therapeutic system 
UV ultraviolet 
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9.2 Appendix 2: Bioanalytical studies 
 
Figure 9.1. Kinetics of hydrolysis of 3.1 
(two diasteromers) in phosphate buffer. 
 
Figure 9.2. Kinetics of hydrolysis of 3.3 
(two diasteromers) in phosphate buffer. 
 
Figure 9.3. Kinetics of hydrolysis of 3.7 
(two diasteromers) in phosphate buffer. 
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Figure 9.4. LC-MS analysis of a sample of 3.2 incubated for 3 h in porcine skin homogenate. A: TIC, B: UV, C: 
ESI-MS spectrum of 3.29, D: ESI-MS spectrum of CIL, E: ESI-MS spectrum of one diastereomer of 3.2a, F+G: 
ESI-MS spectra of the two diastereomers of 3.2. 
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Figure 9.5. Kinetics of hydrolysis of 3.25 in 
the presence of porcine liver esterase. 
 
Figure 9.6. Kinetics of hydrolysis of 3.26 in 
the presence of porcine liver esterase. 
 
Figure 9.7. Kinetics of hydrolysis of 3.27 in 
porcine skin homogenate. 
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Figure 9.8. Kinetics of hydrolysis of 3.27 in 
human plasma. 
 
Figure 9.9. Kinetics of hydrolysis of 3.27 in 
the presence of porcine liver esterase. 
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Figure 9.10. LC-MS analysis of a sample of 3.14 incubated for 1 h with buffered porcine liver esterase. A: TIC, B:
UV, C: ESI-MS spectrum of 3.14a, D: ESI-MS spectrum of 3.14b, E: ESI-MS spectrum of 3.14, F: ESI-MS
spectrum of cilazapril (CIL). 
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Figure 9.11. Kinetics of hydrolysis of 3.28 in 
the presence of porcine liver esterase. 
 
Figure 9.12. Kinetics of hydrolysis of 3.28 in 
human plasma. 
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